keyword,recent_count,prior_count,growth
experiments,928,9,1271.7
black,180,2,1110.0
disparity population,45,0,999.0
addicted to cocaine,235,0,999.0
sex based differences,120,0,999.0
genetic propensity,46,0,999.0
racial minority population,46,0,999.0
racial minority people,46,0,999.0
racial minority individual,46,0,999.0
racial minority group,46,0,999.0
gene network,119,0,999.0
proctor evaluation model,17,0,999.0
proctor framework,17,0,999.0
proctor multi-level outcomes framework,17,0,999.0
proctor multilevel outcomes framework,17,0,999.0
proctor process outcomes,17,0,999.0
proctor taxonomy,17,0,999.0
framework by proctor,17,0,999.0
proctor conceptual model,17,0,999.0
proctor implementation,17,0,999.0
proctor model,17,0,999.0
addiction to cocaine,235,0,999.0
adjuvant treatment,10,0,999.0
preparations,239,0,999.0
disadvantaged individual,45,0,999.0
community level disadvantage,18,0,999.0
disadvantaged community,18,0,999.0
primary care practice,18,0,999.0
crispr-dcas9-mediated repression,18,0,999.0
crispr/dcas9 interference,18,0,999.0
crispr/dcas9-mediated transcriptional inhibition,18,0,999.0
repressing crispr-dcas9 system,18,0,999.0
learning strategies,18,0,999.0
stress-related coping,18,0,999.0
disparity between groups,45,0,999.0
disparity among subgroups,45,0,999.0
manufacture,121,0,999.0
stimulant,232,0,999.0
disparity among groups,45,0,999.0
disparity across subgroups,45,0,999.0
disparities across groups,45,0,999.0
homes,233,0,999.0
disadvantaged subgroup,45,0,999.0
disadvantaged people,45,0,999.0
disadvantaged group,45,0,999.0
gene regulatory network,46,0,999.0
tropical cyclone,16,0,999.0
inducible cre,17,0,999.0
population specific intervention,17,0,999.0
mother outcome,17,0,999.0
providers from primary care,17,0,999.0
providers of primary care,17,0,999.0
financial adversity,17,0,999.0
financial insecurity,17,0,999.0
adult females,17,0,999.0
adult women,17,0,999.0
females in adulthood,17,0,999.0
women in adulthood,17,0,999.0
age correlated,17,0,999.0
health disparities research,48,0,999.0
placebo controlled,116,0,999.0
age linked,17,0,999.0
age specific,17,0,999.0
health level,17,0,999.0
community engaged participatory research,17,0,999.0
community partnered research,17,0,999.0
community-engaged study,17,0,999.0
population based intervention,17,0,999.0
induced cre,17,0,999.0
brain based,47,0,999.0
dose limiting,17,0,999.0
high schoolers,47,0,999.0
disparity,241,0,999.0
disparities,241,0,999.0
non-contrast ct,17,0,999.0
noncontrast ct,17,0,999.0
noncontrast computed tomography,17,0,999.0
gene repair therapy,47,0,999.0
lived experiences,48,0,999.0
lived experience,48,0,999.0
effectiveness/implementation trial,48,0,999.0
minority individual,117,0,999.0
effectiveness/implementation hybrid trial,48,0,999.0
effectiveness and implementation trial,48,0,999.0
remote intervention,17,0,999.0
alcohol-related liver disease,48,0,999.0
coping with stress,48,0,999.0
health disparities related research,48,0,999.0
whole health,17,0,999.0
whole person health,17,0,999.0
verbal,18,0,999.0
primary care visit,18,0,999.0
transgene,18,0,999.0
fentanyl self-administration,44,0,999.0
mental wellness,19,0,999.0
reduction in disparity,45,0,999.0
mitigate disparity,45,0,999.0
lower disparity,45,0,999.0
human centered design,19,0,999.0
therapy response,215,0,999.0
under represented people,123,0,999.0
prostate malignancy,19,0,999.0
response to therapy,215,0,999.0
vulnerable individual,216,0,999.0
resilience factor,19,0,999.0
resiliency factor,19,0,999.0
after pregnancy,19,0,999.0
post pregnancy,19,0,999.0
effectiveness/implementation hybrid,19,0,999.0
cannabis use behavior,19,0,999.0
cannabis use patterns,19,0,999.0
cocaine cue,19,0,999.0
bipolar mood disorder,19,0,999.0
emotional wellness,19,0,999.0
ruminative,19,0,999.0
post-pandemic,18,0,999.0
rumination,19,0,999.0
transient receptor potential cation channel v1,20,0,999.0
self direction,20,0,999.0
medical expenses,20,0,999.0
mhealth therapeutic,20,0,999.0
mhealth therapy,20,0,999.0
mhealth treatment,20,0,999.0
mhealth interventions,20,0,999.0
mobile health intervention,20,0,999.0
mobile health therapeutic,20,0,999.0
mobile health therapy,20,0,999.0
mobile health treatment,20,0,999.0
hiv neurocognitive impairment,43,0,999.0
hiv induced neurocognitive impairment,43,0,999.0
hiv induced neurocognitive deficit,43,0,999.0
hiv associated neurocognitive impairment,43,0,999.0
african ancestry,19,0,999.0
african descent,19,0,999.0
hiv associated neurocognitive deficit,43,0,999.0
ruminate,19,0,999.0
liver malignancy,18,0,999.0
underrepresented people,123,0,999.0
decrease disparity,45,0,999.0
unequal population,45,0,999.0
inequity across groups,45,0,999.0
inequities in populations,45,0,999.0
inequities between populations,45,0,999.0
inequities among populations,45,0,999.0
inequality in groups,45,0,999.0
inequality between groups,45,0,999.0
inequality among groups,45,0,999.0
inequality across populations,45,0,999.0
inequalities in populations,45,0,999.0
inequalities between populations,45,0,999.0
inequalities among populations,45,0,999.0
group inequity,45,0,999.0
group inequality,45,0,999.0
group disparity,45,0,999.0
disparity between subgroups,45,0,999.0
fentanyl exposure,18,0,999.0
national institute of minority health and health disparities,18,0,999.0
research faculty,18,0,999.0
immunosuppressive response,18,0,999.0
inequity across populations,45,0,999.0
evaluate implementation,122,0,999.0
implementation assessment,122,0,999.0
brain magnetic resonance imaging,18,0,999.0
unequal group,45,0,999.0
subgroup disparity,45,0,999.0
population inequity,45,0,999.0
exposure to psychostimulants,18,0,999.0
exposure to stimulants,18,0,999.0
psychostimulant exposure,18,0,999.0
stimulant exposure,18,0,999.0
brain mri,18,0,999.0
cerebral mri,18,0,999.0
coronavirus disease-19 virus,18,0,999.0
cerebral magnetic resonance imaging,18,0,999.0
population inequality,45,0,999.0
inequity in groups,45,0,999.0
sars-co-v2,18,0,999.0
sars-covid-2,18,0,999.0
severe acute respiratory coronavirus 2,18,0,999.0
inequity between groups,45,0,999.0
assess implementation,122,0,999.0
community-partnered study,17,0,999.0
imaging center,16,0,999.0
web enabled platform,20,0,999.0
epigenetically,293,0,999.0
long-term sequelae of sars-cov-2,15,0,999.0
long-term sequelae of coronavirus disease 2019,15,0,999.0
long-term sequelae of severe acute respiratory syndrome coronavirus 2,15,0,999.0
diagnostic criteria,53,0,999.0
post-acute sequelae following sars-cov-2 infection,15,0,999.0
validations,295,0,999.0
post-acute sequelae of covid-19,15,0,999.0
controlled trials,296,0,999.0
post-acute sequelae of acute covid infection,15,0,999.0
post-acute sequelae of coronavirus disease 2019,15,0,999.0
practical implementation,15,0,999.0
pragmatic implementation,15,0,999.0
acute to chronic pain transition,53,0,999.0
naming,54,0,999.0
named,54,0,999.0
name,54,0,999.0
intervention delivery,54,0,999.0
reduce health disparities,54,0,999.0
mitigate health disparities,54,0,999.0
long-term sequelae of covid-19,15,0,999.0
long haul sequelae of coronavirus disease 2019,15,0,999.0
mris,250,0,999.0
long haul sequelae of covid-19,15,0,999.0
socioeconomic inequity,15,0,999.0
synergistic epidemic,53,0,999.0
syndemic,53,0,999.0
treat chronic pain,290,0,999.0
chronic pain treatment,290,0,999.0
chronic pain therapy,290,0,999.0
chronic pain intervention,290,0,999.0
chronic pain control,290,0,999.0
pasc,15,0,999.0
post acute sequelae of covid19,15,0,999.0
post acute sequelae of sars-cov-2,15,0,999.0
post acute sequelae of sars-cov2,15,0,999.0
post acute sequelae of severe acute respiratory syndrome coronavirus 2,15,0,999.0
post-acute sequelae of sars-cov-2 infection,15,0,999.0
adverse sequelae of covid,15,0,999.0
adverse sequelae of covid-19,15,0,999.0
adverse sequelae of coronavirus disease,15,0,999.0
adverse sequelae of coronavirus disease 2019,15,0,999.0
chronic covid-19 sequelae,15,0,999.0
kids,298,0,999.0
lower health disparities,54,0,999.0
health disparity reduction,54,0,999.0
daily living function,15,0,999.0
racial background,307,0,999.0
races,307,0,999.0
decrease health disparities,54,0,999.0
treatment inequity,15,0,999.0
examination questions,15,0,999.0
monoclonal abs,15,0,999.0
fentalogs,15,0,999.0
fentalogues,15,0,999.0
fentanyl analog,15,0,999.0
parent award,15,0,999.0
differences due to race,15,0,999.0
differences in race,15,0,999.0
differs by race,15,0,999.0
differs in race,15,0,999.0
race based differences,15,0,999.0
race related differences,15,0,999.0
racially different,15,0,999.0
distribute naloxone,15,0,999.0
naloxone availability,15,0,999.0
racial origin,307,0,999.0
treatment inequality,15,0,999.0
inequality in treatment,15,0,999.0
urban group,15,0,999.0
health disparity mitigation,54,0,999.0
process improvement,15,0,999.0
posttranscriptional,15,0,999.0
digital platform,15,0,999.0
mind/body,15,0,999.0
complementation analysis,15,0,999.0
complementation approach,15,0,999.0
effectiveness using,15,0,999.0
urban individual,15,0,999.0
pandemic outcome,15,0,999.0
urban people,15,0,999.0
crispr activator,15,0,999.0
crispr-dcas9 activator,15,0,999.0
crispr/dcas9 activation,15,0,999.0
crispr/dcas9-based transcriptional activation,15,0,999.0
activating crispr technology,15,0,999.0
pandemic effect,15,0,999.0
pandemic impact,15,0,999.0
socioeconomic inequality,15,0,999.0
socio-economic inequity,15,0,999.0
socio-economic inequality,15,0,999.0
sustained recovery,16,0,999.0
machine learning model,51,0,999.0
machine learning based model,51,0,999.0
diagnostic tool,16,0,999.0
hiv associated neurological disorder,51,0,999.0
hiv associated neurological disease,51,0,999.0
coronavirus disease-19 pandemic,259,0,999.0
coronavirus disease-19 global pandemic,259,0,999.0
clinical training,35,0,999.0
effectiveness/implementation design,16,0,999.0
effectiveness/implementation hybrid design,16,0,999.0
integrated system of care,16,0,999.0
postbaccalaureate,16,0,999.0
postbac,16,0,999.0
postbacc,16,0,999.0
selection of treatment,16,0,999.0
treatment selection,16,0,999.0
telemetric,16,0,999.0
genome segment,16,0,999.0
transcranial direct current stimulation,16,0,999.0
transcriptomic sequencing,255,0,999.0
delivery vehicle,16,0,999.0
delivery vector,16,0,999.0
nicotine self-administration,49,0,999.0
internalized stigma,16,0,999.0
self-stigma,16,0,999.0
lung health,16,0,999.0
pulmonary health,16,0,999.0
hepatic inflammation,16,0,999.0
inflamed liver,16,0,999.0
translation,251,0,999.0
genetic predisposing factor,49,0,999.0
cryogenic electron microscopy,49,0,999.0
chipseq,51,0,999.0
translational applications,16,0,999.0
identification of biomarkers,50,0,999.0
brain impairment,50,0,999.0
radiologic imaging,16,0,999.0
radiological imaging,16,0,999.0
crystal methamphetamine,253,0,999.0
abnormal brain function,50,0,999.0
translational investigation,254,0,999.0
autoimmunity disease,16,0,999.0
gene modified,16,0,999.0
stimulant user,15,0,999.0
biological sex as a modifier,16,0,999.0
alcohol addiction treatment,16,0,999.0
alcohol dependence treatment,16,0,999.0
american indian population,16,0,999.0
american indian group,16,0,999.0
american indian individual,16,0,999.0
american indian people,16,0,999.0
drug repositioning,16,0,999.0
randomized placebo control trial,15,0,999.0
genomic location,52,0,999.0
overdose education,15,0,999.0
risk taking,52,0,999.0
randomized control study,15,0,999.0
high risk individual,115,0,999.0
high risk people,115,0,999.0
diffusions,53,0,999.0
diffusing,53,0,999.0
diffuses,53,0,999.0
diffused,53,0,999.0
psychostimulant user,15,0,999.0
≥65 years,16,0,999.0
over 65 years,16,0,999.0
aged 65+,16,0,999.0
ineuron,16,0,999.0
sex as a biological factor,16,0,999.0
sex as a biological measure,16,0,999.0
sex as a biological risk factor,16,0,999.0
sex as a biological variable,16,0,999.0
sex as a biological variance,16,0,999.0
sex as a biologically significant variable,16,0,999.0
sex as a fundamental variable,16,0,999.0
induced neurons,16,0,999.0
age associated,16,0,999.0
age 65 or older,16,0,999.0
65 and older,16,0,999.0
65 or older,16,0,999.0
65 years of age and older,16,0,999.0
65 years of age or more,16,0,999.0
65 years of age or older,16,0,999.0
65+ years,16,0,999.0
above age 65,16,0,999.0
after age 65,16,0,999.0
electronic health,20,0,999.0
web based platform,20,0,999.0
web based system,20,0,999.0
neural inflammation,135,0,999.0
meth,164,0,999.0
self-reported discrimination,37,0,999.0
perception of discrimination,37,0,999.0
perceived discrimination,37,0,999.0
experienced discrimination,37,0,999.0
healthcare inequity,37,0,999.0
healthcare inequality,37,0,999.0
consults,29,0,999.0
smoking and dependence,29,0,999.0
health disparities science,29,0,999.0
recovery services,29,0,999.0
recovery support services,29,0,999.0
d9-tetrahydrocannabinol,29,0,999.0
vulnerable community,28,0,999.0
patient oriented outcomes,166,0,999.0
health care inequity,37,0,999.0
access disparities,28,0,999.0
accessibility disparities,28,0,999.0
disparities in access,28,0,999.0
bases,135,0,999.0
transcriptome profiling,37,0,999.0
latino individual,26,0,999.0
transcriptomic profiling,37,0,999.0
cannabis law,30,0,999.0
cannabis policy,30,0,999.0
cannabis regulation,30,0,999.0
cannabis use law,30,0,999.0
cannabis use policy,30,0,999.0
marijuana law,30,0,999.0
marijuana policy,30,0,999.0
older adulthood,30,0,999.0
nonpharmacologic intervention,30,0,999.0
nonpharmacologic approach,30,0,999.0
nonpharmacologic treatment,30,0,999.0
community advisory board,30,0,999.0
community advisory committee,30,0,999.0
community advisory panel,30,0,999.0
long term abstinence,37,0,999.0
atac sequencing,37,0,999.0
ethanol liver disease,37,0,999.0
alcohol-associated liver disease,37,0,999.0
alcohol related liver disease,37,0,999.0
inequity in access,28,0,999.0
inequity in accessibility,28,0,999.0
community partnered participatory research,28,0,999.0
health care inequality,37,0,999.0
crispr approach,169,0,999.0
increase resiliency,27,0,999.0
promote resilience,27,0,999.0
promote resiliency,27,0,999.0
primary care clinic,38,0,999.0
resilience development,27,0,999.0
prevent relapse,170,0,999.0
cocaine craving,27,0,999.0
patient subclass,27,0,999.0
patient subcluster,27,0,999.0
in vivo analysis,27,0,999.0
oxycodone self-administration,27,0,999.0
self-administer oxycodone,27,0,999.0
case-controlled,26,0,999.0
analyzing longitudinal,38,0,999.0
nccih,26,0,999.0
national center for complementary and integrative health,26,0,999.0
national center for complementary and integrative medicine,26,0,999.0
cocaine addicted,132,0,999.0
crispr based approach,169,0,999.0
increase resilience,27,0,999.0
improve resiliency,27,0,999.0
disparate,38,0,999.0
perception of stress,27,0,999.0
self-reported stress,27,0,999.0
stress perception,27,0,999.0
biological engineering,37,0,999.0
individuals of minority,38,0,999.0
individuals from minority,38,0,999.0
clustered regularly interspaced short palindromic repeats approach,169,0,999.0
community based organizations,38,0,999.0
prospective study,27,0,999.0
improve resilience,27,0,999.0
crispr/cas approach,169,0,999.0
build resilience,27,0,999.0
build resiliency,27,0,999.0
develop resilience,27,0,999.0
develop resiliency,27,0,999.0
enhance resilience,27,0,999.0
crispr tools,169,0,999.0
enhance resiliency,27,0,999.0
primary care patient,30,0,999.0
health disparity group,30,0,999.0
health disparity community,30,0,999.0
covid-19 impact,35,0,999.0
reducing risk,141,0,999.0
reducing the risk,141,0,999.0
risk-reducing,141,0,999.0
coronavirus disease-19 impact,35,0,999.0
coronavirus disease 2019 impact,35,0,999.0
data set repository,33,0,999.0
dataset repository,33,0,999.0
coronavirus disease 2019 effect,35,0,999.0
coronavirus disease 2019 consequence,35,0,999.0
shocks,33,0,999.0
marginalized background,33,0,999.0
disparity in ethnic,33,0,999.0
ethnic based disparity,33,0,999.0
ethnic inequality,33,0,999.0
ethnic inequity,33,0,999.0
cue-induced relapse,33,0,999.0
community partners,33,0,999.0
community-based partners,33,0,999.0
dissemination science,32,0,999.0
medication-assisted therapy,146,0,999.0
reduces the risk,141,0,999.0
reduces risk,141,0,999.0
reduce risk,141,0,999.0
cocaine seeking,143,0,999.0
comparable efficacy,35,0,999.0
fentanyl use,35,0,999.0
panomics,35,0,999.0
hispanic people,35,0,999.0
infusions,142,0,999.0
hispanic individual,35,0,999.0
hispanic group,35,0,999.0
reduce risks,141,0,999.0
reduce these risks,141,0,999.0
reduce that risk,141,0,999.0
resilient,145,0,999.0
ethnic disadvantage,34,0,999.0
peer recovery,34,0,999.0
long term recovery,34,0,999.0
and inclusiveness,34,0,999.0
and inclusion,34,0,999.0
reduce the risk,141,0,999.0
covid-19 impacted,35,0,999.0
covid-19 effect,35,0,999.0
pre-investigational new drug meeting,30,0,999.0
ingest,32,0,999.0
stress to minorities,31,0,999.0
cocaine withdrawal,36,0,999.0
exposure to methamphetamine,36,0,999.0
tobacco disorder,31,0,999.0
model developments,31,0,999.0
polymer,31,0,999.0
polymeric,31,0,999.0
exposure to meth,36,0,999.0
immune suppressive activity,30,0,999.0
immune suppressive function,30,0,999.0
immunosuppressive activity,30,0,999.0
immunosuppressive function,30,0,999.0
process evaluation,36,0,999.0
community care,30,0,999.0
pre ind fda meeting,30,0,999.0
pre-ind mtg,30,0,999.0
pre-ind consultation,30,0,999.0
pre-ind discussion,30,0,999.0
pre-ind meeting,30,0,999.0
electronic medical health record,138,0,999.0
stress in minorities,31,0,999.0
stress among minorities,31,0,999.0
national institute on minority health and health disparities,31,0,999.0
cocaine behavior,32,0,999.0
cocaine motivated behaviors,32,0,999.0
cocaine related behaviors,32,0,999.0
cocaine-associated behaviors,32,0,999.0
covid-19 consequence,35,0,999.0
covid-19 affected,35,0,999.0
asian,35,0,999.0
nimhd,31,0,999.0
wearables,36,0,999.0
minority stress,31,0,999.0
wearable tool,36,0,999.0
neuropathological,36,0,999.0
neuropathologic,36,0,999.0
data representations,36,0,999.0
rat transgene,36,0,999.0
electronic health medical record,138,0,999.0
electronic health plan record,138,0,999.0
electronic health registry,138,0,999.0
latino group,26,0,999.0
latino people,26,0,999.0
naloxone dispensation,15,0,999.0
reach efficacy adoption implementation and maintenance,21,0,999.0
translational mission,21,0,999.0
multimodal neuro-imaging,41,0,999.0
multi-modal neuroimaging,41,0,999.0
double-blind placebo control trial,21,0,999.0
multi-modal neuro-imaging,41,0,999.0
minority stresses,21,0,999.0
minority stressor,21,0,999.0
medication for opioid use disorder,197,0,999.0
sexual minority group,21,0,999.0
sexual minority individual,21,0,999.0
sexual minority people,21,0,999.0
sexual minority population,21,0,999.0
sexual activities,21,0,999.0
men having sex with men,21,0,999.0
cohort study,21,0,999.0
efficacy determination,198,0,999.0
determine efficacy,198,0,999.0
data acquisitions,21,0,999.0
deep learning method,21,0,999.0
translational goal,21,0,999.0
reach effectiveness adoption implementation and maintenance,21,0,999.0
latinos,26,0,999.0
inhibitor therapy,21,0,999.0
improved functional outcomes,22,0,999.0
smoking treatment,22,0,999.0
smoking therapy,22,0,999.0
identification of new biomarkers,22,0,999.0
single nucleus seq,41,0,999.0
single-nucleus sequencing,41,0,999.0
machine based learning,191,0,999.0
graduate school,41,0,999.0
coronavirus infectious disease-19,191,0,999.0
coronavirus disease-19,191,0,999.0
customs,41,0,999.0
economic assessment,41,0,999.0
structural factors,41,0,999.0
structural determinants,41,0,999.0
equity,193,0,999.0
cocaine use disorder,193,0,999.0
multimodal neuroimaging,41,0,999.0
inhibitor drug,21,0,999.0
inhibitor therapeutic,21,0,999.0
deep learning strategy,21,0,999.0
gene biomarker,21,0,999.0
gene expression biomarker,21,0,999.0
gene marker,21,0,999.0
crispr transcriptional activation,20,0,999.0
crispr-cas-9-mediated gene activation,20,0,999.0
crispr-based gene activation,20,0,999.0
crispr-mediated transcriptional activation,20,0,999.0
crispr/cas9 activation,20,0,999.0
crispr/cas9 gene activation,20,0,999.0
crispra,20,0,999.0
pain measure,43,0,999.0
pilot test,204,0,999.0
autism spectral disorder,43,0,999.0
asd,43,0,999.0
neurocognitive impairment in hiv-1,43,0,999.0
neurocognitive impairment in hiv,43,0,999.0
hiv-1 associated neurocognitive impairment,43,0,999.0
hiv-1 associated neurocognitive deficit,43,0,999.0
fentanyl seeking,20,0,999.0
technology platform,20,0,999.0
technology system,20,0,999.0
internet based platform,20,0,999.0
crispr transcription activation,20,0,999.0
crispr gene activation,20,0,999.0
crispr based activation,20,0,999.0
new treatment strategy,200,0,999.0
gene signature biomarker,21,0,999.0
assay for transposase-accessible chromatin using sequencing,21,0,999.0
assay for transposase accessible chromatin followed by sequencing,21,0,999.0
assay for transposase accessible chromatin seq,21,0,999.0
assay for transposase accessible chromatin sequencing,21,0,999.0
assay for transposase-accessible chromatin with sequencing,21,0,999.0
minority female,20,0,999.0
minority women,20,0,999.0
new treatment approach,200,0,999.0
crispr activation,20,0,999.0
weights,42,0,999.0
rural individual,42,0,999.0
rural people,42,0,999.0
rural group,42,0,999.0
enzyme linked immunoassay,42,0,999.0
neighborhood barrier,20,0,999.0
neighborhood-level barrier,20,0,999.0
neighborhood-level disadvantage,20,0,999.0
improve function,22,0,999.0
snrna sequencing,41,0,999.0
biologically based therapeutics,22,0,999.0
group of color,24,0,999.0
predicts risk,39,0,999.0
predictive risk,39,0,999.0
predicting risks,39,0,999.0
predicted risks,39,0,999.0
predicted risk,39,0,999.0
predict risks,39,0,999.0
predict risk,39,0,999.0
predicting risk,39,0,999.0
hands,39,0,999.0
infection by hepatitis c virus,39,0,999.0
poor health outcome,25,0,999.0
reduced health outcome,25,0,999.0
worse health outcome,25,0,999.0
intuitive,25,0,999.0
cocaine reward,25,0,999.0
community factor,24,0,999.0
community-level factor,24,0,999.0
minority health disparity,24,0,999.0
integrated model of care,40,0,999.0
gemm model,25,0,999.0
risk predictions,39,0,999.0
e-stim,26,0,999.0
adolescent minority,26,0,999.0
gender minority group,26,0,999.0
gender minority individual,26,0,999.0
gender minority people,26,0,999.0
gender minority population,26,0,999.0
reverse overdose,38,0,999.0
overdose reversal,38,0,999.0
naturally occurring product,39,0,999.0
care as usual,173,0,999.0
minority children,26,0,999.0
effectiveness/implementation study,26,0,999.0
minority youth,26,0,999.0
pediatric minority,26,0,999.0
young minority,26,0,999.0
addiction potential,173,0,999.0
addiction liability,173,0,999.0
personalized health intervention,26,0,999.0
implementation/effectiveness,26,0,999.0
effectiveness/implementation hybrid study,26,0,999.0
integrated care,40,0,999.0
individual of color,24,0,999.0
single cell transcriptomic profiling,129,0,999.0
person of color,24,0,999.0
women vs men,24,0,999.0
community marginalization,23,0,999.0
marginalized community,23,0,999.0
randomized control clinical trial,23,0,999.0
clinical practice and guidelines,23,0,999.0
neurodevelopmental disease,23,0,999.0
research and methods,187,0,999.0
radiolabels,23,0,999.0
wearable,23,0,999.0
pain-related outcome,23,0,999.0
covid-19 pandemic affected,22,0,999.0
covid-19 pandemic consequence,22,0,999.0
covid-19 pandemic effects,22,0,999.0
covid-19 pandemic impact,22,0,999.0
covid-19 pandemic impacted,22,0,999.0
coronavirus disease 2019 pandemic consequence,22,0,999.0
coronavirus disease 2019 pandemic impact,22,0,999.0
effects following the covid-19 pandemic,22,0,999.0
single cell expression profiling,129,0,999.0
women versus men,24,0,999.0
women compared with men,24,0,999.0
women compared to men,24,0,999.0
research associates,185,0,999.0
population of color,24,0,999.0
disabling pain,24,0,999.0
pain-related disability,24,0,999.0
latinx group,24,0,999.0
latinx individual,24,0,999.0
latinx people,24,0,999.0
latinx population,24,0,999.0
examine effectiveness,185,0,999.0
post-doctoral trainee,185,0,999.0
females vs males,24,0,999.0
patient retention,24,0,999.0
treatment and outcome,24,0,999.0
age years,24,0,999.0
comparing females and males,24,0,999.0
comparing women and men,24,0,999.0
females compared to males,24,0,999.0
females compared with males,24,0,999.0
females versus males,24,0,999.0
naloxone dispensary,15,0,999.0
neuroprotective,35,0,999.0
latine,55,0,999.0
scale up production,12,0,999.0
social cultural factor,12,0,999.0
social culture determinant,12,0,999.0
sociocultural determinant,12,0,999.0
sociocultural factor,12,0,999.0
program sustainment,12,0,999.0
fetal reduction,12,0,999.0
multifetal pregnancy reduction,12,0,999.0
selective fetal terminations,12,0,999.0
drug-like chemical,12,0,999.0
drug-like compound,12,0,999.0
drug-like molecule,12,0,999.0
seizure drug,12,0,999.0
seizure medication,12,0,999.0
sexually acquired infection,12,0,999.0
tribal governance,12,0,999.0
upscale manufacturing,12,0,999.0
scale up batch,12,0,999.0
tribal self-governance,12,0,999.0
manufacturing ramp-up,12,0,999.0
post implementation,12,0,999.0
alcohol tobacco and other drug,12,0,999.0
alcohol tobacco or other drug,12,0,999.0
race based disparity,72,0,999.0
inequity due to race,72,0,999.0
inequality due to race,72,0,999.0
neurological imaging,508,0,999.0
disparity due to race,72,0,999.0
snrna-seq,72,0,999.0
psychostimulant misuse,12,0,999.0
single-nucleus rna-seq,72,0,999.0
analyze gene expression,55,0,999.0
compare cost,12,0,999.0
cost comparison,12,0,999.0
commercial scale manufacturing,12,0,999.0
tribal government,12,0,999.0
culturally adapted intervention,12,0,999.0
translational opportunities,62,0,999.0
asian individual,11,0,999.0
asian population,11,0,999.0
conformations,76,0,999.0
conformationally,76,0,999.0
african american group,104,0,999.0
african american individual,104,0,999.0
african american people,104,0,999.0
african american population,104,0,999.0
african americans,104,0,999.0
conformational,76,0,999.0
coping strategy,76,0,999.0
future implementation,76,0,999.0
mental healthcare,76,0,999.0
mental health care,76,0,999.0
facilitators to implementation,76,0,999.0
self administered,600,0,999.0
asian people,11,0,999.0
asian group,11,0,999.0
culturally appropriate intervention,12,0,999.0
statistic methods,75,0,999.0
culturally centered intervention,12,0,999.0
culturally focused intervention,12,0,999.0
culturally informed intervention,12,0,999.0
culturally responsive intervention,12,0,999.0
culturally tailored intervention,12,0,999.0
antagonist,542,0,999.0
placebo control trial,11,0,999.0
native hawaiian and other pacific islander,11,0,999.0
native hawaiian and pacific islander,11,0,999.0
native hawaiian or pacific islander,11,0,999.0
ethnoracial disparities,11,0,999.0
snuc-seq,72,0,999.0
consultation,74,0,999.0
cannabinoid type 1,74,0,999.0
incomes,75,0,999.0
race based inequality,72,0,999.0
race based inequity,72,0,999.0
race related disparity,72,0,999.0
two arm randomized control trial,13,0,999.0
castration resistant cap,13,0,999.0
alcohol associated hepatitis,13,0,999.0
alcohol hepatitis,13,0,999.0
alcohol induced hepatitis,13,0,999.0
alcohol related hepatitis,13,0,999.0
limited intellectual functioning,13,0,999.0
shareable platform,13,0,999.0
mechanic,108,0,999.0
european ancestry,13,0,999.0
age months,13,0,999.0
digital technology,13,0,999.0
cannabis addiction,13,0,999.0
hospital care,13,0,999.0
psilocibin,13,0,999.0
psilocybin,13,0,999.0
two arm randomized controlled trial,13,0,999.0
two arm rct,13,0,999.0
race related inequality,72,0,999.0
2 arm randomized controlled trial,13,0,999.0
marginalized people,62,0,999.0
marginalized individual,62,0,999.0
marginalized group,62,0,999.0
strokes,63,0,999.0
stroked,63,0,999.0
psychostimulant use disorder,108,0,999.0
bone fracture healing,13,0,999.0
bone fracture repair,13,0,999.0
fracture repair,13,0,999.0
integrated system,13,0,999.0
system integration,13,0,999.0
good manufacturing process,13,0,999.0
good manufacturing practice,13,0,999.0
2 arm rct,13,0,999.0
2 arm randomized control trial,13,0,999.0
community level intervention,13,0,999.0
community-based intervention,13,0,999.0
collaboration with communities,13,0,999.0
community collaboration,13,0,999.0
software toolkit,12,0,999.0
randomized control trial,454,0,999.0
black group,67,0,999.0
diversity,68,0,999.0
hypertensive disorder,68,0,999.0
mechanical stimulus,12,0,999.0
recovery support,106,0,999.0
sustained abstinence,70,0,999.0
prolonged abstinence,70,0,999.0
histories,459,0,999.0
persons at risk,71,0,999.0
people at risk,71,0,999.0
groups at risk,71,0,999.0
treatment responsiveness,72,0,999.0
race related inequity,72,0,999.0
black individual,67,0,999.0
black people,67,0,999.0
new pharmacological therapeutic,449,0,999.0
stressful life experience,65,0,999.0
community-based collaboration,13,0,999.0
single cell seq,13,0,999.0
single cell next generation sequencing,13,0,999.0
coronavirus infectious disease 2019,65,0,999.0
racial subgroup,65,0,999.0
ethanol dependent,65,0,999.0
stressful life event,65,0,999.0
novel pharmaco-therapeutic,449,0,999.0
stressful experience,65,0,999.0
remote evaluation,66,0,999.0
remote assessment,66,0,999.0
machine learning based algorithm,66,0,999.0
blacks,67,0,999.0
novel pharmacological therapeutic,449,0,999.0
rational design,77,0,999.0
cocaine-addicted,103,0,999.0
underserved individual,78,0,999.0
operations,93,0,999.0
patient prognosis,10,0,999.0
use of stimulants,95,0,999.0
psychostimulant use,95,0,999.0
hispanic,95,0,999.0
social contact,10,0,999.0
ostracism,10,0,999.0
ostracize,10,0,999.0
peer exclusion,10,0,999.0
lgb,10,0,999.0
lesbian gay bi-sexual,10,0,999.0
lesbian gay bisexual,10,0,999.0
pulmonary damage,10,0,999.0
pulmonary injury,10,0,999.0
pulmonary tissue damage,10,0,999.0
pulmonary tissue injury,10,0,999.0
translational potential,94,0,999.0
barriers to implementation,92,0,999.0
front line staff,10,0,999.0
stress during the pandemic,10,0,999.0
frontline employee,10,0,999.0
frontline person,10,0,999.0
frontline personnel,10,0,999.0
frontline staff,10,0,999.0
frontline worker,10,0,999.0
transfer learning,10,0,999.0
ethnic individual,90,0,999.0
psychiatric comorbidity,91,0,999.0
substance use and disorder,1009,0,999.0
psychiatric co-morbidity,91,0,999.0
pandemic associated stress,10,0,999.0
pandemic induced stress,10,0,999.0
pandemic related stress,10,0,999.0
pandemic stress,10,0,999.0
stress due to pandemic,10,0,999.0
alzheimer disease dementia,97,0,999.0
pain-sensing somatosensory neurons,97,0,999.0
pain-sensing sensory neurons,97,0,999.0
pain-sensing neurons,97,0,999.0
ehr system,10,0,999.0
electronic health record system,10,0,999.0
incremental cost,10,0,999.0
disparate effect,10,0,999.0
disparate impact,10,0,999.0
disparate result,10,0,999.0
inequitable effect,10,0,999.0
inequitable impact,10,0,999.0
inequitable outcome,10,0,999.0
outcome disparities,10,0,999.0
outcome inequality,10,0,999.0
outcome inequity,10,0,999.0
unequal effect,10,0,999.0
unequal impact,10,0,999.0
unequal outcome,10,0,999.0
new chemical entity,10,0,999.0
bench to clinical practice,10,0,999.0
structural imaging,10,0,999.0
web based app,10,0,999.0
nociceptive neurons,97,0,999.0
covid-19 years,99,0,999.0
covid-19 period,99,0,999.0
precancer,10,0,999.0
covid-19 era,99,0,999.0
online app,10,0,999.0
web based application,10,0,999.0
test for fentanyl,10,0,999.0
policy evaluation,10,0,999.0
superresolution microscopy,10,0,999.0
patient navigation,10,0,999.0
minority researcher,10,0,999.0
vocation,10,0,999.0
fentanyl test,10,0,999.0
front line worker,10,0,999.0
front line personnel,10,0,999.0
under served individual,78,0,999.0
super high resolution,11,0,999.0
low income group,11,0,999.0
low income individual,11,0,999.0
low income people,11,0,999.0
and sustainability,11,0,999.0
brain mr imaging,11,0,999.0
cerebral mr imaging,11,0,999.0
cellular therapeutic,11,0,999.0
animal experiment,11,0,999.0
experimental animal,11,0,999.0
experimental animals,11,0,999.0
function socially,11,0,999.0
functioning social,11,0,999.0
female treatment,11,0,999.0
treat females,11,0,999.0
treat women,11,0,999.0
superresolution,11,0,999.0
alcohol memory,11,0,999.0
front line person,10,0,999.0
ses disparity,11,0,999.0
ethical legal and social,11,0,999.0
migraine therapy,11,0,999.0
migraine treatment,11,0,999.0
meth use disorder,78,0,999.0
methamphetamine use disorder,78,0,999.0
data-driven model,11,0,999.0
complementation,80,0,999.0
suicides,82,0,999.0
end stage liver disease,11,0,999.0
end stage liver failure,11,0,999.0
antinociceptive,84,0,999.0
antinociception,84,0,999.0
excitotoxic,11,0,999.0
chronic and inflammatory pain,11,0,999.0
pack/year,11,0,999.0
treatment among females,11,0,999.0
treatment among women,11,0,999.0
treatment in females,11,0,999.0
treatment in women,11,0,999.0
racially unequal,86,0,999.0
racial inequity,86,0,999.0
racial inequality,86,0,999.0
comparison control,87,0,999.0
compare to control,87,0,999.0
cocaine misuse,10,0,999.0
data management center,88,0,999.0
data management and coordinating center,88,0,999.0
reduction in overdose,89,0,999.0
reduce overdose,89,0,999.0
implementation context,10,0,999.0
machine learning based classifier,10,0,999.0
machine learning classifier,10,0,999.0
overdose reduction,89,0,999.0
front line employee,10,0,999.0
cell cultures,85,0,999.0
inducible pluripotent stem cell,84,0,999.0
alcohol tobacco and other drug use,10,0,999.0
human induced pluripotent cell,11,0,999.0
women's treatment,11,0,999.0
65>age of 65 years onward,11,0,999.0
hipsc,11,0,999.0
human ips,11,0,999.0
pharmacologic,768,0,999.0
human ipsc,11,0,999.0
human induced pluripotent stem cells,11,0,999.0
disabling,11,0,999.0
human inducible stem cells,11,0,999.0
induced human pluripotent stem cells,11,0,999.0
technology intervention,11,0,999.0
technology-based interventions,11,0,999.0
technology-enabled interventions,11,0,999.0
technology-focused interventions,11,0,999.0
marijuana use and disorder,62,0,999.0
single nucleus rna-sequencing,72,0,999.0
attenuate,364,0,999.0
radiation or chemotherapy,14,0,999.0
addiction to stimulants,56,0,999.0
periodical,14,0,999.0
chimeras,14,0,999.0
translational therapy,13,0,999.0
antagonism,358,0,999.0
alcohol dependent,352,0,999.0
all of us program,14,0,999.0
induced pluripotent cell,56,0,999.0
health and care delivery,61,0,999.0
periodic,14,0,999.0
attenuates,364,0,999.0
resource-constrained setting,61,0,999.0
resource-constrained region,61,0,999.0
advertisement,14,0,999.0
digital tool,14,0,999.0
cell phone based app,56,0,999.0
animal experimentations,14,0,999.0
smartphone based application,56,0,999.0
measurable outcome,113,0,999.0
outcome measurement,113,0,999.0
biologics,61,0,999.0
low-resource area,61,0,999.0
inequity,56,0,999.0
low-resource community,61,0,999.0
health determinants,14,0,999.0
chemo/radiation therapy,14,0,999.0
smartphone based app,56,0,999.0
mobile phone app,56,0,999.0
low-resource environment,61,0,999.0
chemotherapy and radiotherapy,14,0,999.0
evaluate cost,60,0,999.0
low-resource region,61,0,999.0
translational therapeutics,13,0,999.0
physical distancing,14,0,999.0
addiction to psychostimulants,56,0,999.0
ethnic minority individual,59,0,999.0
aourp,14,0,999.0
resolutions,339,0,999.0
resource-poor region,61,0,999.0
resource-constrained community,61,0,999.0
resource-poor environment,61,0,999.0
benchmark,59,0,999.0
mortality rate,59,0,999.0
return to use,14,0,999.0
mortality ratio,59,0,999.0
resource-poor community,61,0,999.0
resource-poor area,61,0,999.0
resource-constrained environment,61,0,999.0
resource-limited setting,61,0,999.0
ethnic minority people,59,0,999.0
race-related discrimination,14,0,999.0
care for patients,58,0,999.0
discrimination due to race,14,0,999.0
discrimination based on race,14,0,999.0
resource-constrained area,61,0,999.0
care of patients,58,0,999.0
resource-poor setting,61,0,999.0
ethnic minority group,59,0,999.0
low-resource setting,61,0,999.0
caring for patients,58,0,999.0
examine cost,60,0,999.0
all of us research project,14,0,999.0
all of us research program,14,0,999.0
maladaptive behavior,109,0,999.0
inequality in access,14,0,999.0
social influence,57,0,999.0
neural imaging,338,0,999.0
machine learning based method,60,0,999.0
redshift,14,0,999.0
cognitive treatment,56,0,999.0
pediatric health care provider,14,0,999.0
abuse potential,319,0,999.0
abuse liability,319,0,999.0
computational toolset,15,0,999.0
cellular therapy,13,0,999.0
pediatric care provider,14,0,999.0
resource-limited community,61,0,999.0
pediatric healthcare provider,14,0,999.0
risk predictors,14,0,999.0
national center for advancing translational sciences,55,0,999.0
md students,14,0,999.0
resource-limited area,61,0,999.0
ncats,55,0,999.0
cell-based therapeutic,13,0,999.0
pediatric provider,14,0,999.0
debilitating pain,13,0,999.0
computational toolbox,15,0,999.0
xtandi,13,0,999.0
cost evaluation,60,0,999.0
self-administer cocaine,318,0,999.0
computational toolkit,15,0,999.0
alaska native population,15,0,999.0
enzalutamide,13,0,999.0
alaska native people,15,0,999.0
child healthcare provider,14,0,999.0
alaska native individual,15,0,999.0
alaska native group,15,0,999.0
child health care provider,14,0,999.0
provide naloxone,15,0,999.0
naloxone provision,15,0,999.0
naloxone distribution,15,0,999.0
naloxone dispensing,15,0,999.0
risk predictor,14,0,999.0
vulnerable people,327,0,999.0
research in minorities,14,0,999.0
minority health research,14,0,999.0
ethnic subgroup,62,0,999.0
meeting,333,0,999.0
research with minorities,14,0,999.0
research related to minorities,14,0,999.0
research on minorities,14,0,999.0
minority research,14,0,999.0
engagement with communities,59,0,999.0
resource-limited region,61,0,999.0
resource-limited environment,61,0,999.0
racial population,67,1,826.33
black race,163,4,502.58
patient enrollment,60,2,370.0
participant enrollment,60,2,370.0
people of color,41,2,252.83
implementation evaluation,122,6,250.78
evaluation of implementation,122,6,250.78
intra-uterine growth,19,1,234.33
dryness,18,1,222.0
racial equity,17,1,209.67
clinically translatable,61,4,188.08
service engagement,13,1,160.33
access restrictions,13,1,160.33
focused ultrasound ablation,12,1,148.0
cis-gender,12,1,148.0
lesbian gay bisexual transgender queer,12,1,148.0
muscarinic 1,12,1,148.0
cisgender,12,1,148.0
lgbtq,12,1,148.0
lesbian gay bi-sexual transgender queer,12,1,148.0
focused ultrasound treatment,12,1,148.0
hate crimes,11,1,135.67
aggressive breast cancer,11,1,135.67
service uptake,11,1,135.67
implementation facilitators,76,7,133.9
fhir,10,1,123.33
osteopathic medicine,10,1,123.33
osteopathy,10,1,123.33
estrogen receptor 1,10,1,123.33
fast healthcare interoperability resources,10,1,123.33
economic,167,17,121.16
small molecular inhibitor,29,3,119.22
predict responsiveness,18,2,111.0
prenatal alcohol consumption,18,2,111.0
alcohol during pregnancy,18,2,111.0
alcohol intake during pregnancy,18,2,111.0
bipoc,17,2,104.83
improvement on sleep,33,4,101.75
sleep improvement,33,4,101.75
intervention refinement,41,5,101.13
data ecosystem,24,3,98.67
data sharing ecosystem,24,3,98.67
marginalized population,62,8,95.58
genetically modified,15,2,92.5
mendelian randomization,15,2,92.5
exploration,22,3,90.44
efficacious intervention,29,4,89.42
remote delivery,43,6,88.39
delivered remotely,43,6,88.39
entrepreneurship,14,2,86.33
hyaluronic acid,14,2,86.33
cutaneous tissue,14,2,86.33
economic disparity,14,2,86.33
entrepreneurial skill,14,2,86.33
recovery following surgery,14,2,86.33
postoperative recovery,14,2,86.33
post-operative recovery,14,2,86.33
recovery after surgery,14,2,86.33
bloodbrain barrier crossing,26,4,80.17
fentanyl overdose,26,4,80.17
stakeholder insights,26,4,80.17
stakeholder perspectives,26,4,80.17
black female,13,2,80.17
black women,13,2,80.17
bbb crossing,26,4,80.17
blood-brain barrier crossing,26,4,80.17
delivered virtually,13,2,80.17
virtual delivery,13,2,80.17
severe acute respiratory syndrome cov 2 epidemic,259,42,76.06
sars-coronavirus-2 epidemic,259,42,76.06
coronavirus disease 2019 public health crisis,259,42,76.06
coronavirus disease crisis,259,42,76.06
severe acute respiratory syndrome coronavirus 2 global pandemic,259,42,76.06
sars-coronavirus-2 pandemic,259,42,76.06
severe acute respiratory syndrome coronavirus 2 global health crisis,259,42,76.06
coronavirus disease 2019 health crisis,259,42,76.06
coronavirus disease epidemic,259,42,76.06
severe acute respiratory syndrome cov 2 pandemic,259,42,76.06
coronavirus disease pandemic,259,42,76.06
severe acute respiratory syndrome coronavirus 2 epidemic,259,42,76.06
sars-cov-2 global pandemic,259,42,76.06
coronavirus disease 2019 global pandemic,259,42,76.06
coronavirus disease 2019 global health crisis,259,42,76.06
coronavirus disease 2019 crisis,259,42,76.06
severe acute respiratory syndrome coronavirus 2 pandemic,259,42,76.06
sars-cov-2 pandemic,259,42,76.06
covid crisis,259,42,76.06
sars-cov-2 global health crisis,259,42,76.06
covid-19 global pandemic,259,42,76.06
covid pandemic,259,42,76.06
covid-19 crisis,259,42,76.06
covid-19 global health crisis,259,42,76.06
covid epidemic,259,42,76.06
covid-19 health crisis,259,42,76.06
covid-19 public health crisis,259,42,76.06
sars-cov-2 epidemic,259,42,76.06
health inequity,67,11,75.12
inequalities in health,67,11,75.12
inequities in health,67,11,75.12
online intervention,12,2,74.0
salivary sample,12,2,74.0
saliva sample,12,2,74.0
immunologic surveillance,12,2,74.0
immunologic surveillances,12,2,74.0
immunological surveillance,12,2,74.0
immunological surveillances,12,2,74.0
glycosaminoglycans,12,2,74.0
mucopolysaccharides,12,2,74.0
high-intensity focused ultrasound,12,2,74.0
structural racism,90,15,74.0
immune surveillance,12,2,74.0
immersive virtual reality,23,4,70.92
immersive virtual environment,23,4,70.92
immersive environment,23,4,70.92
immersive digital environment,23,4,70.92
virtual reality environment,23,4,70.92
health disparity populations,40,7,70.48
environmental hazards,68,12,69.89
native hawaiian or other pacific islander,11,2,67.83
tyrosine-protein kinase jak1,11,2,67.83
jak1 kinase,11,2,67.83
searchable data base,11,2,67.83
searchable database,11,2,67.83
jak1 protein,11,2,67.83
janus kinase 1,11,2,67.83
black patient,11,2,67.83
old age,33,6,67.83
polydrug use,27,5,66.6
multidrug use,27,5,66.6
poly drug use,27,5,66.6
chronic pain transition,53,10,65.37
pain chronification,53,10,65.37
multidimensional datasets,53,10,65.37
transition to chronic pain,53,10,65.37
biologic,890,168,65.34
test strip,21,4,64.75
digital intervention,36,7,63.43
cranial nerves,10,2,61.67
rapid test,10,2,61.67
volatilization,10,2,61.67
text intervention,10,2,61.67
text based intervention,10,2,61.67
rapid assay,10,2,61.67
racial bias,10,2,61.67
neonatal health,20,4,61.67
rapid tests,10,2,61.67
tobacco flavor,25,5,61.67
morphogenic factors,10,2,61.67
race bias,10,2,61.67
alcohol risk reduction,10,2,61.67
text messaging intervention,10,2,61.67
social disadvantage,15,3,61.67
biopsychosocial variable,10,2,61.67
biopsychosocial factor,10,2,61.67
differentiation factors,10,2,61.67
knowledge integration,10,2,61.67
feasibility testing,125,25,61.67
disparate healthcare,10,2,61.67
cellular stress response,10,2,61.67
disparate health care,10,2,61.67
newborn health,20,4,61.67
implementation challenges,92,19,59.72
implementation barriers,92,19,59.72
recreation,87,18,59.61
latinx,72,15,59.2
implementation intervention,72,15,59.2
hybrid type 1 design,24,5,59.2
hybrid type 1 factorial design,24,5,59.2
hybrid type i design,24,5,59.2
disadvantaged background,48,10,59.2
polysubstance use,129,27,58.93
poly substance use,129,27,58.93
multisubstance use,129,27,58.93
multiple substance use,129,27,58.93
risk prediction,52,11,58.3
forecasting risk,52,11,58.3
re-aim,94,20,57.97
community engagement,136,29,57.84
b-cell antigen receptor,14,3,57.56
transplant centers,14,3,57.56
participant engagement,112,24,57.56
pregnancy associated death,14,3,57.56
pancreatic ductal adenocarcinoma cell,14,3,57.56
pdac cell,14,3,57.56
pregnancy associated mortality,14,3,57.56
pdac cancer cell,14,3,57.56
12-methoxy-ibogamine,14,3,57.56
efficacy analysis,279,60,57.35
evaluate efficacy,279,60,57.35
examine efficacy,279,60,57.35
efficacy assessment,279,60,57.35
efficacy examination,279,60,57.35
helping end addiction long-term,595,130,56.45
heal initiative,595,130,56.45
helping end addiction longterm,595,130,56.45
helping to end addiction long-term,595,130,56.45
helping to end addiction longterm,595,130,56.45
chemoresistance,27,6,55.5
chemotherapy resistance,27,6,55.5
chemotherapy resistant,27,6,55.5
chemoresistant,27,6,55.5
multidimensional data,53,12,54.47
high dimensional data,53,12,54.47
effectiveness-related outcomes,44,10,54.27
effectiveness outcome,44,10,54.27
data streams,13,3,53.44
remote monitoring,13,3,53.44
head/neck cancer,13,3,53.44
safety assessment,52,12,53.44
cell mediated therapies,13,3,53.44
bmi,26,6,53.44
fracture healing,13,3,53.44
chronic pain management,290,67,53.38
cigarette craving,30,7,52.86
lymphatic cell,17,4,52.42
cv-19,191,45,52.35
under served community,55,13,52.18
underserved community,55,13,52.18
urban environment,25,6,51.39
traffic crash,25,6,51.39
traffic collision,25,6,51.39
data infrastructure,37,9,50.7
transcriptional profile,142,35,50.04
stratify risk,20,5,49.33
on-line delivery,12,3,49.33
noninvasive brain stimulation,44,11,49.33
non-invasive brain stimulation,44,11,49.33
publicly available repository,16,4,49.33
online delivery,12,3,49.33
publicly accessible repository,16,4,49.33
delivered online,12,3,49.33
delivered on-line,12,3,49.33
rural under served,12,3,49.33
nerve damage,12,3,49.33
implementation tool,12,3,49.33
health equity,133,34,48.25
implementation,168,43,48.19
xenotransplant model,39,10,48.1
xenograft transplant model,39,10,48.1
wearable biosensor,35,9,47.96
national center on minority health and health disparities,31,8,47.79
ncmhd,31,8,47.79
fetal substance exposure,27,7,47.57
prenatal substance exposure,27,7,47.57
tissue repository,27,7,47.57
implementation outcomes,115,30,47.28
covid19 public health crisis,160,42,46.98
covid19 health crisis,160,42,46.98
sars-cov2 pandemic,160,42,46.98
covid19 crisis,160,42,46.98
covid19 global pandemic,160,42,46.98
sars-cov2 epidemic,160,42,46.98
covid19 global health crisis,160,42,46.98
nicotine treatment,38,10,46.87
detection limit,19,5,46.87
consolidated framework for implementing change,98,26,46.49
consolidated framework for implementation science,98,26,46.49
consolidated framework for implementation research,98,26,46.49
wound resolution,15,4,46.25
dedications,180,48,46.25
prebotzinger complex,15,4,46.25
socio-economic disparity,15,4,46.25
health inequalities,67,18,45.91
overdose fatalities,528,143,45.54
acceleration,372,101,45.43
social stresses,11,3,45.22
igif gene,11,3,45.22
ifn-gamma-inducing factor gene,11,3,45.22
il-18 gene,11,3,45.22
implementation science framework,77,21,45.22
acceptability and feasibility,242,66,45.22
implementation research framework,77,21,45.22
il-1 gamma gene,11,3,45.22
implementation framework,77,21,45.22
il-1g gene,11,3,45.22
interleukin-1 gamma gene,11,3,45.22
and sustainment,11,3,45.22
military service,11,3,45.22
mgc12320 gene,11,3,45.22
il18,11,3,45.22
implementation research design,11,3,45.22
implementation design,11,3,45.22
interleukin-18 precursor gene,11,3,45.22
interleukin 18 proprotein gene,11,3,45.22
il1f4 gene,11,3,45.22
il18 gene,11,3,45.22
interferon-gamma-inducing factor gene,11,3,45.22
interleukin 18 (interferon-gamma-inducing factor) gene,11,3,45.22
and maintenance,146,40,45.02
reach,146,40,45.02
efficacy,73,20,45.02
covid-19 pandemic,259,71,44.99
covid-19 epidemic,259,71,44.99
coronavirus disease 2019 epidemic,259,71,44.99
coronavirus disease 2019 pandemic,259,71,44.99
catalog,51,14,44.93
under represented groups,123,34,44.62
under represented populations,123,34,44.62
underrepresentation of groups,123,34,44.62
under representation of groups,123,34,44.62
ethnicity disparity,36,10,44.4
tobacco product advertising,18,5,44.4
driver lesion,18,5,44.4
fair guiding principles,18,5,44.4
interoperable and re-usable,18,5,44.4
prenatal drinking,18,5,44.4
ethnic disparity,36,10,44.4
prenatal alcohol use,18,5,44.4
pharmaceutical,124,35,43.7
multiphoton excitation microscopy,14,4,43.17
multiphoton microscopy,14,4,43.17
intervention mapping,14,4,43.17
bone tissue formation,14,4,43.17
periodicals,14,4,43.17
mφ,101,29,42.95
strategies for implementation,169,49,42.54
multiomics,79,23,42.36
intersectionalities,24,7,42.29
patient derived xenograft model,82,24,42.14
pdx model,82,24,42.14
patient derived xenograft,82,24,42.14
implementation investment,34,10,41.93
implementation cost,34,10,41.93
chemotherapy and/or radiation,17,5,41.93
comparative effectiveness study,17,5,41.93
chemotherapy and radiation,17,5,41.93
efficacy outcomes,17,5,41.93
web-based intervention,17,5,41.93
internet-based intervention,17,5,41.93
community-based health,61,18,41.8
healthcare disparity,37,11,41.48
disparity in healthcare,37,11,41.48
disparity in care,37,11,41.48
health care disparity,37,11,41.48
veterans affairs,94,28,41.4
novel therapeutic strategies,304,91,41.2
job loss,10,3,41.11
bacteria pathogen,10,3,41.11
quasi-experimental analysis,40,12,41.11
effectiveness assessment,270,81,41.11
determine effectiveness,270,81,41.11
quasi-experimental approach,40,12,41.11
quasi-experiment,40,12,41.11
assess effectiveness,270,81,41.11
clinical outcome assessment,10,3,41.11
quasi-experimental research,40,12,41.11
quasi-experimental design,40,12,41.11
quasi-experimental methods,40,12,41.11
decentralization,10,3,41.11
provider behavior,20,6,41.11
physician behavior,20,6,41.11
clinician behavior,20,6,41.11
pain scale,10,3,41.11
quasi-experimental technique,40,12,41.11
quasi-experimental study,40,12,41.11
dissemination strategy,20,6,41.11
substance use treatment,386,116,41.04
military population,66,20,40.7
pain after surgery,132,40,40.7
degree program,23,7,40.52
combustible tobacco,46,14,40.52
prescription pain medication,36,11,40.36
prescription analgesic,36,11,40.36
community participatory research,88,27,40.2
community led research,88,27,40.2
il-1bc,13,4,40.08
caspase-1 gene,13,4,40.08
casp1,13,4,40.08
il1bce,13,4,40.08
casp1 gene,13,4,40.08
casp-1,13,4,40.08
educational practices,13,4,40.08
educational principles,13,4,40.08
treatment as prevention,13,4,40.08
treatment-based prevention,13,4,40.08
in situ sequencing,13,4,40.08
acute infection,13,4,40.08
multiethnic,13,4,40.08
multi-ethnic,13,4,40.08
educational methods,13,4,40.08
community engaged research,39,12,40.08
irregular sleep,144,45,39.47
video conferencing,32,10,39.47
community building,16,5,39.47
diets,67,21,39.35
newborn abstinence syndrome,114,36,39.06
veterans health affairs,88,28,38.76
veterans health administration,88,28,38.76
web platform,22,7,38.76
internet platform,22,7,38.76
k12 award,25,8,38.54
ethnicity people,90,29,38.28
ethnic people,90,29,38.28
ethnic population,90,29,38.28
ethnicity population,90,29,38.28
interindividual variability,34,11,38.12
sleep illness,79,26,37.47
immune system response,91,30,37.41
implementation determinants,27,9,37.0
digital therapeutics,42,14,37.0
environmental stresses,12,4,37.0
subfamily iic,12,4,37.0
implementation factors,27,9,37.0
pdac model,12,4,37.0
cancer-related health disparity,12,4,37.0
pancreatic ductal adenocarcinoma model,12,4,37.0
hi-c,24,8,37.0
pda model,12,4,37.0
digital treatment,42,14,37.0
chromium,12,4,37.0
cr element,12,4,37.0
machine learning methodologies,60,20,37.0
digital therapy,42,14,37.0
health delivery systems,91,31,36.2
multiple omics,79,27,36.09
implementation process,58,20,35.77
vaping nicotine,26,9,35.63
non-opioid therapeutics,288,100,35.52
autoimmune condition,23,8,35.46
traditional cigarette,91,32,35.07
conventional cigarette,91,32,35.07
castration resistant pca,17,6,34.94
neuro-aids,51,18,34.94
neuro-hiv,51,18,34.94
safety outcomes,17,6,34.94
sharing platform,17,6,34.94
neurohiv,51,18,34.94
wearable system,48,17,34.82
intervention for prevention,189,67,34.79
under served group,118,42,34.65
under served people,118,42,34.65
underserved group,118,42,34.65
cv19,126,45,34.53
nr4a2 gene,14,5,34.53
refractory cancer,14,5,34.53
nurr1,14,5,34.53
resistant cancer,14,5,34.53
nr4a2,14,5,34.53
minority people,117,42,34.36
minority population,117,42,34.36
peripheral nerve crush injuries,25,9,34.26
accessible,36,13,34.15
findable,36,13,34.15
condomless anal sex,11,4,33.92
data standardization,88,32,33.92
2nd trimester,88,32,33.92
nnal,11,4,33.92
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol,11,4,33.92
unsafe anal intercourse,11,4,33.92
anti-tumor immune response,11,4,33.92
diversity and inclusion,11,4,33.92
elsi,11,4,33.92
anal intercourse without condom,11,4,33.92
unsafe anal sex,11,4,33.92
multiracial,11,4,33.92
individualized therapeutic strategy,99,36,33.92
condomless anal intercourse,11,4,33.92
anal sex without condom,11,4,33.92
unprotected anal sex,11,4,33.92
unprotected anal intercourse,11,4,33.92
data standards,88,32,33.92
drug stability,11,4,33.92
multi-racial,11,4,33.92
smoking initiation,33,12,33.92
fatality rate,19,7,33.48
health related behavior,89,33,33.26
nondrug therapy,35,13,33.21
non-drug treatment,35,13,33.21
non-drug therapy,35,13,33.21
nondrug treatment,35,13,33.21
cocaine self-administration,318,119,32.96
obesity therapy,16,6,32.89
detection method,16,6,32.89
implementation efforts,32,12,32.89
obesity intervention,16,6,32.89
detection procedure,16,6,32.89
detection technique,16,6,32.89
cancer-directed therapy,116,44,32.52
medication prescription,174,66,32.52
prescribed medication,174,66,32.52
community research,71,27,32.43
undergraduate research experience,21,8,32.38
undergraduate research opportunities,21,8,32.38
undergraduate research programs,21,8,32.38
tobacco product use,382,146,32.27
therapeutic opioid,34,13,32.26
promote health equity,13,5,32.07
hvtn,13,5,32.07
detection platform,13,5,32.07
detection system,13,5,32.07
frontal lobe dementia,13,5,32.07
health equity promotion,13,5,32.07
hiv vaccine trials network,13,5,32.07
multiple substance abuse,13,5,32.07
socio-economic factors,13,5,32.07
respiratory airway volume,13,5,32.07
tidal volume,13,5,32.07
repurposing agent,31,12,31.86
drug repurposing,31,12,31.86
repurposing medication,31,12,31.86
undergrad,126,49,31.71
implementation measures,18,7,31.71
impoverished,117,46,31.37
multimodal datasets,38,15,31.24
multi-modal datasets,38,15,31.24
dissemination and implementation,93,37,31.0
covid-19,191,76,31.0
coronavirus disease 2019,191,76,31.0
bacteria in the gut,10,4,30.83
social outcome,20,8,30.83
under served minority,10,4,30.83
bradycardia,10,4,30.83
transplantation rejection,10,4,30.83
sickle cell disorder,20,8,30.83
culturally competent,20,8,30.83
marker identification,55,22,30.83
transplant rejection,10,4,30.83
gut bacteria,10,4,30.83
biomarker identification,55,22,30.83
adolescent alcohol co-abuse,10,4,30.83
subdermal,25,10,30.83
graft rejection,10,4,30.83
implementation study,47,19,30.51
sexual and gender minorities,37,15,30.42
gender and sexual minorities,37,15,30.42
barcode,37,15,30.42
veteran population,118,48,30.32
military veteran,118,48,30.32
random forest,22,9,30.15
higher education,22,9,30.15
proteins structure,17,7,29.95
bionomics,17,7,29.95
protein structures,17,7,29.95
mobile device application,80,33,29.9
δ or,29,12,29.81
δ ors,29,12,29.81
δ-ors,29,12,29.81
δors,29,12,29.81
prenatally exposed to cannabis,12,5,29.6
language delays,12,5,29.6
prenatally exposed to marijuana,12,5,29.6
cannabis in utero,12,5,29.6
fetal cannabis exposure,12,5,29.6
advanced prostate cancer,12,5,29.6
prenatal cannabis exposure,12,5,29.6
effectiveness study,43,18,29.46
candidate identification,50,21,29.37
rural location,138,58,29.34
neurologic symptoms,19,8,29.29
neurological signs and symptoms,19,8,29.29
alternative tobacco,19,8,29.29
non-cigarette tobacco product,19,8,29.29
non-cigarette products,19,8,29.29
efficacy evaluation,279,118,29.16
nr4a2 protein,14,6,28.78
nuclear receptor-related factor 1,14,6,28.78
nur-related factor 1,14,6,28.78
nurr1 nuclear receptor,14,6,28.78
high-throughput drug screening,14,6,28.78
military member,21,9,28.78
aged population,21,9,28.78
combat veteran,14,6,28.78
social determinants,51,22,28.59
sociodeterminant,51,22,28.59
10 years of age,69,30,28.37
ten years of age,69,30,28.37
digital health,39,17,28.29
public repository,16,7,28.19
clinical pathways,16,7,28.19
motor behavior,16,7,28.19
imaging facilities,16,7,28.19
implicit bias,16,7,28.19
transient receptor potential channel,16,7,28.19
systemic inflammation,32,14,28.19
blood-brain barrier permeabilization,25,11,28.03
blood-brain barrier permeable,25,11,28.03
substance user,50,22,28.03
bbb permeable,25,11,28.03
bbb permeabilization,25,11,28.03
bloodbrain barrier permeable,25,11,28.03
bloodbrain barrier permeabilization,25,11,28.03
data harmonization,75,33,28.03
harmonized data,75,33,28.03
tobacco regulatory efforts,34,15,27.96
tobacco regulation,34,15,27.96
regulate tobacco,34,15,27.96
second trimester,88,39,27.83
midtrimester,88,39,27.83
second pregnancy trimester,88,39,27.83
corona virus disease 2019 pandemic,160,71,27.79
corona virus disease 2019 epidemic,160,71,27.79
covid19 pandemic,160,71,27.79
covid19 epidemic,160,71,27.79
severe acute respiratory syndrome-associated coronavirus 2,18,8,27.75
fair data,18,8,27.75
severe acute respiratory syndrome-related coronavirus 2,18,8,27.75
severe acute respiratory syndrome related corona virus 2,18,8,27.75
coronavirus disease 2019 virus,18,8,27.75
severe acute respiratory syndrome cov 2,18,8,27.75
deep learning based neural network,18,8,27.75
school climate,27,12,27.75
ncov2,18,8,27.75
fair principles,18,8,27.75
severe acute respiratory syndrome associated corona virus 2,18,8,27.75
interoperable,18,8,27.75
sarscov2,18,8,27.75
and reusable,18,8,27.75
severe acute respiratory distress syndrome coronavirus 2,18,8,27.75
stimulant use disorder,108,48,27.75
severe acute respiratory distress syndrome corona virus 2,18,8,27.75
deep learning neural network,18,8,27.75
severe acute respiratory distress syndrome cov 2,18,8,27.75
cov2,18,8,27.75
cov-2,18,8,27.75
sars-related corona virus 2,18,8,27.75
deep neural net,18,8,27.75
hcov19,18,8,27.75
2019 novel corona virus,18,8,27.75
covid-19 virus,18,8,27.75
sars-associated corona virus 2,18,8,27.75
sars corona virus 2,18,8,27.75
covid19 virus,18,8,27.75
nicotine reward,40,18,27.41
multiphase optimization strategy,20,9,27.41
evaluate effectiveness,270,122,27.3
effectiveness evaluation,270,122,27.3
callus,11,5,27.13
bone callus,11,5,27.13
bony callus,11,5,27.13
amputation,11,5,27.13
blood stem cell,11,5,27.13
claustral structure,11,5,27.13
hemopoietic progenitor,11,5,27.13
hemopoietic stem cell,11,5,27.13
medically under served,11,5,27.13
urban location,44,20,27.13
urban region,44,20,27.13
2-arm trial,11,5,27.13
claustrum,11,5,27.13
teratogenic effects,11,5,27.13
single cell rnaseq,129,59,26.97
sars-cov-2 infection,13,6,26.72
infected with covid19,13,6,26.72
diverse data,26,12,26.72
data diversity,26,12,26.72
covid-19 infection,13,6,26.72
covid19 infection,13,6,26.72
sars-cov2 infection,13,6,26.72
severe acute respiratory syndrome coronavirus 2 infection,13,6,26.72
coronavirus disease 2019 infection,13,6,26.72
infected with covid-19,13,6,26.72
apoptosis-related cysteine protease caspase 1,13,6,26.72
infected with sars-cov-2,13,6,26.72
infected with coronavirus disease 2019,13,6,26.72
infected with sars-cov2,13,6,26.72
educational models,13,6,26.72
infected with severe acute respiratory syndrome coronavirus 2,13,6,26.72
racial,307,142,26.66
brain research through advancing innovative neurotechnologies initiative,28,13,26.56
electroencephalogram,159,74,26.5
longterm prospective studies,30,14,26.43
wounds,15,7,26.43
sociocultural,45,21,26.43
wounding,15,7,26.43
computing platform,15,7,26.43
computational platform,15,7,26.43
socio-cultural,45,21,26.43
social culture,45,21,26.43
tissue wound,15,7,26.43
systemic inflammatory response,32,15,26.31
neonatal research network,17,8,26.21
multicenter neonatal research network,17,8,26.21
metabolome,17,8,26.21
multi-center neonatal research network,17,8,26.21
metabonome,17,8,26.21
clinical encounter,17,8,26.21
diverse workforce,19,9,26.04
x-ray radiation,19,9,26.04
workplace diversity,19,9,26.04
clinical pain,164,78,25.93
lymphoma cell,23,11,25.79
cre driver,25,12,25.69
aged 65 and greater,33,16,25.44
aged ≥65,33,16,25.44
age 65 and greater,33,16,25.44
age 65 and older,33,16,25.44
wearable sensor technology,35,17,25.39
efficacious treatment,73,36,25.01
efficacious therapy,73,36,25.01
multi-modal data,38,19,24.67
multimodal data,38,19,24.67
marginalization,58,29,24.67
virtual screening,20,10,24.67
xcl1 gene,14,7,24.67
scm-1,14,7,24.67
multiomic data,26,13,24.67
mrna seq,10,5,24.67
kmt6a,12,6,24.67
12-methoxyibogamine,14,7,24.67
atac,14,7,24.67
osteoarthritis associated pain,32,16,24.67
bacterial pathogen,10,5,24.67
lptn,14,7,24.67
scm-1a,14,7,24.67
multiple omic data,26,13,24.67
scm1,14,7,24.67
scyc1,14,7,24.67
xcl1,14,7,24.67
anxiety reduction,30,15,24.67
enhancer of zeste 2 polycomb repressive complex 2 subunit,12,6,24.67
kmt6,12,6,24.67
ultra high resolution,12,6,24.67
pollution,12,6,24.67
mrnaseq,10,5,24.67
matriculation,28,14,24.67
deep neural network,18,9,24.67
dna repair gene,10,5,24.67
tabernanthe iboga,10,5,24.67
iboga,10,5,24.67
data science resource core,10,5,24.67
data science core,10,5,24.67
intense pain,10,5,24.67
tobacco specific carcinogen,10,5,24.67
tobacco related carcinogen,10,5,24.67
dna repair protein,10,5,24.67
early clinical trial,10,5,24.67
anti-adrenergic agents,12,6,24.67
cancer immunity,10,5,24.67
virtual screenings,20,10,24.67
image interpretation,18,9,24.67
early phase clinical trial,10,5,24.67
maternal outcome,22,11,24.67
large data sets,81,41,24.37
large datasets,81,41,24.37
data integrity,59,30,24.26
wearable electronics,51,26,24.19
patient reported measures,92,47,24.14
electronic nicotine delivery product,90,46,24.13
electronic nicotine distribution system,90,46,24.13
cryo-em,70,36,23.98
community health worker,33,17,23.94
community health aides,33,17,23.94
opioid tapering,33,17,23.94
darkness,77,40,23.74
complex data,23,12,23.64
race disparity,86,45,23.57
disparities in race,86,45,23.57
national institute of children's health and human development,40,21,23.49
minority undergraduate,19,10,23.43
racism,53,28,23.35
active service,17,9,23.3
quitting ecigs,17,9,23.3
supervised machine learning,34,18,23.3
supervised learning,34,18,23.3
active duty,17,9,23.3
first generation college students,17,9,23.3
e-cig cessation,17,9,23.3
e-cigarette cessation,17,9,23.3
first generation college graduates,17,9,23.3
first generation students,17,9,23.3
data management system,17,9,23.3
quitting ecigarettes,17,9,23.3
quitting e-cigs,17,9,23.3
quitting e-cigarettes,17,9,23.3
ecig cessation,17,9,23.3
genetically perturb,147,78,23.24
genetically manipulate,147,78,23.24
gene manipulation,147,78,23.24
clinician factors,15,8,23.12
clinician-level factors,15,8,23.12
physician factors,15,8,23.12
healthcare professional practice,15,8,23.12
physician-level factors,15,8,23.12
provider factors,15,8,23.12
health warning,15,8,23.12
miniaturized,15,8,23.12
provider-level factors,15,8,23.12
economic analysis,58,31,23.08
social factors,86,46,23.06
three dimensional,224,120,23.02
interleukin-1 beta converting enzyme,13,7,22.9
secondhand tobacco smoke exposure,13,7,22.9
exposure to secondhand smoke,13,7,22.9
comparative effectiveness research,13,7,22.9
treatment risk,39,21,22.9
biomechanical,13,7,22.9
chronic inflammatory disease,13,7,22.9
interleukin-1 converting enzyme,13,7,22.9
interleukin 1-beta convertase,13,7,22.9
interleukin 1-b converting enzyme,13,7,22.9
il1bc,13,7,22.9
il1b-convertase,13,7,22.9
il-1b converting enzyme,13,7,22.9
il-1 beta-converting enzyme,13,7,22.9
il-1 beta convertase,13,7,22.9
ice protease,13,7,22.9
caspase-1,13,7,22.9
synthetic opiate,172,93,22.81
synthetic opioid,172,93,22.81
traumatic stress,35,19,22.72
risk mitigation,46,25,22.69
implementation of clinical trials,11,6,22.61
emerging tobacco products,11,6,22.61
budget impact,22,12,22.61
signal induction,22,12,22.61
multi-photon imaging,11,6,22.61
clinical trial implementation,11,6,22.61
opioid patient,11,6,22.61
opioid growth factor,11,6,22.61
point of care testing,11,6,22.61
multiphoton imaging,11,6,22.61
stressed mothers,73,40,22.51
maternal stress,73,40,22.51
wearable technology,51,28,22.46
precision treatment,20,11,22.42
precision therapeutics,20,11,22.42
neighborhood disadvantage,20,11,22.42
precision therapies,20,11,22.42
social health determinants,139,77,22.26
smoking-related disease,18,10,22.2
smoking-related disorder,18,10,22.2
health assessment,18,10,22.2
ubiquitin protein ligase,18,10,22.2
ubiquitin-protein ligase complexes,18,10,22.2
alcohol consumption during pregnancy,18,10,22.2
drinking alcohol during pregnancy,18,10,22.2
ethanol consumption during pregnancy,18,10,22.2
polygenic risk score,61,34,22.13
single cell sequencing,34,19,22.07
social disorders,25,14,22.02
social dysfunction,25,14,22.02
sleep behavior,25,14,22.02
sleep habit,25,14,22.02
social defects,25,14,22.02
social deficits,25,14,22.02
sex disparity,16,9,21.93
endocrine therapy,16,9,21.93
post-natal development,16,9,21.93
hormonal therapy,16,9,21.93
sociodemographic factors,16,9,21.93
disparities in sex,16,9,21.93
socio-demographic factors,16,9,21.93
malleable risk,55,31,21.88
low molecular weight nuclear rna,21,12,21.58
urna,21,12,21.58
snrna,21,12,21.58
small nuclear rna,21,12,21.58
small molecular weight rna,21,12,21.58
single cell technology,14,8,21.58
respiratory dysfunction,14,8,21.58
implementation fidelity,14,8,21.58
maternal health,112,64,21.58
socio-economic disadvantage,40,23,21.45
socio-economically underprivileged,40,23,21.45
socio-economically disadvantaged,40,23,21.45
large scale data sets,26,15,21.38
large scale datasets,26,15,21.38
cost metrics,26,15,21.38
large scale data,26,15,21.38
stress reduction,38,22,21.3
racial disparity,86,50,21.21
ezh2 gene,12,7,21.14
pik3cg gene,12,7,21.14
ezh2,12,7,21.14
food insecurity,24,14,21.14
maternal cannabis use,12,7,21.14
ezh1,12,7,21.14
pi3k,12,7,21.14
enx-1,12,7,21.14
pik3,12,7,21.14
pi3cg,12,7,21.14
web-based service,12,7,21.14
pi3kgamma,12,7,21.14
pik3cg,12,7,21.14
lipidomics,12,7,21.14
data management resources,17,10,20.97
post-trauma stress,17,10,20.97
computer tomography,17,10,20.97
posttrauma stress,17,10,20.97
ct xray,17,10,20.97
xray cat scan,17,10,20.97
xray computerized tomography,17,10,20.97
malnourished,66,39,20.87
genetic strategy,213,126,20.85
participant retention,27,16,20.81
atac-seq,62,37,20.67
atacseq,62,37,20.67
castrate resistant prostate cancer,10,6,20.56
hospitalization cost,20,12,20.56
teacher recruitment,10,6,20.56
neonatal care,15,9,20.56
recruit teachers,10,6,20.56
faculty recruitment,10,6,20.56
castrate resistant pca,10,6,20.56
socioeconomic diversity,10,6,20.56
socially stressed,20,12,20.56
socio-economic diversity,10,6,20.56
big-data science,15,9,20.56
promoting action on research implementation in health services framework,10,6,20.56
familial burden,10,6,20.56
sensory integration,20,12,20.56
parihs framework,10,6,20.56
tissue injury,25,15,20.56
burden on families,10,6,20.56
former smoker,15,9,20.56
injury to tissue,25,15,20.56
focused ultrasound,25,15,20.56
burden to families,10,6,20.56
immunosuppressive drug,10,6,20.56
immunosuppressive treatment,10,6,20.56
effectiveness implementation design,10,6,20.56
postpartum depression,15,9,20.56
family burden,10,6,20.56
adverse childhood experiences,35,21,20.56
ex-smoker,15,9,20.56
emergency hospital visit,128,77,20.5
lasting pain,88,53,20.48
constant pain,88,53,20.48
corona virus disease 2019,126,76,20.45
covid19,126,76,20.45
feasibility trial,38,23,20.38
machine learned algorithm,66,40,20.35
biological agent,61,37,20.33
biopharmaceutical,61,37,20.33
data transfer,23,14,20.26
urban community,18,11,20.18
orthopedic surgery,18,11,20.18
peer-group atmosphere,31,19,20.12
interdisciplinary atmosphere,31,19,20.12
business-friendly atmosphere,31,19,20.12
interactive atmosphere,31,19,20.12
collaborative atmosphere,31,19,20.12
conditional knockout,70,43,20.08
conditional knock-out,70,43,20.08
chronic kidney failure,13,8,20.04
data deposition,13,8,20.04
biomechanics,13,8,20.04
randomized placebo-controlled clinical trial,13,8,20.04
tumor-immune system interactions,13,8,20.04
tumor immune microenvironment,13,8,20.04
immunosuppressive tumor microenvironment,13,8,20.04
umbilical cord,13,8,20.04
umbilical cord structure,13,8,20.04
instructional models,13,8,20.04
immunosuppressive microenvironment,13,8,20.04
immune microenvironment,13,8,20.04
data submission,13,8,20.04
perinatal care,13,8,20.04
machine learning method,60,37,20.0
candidate validation,21,13,19.92
multi-center studies,21,13,19.92
early life exposure,61,38,19.8
genomic locus,77,48,19.78
genetic locus,77,48,19.78
gene locus,77,48,19.78
mri/eeg,24,15,19.73
magnetic resonance imaging/electroencephalography,24,15,19.73
clustered regularly interspaced short palindromic repeats method,169,106,19.66
clustered regularly interspaced short palindromic repeats technology,169,106,19.66
clustered regularly interspaced short palindromic repeats technique,169,106,19.66
clustered regularly interspaced short palindromic repeats methodology,169,106,19.66
adverse childhood events,35,22,19.62
deep learning,54,34,19.59
maternal death,19,12,19.53
maternal mortality,19,12,19.53
under served geographic area,11,7,19.38
surgical models,11,7,19.38
hematopoietic progenitor,11,7,19.38
managed care plan,11,7,19.38
managed care insurance,11,7,19.38
rural patients,11,7,19.38
under served location,11,7,19.38
underserved region,11,7,19.38
underserved location,11,7,19.38
underserved geographic area,11,7,19.38
underserved area,11,7,19.38
under served area,11,7,19.38
pyramidal tracts,11,7,19.38
under served region,11,7,19.38
hematopoietic stem progenitor cell,11,7,19.38
managed healthcare insurance plans,11,7,19.38
rural dwellers,11,7,19.38
rural resident,11,7,19.38
liquid nicotine,11,7,19.38
jak1a,11,7,19.38
jak1 gene,11,7,19.38
jak1,11,7,19.38
early adversity,47,30,19.32
early childhood adversity,47,30,19.32
differs between sexes,358,229,19.28
differences between sexes,358,229,19.28
sexual differences,358,229,19.28
cost estimation,64,41,19.25
cost estimate,64,41,19.25
service organization,14,9,19.19
risk factor for dementia,14,9,19.19
risk for dementia,14,9,19.19
dementia risk,14,9,19.19
stroke model,14,9,19.19
nonpharmacologic therapy,45,29,19.14
non-pharmacologic therapy,45,29,19.14
longterm followup,31,20,19.12
longterm follow-up,31,20,19.12
long-term follow-up,31,20,19.12
long-term followup,31,20,19.12
co-morbid symptom,79,51,19.1
co-occuring symptom,79,51,19.1
pre-adolescent,17,11,19.06
pharmacoepidemiology,34,22,19.06
pharmaceutical epidemiology,34,22,19.06
pharmacoepidemiological,34,22,19.06
pharmacoepidemiologic,34,22,19.06
drug epidemiology,34,22,19.06
racial minority,114,74,19.0
lab training,20,13,18.97
infection risk,20,13,18.97
nuclear rna,20,13,18.97
alzheimer risk factor,20,13,18.97
perinatal phase,20,13,18.97
perinatal period,20,13,18.97
alzheimer risk,20,13,18.97
hpa axis,63,41,18.95
age 10 years,69,45,18.91
advanced analytics,29,19,18.82
biological products,61,40,18.81
genetic signature,38,25,18.75
gene signatures,38,25,18.75
single cell rna-seq,129,85,18.72
scrna-seq,129,85,18.72
single-cell rna sequencing,129,85,18.72
prenatal appointment,47,31,18.7
prenatal checkup,47,31,18.7
prenatal visit,47,31,18.7
effectiveness testing,130,86,18.64
ad dementia,157,104,18.62
ligase gene,12,8,18.5
maternal marijuana use,12,8,18.5
oxidative injury,15,10,18.5
metabolic dysfunction,12,8,18.5
rat genome database,12,8,18.5
immune competent,15,10,18.5
sensory ganglia,12,8,18.5
tissue processing,12,8,18.5
3-arm study,12,8,18.5
gender disparity,15,10,18.5
child custody,12,8,18.5
ad related dementia,12,8,18.5
child custodies,12,8,18.5
ten year old,69,46,18.5
integration site,15,10,18.5
10 year old,69,46,18.5
high power focused ultrasound,12,8,18.5
focused ultrasound therapy,12,8,18.5
imaging platform,12,8,18.5
pharmacokinetics and pharmacodynamics,91,61,18.4
treatment research,88,59,18.4
pk/pd,91,61,18.4
depository,70,47,18.37
adaptive intervention,58,39,18.34
3d,224,152,18.18
ethnoracial,103,70,18.15
early life adversity,47,32,18.11
data base management systems,22,15,18.09
database systems,22,15,18.09
m mulatta,63,43,18.07
behavioral phenotyping,189,129,18.07
m. mulatta,63,43,18.07
behavior phenotype,189,129,18.07
adverse event risk,19,13,18.03
tribal nation,19,13,18.03
community clinic,19,13,18.03
model of human,130,89,18.01
pneumogastric nerve,16,11,17.94
tenth cranial nerve,16,11,17.94
cranial nerve x,16,11,17.94
postnatal development,16,11,17.94
vagus nerve structure,16,11,17.94
rurality,29,20,17.88
fetal opiate exposures,42,29,17.86
fetal opioid exposure,42,29,17.86
gestational opioid exposure,42,29,17.86
prenatal opioid exposure,42,29,17.86
comparison intervention,55,38,17.85
compare intervention,55,38,17.85
actiq,363,251,17.84
fentanest,363,251,17.84
duragesic,363,251,17.84
analyze microbiome,13,9,17.81
microbiome analysis,13,9,17.81
juul,26,18,17.81
newborn children,128,89,17.74
newborn child,128,89,17.74
patient engagement,112,78,17.71
e-course,10,7,17.62
self-management program,10,7,17.62
archiving data,10,7,17.62
archive data,10,7,17.62
social cohesion,10,7,17.62
nr3a1,10,7,17.62
esr1 gene,10,7,17.62
online curriculum,10,7,17.62
source localization,10,7,17.62
esr1,10,7,17.62
health disparate populations,10,7,17.62
prenatal marijuana use,10,7,17.62
ecological systems,30,21,17.62
pain catastrophizing,30,21,17.62
prenatal cannabis use,10,7,17.62
online course,10,7,17.62
nanosized particle,37,26,17.55
nano-sized particle,37,26,17.55
injuries,270,190,17.53
maternal morbidity,17,12,17.47
maternal opioid use,51,36,17.47
maternal opiates use,51,36,17.47
central nervous system plasticity,237,168,17.4
pancreatic malignancy,31,22,17.38
implementation facilitation,31,22,17.38
wildtype mouse,100,71,17.37
fifth cranial nerve,14,10,17.27
population forecasts,14,10,17.27
multiple data sources,21,15,17.27
cranial nerve v,14,10,17.27
trigeminal nerve structure,14,10,17.27
nervus trigeminus,14,10,17.27
population projection,14,10,17.27
emotional functioning,32,23,17.16
cognitive interview,25,18,17.13
biotherapeutic agent,61,44,17.1
posttrauma stress disorder,316,228,17.09
post-trauma stress disorder,316,228,17.09
sleep diseases,79,57,17.09
covid,29,21,17.03
cov disease,29,21,17.03
coronavirus disease,29,21,17.03
corona virus disease,29,21,17.03
stimulant use,95,69,16.98
abdominal pain,11,8,16.96
sleep quantity,11,8,16.96
alzheimer's patient,11,8,16.96
knowledge management,11,8,16.96
relational database management systems,22,16,16.96
millimeter,11,8,16.96
database management systems,22,16,16.96
alzheimer's disease patient,11,8,16.96
mechanical properties,11,8,16.96
transcriptomics,363,265,16.89
organoids,78,57,16.88
knee joint osteoarthritis,41,30,16.86
knee joint oa,41,30,16.86
knee oa,41,30,16.86
data dissemination,15,11,16.82
professional practice,15,11,16.82
sexual identity,15,11,16.82
neurocircuitry,833,612,16.79
kratom,19,14,16.74
patient specific treatment,99,73,16.73
patient specific therapies,99,73,16.73
lead optimization,120,89,16.63
body sensor,35,26,16.6
body worn sensor,35,26,16.6
co-morbid,808,605,16.47
fentanyl abuse,12,9,16.44
lonely,20,15,16.44
post-traumatic stress symptoms,16,12,16.44
dna repair pathway,12,9,16.44
overdose risk,164,123,16.44
posttraumatic symptoms,16,12,16.44
posttraumatic stress symptoms,16,12,16.44
post-traumatic symptoms,16,12,16.44
cancer pain management,24,18,16.44
manufacturing scale-up,20,15,16.44
sleep dysregulation,144,108,16.44
conditioned place preference,283,214,16.31
place conditioning,283,214,16.31
injury to cells,29,22,16.26
care costs,29,22,16.26
gut-brain signaling,29,22,16.26
damage to cells,29,22,16.26
cellular damage,29,22,16.26
gut to brain axis,29,22,16.26
gut-brain axis,29,22,16.26
gut-brain communication,29,22,16.26
gut-brain relationship,29,22,16.26
gut-brain interactions,29,22,16.26
sequential multiple assignment randomized trial,25,19,16.23
predictive tools,25,19,16.23
anti-sense agent,21,16,16.19
multisite trial,38,29,16.16
intelligence quotient deficit,64,49,16.11
immune mediated therapy,43,33,16.07
aspirate,13,10,16.03
chronic kidney disease,13,10,16.03
chronic renal disease,13,10,16.03
cost measurement,26,20,16.03
patient subgroups,74,57,16.01
patient subpopulations,74,57,16.01
social relationships,22,17,15.96
prematurely delivering,36,28,15.86
responders and non-responders,18,14,15.86
responders vs non-responders,18,14,15.86
responders versus non-responders,18,14,15.86
comparative effectiveness trial,36,28,15.86
responders or non-responders,18,14,15.86
health care sector,18,14,15.86
responders from non-responders,18,14,15.86
ion channel gatings,45,35,15.86
rehab therapy,86,67,15.83
0-4 weeks old,128,100,15.79
osteoarthritis pain,32,25,15.79
service provision,23,18,15.76
amyloid alzheimer's dementia amyloid protein,23,18,15.76
tetrahydrocannabinol use,249,195,15.75
tetrahydrocannabinol co-use,249,195,15.75
urm student,37,29,15.74
underrepresented minority student,37,29,15.74
data science,93,73,15.71
photometry,307,241,15.71
race-based discrimination,14,11,15.7
social disparities,14,11,15.7
data centers,14,11,15.7
anti-cancer,19,15,15.62
neural manifestation,19,15,15.62
neurologic signs and symptoms,19,15,15.62
neurological manifestations,19,15,15.62
mouse genetics,72,57,15.58
bipolar illness,58,46,15.55
single nucleotide variant,63,50,15.54
clinical center,73,58,15.52
socio-demographics,84,67,15.46
sociodemographics,84,67,15.46
convolutional network,10,8,15.42
frameless stereotaxy,10,8,15.42
protomer,10,8,15.42
warning label,10,8,15.42
synaptic pruning,10,8,15.42
neuronavigation,10,8,15.42
patient participation,10,8,15.42
post-partum depression,15,12,15.42
postnatal depression,15,12,15.42
reduced nicotine cigarette,15,12,15.42
national institute of neurological diseases and stroke,65,52,15.42
reduced nicotine content cigarette,15,12,15.42
patient admission,10,8,15.42
opioid sparing,60,48,15.42
low nicotine content cigarette,15,12,15.42
low nicotine cigarette,15,12,15.42
applied skills,15,12,15.42
algorithm development,10,8,15.42
summer student,10,8,15.42
community involvement,10,8,15.42
acute care,40,32,15.42
post-natal depression,15,12,15.42
bearing children,83,67,15.28
child bearing,83,67,15.28
bear children,83,67,15.28
sexually dimorphic,57,46,15.28
comparator group,47,38,15.25
pregnancy care,47,38,15.25
trauma in children,21,17,15.24
multicenter studies,21,17,15.24
empowerment,80,65,15.18
perceived stress,27,22,15.14
neurodevelopmental disability,11,9,15.07
patient portal,11,9,15.07
nonpainful,11,9,15.07
gi cancers,11,9,15.07
gi malignancies,11,9,15.07
gi tract cancers,11,9,15.07
collaborative approach,11,9,15.07
65+ years old,33,27,15.07
machine learning algorithm,66,54,15.07
surgery complication,11,9,15.07
childbearing,83,68,15.05
genetic promoter sequence,17,14,14.98
data analysis pipeline,17,14,14.98
data processing pipeline,17,14,14.98
promoter sequence,17,14,14.98
crispr editing screen,23,19,14.93
immune cell activation,46,38,14.93
ai system,52,43,14.91
surgical pain,35,29,14.89
surgery pain,35,29,14.89
knee osteoarthritis,41,34,14.87
precision-based medicine,153,127,14.86
interoception,18,15,14.8
spasticity,12,10,14.8
alzheimer's disease related dementia,12,10,14.8
indigenous community,12,10,14.8
adrd,12,10,14.8
brain health,30,25,14.8
human engineering,12,10,14.8
prenatally marijuana exposed,12,10,14.8
prenatal marijuana exposure,12,10,14.8
gestational marijuana exposure,12,10,14.8
fetal marijuana exposure,12,10,14.8
lsd-25,12,10,14.8
lysergide,12,10,14.8
racial diversity,74,62,14.72
racially diverse,74,62,14.72
mhealth application,31,26,14.71
m-health app,31,26,14.71
residential building,31,26,14.71
m-health application,31,26,14.71
urban setting,25,21,14.68
molecular phenotype,25,21,14.68
spinal cord stimulation,19,16,14.65
mental wellbeing,19,16,14.65
psychological wellbeing,19,16,14.65
emotional wellbeing,19,16,14.65
sense of wellbeing,19,16,14.65
blood-brain barrier penetration,19,16,14.65
bbb penetration,19,16,14.65
neurostimulation procedures of spinal cord tissue,19,16,14.65
aerosolized nicotine,19,16,14.65
bloodbrain barrier penetration,19,16,14.65
pandemic,134,113,14.63
pandemic disease,134,113,14.63
data coordination center,136,115,14.59
data coordinating center,136,115,14.59
essential drugs,13,11,14.58
implementation strategy,169,143,14.58
gastrointestinal diseases,26,22,14.58
suicidal,65,55,14.58
ph.d student,33,28,14.54
ph. d. student,33,28,14.54
ph.d. student,33,28,14.54
phd. student,33,28,14.54
nonhispanic,66,56,14.54
ph d. student,33,28,14.54
ph d student,33,28,14.54
phd student,33,28,14.54
pain assay,106,90,14.53
emotional symptom,20,17,14.51
eye tracking,20,17,14.51
nonneuronal cell,182,155,14.48
mentored clinical scientist development program,27,23,14.48
k12 program,27,23,14.48
k12 mechanism,27,23,14.48
clustered regularly interspaced short palindromic repeats interference,27,23,14.48
data sharing,115,98,14.47
multi-modality,294,251,14.45
on-line education,35,30,14.39
on-line learning,35,30,14.39
osteogenesis,14,12,14.39
er+,14,12,14.39
functional magnetic resonance imaging scan,35,30,14.39
er positive,14,12,14.39
prenatal experience,14,12,14.39
burned,14,12,14.39
community partnership,28,24,14.39
bone formation,14,12,14.39
telehealth,138,119,14.3
causative variant,37,32,14.26
causal allele,37,32,14.26
causal gene,37,32,14.26
causal mutation,37,32,14.26
causal variant,37,32,14.26
causative mutation,37,32,14.26
biological sex,37,32,14.26
opiate use disorder,1294,1120,14.25
ecosystem,30,26,14.23
ecologic systems,30,26,14.23
long-term prospective studies,30,26,14.23
obstacle to healthcare,98,85,14.22
obstacle to care,98,85,14.22
barrier to treatment,98,85,14.22
barrier to health care,98,85,14.22
barrier to care,98,85,14.22
barrier to healthcare,98,85,14.22
longitudinal outcome studies,217,189,14.16
opioid induced overdose,569,496,14.15
e-cigarette liquids,48,42,14.1
translatome,16,14,14.1
ecigarette liquids,48,42,14.1
ejuice,48,42,14.1
electronic liquid,48,42,14.1
eliquid,48,42,14.1
e-cig liquids,48,42,14.1
ecig liquids,48,42,14.1
adme study,16,14,14.1
and excretion study,16,14,14.1
e-juice,48,42,14.1
e-liquid,48,42,14.1
morphine administration,49,43,14.05
opiate exposure,241,212,14.02
pre-clinical evaluation,25,22,14.02
opioid exposure,241,212,14.02
biologic products,42,37,14.0
gestational opiate exposure,42,37,14.0
prenatal opiate exposure,42,37,14.0
prenatally opiate exposed,42,37,14.0
interleukin-18 precursor,17,15,13.98
il-1g,17,15,13.98
il-18,17,15,13.98
igif,17,15,13.98
ifn-gamma-inducing factor,17,15,13.98
il18 protein,17,15,13.98
il1f4,17,15,13.98
interferon-gamma-inducing factor,17,15,13.98
interleukin 18 (interferon-gamma-inducing factor),17,15,13.98
interleukin 18 proprotein,17,15,13.98
interleukin-1 gamma,17,15,13.98
castration resistant prostate cancer,17,15,13.98
il-1 gamma,17,15,13.98
interleukin-18,17,15,13.98
mgc12320,17,15,13.98
sleep-related breathing disorder,17,15,13.98
flare,17,15,13.98
multi-level model,71,63,13.9
multi-level analysis,71,63,13.9
polymorphonuclear neutrophils,18,16,13.88
polymorphonuclear leukocytes,18,16,13.88
polymorphonuclear cell,18,16,13.88
blood neutrophil,18,16,13.88
blood polymorphonuclear neutrophil,18,16,13.88
neutrophilic leukocyte,18,16,13.88
multidrug resistance proteins,18,16,13.88
multidrug resistant proteins,18,16,13.88
neutrophilic granulocyte,18,16,13.88
marrow neutrophil,18,16,13.88
protective factors,156,139,13.84
bio-engineered,37,33,13.83
bio-engineers,37,33,13.83
actigraph,38,34,13.78
trans*,19,17,13.78
treatment prediction,67,60,13.77
therapy prediction,67,60,13.77
predict therapy response,67,60,13.77
predict therapeutic response,67,60,13.77
socio-structural,29,26,13.76
neuro-genomics,29,26,13.76
social structure,29,26,13.76
neurogenomics,29,26,13.76
social structural,29,26,13.76
clinical translation,77,69,13.76
sociostructural,29,26,13.76
treatment comparison,40,36,13.7
convnet,10,9,13.7
convolutional neural network,10,9,13.7
compare treatment,40,36,13.7
exogenous cannabinoid,10,9,13.7
icd code,10,9,13.7
international classification of disease codes,10,9,13.7
on-line portal,10,9,13.7
online portal,10,9,13.7
web-based portal,10,9,13.7
convolutional neural nets,10,9,13.7
marijuana use during pregnancy,10,9,13.7
cannabis use in pregnancy,10,9,13.7
cannabis use during pregnancy,10,9,13.7
olfactory cortex,10,9,13.7
abiraterone,10,9,13.7
antitumor immunity,10,9,13.7
anti-tumor immunity,10,9,13.7
sleep loss,41,37,13.67
inadequate sleep,41,37,13.67
sleep insufficiency,41,37,13.67
sleep deficit,41,37,13.67
deficient sleep,41,37,13.67
wearable device,51,46,13.67
insufficient sleep,41,37,13.67
sleep debt,41,37,13.67
sleep deficiency,41,37,13.67
high dimensionality,72,65,13.66
bloodbrain barrier,84,76,13.63
wellbeing,254,230,13.62
high risk infant,22,20,13.57
patient-level barriers,22,20,13.57
patient barriers,22,20,13.57
vulnerable infant,22,20,13.57
managed care programs,11,10,13.57
gastrointestinal malignancies,11,10,13.57
organizational readiness,11,10,13.57
goggles,11,10,13.57
managed health care insurance plans,11,10,13.57
tribal leader,11,10,13.57
fertility loss,11,10,13.57
weight-bearing state,11,10,13.57
social stressor,11,10,13.57
methylomics,11,10,13.57
fertility cessation,11,10,13.57
pain score,33,30,13.57
chronic msk pain,34,31,13.53
chronic musculoskeletal pain,34,31,13.53
neonatal opioid withdrawal syndrome,114,104,13.52
serious adverse experience,35,32,13.49
healthcare availability,70,64,13.49
healthcare accessibility,70,64,13.49
health care access,70,64,13.49
serious adverse reaction,35,32,13.49
fish assay,59,54,13.48
translation to humans,12,11,13.45
visceral pain,12,11,13.45
non-steroidal anti-inflammatory drugs,72,66,13.45
inter-institutional,12,11,13.45
computer based method,84,77,13.45
autonomic pain,12,11,13.45
visualization tool,12,11,13.45
visualization software,12,11,13.45
bayesian computation,12,11,13.45
service availability,244,224,13.43
patient subsets,74,68,13.42
patient subtypes,74,68,13.42
gender identity,25,23,13.41
regional anesthesia,13,12,13.36
animal diseases,13,12,13.36
pack years,13,12,13.36
conduction anesthesia,13,12,13.36
tribal health,13,12,13.36
cell therapy,13,12,13.36
waitlist,52,48,13.36
prediction of response to therapy,67,62,13.33
opioid use disorder,1294,1200,13.3
knee replacement arthroplasty,28,26,13.28
cryoem,70,65,13.28
electron cryomicroscopy,70,65,13.28
trigeminal nerve,14,13,13.28
cryo-electron microscopy,70,65,13.28
rehab research,14,13,13.28
pre-exposure prophylaxis,73,68,13.24
prep,73,68,13.24
pharmacobehavioral,131,122,13.24
minority communities,31,29,13.18
sleep disruption,144,135,13.16
opiate withdrawal,256,240,13.16
opioid detox,256,240,13.16
opioid detoxification,256,240,13.16
aberrant sleep,144,135,13.16
disrupted sleep,144,135,13.16
disturbed sleep,144,135,13.16
impaired sleep,144,135,13.16
vaping,147,138,13.14
early-career faculty,33,31,13.13
pragmatic effectiveness trial,50,47,13.12
data tools,17,16,13.1
druggable target,52,49,13.09
electronic communication,89,84,13.07
longitudinal data set,36,34,13.06
circadian abnormality,18,17,13.06
circadian impairment,18,17,13.06
circadian disruption,18,17,13.06
orofacial pain,18,17,13.06
longitudinal dataset,36,34,13.06
circadian dysfunction,18,17,13.06
circadian disturbance,18,17,13.06
electronic device,73,69,13.05
disadvantaged population,55,52,13.04
sex-specific differences,358,339,13.02
neurologic manifestations,19,18,13.02
sex-related differences,358,339,13.02
sex-dependent differences,358,339,13.02
complementary health,21,20,12.95
career mobility,43,41,12.93
career advancement,43,41,12.93
career transition,43,41,12.93
nutritional deficiency disorder,66,63,12.92
nutrition deficiency disorder,66,63,12.92
nutrition deficiency,66,63,12.92
electronic nicotine delivery device,90,86,12.91
health difference,23,22,12.89
differences in health,23,22,12.89
precision medicine,153,148,12.75
mobile health app,31,30,12.74
mobile health application,31,30,12.74
mhealth app,31,30,12.74
tobacco smokers,31,30,12.74
preventing alcohol,40,39,12.65
prevent alcohol,42,41,12.63
ongoing pain,88,86,12.62
on-going pain,88,86,12.62
peer support,89,87,12.62
participatory action research,88,87,12.48
non-opioid,288,285,12.46
non-medical opioid use,511,506,12.46
nonmedical opioid use,511,506,12.46
opiate misuse,511,506,12.46
transcriptional signature,142,141,12.42
opioid epidemic,972,966,12.41
opiate crisis,972,966,12.41
opioid crisis,972,966,12.41
data visualization,15,15,12.33
adolescent polysubstance use,12,12,12.33
engineering and math career,10,10,12.33
financial hardship,60,60,12.33
youth aod use,12,12,12.33
socioeconomic disparity,15,15,12.33
phosphatidylethanol,15,15,12.33
adrenergic beta-blockers,10,10,12.33
legal system,19,19,12.33
socioenvironmental,86,86,12.33
cancer survival,21,21,12.33
rural counties,36,36,12.33
youth alcohol and other drugs use,12,12,12.33
fetal growth,19,19,12.33
hospital admission,210,210,12.33
health care delivery model,37,37,12.33
vagus nerve,16,16,12.33
adolescent alcohol/drug use,12,12,12.33
cardiac function,15,15,12.33
gene conservation,12,12,12.33
financial stress,60,60,12.33
financial strain,60,60,12.33
engineering and mathematics workforce,10,10,12.33
financial distress,60,60,12.33
function of the heart,15,15,12.33
engineering and mathematics career,10,10,12.33
financial burden,60,60,12.33
engineering and math workforce,10,10,12.33
exposure to violence,21,21,12.33
infective endocarditis,10,10,12.33
violence exposure,21,21,12.33
unsupervised machine learning,15,15,12.33
unsupervised learning,15,15,12.33
marijuana use in pregnancy,10,10,12.33
adolescent alcohol and substance use,12,12,12.33
bacteria infection,16,16,12.33
fibrotic liver,12,12,12.33
non-alcoholic fatty liver disease,12,12,12.33
non-alcoholic liver disease,12,12,12.33
ineffective therapies,19,19,12.33
nonalcoholic fatty liver disease,12,12,12.33
network architecture,10,10,12.33
systematic bias,12,12,12.33
ineffective treatment,19,19,12.33
national institute for occupational safety and health,10,10,12.33
immunologic therapeutics,12,12,12.33
foundational skills,10,10,12.33
knowledge acquisition,24,24,12.33
morphogenetic process,11,11,12.33
data access,20,20,12.33
enhancer sequence,11,11,12.33
non-alcohol fatty liver disease,12,12,12.33
professional atmosphere,17,17,12.33
work atmosphere,17,17,12.33
alcohol demand,16,16,12.33
learning algorithm,11,11,12.33
community center,16,16,12.33
community pharmacy,16,16,12.33
liver inflammation,16,16,12.33
interferon type i,11,11,12.33
adolescent aod use,12,12,12.33
smokeless tobacco use,11,11,12.33
adolescent alcohol and drug use,12,12,12.33
adolescent alcohol and other drug (aod) use,12,12,12.33
adolescent alcohol and other drug use,12,12,12.33
adolescent alcohol and other substance use,12,12,12.33
tobacco-free,17,17,12.33
subject safety,10,10,12.33
3d cell culture,15,15,12.33
genetic enhancer sequence,11,11,12.33
3d culture,15,15,12.33
immunosuppressor,10,10,12.33
vaper,27,27,12.33
nrem,29,29,12.33
nonrem,29,29,12.33
prevent substance misuse,11,11,12.33
catalytic,14,14,12.33
substance misuse prevention,11,11,12.33
research contracts,36,36,12.33
compare cost effectiveness,13,13,12.33
frontotemporal lobe degeneration associated with dementia,13,13,12.33
inflammasome,28,28,12.33
cynomolgus macaque,10,10,12.33
m fascicularis,10,10,12.33
m. fascicularis,10,10,12.33
underrepresented students,25,25,12.33
sleep hygiene,14,14,12.33
chronic renal failure,13,13,12.33
skin tissue,14,14,12.33
estrogen receptor positive,14,14,12.33
workforce development,29,29,12.33
immunosuppressive substance,10,10,12.33
participant safety,10,10,12.33
immune suppressor,10,10,12.33
immune suppressive agent,10,10,12.33
pathogenic bacteria,10,10,12.33
total knee arthroplasty,28,28,12.33
three dimensional cell culture,15,15,12.33
adolescent alcohol effect,14,14,12.33
skill development,117,118,12.23
exposed in utero,103,104,12.21
combustible cigarette,91,92,12.2
nonopiate analgesic,288,293,12.12
non-opioid analgesic,288,293,12.12
non-opiate analgesic,288,293,12.12
non-narcotic analgesic,288,293,12.12
osteoarthritic,50,51,12.09
underrepresented populations,123,126,12.04
2-photon microscopy,37,38,12.01
two photon excitation microscopy,37,38,12.01
two photon microscopy,37,38,12.01
bar codes,37,38,12.01
opioid related overdose,569,586,11.98
opioid poisoning,569,586,11.98
opioid overdose,569,586,11.98
opiate related overdose,569,586,11.98
opioid intoxication,569,586,11.98
opioid medication overdose,569,586,11.98
first-in-human,67,69,11.98
first in man,67,69,11.98
opioid drug overdose,569,586,11.98
opiate overdose,569,586,11.98
opioid toxicity,569,586,11.98
biocompatibility,30,31,11.94
chronic obstruction pulmonary disease,29,30,11.92
acute pain management,29,30,11.92
death risk,58,60,11.92
mortality risk,58,60,11.92
pregnant mothers,222,230,11.9
imaging based approach,53,55,11.88
confocal imaging,25,26,11.86
knock-out animal,24,25,11.84
cryoelectron microscopy,70,73,11.83
clustered regularly interspaced short palindromic repeats screen,23,24,11.82
crispr screen,23,24,11.82
single-blind,23,24,11.82
crispr-based screen,23,24,11.82
crispr/cas9 screen,23,24,11.82
treatment response prediction,67,70,11.8
biological therapeutic,22,23,11.8
biological treatment,22,23,11.8
safety and feasibility,21,22,11.77
parabrachial nucleus,41,43,11.76
hospital costs,20,21,11.75
analysis pipeline,20,21,11.75
microflora,20,21,11.75
laboratory training,20,21,11.75
sleep pattern,20,21,11.75
laboratory experience,20,21,11.75
lab experience,20,21,11.75
pwuo,99,104,11.74
fluorescence in situ hybridization,59,62,11.74
people who use opioids,99,104,11.74
persons who use opioids,99,104,11.74
accurate diagnosis,19,20,11.72
adherence rate,19,20,11.72
xray,19,20,11.72
oral cavity cancer,19,20,11.72
re-admission,38,40,11.72
rehospitalization,38,40,11.72
re-hospitalization,38,40,11.72
hospital re-admission,38,40,11.72
electronic nicotine delivery systems,90,95,11.68
image guidance,18,19,11.68
image guided,18,19,11.68
incrementally cost effective,18,19,11.68
summer session,18,19,11.68
summer program,18,19,11.68
bioprinting,18,19,11.68
bio-printing,18,19,11.68
retrospective cohort study,18,19,11.68
oral facial pain,18,19,11.68
wearable sensor,35,37,11.67
malignant childhood cancer,17,18,11.65
nonnarcotic analgesics,288,305,11.65
on-line compendium,17,18,11.65
online compendium,17,18,11.65
pediatric malignancy,17,18,11.65
childhood malignancy,17,18,11.65
cancer in a child,17,18,11.65
child with cancer,17,18,11.65
cancer in children,17,18,11.65
nutritional deficiency,66,70,11.63
dietary deficiency,66,70,11.63
undernutrition,66,70,11.63
tumor promotion,16,17,11.61
pain perception,79,84,11.6
glial cell activation,47,50,11.59
glial activation,47,50,11.59
perioperative,77,82,11.58
tribal community,30,32,11.56
biomaterial compatibility,30,32,11.56
antepartum,15,16,11.56
bodily sensation,15,16,11.56
rehabilitative therapy,86,92,11.53
genomic dataset,71,76,11.52
genomic data-set,71,76,11.52
off-label prescribing,14,15,11.51
transplant patient,14,15,11.51
transplant recipients,14,15,11.51
sleep health,14,15,11.51
colorectum,14,15,11.51
off-label use,14,15,11.51
off-label application,14,15,11.51
alaskan native american,69,74,11.5
nonopioid analgesics,288,310,11.46
nonopioid,288,310,11.46
trauma symptom,13,14,11.45
arthralgia,13,14,11.45
joint pain,13,14,11.45
gastrointestinal disorder,26,28,11.45
population assessment of tobacco and health,25,27,11.42
phentanyl,363,392,11.42
fentyl,363,392,11.42
peer instruction,36,39,11.38
teratogenicity,12,13,11.38
stem-like cell,12,13,11.38
stimulant misuse,12,13,11.38
peer coaching,36,39,11.38
peer led team learning,36,39,11.38
peer mentoring,36,39,11.38
healthcare model,12,13,11.38
peer teaching,36,39,11.38
teratogenic,12,13,11.38
severe adverse event,35,38,11.36
single domain antibodies,23,25,11.35
sdab,23,25,11.35
medical costs,57,62,11.34
cream,11,12,11.31
transgender women,11,12,11.31
data registry,11,12,11.31
transwomen,11,12,11.31
transwoman,11,12,11.31
effector cell,11,12,11.31
supportive atmosphere,22,24,11.31
enthusiastic atmosphere,22,24,11.31
magnetoencephalographic imaging,11,12,11.31
childhood adversity,11,12,11.31
meg imaging,11,12,11.31
trans-women,11,12,11.31
weapons,11,12,11.31
pediatric adversity,11,12,11.31
followup assessment,65,71,11.29
peripartum,83,91,11.25
socio-economically,250,274,11.25
faculty mentor,73,80,11.25
indigenous,61,67,11.23
fragile x mental retardation 1,10,11,11.21
fraxa,10,11,11.21
cigarette user,20,22,11.21
morphogens,10,11,11.21
fragile x mental retardation 1 gene,10,11,11.21
hispanic-serving institution,30,33,11.21
fmr1 gene,10,11,11.21
paraventricular nucleus of thalamus,60,66,11.21
paraventricular thalamic nucleus,60,66,11.21
structure of paraventricular nucleus of thalamus,60,66,11.21
cost outcomes,10,11,11.21
student recruitment,19,21,11.16
hydrogels,19,21,11.16
genomic therapy,47,52,11.15
health care management,28,31,11.14
3-dimensional,224,248,11.14
opiate deaths,264,293,11.11
opioid mortality,264,293,11.11
opioid deaths,264,293,11.11
opioid overdose death,264,293,11.11
opiate mortality,264,293,11.11
opioid related death,264,293,11.11
maternal exposure,18,20,11.1
affective disturbance,27,30,11.1
musculoskeletal,35,39,11.07
open science,26,29,11.06
open-source data,26,29,11.06
open data,26,29,11.06
immune therapeutic strategy,43,48,11.05
immune therapeutic regimens,43,48,11.05
immune therapeutic approach,43,48,11.05
pain model,170,190,11.04
quality of sleep,68,76,11.04
knee pain,17,19,11.04
early biomarkers,17,19,11.04
cicatrix,25,28,11.01
scars,25,28,11.01
degenerative arthritis,50,56,11.01
biobank,91,102,11.0
biorepository,91,102,11.0
reduce pain,201,226,10.97
pain reduction,201,226,10.97
distribution,16,18,10.96
doctoral degree,16,18,10.96
imaging capabilities,16,18,10.96
oxidative phosphorylation pathway,16,18,10.96
rural locality,40,45,10.96
rural place,40,45,10.96
phosphatidylinositol 4,16,18,10.96
sleep dysfunction,79,89,10.95
amyloid β,23,26,10.91
single-blind study,23,26,10.91
epidemiological data,53,60,10.89
epidemiology data,53,60,10.89
bio-informatics tool,15,17,10.88
post-partum,75,85,10.88
locales,15,17,10.88
antenatal,15,17,10.88
bioinformatics tool,15,17,10.88
creativity,37,42,10.87
creativeness,37,42,10.87
natural language processing,59,67,10.86
natural language understanding,59,67,10.86
drug safety,29,33,10.84
medication safety,29,33,10.84
pharmaceutical safety,29,33,10.84
prescription pain reliever,36,41,10.83
global gene expression,274,313,10.8
global transcription profile,274,313,10.8
total knee replacement,28,32,10.79
low ses,77,88,10.79
neural blockade,21,24,10.79
neural block,21,24,10.79
nerve block,21,24,10.79
knee replacement,28,32,10.79
3-d,224,256,10.79
pythons,14,16,10.79
improve symptom,35,40,10.79
symptom improvement,35,40,10.79
symptomatic improvement,35,40,10.79
hepatic metabolism,14,16,10.79
knee arthroplasty,28,32,10.79
knee joint replacement operation,28,32,10.79
short message service,67,77,10.73
texting,67,77,10.73
tailored approach,67,77,10.73
precision approach,67,77,10.73
personalized approach,67,77,10.73
personalized medical approach,67,77,10.73
individualized approach,67,77,10.73
alzheimer's disease risk,20,23,10.72
microbe,20,23,10.72
expecting mother,222,256,10.7
expectant mother,222,256,10.7
cervical,13,15,10.69
intestinal microflora,26,30,10.69
colo-rectal,13,15,10.69
intestinal flora,26,30,10.69
gut microbial consortia,26,30,10.69
gut microbial composition,26,30,10.69
gut microbial community,26,30,10.69
gastrointestinal microbiota,26,30,10.69
gastrointestinal microbial flora,26,30,10.69
gi microbiota,26,30,10.69
gut flora,26,30,10.69
enteric microbial community,26,30,10.69
enteric microbiota,26,30,10.69
midcareer faculty,26,30,10.69
gut community,26,30,10.69
gut commensal,26,30,10.69
gut microbe community,26,30,10.69
oxidoreductase gene,13,15,10.69
dopamine β-hydroxylase,13,15,10.69
irb,91,105,10.69
developing fetus,32,37,10.67
drug use behavior,45,52,10.67
gestational ethanol exposure,32,37,10.67
hepatology,19,22,10.65
mitragyna,19,22,10.65
prevent alcohol use,25,29,10.63
sciatic nerve,25,29,10.63
opioid dependent,1157,1345,10.61
patient reported outcomes,92,107,10.6
patient outcomes assessments,92,107,10.6
efficacy study,115,134,10.58
engineering and mathematics course,12,14,10.57
web services,12,14,10.57
healthcare sector,12,14,10.57
engineering and mathematics class,12,14,10.57
engineering and mathematics discipline,12,14,10.57
engineering and mathematics field,12,14,10.57
engineering and mathematics major,12,14,10.57
prospective cohort,24,28,10.57
cord blood,18,21,10.57
obesity epidemic,12,14,10.57
engineering and math major,12,14,10.57
immunosurveillance,12,14,10.57
engineering and math field,12,14,10.57
educational resources,12,14,10.57
engineering and math course,12,14,10.57
engineering and math class,12,14,10.57
structured data,12,14,10.57
education resources,12,14,10.57
blood infection,18,21,10.57
engineering and math discipline,12,14,10.57
crispr/cas system,179,209,10.56
crispr,179,209,10.56
clustered regularly interspaced short palindromic repeats,179,209,10.56
opiate intake,1042,1220,10.53
opiate use,1042,1220,10.53
opioid consumption,1042,1220,10.53
opiate consumption,1042,1220,10.53
opioid drug use,1042,1220,10.53
opioid intake,1042,1220,10.53
htlv-iii seronegativity,35,41,10.53
opiate drug use,1042,1220,10.53
hiv seronegativities,35,41,10.53
hiv seronegativity,35,41,10.53
hiv negative,35,41,10.53
htlv-iii seronegativities,35,41,10.53
experimental group,29,34,10.52
followup,650,763,10.51
active followup,650,763,10.51
pain self-management,23,27,10.51
socioeconomically underprivileged,40,47,10.5
rural setting,40,47,10.5
socioeconomically disadvantaged,40,47,10.5
inter-individual variability,34,40,10.48
common data element,34,40,10.48
newborn infant,128,151,10.45
pain processing,61,72,10.45
biotherapy,22,26,10.44
biotherapeutics,22,26,10.44
biological therapy,22,26,10.44
malnutrition,66,78,10.44
augmented reality,11,13,10.44
after stroke,11,13,10.44
biological response modifier therapy,22,26,10.44
drug binding site,11,13,10.44
data depository,33,39,10.44
biological sensor,99,117,10.44
people who use drugs,131,155,10.42
pwud,131,155,10.42
persons who use drugs,131,155,10.42
people who use illicit drugs,131,155,10.42
fish analysis,59,70,10.4
fish technic,59,70,10.4
olfactory perception,43,51,10.4
odor perception,43,51,10.4
fish technique,59,70,10.4
aged brain,16,19,10.39
data scientist,16,19,10.39
burn-out,16,19,10.39
burnout,16,19,10.39
doctor's degree,16,19,10.39
doctorate degree,16,19,10.39
hormone therapy,16,19,10.39
crispr-based tool,169,201,10.37
crispr-based technology,169,201,10.37
crispr/cas9 technology,169,201,10.37
crispr-based technique,169,201,10.37
crispr-based method,169,201,10.37
crispr methodology,169,201,10.37
hepatitis c virus incidence,21,25,10.36
longterm cohort study,42,50,10.36
self assessment,31,37,10.33
stigmatization,92,110,10.32
underrepresented groups,123,147,10.32
webinar,41,49,10.32
anti-cancer therapy,116,139,10.29
community health care,40,48,10.28
lung damage,10,12,10.28
social distance,20,24,10.28
tenure track,60,72,10.28
patient specific response,15,18,10.28
tenure process,60,72,10.28
flavorant,30,36,10.28
system-level barriers,15,18,10.28
visual tracking,20,24,10.28
human biology,35,42,10.28
network infrastructure,10,12,10.28
model the data,35,42,10.28
model of data,35,42,10.28
noninsulin dependent diabetes,35,42,10.28
modeling of the data,35,42,10.28
mabs,24,29,10.21
persistent symptom,19,23,10.19
chronic symptom,19,23,10.19
translational scientist,38,46,10.19
translational researcher,38,46,10.19
translational investigator,38,46,10.19
post-partum women,33,40,10.17
spared nerve,28,34,10.16
microorganism,14,17,10.16
overdose prevention,79,96,10.15
data transmission,23,28,10.13
data exchange,23,28,10.13
serotonin receptor 5-ht2a,23,28,10.13
degenerative polyarthritis,50,61,10.11
osteoarthrosis,50,61,10.11
degenerative joint disease,50,61,10.11
hypertrophic arthritis,50,61,10.11
fetal cord blood,18,22,10.09
myeloid cells,18,22,10.09
neonatal outcome,18,22,10.09
low and middle-income countries,36,44,10.09
lmic,36,44,10.09
umbilical cord blood,18,22,10.09
fluorescence light microscopy,22,27,10.05
cluster randomization trial,44,54,10.05
cluster randomized trial,44,54,10.05
front temporal dementia,13,16,10.02
cell-based therapy,13,16,10.02
young adult alcohol use,13,16,10.02
nccam,26,32,10.02
high resolution imaging,13,16,10.02
social inequality,13,16,10.02
young adult alcohol consumption,13,16,10.02
internet resource,17,21,9.98
web resource,17,21,9.98
web-based resource,17,21,9.98
oligos,17,21,9.98
on-line resource,17,21,9.98
malignant pediatric neoplasm,17,21,9.98
sleep apnea syndromes,17,21,9.98
online resource,17,21,9.98
malignant childhood tumor,17,21,9.98
childhood cancers,17,21,9.98
malignant childhood neoplasm,17,21,9.98
sleep hypopnea,17,21,9.98
malignant pediatric tumor,17,21,9.98
pediatric cancer,17,21,9.98
early detection markers,17,21,9.98
therapeutic testing,34,42,9.98
early detection biomarkers,17,21,9.98
sleep-disordered breathing,17,21,9.98
injury to liver,38,47,9.97
pain outcome,59,73,9.97
service gap,21,26,9.96
healing,96,119,9.95
antisense oligo,25,31,9.95
adolescent intermittent ethanol exposure,33,41,9.93
adolescent exposure to alcohol,33,41,9.93
adolescent exposure to ethanol,33,41,9.93
suicidality prevention,41,51,9.92
prevent suicide,41,51,9.92
prevent suicidality,41,51,9.92
risk minimization,41,51,9.92
infant and child development,134,167,9.9
child development,134,167,9.9
congenital deformity,24,30,9.87
multi-center trial,16,20,9.87
congenital abnormality,24,30,9.87
infant health,28,35,9.87
anticancer,12,15,9.87
congenital anatomical abnormality,24,30,9.87
psychiatric genomics,20,25,9.87
genomic profiles,16,20,9.87
multimorbidity,16,20,9.87
congenital malformation,24,30,9.87
patient stratification,20,25,9.87
brain reward regions,48,60,9.87
congenital defects,24,30,9.87
stratified patient,20,25,9.87
birth defects,24,30,9.87
nafld,12,15,9.87
videoconferencing,32,40,9.87
humanized mouse,20,25,9.87
humanized mice,20,25,9.87
symptom comorbidity,79,99,9.84
associated symptom,79,99,9.84
symptom association,79,99,9.84
cooccuring symptom,79,99,9.84
concurrent symptom,79,99,9.84
comorbid symptom,79,99,9.84
illicit opioid,147,185,9.8
illicit opiate,147,185,9.8
high-end computing,19,24,9.76
τ proteins,19,24,9.76
pain quality,19,24,9.76
x-ray,19,24,9.76
wound,15,19,9.74
transcriptional profiling,93,118,9.72
predict clinical outcome,26,33,9.72
in vivo calcium imaging,92,117,9.7
in vivo two-photon calcium imaging,92,117,9.7
fluorescent in situ hybridization,59,75,9.7
lower extremity,11,14,9.69
malignant neoplasm of gastrointestinal tract,11,14,9.69
doctor of pharmacy,11,14,9.69
pharm.d.,11,14,9.69
pharmd,11,14,9.69
lower limb,11,14,9.69
membrum inferius,11,14,9.69
malignant gastrointestinal neoplasm,11,14,9.69
gastrointestinal tract cancer,11,14,9.69
er stress,22,28,9.69
epigenome editing,11,14,9.69
mini-swine,11,14,9.69
neuroimmune system,22,28,9.69
multisensory,11,14,9.69
alzheimer model,11,14,9.69
miniature swine,11,14,9.69
minipigs,11,14,9.69
mini pig,11,14,9.69
gastrointestinal cancer,11,14,9.69
miniswine,11,14,9.69
enteric microbiome,40,51,9.67
socioeconomic disadvantage,40,51,9.67
gi microbiome,40,51,9.67
prostate,40,51,9.67
intestinal biome,40,51,9.67
gut-associated microbiome,40,51,9.67
multimodality,294,375,9.67
rheumatic arthritis,18,23,9.65
atherosclerotic disease,18,23,9.65
circadian dysregulation,18,23,9.65
microscopic imaging,25,32,9.64
microscopy imaging,25,32,9.64
conduction-blocking anesthetics,25,32,9.64
microscope imaging,25,32,9.64
dissemination of results,46,59,9.62
midwest,28,36,9.59
student-led learning,14,18,9.59
learning outcome,21,27,9.59
instably housed,35,45,9.59
disparity reduction,56,72,9.59
reduce disparity,56,72,9.59
unstably housed,35,45,9.59
pain signal,56,72,9.59
death rate,105,135,9.59
housing instability,35,45,9.59
biomarker validation,21,27,9.59
marker validation,21,27,9.59
student mentoring,14,18,9.59
unstable housing,35,45,9.59
stemness,21,27,9.59
toxic exposure,94,121,9.58
toxicant exposure,94,121,9.58
medication misuse,59,76,9.57
public health emergency,76,98,9.56
gestational opioid use,24,31,9.55
prenatal opioid use,24,31,9.55
suicide prevention,41,53,9.54
suicide precaution,41,53,9.54
suicide intervention,41,53,9.54
therapeutic evaluation,34,44,9.53
healthcare technology,64,83,9.51
therapeutic cannabis,27,35,9.51
therapeutic marijuana,27,35,9.51
medical care costs,57,74,9.5
secondary end point,20,26,9.49
chemotherapy-induced peripheral neuropathy,20,26,9.49
synthetic biology,10,13,9.49
tumor immunity,10,13,9.49
painful sensation,30,39,9.49
pain sensation,30,39,9.49
vagus nerve stimulation,10,13,9.49
tobacco-associated carcinogen,10,13,9.49
head and neck cancer patient,10,13,9.49
developmental plasticity,10,13,9.49
secondary endpoint,20,26,9.49
ribosome footprint profiling,10,13,9.49
hnc patient,10,13,9.49
tobacco carcinogen,10,13,9.49
iphone application,83,108,9.48
iphone app,83,108,9.48
smartphone application,83,108,9.48
ios application,83,108,9.48
cellular phone application,83,108,9.48
cellular phone app,83,108,9.48
smartphone app,83,108,9.48
smart phone app,83,108,9.48
cell phone app,83,108,9.48
cell phone application,83,108,9.48
opioid exposed,163,212,9.48
smart phone application,83,108,9.48
android application,83,108,9.48
ios app,83,108,9.48
electronic health care record,213,277,9.48
opiate exposed,163,212,9.48
android app,83,108,9.48
amyloid β-protein,23,30,9.46
amyloid β-peptide,23,30,9.46
faculty professional development,36,47,9.45
faculty development,36,47,9.45
teacher development,36,47,9.45
instructor training,36,47,9.45
transcriptional silencing,26,34,9.43
sleep quality,68,89,9.42
radiography,16,21,9.4
roentgenography,16,21,9.4
mobile phones,127,167,9.38
antiretroviral treatment,174,229,9.37
readmission,38,50,9.37
social standing,19,25,9.37
social position,19,25,9.37
insurance claims,19,25,9.37
community participation,19,25,9.37
optimal therapies,44,58,9.36
treatment disparity,22,29,9.36
optimal treatments,44,58,9.36
genetic architecture,41,54,9.36
disparities in treatment,22,29,9.36
primary endpoint,47,62,9.35
primary end point,47,62,9.35
rural region,138,182,9.35
overdose death,528,697,9.34
reduction in substance use,109,144,9.34
capsule,25,33,9.34
substance use reduction,109,144,9.34
translational model,34,45,9.32
multi-modal treatment,95,126,9.3
buprenorphine treatment,101,134,9.3
multi-modal therapy,95,126,9.3
economic evaluation,58,77,9.29
μor,322,428,9.28
μ-or,322,428,9.28
non-translated rna,73,97,9.28
fentanyl,363,483,9.27
drug use vulnerability,24,32,9.25
wuhan coronavirus,18,24,9.25
vulnerability to drug use,24,32,9.25
behavior construct,12,16,9.25
crispri,27,36,9.25
severe acute respiratory syndrome coronavirus 2,18,24,9.25
crispr interference,27,36,9.25
sars-related coronavirus 2,18,24,9.25
behavioral construct,12,16,9.25
sars-cov2,18,24,9.25
psychological symptom,24,32,9.25
sars-cov-2,18,24,9.25
2019-ncov,18,24,9.25
sars-associated coronavirus 2,18,24,9.25
2019 novel coronavirus,18,24,9.25
hormone signals,12,16,9.25
three-arm study,12,16,9.25
hormonal signals,12,16,9.25
gastroenterology,12,16,9.25
gender minority,12,16,9.25
survivors,45,60,9.25
sars-coronavirus-2,18,24,9.25
lysergic acid diethylamide,12,16,9.25
assess cost,74,99,9.22
cost assessment,74,99,9.22
(tnf)-α,73,98,9.19
maternal and child health,38,51,9.19
arrestin b,64,86,9.18
pain treatment,785,1056,9.17
child wellbeing,29,39,9.17
health data,49,66,9.16
videorecording,23,31,9.15
video recording,23,31,9.15
retention strategy,89,120,9.15
aβ,23,31,9.15
retention rate,89,120,9.15
microbial consortia,20,27,9.14
multispecies consortia,20,27,9.14
microbial flora,20,27,9.14
cultural competence,20,27,9.14
care delivery model,37,50,9.13
service model,37,50,9.13
service delivery model,37,50,9.13
healthcare delivery model,37,50,9.13
dashboard,51,69,9.12
emotional behavior,51,69,9.12
respiratory signs and symptoms,17,23,9.12
airway symptom,17,23,9.12
respiratory symptom,17,23,9.12
longterm potentiation,48,65,9.11
pain sensitivity,87,118,9.09
healthcare access,70,95,9.09
undergraduate,126,171,9.09
accessibility to healthcare,70,95,9.09
accessibility to health care,70,95,9.09
physical therapeutics,39,53,9.08
machine intelligence,53,72,9.08
novel biomarker,39,53,9.08
physiatric procedure,39,53,9.08
physical medicine procedure,39,53,9.08
computer reasoning,53,72,9.08
physiotherapy,39,53,9.08
longterm study,217,295,9.07
opioid use,1042,1419,9.06
multisite clinical trial,58,79,9.05
multicenter clinical trial,58,79,9.05
tobacco products,176,240,9.04
pituitary adenylate cyclase activating polypeptide,11,15,9.04
15 years of age,11,15,9.04
pituitary adenylate cyclase activating peptide,11,15,9.04
injury response,11,15,9.04
fifteen years of age,11,15,9.04
surgical complication,11,15,9.04
response to injury,11,15,9.04
north dakota,11,15,9.04
pacap,11,15,9.04
student participation,19,26,9.01
student motivation,19,26,9.01
student engagement,19,26,9.01
pre-clinical safety,19,26,9.01
high performance computing,19,26,9.01
orofacial,27,37,9.0
immune-based therapies,43,59,8.99
immune-based treatments,43,59,8.99
immuno therapy,43,59,8.99
immune therapeutic interventions,43,59,8.99
opioids in pregnancy,24,33,8.97
opioid use in pregnancy,24,33,8.97
opioids during pregnancy,24,33,8.97
nicotine user,16,22,8.97
opoid use during pregnancy,24,33,8.97
relieve pain,264,364,8.95
pain relief,264,364,8.95
administrative supplement,82,113,8.95
osteoarthritis,50,69,8.94
promoting health,63,87,8.93
population aging,21,29,8.93
service delivery,84,116,8.93
hcv incidence,21,29,8.93
hepatitis c incidence,21,29,8.93
aging population,21,29,8.93
data integration,94,130,8.92
screening tools,47,65,8.92
heavy metals,13,18,8.91
outcome assessment,52,72,8.91
knee,26,36,8.91
program costs,13,18,8.91
comparative cost effectiveness,13,18,8.91
central sensitization,36,50,8.88
crispr/cas method,169,235,8.87
crispr/cas9,169,235,8.87
crispr/cas technology,169,235,8.87
crispr-cas-9,169,235,8.87
crispr method,169,235,8.87
crispr technique,169,235,8.87
nicotine consumption,177,246,8.87
nicotine use,177,246,8.87
crispr technology,169,235,8.87
service programs,23,32,8.86
rural population,66,92,8.85
center of biomedical research excellence,56,78,8.85
cobre,56,78,8.85
centers of research excellence,56,78,8.85
individual response,33,46,8.85
individualized response,33,46,8.85
colorectal,20,28,8.81
big data tools,10,14,8.81
tooth,10,14,8.81
viread,10,14,8.81
exposure to trauma,50,70,8.81
undergraduate degree,15,21,8.81
big data methods,10,14,8.81
implementation science,323,452,8.81
community organizations,45,63,8.81
big data analytics,10,14,8.81
trauma exposure,50,70,8.81
beta-adrenergic receptor blockaders,10,14,8.81
beta blocker,10,14,8.81
career fair,15,21,8.81
career networking,15,21,8.81
methods epidemiology,20,28,8.81
imaging spectroscopy,10,14,8.81
beta-adrenergic blocking agents,10,14,8.81
tribal member,10,14,8.81
adrenergic beta-antagonists,10,14,8.81
rearrest,10,14,8.81
stress state,10,14,8.81
speed networking,15,21,8.81
provider-level barriers,10,14,8.81
professional networking,15,21,8.81
provider barriers,10,14,8.81
opioid misuse,511,715,8.81
teeth,10,14,8.81
community healthcare,40,56,8.81
stem workforce,10,14,8.81
stem career,10,14,8.81
tooth structure,10,14,8.81
nurse,89,125,8.78
conceptions,89,125,8.78
population diversity,163,229,8.78
pain measurement,106,149,8.77
analgesia tests,106,149,8.77
nicotine cessation,32,45,8.77
pain assessment,106,149,8.77
nociception tests,106,149,8.77
individual variation,93,131,8.76
individual variability,93,131,8.76
individual heterogeneity,93,131,8.76
ribotag,22,31,8.75
twitter,17,24,8.74
supportive care,29,41,8.72
meter,29,41,8.72
supportive therapy,29,41,8.72
inpatient care,29,41,8.72
data structure,12,17,8.71
lactating,12,17,8.71
early onset gene breast cancer 1,12,17,8.71
lactational,12,17,8.71
cesarean,12,17,8.71
bayesian spatial analysis,12,17,8.71
bayesian network analysis,12,17,8.71
bayesian statistical inference,12,17,8.71
abdominal delivery,12,17,8.71
bayesian statistical analysis,12,17,8.71
teratogens,12,17,8.71
medical school students,24,34,8.71
rural underserved,12,17,8.71
bayesian inference,12,17,8.71
bayesian statistics,12,17,8.71
patient selection,31,44,8.69
novel therapy approach,304,432,8.68
new therapeutic strategies,304,432,8.68
cranium,19,27,8.68
skull,19,27,8.68
new therapy approaches,304,432,8.68
computational analyses,78,111,8.67
computer analyses,78,111,8.67
postsurgical pain,132,188,8.66
post-surgical pain,132,188,8.66
human old age (65+),33,47,8.66
speed,406,579,8.65
midwestern united states,28,40,8.63
iatrogenically,21,30,8.63
orthopedic surgical profession,21,30,8.63
iatrogenic,21,30,8.63
patient preferences,28,40,8.63
β-adrenergic receptor,14,20,8.63
orthopedics,21,30,8.63
iatrogenicity,21,30,8.63
midwest us,28,40,8.63
midwest u.s.,28,40,8.63
medical device,28,40,8.63
phenomenology,21,30,8.63
newborns,128,183,8.63
phenomenological models,21,30,8.63
breathing disorder,14,20,8.63
non-steroidal antiinflammatory drugs,46,66,8.6
hands on research,30,43,8.6
stretching,23,33,8.6
hiv-1 test,39,56,8.59
hiv-2 test,39,56,8.59
decision aid,16,23,8.58
pathogenicity,64,92,8.58
hurricane,16,23,8.58
oxidative phosphorylation,16,23,8.58
cas nuclease technology,169,243,8.58
postoperative pain,132,190,8.57
inter-individual variation,34,49,8.56
interindividual variation,34,49,8.56
local anesthetics,25,36,8.56
full genome,86,124,8.55
real world application,18,26,8.54
driver mutation,18,26,8.54
device designs,18,26,8.54
neighborhood health center,27,39,8.54
user centered design,36,52,8.54
bioscience,45,65,8.54
endogenous opioids,101,146,8.53
endogenous opiate,101,146,8.53
post-operative pain,132,191,8.52
protein design,29,42,8.52
patient outcome,243,352,8.51
placenta embryonic tissue,40,58,8.51
imaging in vivo,60,87,8.51
normal placentoma,40,58,8.51
cells placenta-tissue,40,58,8.51
service providers,51,74,8.5
early life stress,42,61,8.49
methionine enkephalin,11,16,8.48
robot,11,16,8.48
alcohol impaired driving,11,16,8.48
invaded,24,35,8.46
lead candidate,35,51,8.46
machine learning,279,407,8.45
adaptive learning,13,19,8.44
daily pain,13,19,8.44
protein homeostasis,13,19,8.44
proteostasis,13,19,8.44
physical therapy,39,57,8.44
longterm care,13,19,8.44
population-level research,13,19,8.44
apprentice,13,19,8.44
population-based research,13,19,8.44
translational repression,13,19,8.44
translational inhibition,13,19,8.44
apprenticeship,13,19,8.44
contraceptive agents,13,19,8.44
antibiotic drug resistance,13,19,8.44
social media,95,139,8.43
pain interference,58,85,8.42
quality-adjusted life expectancy,28,41,8.42
health care professional practice,15,22,8.41
estrogen receptor α,15,22,8.41
estradiol receptor α,15,22,8.41
phytocannabinoid,15,22,8.41
opioid treatment program,62,91,8.4
prenatal care,47,69,8.4
antiporter,17,25,8.39
relieves symptoms,81,119,8.39
symptom alleviation,81,119,8.39
alleviate symptom,81,119,8.39
nociceptive stimulus,17,25,8.39
ameliorating symptom,81,119,8.39
decrease symptom,81,119,8.39
neurovascular,17,25,8.39
neuro-vascular,17,25,8.39
fewer symptoms,81,119,8.39
nociceptive impulse,17,25,8.39
extracellular vesicles,34,50,8.39
symptom relief,81,119,8.39
symptom reduction,81,119,8.39
reduce symptoms,81,119,8.39
minority institution,36,53,8.38
intrauterine growth,19,28,8.37
intuition,40,59,8.36
orthopedic,21,31,8.35
18 years of age,44,65,8.35
anti-sense oligo,21,31,8.35
eighteen years of age,44,65,8.35
cognitive development,73,108,8.34
µfluidic,23,34,8.34
underrepresented ethnic minority,100,148,8.33
neural precursor cell,25,37,8.33
underrepresentation of minorities,100,148,8.33
contractor,77,114,8.33
under-representation of minorities,100,148,8.33
non rapid eye movement,29,43,8.32
non-rapid eye movement,29,43,8.32
harm minimization,218,323,8.32
harm reduction,218,323,8.32
digital,176,261,8.32
nonrapid eye movement,29,43,8.32
non-rem,29,43,8.32
professional association,31,46,8.31
professional society,31,46,8.31
professional membership,31,46,8.31
chronic pain disorder,99,147,8.31
chronic pain condition,99,147,8.31
pre-clinical efficacy,35,52,8.3
technical skills,84,125,8.29
resource allocation,41,61,8.29
tobacco cessation intervention,51,76,8.28
tobacco cessation treatment,51,76,8.28
ecological momentary assessment,205,307,8.24
patient-centered outcomes,243,364,8.23
patient-focused outcomes,243,364,8.23
theory of change,12,18,8.22
coenzyme r,16,24,8.22
program sustainabilities,16,24,8.22
vitamin h,16,24,8.22
common symptom,28,42,8.22
neurosurgery,18,27,8.22
opioid policy,28,42,8.22
calcitonin gene-related peptide,14,21,8.22
brief pain inventory,14,21,8.22
innate immune response,10,15,8.22
opioid legislation,28,42,8.22
health management,28,42,8.22
trigeminal system,20,30,8.22
trigeminal,20,30,8.22
cost measures,26,39,8.22
advanced illness,14,21,8.22
program sustainability,16,24,8.22
nociceptive response,16,24,8.22
data representation,50,75,8.22
c section,12,18,8.22
intellectual and developmental disability,20,30,8.22
cesarean section,12,18,8.22
cytometry,10,15,8.22
syringe exchange,48,72,8.22
otomy,28,42,8.22
surgical incisions,28,42,8.22
incision,28,42,8.22
metastatic cancer,14,21,8.22
body water dehydration,10,15,8.22
superior colliculus corpora quadrigemina,14,21,8.22
healthcare management,28,42,8.22
effectiveness implementation trial,24,36,8.22
dehydration,10,15,8.22
opioid guideline,28,42,8.22
ppar-α,18,27,8.22
nonspecific immunity,16,24,8.22
health informatics,24,36,8.22
cancer progenitor cells,10,15,8.22
tech development,26,39,8.22
metastatic malignant neoplasm,14,21,8.22
induction of apoptosis,16,24,8.22
ligase,12,18,8.22
translational genetics,12,18,8.22
peroxisome proliferator-activated receptor α,18,27,8.22
consumer informatics,24,36,8.22
medicaid eligibility,10,15,8.22
pparα,18,27,8.22
opioid law,28,42,8.22
ethanol-induced hepatitis,18,27,8.22
syringe exchange services,48,72,8.22
syringe service programs,48,72,8.22
expression subtypes,12,18,8.22
disseminated malignant neoplasm,14,21,8.22
faculty support,10,15,8.22
synthetases,12,18,8.22
minority investigator,14,21,8.22
atod use,10,15,8.22
public health informatics,24,36,8.22
prediction model,157,236,8.2
medication therapy management,53,80,8.17
mu opioid receptors,322,486,8.17
neonatal substance withdrawal,114,172,8.17
outbreaks,55,83,8.17
disease outbreaks,55,83,8.17
therapeutic agent development,208,314,8.17
ethnicity group,90,136,8.16
depressed breathing,199,301,8.15
depression of breathing,199,301,8.15
modernization,160,242,8.15
intravenous opioid,60,91,8.13
intravenous opiate,60,91,8.13
opioid injector,60,91,8.13
opioid injection,60,91,8.13
opiate injection,60,91,8.13
deter alcohol use,25,38,8.11
alcohol use prevention,25,38,8.11
5-hydroxytryptamine receptor 2a,23,35,8.1
serotonin 5-ht-2a receptor,23,35,8.1
nanobody,23,35,8.1
nanobodies,23,35,8.1
executive impairment,63,96,8.09
executive function deficit,63,96,8.09
placentome,40,61,8.09
executive dysfunction,63,96,8.09
neuroinflammatory,204,311,8.09
3rd trimester,19,29,8.08
first responder,19,29,8.08
clinical development,123,188,8.07
surgery outcome,17,26,8.06
forward genetics,17,26,8.06
surgical outcome,17,26,8.06
kappa opiate,109,167,8.05
κ opiate,109,167,8.05
κ opioid,109,167,8.05
κor,109,167,8.05
kappa opioid,109,167,8.05
κ-or,109,167,8.05
animal pain,15,23,8.04
transposase,15,23,8.04
estrogen receptor alpha,15,23,8.04
small molecule therapeutics,15,23,8.04
estradiol receptor alpha,15,23,8.04
erα,15,23,8.04
eralpha,15,23,8.04
traumatic myelopathy,28,43,8.03
pain research,99,152,8.03
healthy life-style,13,20,8.02
clinical trial analysis,13,20,8.02
neonatal icu,13,20,8.02
pain behavior,67,103,8.02
serotonin receptor 5-ht1b,13,20,8.02
health insurance plan,39,60,8.02
predict treatment response,39,60,8.02
neuromodulatory,284,437,8.02
lenses,76,117,8.01
veterans administration,94,145,8.0
united states veterans administration,94,145,8.0
united states department of veterans affairs,94,145,8.0
dna bound,24,37,8.0
genome editing,48,74,8.0
genomic editing,48,74,8.0
drug misuse,59,91,8.0
data base,261,403,7.99
numeric rating scale,11,17,7.98
sleep apnea,22,34,7.98
acute inflammatory pain,11,17,7.98
tb infection,11,17,7.98
tuberculosis infection,11,17,7.98
human model,130,201,7.98
metabolic rate,11,17,7.98
numerical scale,11,17,7.98
intellectual functioning disability,20,31,7.96
intellectual limitation,20,31,7.96
product development,60,93,7.96
intestinal microbiome,40,62,7.96
gut microbiome,40,62,7.96
digestive tract microbiome,40,62,7.96
gastrointestinal microbiome,40,62,7.96
intellectual disability,20,31,7.96
training opportunity,130,202,7.94
motor dysfunction,18,28,7.93
nociceptin opioid receptor,18,28,7.93
exposure to tobacco,27,42,7.93
nociceptin opioid peptide receptor,18,28,7.93
anti-cancer drug,36,56,7.93
prediction algorithm,27,42,7.93
non-steroidal anti-inflammatory agents,72,112,7.93
substance misuse,108,168,7.93
motor cortex,54,84,7.93
pain intensity,100,156,7.91
integrated healthcare systems,25,39,7.91
predictive modeling,225,351,7.91
computer based prediction,225,351,7.91
integrated health system,25,39,7.91
early experience,89,139,7.9
chronic pain relief,16,25,7.89
directed molecular evolution,16,25,7.89
trp channel,16,25,7.89
synthetic cannabinoid,23,36,7.88
phagocytosis,23,36,7.88
antiinflammatory,85,133,7.88
peripheral nervous system diseases,30,47,7.87
peripheral nerve diseases,30,47,7.87
pns diseases,30,47,7.87
vivitrol,236,370,7.87
peripheral neuropathy,30,47,7.87
evaluate cost-effectiveness,30,47,7.87
cost-effectiveness evaluation,30,47,7.87
care facilities,30,47,7.87
seventeen years of age,14,22,7.85
iatrogenesis,21,33,7.85
itch sensation,28,44,7.85
safety testing,56,88,7.85
17 years of age,14,22,7.85
time study,63,99,7.85
tobacco regulatory science,54,85,7.84
high risk group,173,272,7.84
high risk population,173,272,7.84
in vivo testing,68,107,7.84
in vivo evaluation,68,107,7.84
genomic approach,47,74,7.83
genomic effort,47,74,7.83
genomic strategy,47,74,7.83
predictive biomarkers,47,74,7.83
predictive molecular biomarker,47,74,7.83
activity marker,26,41,7.82
pre-clinical development,57,90,7.81
preclinical development,57,90,7.81
geography,221,349,7.81
exclusion,83,131,7.81
congenital anatomic abnormality,19,30,7.81
electric field,19,30,7.81
ventilation,19,30,7.81
intestinal microbes,19,30,7.81
nonfatal attempt,38,60,7.81
text messaging,67,106,7.8
neuroimmune,98,155,7.8
hereditary breast cancer 1,12,19,7.79
protein biomarkers,12,19,7.79
replacement arthroplasty,12,19,7.79
ncam,12,19,7.79
cd56,12,19,7.79
joint replacement,12,19,7.79
brca1 gene,12,19,7.79
breast cancer 1 gene,12,19,7.79
protein markers,12,19,7.79
rnf53,12,19,7.79
adolescent onset binge drinking,12,19,7.79
adolescent binge alcohol drinking,12,19,7.79
ncam1,12,19,7.79
adolescent alcohol binge exposure,12,19,7.79
breast cancer type 1 susceptibility gene,12,19,7.79
bayesian analysis,12,19,7.79
brca 1 gene,12,19,7.79
brca1,12,19,7.79
mindfulness-based therapy,36,57,7.79
mindfulness treatment,36,57,7.79
synthetic cathinones,12,19,7.79
ncam1 gene,12,19,7.79
joint prosthesis implantation,12,19,7.79
mindfulness therapy,36,57,7.79
mindfulness approach,36,57,7.79
mindfulness-based treatment,36,57,7.79
bath salts,12,19,7.79
ultrasonics,24,38,7.79
mindfulness-based approach,36,57,7.79
mindfulness-based training,36,57,7.79
joint arthroplasty,12,19,7.79
mindfulness training,36,57,7.79
safety study,111,176,7.78
treatment with radiation,17,27,7.77
radiation treatment,17,27,7.77
co-morbid with depression,17,27,7.77
depression co-morbidity,17,27,7.77
post-traumatic stress,17,27,7.77
co-morbid depression,17,27,7.77
posttraumatic stress,17,27,7.77
data element,17,27,7.77
co-morbidity with depression,17,27,7.77
synthetic drug,17,27,7.77
thc use,249,396,7.76
accessibility to health services,244,388,7.76
thc co-use,249,396,7.76
treatment access,244,388,7.76
health service access,244,388,7.76
infant development,22,35,7.75
alaska indian,69,110,7.74
alaska native,69,110,7.74
alaskan american,69,110,7.74
educational environment,27,43,7.74
alaskan indian,69,110,7.74
classroom environment,27,43,7.74
alaskan native,69,110,7.74
therapy optimization,54,86,7.74
tissue collection,27,43,7.74
qualitative reasoning,113,180,7.74
tissue banks,27,43,7.74
learning environment,27,43,7.74
treatment optimization,54,86,7.74
statistical analysis,127,203,7.72
ecigarette user,55,88,7.71
live cell imaging,10,16,7.71
epistatic relationship,10,16,7.71
live cell image,10,16,7.71
cytochrome p450pcn1,10,16,7.71
breast tumor model,10,16,7.71
ecig user,55,88,7.71
live cellular image,10,16,7.71
stress symptom,10,16,7.71
unintended pregnancy,15,24,7.71
opiate drug abuse,357,571,7.71
live cellular imaging,10,16,7.71
integrated health care systems,25,40,7.71
sirt1,10,16,7.71
motrin,10,16,7.71
ibuprofen,10,16,7.71
prostate tumor cell,10,16,7.71
activated b cells,10,16,7.71
or other drug use,10,16,7.71
sirt1 gene,10,16,7.71
e-cigarette user,55,88,7.71
e-cig user,55,88,7.71
holistic approach,15,24,7.71
developmental disease,10,16,7.71
electronic cigarette user,55,88,7.71
family iii p450,10,16,7.71
opioid drug abuse,357,571,7.71
sirtuin 1,10,16,7.71
cytochrome p450 3a4,10,16,7.71
steroid-inducible p450- iii,10,16,7.71
glucocorticoid-inducible p450,10,16,7.71
nifedipine oxidase,10,16,7.71
immunes,236,378,7.7
intervention arm,63,101,7.69
treatment arm,63,101,7.69
immune system dysfunction,33,53,7.68
parent project,33,53,7.68
lens,76,122,7.68
immune system and related disorders,33,53,7.68
immunodeficiency and immunosuppression disorders,33,53,7.68
hospital readmission,38,61,7.68
immunological dysfunction,33,53,7.68
immunological system dysfunction,33,53,7.68
video recording system,23,37,7.67
education and training,74,119,7.67
lesson plans,130,209,7.67
social defeat,18,29,7.66
clinical decision support,36,58,7.66
polypharmacy,18,29,7.66
arkansas,31,50,7.65
histologically,75,121,7.64
histologic,75,121,7.64
fiber,411,664,7.63
participant recruitment,81,131,7.63
data linkages,13,21,7.63
frontal temporal dementia,13,21,7.63
functional improvement,26,42,7.63
triple-negative breast cancer,21,34,7.62
opioid antagonist,131,212,7.62
tnbc,21,34,7.62
opioid receptor antagonist,131,212,7.62
triple-negative invasive breast carcinoma,21,34,7.62
opiate receptor antagonist,131,212,7.62
healthcare service organization,34,55,7.62
healthcare organization,34,55,7.62
pain relief units,37,60,7.61
pain clinics,37,60,7.61
pain centers,37,60,7.61
artificial intelligence,53,86,7.6
ultrasonic,24,39,7.59
metabolic profile,16,26,7.59
marijuana dependent,16,26,7.59
opiate use in pregnancy,24,39,7.59
cc motif,32,52,7.59
nsaids,72,117,7.59
membrane protein gene,51,83,7.58
peripheral nerves,51,83,7.58
ecig,202,329,7.57
ecigarette,202,329,7.57
interoperability,19,31,7.56
substance using,1213,1980,7.56
appalachian,38,62,7.56
peripheral nervous system disorders,30,49,7.55
ethnically diverse,85,139,7.54
skeletal,22,36,7.54
ethnic diversity,85,139,7.54
virus reservoir,22,36,7.54
viral reservoir,22,36,7.54
blood precursor cell,11,18,7.54
children with cancer,11,18,7.54
hematopoietic stem cells,11,18,7.54
hematopoietic progenitor cells,11,18,7.54
teacher education,36,59,7.53
faculty education,36,59,7.53
teacher training,36,59,7.53
teacher preparation,36,59,7.53
faculty training,36,59,7.53
predictive marker,47,77,7.53
teacher educator,36,59,7.53
anxiety-related behavior,25,41,7.52
skill acquisition,117,192,7.52
maltreatment,89,146,7.52
mistreatment,89,146,7.52
opioid withdrawal,256,420,7.52
industry partnership,14,23,7.51
industrial partnership,14,23,7.51
high reward,56,92,7.51
respiratory failure,14,23,7.51
drug modulation,31,51,7.5
disparity in health,337,554,7.5
health plan,17,28,7.49
live birth,17,28,7.49
health plans,17,28,7.49
genomic data,71,117,7.48
infant outcome,37,61,7.48
musculoskeletal pain,37,61,7.48
sexual dimorphism,57,94,7.48
sex dimorphism,57,94,7.48
loneliness,20,33,7.47
standardization,283,467,7.47
intestinal tract microflora,26,43,7.46
gut microflora,26,43,7.46
career track,49,81,7.46
career pathway,49,81,7.46
career interest,49,81,7.46
career aspiration,49,81,7.46
clinical candidate,26,43,7.46
computing method,84,139,7.45
persons,1973,3268,7.45
neurobehavioral symptom,35,58,7.44
treatment resistance,67,111,7.44
adolescent alcohol intake,80,133,7.42
care services,95,158,7.42
youth alcohol use,80,133,7.42
youth alcohol co-use,80,133,7.42
drinking in adolescent,80,133,7.42
adolescent alcohol co-use,80,133,7.42
adolescent alcohol drinking,80,133,7.42
university atmosphere,27,45,7.4
disparity in cancer,12,20,7.4
clinically actionable,12,20,7.4
stem class,12,20,7.4
stem course,12,20,7.4
tumor microenvironment,39,65,7.4
cancer microenvironment,39,65,7.4
stem discipline,12,20,7.4
stem field,12,20,7.4
stem major,12,20,7.4
21 years of age,27,45,7.4
new marker,39,65,7.4
decision analysis,12,20,7.4
training atmosphere,27,45,7.4
twenty-one years of age,27,45,7.4
cell cortex,12,20,7.4
rural appalachian,12,20,7.4
rural appalachia,12,20,7.4
new drug class,15,25,7.4
collegial atmosphere,27,45,7.4
collegiate atmosphere,27,45,7.4
novel drug class,15,25,7.4
education atmosphere,27,45,7.4
opioid overuse,15,25,7.4
educational atmosphere,27,45,7.4
social processes,15,25,7.4
intellectual atmosphere,27,45,7.4
learning atmosphere,27,45,7.4
school atmosphere,27,45,7.4
immune-based therapeutics,12,20,7.4
anti-inflammatory effect,21,35,7.4
antiinflammatory effect,21,35,7.4
immunotherapy agent,12,20,7.4
novel marker,39,65,7.4
college atmosphere,27,45,7.4
long-term cohort study,42,70,7.4
developmental disabilities,12,20,7.4
longitudinal cohort study,42,70,7.4
behavioral prediction,24,40,7.4
molecular subsets,12,20,7.4
molecular subtypes,12,20,7.4
molecular sub-types,12,20,7.4
epigenomics,122,204,7.38
longterm depression,46,77,7.37
longterm synaptic depression,46,77,7.37
ipscs,84,141,7.35
bigdata,81,136,7.35
imaging approach,53,89,7.34
ecm,50,84,7.34
cell-extracellular matrix,50,84,7.34
pharmacologic actions,22,37,7.33
electronic learning,35,59,7.32
digital learning,35,59,7.32
type two diabetes,35,59,7.32
effectiveness implementation study,32,54,7.31
multiple chronic conditions,16,27,7.31
facebook,16,27,7.31
minority trainee,16,27,7.31
hiv 1 associated neurocognitive disorder,67,113,7.31
hiv-1 associated neurocognitive disorder,67,113,7.31
hiv-associated neurocognitive disorder,67,113,7.31
effectiveness implementation hybrid,32,54,7.31
tobacco company,29,49,7.3
growth hormone-inhibiting hormone,55,93,7.29
somatotropin release-inhibiting hormone,55,93,7.29
growth hormone release inhibiting factor,55,93,7.29
somatotropin release inhibiting factors,55,93,7.29
srih-14,55,93,7.29
plethysmography,13,22,7.29
srih,55,93,7.29
cyclic somatostatin,55,93,7.29
somatostatin-14,55,93,7.29
growth hormone inhibiting factors,55,93,7.29
neurological degeneration,110,186,7.29
connectionist models,13,22,7.29
neural network models,13,22,7.29
neural network simulation,13,22,7.29
record linkage study,13,22,7.29
perceptrons,13,22,7.29
neonatal abstinence syndrome,114,193,7.28
neonatal withdrawal syndrome,114,193,7.28
privatization,114,193,7.28
neurotrauma,23,39,7.27
tailored therapy,99,168,7.27
individualized therapy,99,168,7.27
anti-depressant agent,83,141,7.26
connectome,53,90,7.26
anti-depressants,83,141,7.26
anti-depressive agents,83,141,7.26
anti-depressant drugs,83,141,7.26
implantable device,10,17,7.25
power analysis,10,17,7.25
pharmaceutics,10,17,7.25
negative valence,40,68,7.25
infant healthcare,10,17,7.25
biomedical implant,10,17,7.25
carbol,10,17,7.25
carbolic acid,10,17,7.25
hydroxybenzene,10,17,7.25
phenols,10,17,7.25
community reintegration,10,17,7.25
oral communication,10,17,7.25
pharmacy (field),10,17,7.25
genetic selection,10,17,7.25
indwelling device,10,17,7.25
implant device,10,17,7.25
atlases,74,126,7.24
multiple drug use,27,46,7.24
health workforce,296,505,7.23
alzheimer's disease dementia,61,104,7.23
rna sequencing,411,703,7.21
rnaseq,411,703,7.21
rna seq,411,703,7.21
genetic approach,213,365,7.2
adolescent woman,21,36,7.19
disease subgroups,14,24,7.19
cerebral vascular,14,24,7.19
ovary cancer,21,36,7.19
adolescent women,21,36,7.19
cerebro-vascular,14,24,7.19
web app,14,24,7.19
community based care,14,24,7.19
biopsy specimen,14,24,7.19
biopsy sample,14,24,7.19
web application,14,24,7.19
anatomic structures,414,711,7.18
tobacco use disorder,50,86,7.17
p-glycoprotein,18,31,7.16
physical symptom,18,31,7.16
anatomic sites,414,713,7.16
pgy-1 protein,18,31,7.16
p-glycoprotein 1 gene,18,31,7.16
p-gp,18,31,7.16
multidrug resistance gene-1s,18,31,7.16
multidrug resistance gene-1,18,31,7.16
multidrug resistance 1,18,31,7.16
mdr1 protein,18,31,7.16
mdr1,18,31,7.16
abc20,18,31,7.16
mdr-1,18,31,7.16
gp170,18,31,7.16
realtime monitoring,18,31,7.16
abcb1 gene,18,31,7.16
abcb1,18,31,7.16
pgy1,18,31,7.16
kappa opioid receptors,109,188,7.15
met-enkephalin,11,19,7.14
database management,22,38,7.14
guanine,11,19,7.14
met(5)-enkephalin,11,19,7.14
peer networks,22,38,7.14
re-admission rates,11,19,7.14
chronic infection,11,19,7.14
board certification,11,19,7.14
re-hospitalization rate,11,19,7.14
hospital readmission rate,11,19,7.14
hospital re-admission rates,11,19,7.14
rehospitalization rate,11,19,7.14
5-methionine enkephalin,11,19,7.14
persistent infection,11,19,7.14
inequality,26,45,7.13
trans test,15,26,7.12
complementation test,15,26,7.12
population dynamics,15,26,7.12
genetic complementation test,15,26,7.12
head ache,41,71,7.12
allelism test,15,26,7.12
breast tumor cell line,15,26,7.12
breast cancer cell line,15,26,7.12
vapor containing nicotine,19,33,7.1
nicotine vapor,19,33,7.1
care delivery,72,125,7.1
vaporized nicotine,19,33,7.1
ligand 2,27,47,7.09
bayesian spatial models,23,40,7.09
bayesian network model,23,40,7.09
bayesian hierarchical model,23,40,7.09
social isolation,77,134,7.09
bayesian framework,23,40,7.09
bayesian adaptive models,23,40,7.09
bayesian nonparametric models,23,40,7.09
bayesian belief network,23,40,7.09
bayesian spatial image models,23,40,7.09
bayesian modeling,23,40,7.09
bayesian statistical models,23,40,7.09
bayesian belief updating model,23,40,7.09
bayesian adaptive designs,23,40,7.09
big data,81,141,7.09
bayesian spatial data model,23,40,7.09
bayesian tracking algorithms,23,40,7.09
sensory input,43,75,7.07
disabled individual,43,75,7.07
individuals with disabilities,43,75,7.07
blood cancer,12,21,7.05
hepatic toxicity,20,35,7.05
atod,12,21,7.05
chronic liver disorder,16,28,7.05
therapeutic marker,12,21,7.05
habituation,12,21,7.05
chronic hepatic disease,16,28,7.05
therapeutic biomarker,12,21,7.05
ethnic identity,12,21,7.05
hematopoietic and lymphoid neoplasms,12,21,7.05
malignant hematopoietic neoplasm,12,21,7.05
biotin,16,28,7.05
tnfr,12,21,7.05
implementation trial,52,91,7.05
chronic hepatic disorder,16,28,7.05
hematopoietic and lymphoid cell neoplasm,12,21,7.05
hematopoietic malignancies,12,21,7.05
hematopoietic neoplasms including lymphomas,12,21,7.05
hematopoietic neoplasms,12,21,7.05
physiological imaging,56,98,7.05
hematopoietic tumor,12,21,7.05
community integration,12,21,7.05
low birthweight,36,63,7.05
patient screening,16,28,7.05
low birth weight,36,63,7.05
low birth weight infant,36,63,7.05
hematopoietic cell tumor,12,21,7.05
model of animal,999,1750,7.04
astrocytic glia,190,333,7.04
precision interventions,33,58,7.02
environmental toxin,25,44,7.01
methadone treatment,71,125,7.01
methadone maintenance treatment,71,125,7.01
environmental toxicant,25,44,7.01
methadone maintenance therapy,71,125,7.01
toxic environmental substances,25,44,7.01
methadone maintenance program,71,125,7.01
toxic environmental agents,25,44,7.01
actigraphy,38,67,7.0
spatial memory,21,37,7.0
service member,21,37,7.0
imaging-based biomarker,21,37,7.0
imaging-based marker,21,37,7.0
notification,21,37,7.0
imaging-based biological marker,21,37,7.0
nociceptors,97,171,7.0
gasserian ganglion,17,30,6.99
opioid painkiller,226,399,6.99
opioid pain reliever,226,399,6.99
semilunar ganglion,17,30,6.99
opiate pain reliever,226,399,6.99
opioid anesthetic,226,399,6.99
structure of trigeminal ganglion,17,30,6.99
gasser's ganglion,17,30,6.99
trigeminal ganglias,17,30,6.99
trigeminal ganglion,17,30,6.99
negative affectivity,365,645,6.98
negative affect,365,645,6.98
intratumor heterogeneity,13,23,6.97
opioid medication,540,955,6.97
licit opioid,540,955,6.97
intra-tumoral heterogeneity,13,23,6.97
heterogeneity in tumors,13,23,6.97
intratumoral heterogeneity,13,23,6.97
pancreatic tumor cells,13,23,6.97
opiate medication,540,955,6.97
prescribed opioid,540,955,6.97
tumor heterogeneity,13,23,6.97
social stigma,315,557,6.97
prescribed opiate,540,955,6.97
soft tissue,13,23,6.97
extracellular matrix proteins,13,23,6.97
stigma,315,557,6.97
general anesthesia,13,23,6.97
tachycardia,13,23,6.97
alcoholic liver injury,48,85,6.96
data base management,22,39,6.96
phenome,22,39,6.96
summer research,40,71,6.95
formative evaluation,31,55,6.95
formative assessment,31,55,6.95
individual patient,62,110,6.95
therapeutic resistance,67,119,6.94
mental function,18,32,6.94
rabies,18,32,6.94
lyssa,18,32,6.94
caregiving,77,137,6.93
care giving,77,137,6.93
computer analysis,78,139,6.92
fetal development,32,57,6.92
computational analysis,78,139,6.92
physical inactivity,14,25,6.91
colon or rectum,14,25,6.91
alcohol rehabilitation,14,25,6.91
curative therapeutic,14,25,6.91
curative therapy,14,25,6.91
knowledge translation,14,25,6.91
lack of physical activity,14,25,6.91
peptide mimetic,14,25,6.91
peptide mimic,14,25,6.91
bisulfite-based sequencing,14,25,6.91
curative treatments,14,25,6.91
imaging system,14,25,6.91
opiates,2130,3801,6.91
curative intervention,14,25,6.91
nonsmall cell lung carcinoma,14,25,6.91
person centered,42,75,6.91
machine learned,88,157,6.91
cooperative learning,33,59,6.9
glucagon-like peptide-1 receptor,19,34,6.89
glp-i receptor,19,34,6.89
glp-1 receptor,19,34,6.89
longterm memory,29,52,6.88
long-term cohort,34,61,6.87
longitudinal cohort,34,61,6.87
longterm cohort,34,61,6.87
overdose,811,1457,6.87
k12,35,63,6.85
conformational transition,15,27,6.85
conformational conversion,15,27,6.85
positive valence,40,72,6.85
ribosome profiling,10,18,6.85
c-fos protein,10,18,6.85
functional mri scan,35,63,6.85
ribo-seq,10,18,6.85
polypeptide 4,10,18,6.85
fmri scan,35,63,6.85
fos family protein,10,18,6.85
e. coli,10,18,6.85
s-acetate coenzyme a,15,27,6.85
fbj murine osteosarcoma viral oncogene homolog,10,18,6.85
patient recruitments,81,146,6.84
teacher professional development,36,65,6.83
δ(1)-thc,82,148,6.83
δ-9-tetrahydrocannabinol,82,148,6.83
δ9-tetrahydrocannabinol,82,148,6.83
δ(1)-tetrahydrocannabinol,82,148,6.83
δ(9)-thc,82,148,6.83
δ(9)-tetrahydrocannabinol,82,148,6.83
encapsulated,36,65,6.83
biomed informatics,26,47,6.82
biomedical informatics,26,47,6.82
bleeding,21,38,6.82
urban population,21,38,6.82
blood loss,21,38,6.82
care outcomes,58,105,6.81
healthcare outcomes,58,105,6.81
temporal measurement,95,172,6.81
transcriptome sequencing,411,744,6.81
treatment services,143,259,6.81
time measurement,95,172,6.81
health care outcomes,58,105,6.81
temporal resolution,95,172,6.81
memory processing,53,96,6.81
beneficiary,38,69,6.79
emergency health care,44,80,6.78
stability testing,22,40,6.78
emergency medical care,44,80,6.78
emergency healthcare,44,80,6.78
decision modeling,11,20,6.78
hazard,88,160,6.78
animal efficacy,11,20,6.78
olfactory system,11,20,6.78
olfactory circuitry,11,20,6.78
olfactory circuits,11,20,6.78
emergency room care,44,80,6.78
ed care,44,80,6.78
microfluidic chip,11,20,6.78
er care,44,80,6.78
brain hemisphere,11,20,6.78
prescription drug monitoring program,33,60,6.78
nonprofit organizations,11,20,6.78
19s gamma globulin,11,20,6.78
prescription monitoring program,33,60,6.78
cerebral hemisphere,11,20,6.78
non-profit organizations,11,20,6.78
oophorectomy,11,20,6.78
emergency department care,44,80,6.78
liver grafting,28,51,6.77
qaly,28,51,6.77
anesthesiology,28,51,6.77
hepatic transplantation,28,51,6.77
nigms,17,31,6.76
graph theory,17,31,6.76
opioid agonist therapy,63,115,6.76
national institute of general medical sciences,17,31,6.76
opioid agonist treatment,63,115,6.76
pain disorder,46,84,6.75
strategic planning,299,546,6.75
community based participatory research,88,161,6.74
oncoprotein p53,24,44,6.73
phosphoprotein p53,24,44,6.73
protein p53,24,44,6.73
p53 tumor suppressor,24,44,6.73
cellular tumor antigen p53,24,44,6.73
p53 antigen,24,44,6.73
protein tp53,24,44,6.73
genetic repressor,12,22,6.73
antioncogene protein p53,24,44,6.73
phosphoprotein pp53,24,44,6.73
tumor protein p53,24,44,6.73
bi-sexual,24,44,6.73
nonmedical prescription drug use,36,66,6.73
technical expertise,84,154,6.73
candidate biomarker,18,33,6.73
ethnicity difference,18,33,6.73
non-medical prescription drug use,36,66,6.73
prescription medication misuse,36,66,6.73
reward anticipation,37,68,6.71
opioid habituation,56,103,6.71
personalization of treatment,167,307,6.71
movement impairment,25,46,6.7
psychomotor excitement,19,35,6.7
movement limitation,25,46,6.7
translational pipeline,19,35,6.7
translational spectrum,19,35,6.7
immunoblotting,113,208,6.7
2-photon,126,232,6.7
autistic spectrum disorder,139,256,6.7
statistical data interpretation,127,234,6.69
statistical data analysis,127,234,6.69
β-arrestin,64,118,6.69
microbiomics,13,24,6.68
intestinal microbiota,26,48,6.68
contraceptives,13,24,6.68
usual care arm,13,24,6.68
microbiome studies,13,24,6.68
microbiome science,13,24,6.68
microbiome research,13,24,6.68
usual care control group,13,24,6.68
membrane transporters,13,24,6.68
ecigarette use,126,233,6.67
epidemiologic methods,20,37,6.67
e-cigarette use,126,233,6.67
epidemiological methods,20,37,6.67
electronic cigarette use,126,233,6.67
postpartum women,33,61,6.67
ecig use,126,233,6.67
epidemiological techniques,20,37,6.67
e-cig use,126,233,6.67
acetamidophenol,20,37,6.67
chronic pain patient,120,222,6.67
preventable death,106,196,6.67
apap,20,37,6.67
acetominophen,20,37,6.67
hydroxyacetanilide,20,37,6.67
preventable mortality,106,196,6.67
patient with chronic pain,120,222,6.67
paracetamol,20,37,6.67
pain control,785,1456,6.65
data interpretation,471,874,6.65
pain therapy,785,1456,6.65
reproducibility,200,371,6.65
pain management,785,1456,6.65
synergism,158,293,6.65
biomarker discovery,14,26,6.64
pre-clinical testing,21,39,6.64
spinal cord injured,28,52,6.64
pi3k/akt,14,26,6.64
ages,836,1552,6.64
intraperitoneal injections,14,26,6.64
spinal cord trauma,28,52,6.64
novel druggable target,443,823,6.64
pi-3k/akt,14,26,6.64
spinal trauma,28,52,6.64
hemorrhage,21,39,6.64
new druggable target,443,823,6.64
oral contraceptives,14,26,6.64
extracellular matrix,50,93,6.63
e-cig aerosols,22,41,6.62
e-cig vapor,22,41,6.62
electronic cigarette vapor,22,41,6.62
e-cigarette aerosols,22,41,6.62
e-cigarette vapor,22,41,6.62
ecig aerosols,22,41,6.62
ecig vapor,22,41,6.62
ecigarette aerosols,22,41,6.62
linear regressions,22,41,6.62
ecigarette vapor,22,41,6.62
electronic cigarette aerosol,22,41,6.62
acetyl coa,15,28,6.61
differential expression,127,237,6.61
acetyl coenzyme a,15,28,6.61
coping mechanism,15,28,6.61
treatment-refractory depression,15,28,6.61
clinical biomarkers,15,28,6.61
unprotected intercourse,15,28,6.61
clinically useful biomarkers,15,28,6.61
treatment-resistant depression,15,28,6.61
condomless sex,15,28,6.61
condomless intercourse,15,28,6.61
differentially expressed,127,237,6.61
wasting,15,28,6.61
transcriptional differences,127,237,6.61
unpublished works,15,28,6.61
painful symptom,53,99,6.6
pain symptom,53,99,6.6
post-operative,99,185,6.6
postoperative period,99,185,6.6
κ opioid receptors,109,204,6.59
secondary analysis,96,180,6.58
mobile app,80,150,6.58
mobile application,80,150,6.58
tactile sensation,24,45,6.58
olfactory tubercle,16,30,6.58
tailored messaging,16,30,6.58
noncoding,73,137,6.57
epidemiology study,106,199,6.57
trust,109,205,6.56
investigational drugs,100,188,6.56
psychoeducation,33,62,6.56
postoperative,99,186,6.56
intrauterine environmental exposure,103,194,6.55
central nervous system agents,17,32,6.55
training module,111,209,6.55
refractory pain,17,32,6.55
cell metabolism,17,32,6.55
intractable pain syndrome,17,32,6.55
cellular metabaolism,17,32,6.55
cns agent,17,32,6.55
intra-uterine environmental exposure,103,194,6.55
central nervous system drugs,17,32,6.55
in utero exposure,103,194,6.55
intractable pain,17,32,6.55
fetal exposure,103,194,6.55
nanomolar,26,49,6.54
nano-molar,26,49,6.54
cd4 helper t cell,26,49,6.54
e3 ligase,18,34,6.53
small molecule inhibitor,81,153,6.53
ubiquitin-protein ligase e3,18,34,6.53
alcoholic hepatitis,18,34,6.53
atrophic arthritis,18,34,6.53
e3 ubiquitin ligase,18,34,6.53
ubiquitin-protein ligase,18,34,6.53
toxic compound,28,53,6.52
toxic substance,28,53,6.52
toxic chemical,28,53,6.52
poison,28,53,6.52
ethanol induced liver injury,48,91,6.51
ethanol induced liver disorder,48,91,6.51
ethanol induced hepatic injury,48,91,6.51
ethanol-induced hepatic dysfunction,48,91,6.51
ethanol-induced liver disease,48,91,6.51
ethanol-induced liver dysfunction,48,91,6.51
alcohol-mediated liver injury,48,91,6.51
alcohol-mediated liver dysfunction,48,91,6.51
stress and coping,48,91,6.51
alcohol-induced liver dysfunction,48,91,6.51
alcohol-induced liver disease,48,91,6.51
alcohol-induced hepatic dysfunction,48,91,6.51
alcohol induced liver injury,48,91,6.51
alcohol induced liver disorder,48,91,6.51
alcohol induced hepatic injury,48,91,6.51
alcoholic liver diseases,48,91,6.51
appalachia,38,72,6.51
appalachian region,38,72,6.51
gene modification,19,36,6.51
ethanol-mediated liver dysfunction,48,91,6.51
ethanol-mediated liver injury,48,91,6.51
alcohol co-abuse,383,728,6.49
infant mortality total,10,19,6.49
biophysical analysis,10,19,6.49
stat3,10,19,6.49
infant mortality,10,19,6.49
bacterial infectious disease treatment,10,19,6.49
thorace,20,38,6.49
etoh abuse,383,728,6.49
aged 2 years,10,19,6.49
thorax,20,38,6.49
biophysical studies,10,19,6.49
pt element,10,19,6.49
chest,20,38,6.49
aged two years,10,19,6.49
bacterial disease treatment,10,19,6.49
functional adaptation,10,19,6.49
normalities,10,19,6.49
stat3 gene,10,19,6.49
normalcy,10,19,6.49
two years of age,10,19,6.49
2 years of age,10,19,6.49
mammalian genome,10,19,6.49
platinum black,10,19,6.49
opiate receptor agonist,209,398,6.48
opioid agonist,209,398,6.48
opioid receptor agonist,209,398,6.48
translational impact,42,80,6.48
endocarditis,21,40,6.48
nicotine dependent,419,798,6.48
opiate agonist,209,398,6.48
emergency department visit,128,244,6.47
emergency care visit,128,244,6.47
emergency room visit,128,244,6.47
education research,74,141,6.47
er visit,128,244,6.47
ed visit,128,244,6.47
igm,11,21,6.46
physical activity intervention,11,21,6.46
specific child development disorders,11,21,6.46
reduced substance use,109,208,6.46
ca-sensing receptor,11,21,6.46
calcium receptors,11,21,6.46
myelogenous,22,42,6.46
car accident,11,21,6.46
junior high school student,22,42,6.46
treatment guidelines,22,42,6.46
murine model,598,1142,6.46
leukemic cell,11,21,6.46
middle school student,22,42,6.46
calcium-sensing receptors,11,21,6.46
junior high student,22,42,6.46
substance use among youth,81,155,6.45
symptom management,23,44,6.45
autoimmune diseases,23,44,6.45
manage symptom,23,44,6.45
integrative health,23,44,6.45
general taxonomy,23,44,6.45
placebo group,23,44,6.45
sham group,23,44,6.45
tobacco user,68,130,6.45
preclinical efficacy,35,67,6.44
biomarker development,24,46,6.43
muscular contraction,12,23,6.43
muscle contraction,12,23,6.43
muscle cell contraction,12,23,6.43
piriform cortex,12,23,6.43
therapeutic candidate,37,71,6.43
cigarillos,12,23,6.43
antianxiety drugs,62,119,6.43
miscellaneous antibiotic,50,96,6.42
usability,176,338,6.42
antibiotic agents,50,96,6.42
antibiotic drugs,50,96,6.42
emotional dysregulation,39,75,6.41
emotion dysregulation,39,75,6.41
minority student,13,25,6.41
gut microbiotic,26,50,6.41
dental service,13,25,6.41
gut microbiota,26,50,6.41
outpatient treatment,65,125,6.41
unscheduled dna synthesis,26,50,6.41
parvalbumins,65,125,6.41
drug modelings,92,177,6.41
transcranial magnetic stimulation,91,175,6.41
control theory,13,25,6.41
dna damage repair,26,50,6.41
visual tectum,14,27,6.4
birth control pill,14,27,6.4
anterior quadrigeminal body,14,27,6.4
optic tectum,14,27,6.4
liver transplant,28,54,6.4
contraceptive methods,15,29,6.38
anti-epileptic drugs,15,29,6.38
anti-epileptic agents,15,29,6.38
fertility control,15,29,6.38
inhibition of fertilization,15,29,6.38
contraception,15,29,6.38
memory consolidation,31,60,6.37
permissiveness,16,31,6.37
time series analysis,16,31,6.37
biotech,31,60,6.37
palliative therapy,16,31,6.37
protein inhibition,16,31,6.37
protein dynamics,16,31,6.37
needs assessment,46,89,6.37
preservation,80,155,6.37
personalized intervention,33,64,6.36
dysfunctional brain,50,97,6.36
pharmacology study,83,161,6.36
pharmacological study,83,161,6.36
brain dysfunction,50,97,6.36
doctoral student,33,64,6.36
hepatic disease,85,165,6.35
persistent pain,88,171,6.35
obsessive compulsive,17,33,6.35
mesenchymal,18,35,6.34
critical care,18,35,6.34
gene expression assay,93,181,6.34
microgliocyte,197,384,6.33
hortega cell,197,384,6.33
gitter cell,197,384,6.33
mesoglia,197,384,6.33
microglial cell,197,384,6.33
perivascular glial cell,197,384,6.33
smoking abstinence,78,152,6.33
autism spectrum disorder,139,271,6.33
minority scientist,19,37,6.33
potential biological marker,40,78,6.32
potential biomarker,40,78,6.32
hepatocarcinoma,20,39,6.32
practice management,20,39,6.32
midbrain central gray substance,60,117,6.32
calcium indicator,85,166,6.32
investigational new drugs,100,195,6.32
microbiome,40,78,6.32
nicotine exposure,112,219,6.31
exposure to nicotine,112,219,6.31
intersectionality,24,47,6.3
carbon dioxide,24,47,6.3
carbonic anhydride,24,47,6.3
monocyte chemotactive and activating factor,23,45,6.3
co2,24,47,6.3
alzheimer's amyloid beta-protein,23,45,6.3
ed patient,28,55,6.28
emergency room patient,28,55,6.28
er patient,28,55,6.28
email,89,175,6.27
electronic mail,89,175,6.27
e-mail,89,175,6.27
biopsychosocial,89,175,6.27
statistical data analyses,127,250,6.27
work group,34,67,6.26
quantitative rtpcr,35,69,6.26
quantitative reverse transcriptase pcr,35,69,6.26
qrtpcr,35,69,6.26
microglia,197,389,6.25
weaning,39,77,6.25
data resource,43,85,6.24
antibiotics,50,99,6.23
metastatic lesion,70,139,6.21
metastatic mass,70,139,6.21
cannabis use disorder,95,189,6.2
marijuana use disorder,95,189,6.2
chromatin immunoprecipitation-sequencing,87,173,6.2
chip-seq,87,173,6.2
neuromodulation,284,565,6.2
indigenous population,20,40,6.17
adaptor signaling protein gene,16,32,6.17
psychedelic drug,47,94,6.17
genetically engineered murine model,25,50,6.17
opiate pain medication,226,452,6.17
adaptor protein gene,16,32,6.17
molecular aberrations,11,22,6.17
united states health resources and services administration,15,30,6.17
clinical trials unit,11,22,6.17
health resources and services administration,15,30,6.17
antibiotic treatment,10,20,6.17
intervention participants,14,28,6.17
genetically engineered mouse model,25,50,6.17
gut epithelial permeability,12,24,6.17
adolescent health,29,58,6.17
gut hyperpermeability,12,24,6.17
gut permeability,12,24,6.17
intestinal epithelial permeability,12,24,6.17
thoracic,20,40,6.17
reductants,13,26,6.17
epigenetic variation,15,30,6.17
carcinogenicity,19,38,6.17
dysbiosis,14,28,6.17
aerosolized,10,20,6.17
10th grade,12,24,6.17
memory dysfunction,70,140,6.17
cellular metabolic process,17,34,6.17
neonatal intensive care units,13,26,6.17
apnea,15,30,6.17
delirious,14,28,6.17
delirium,14,28,6.17
malignant ovarian neoplasm,21,42,6.17
deacetylase,12,24,6.17
portraits,12,24,6.17
shisha,18,36,6.17
malignant ovarian tumor,21,42,6.17
malignant tumor of the ovary,21,42,6.17
malignant neoplasm of ovary,21,42,6.17
ovarian cancer,21,42,6.17
narghile,18,36,6.17
dysbiotic,14,28,6.17
depressive behavior,11,22,6.17
outpatient programs,18,36,6.17
endowment,21,42,6.17
outpatient services,18,36,6.17
invention,15,30,6.17
laboratory animal models,11,22,6.17
opioid pain medication,226,452,6.17
service setting,16,32,6.17
allografting,11,22,6.17
chronic liver disease,16,32,6.17
psychedelics,47,94,6.17
survivorship,10,20,6.17
antibiotic therapy,10,20,6.17
psychotomimetic agents,47,94,6.17
myeloid,22,44,6.17
psychedelic agents,47,94,6.17
placenta,40,80,6.17
laboratory exercise,18,36,6.17
laboratory assignment,18,36,6.17
laboratory activity,18,36,6.17
innate immune system,20,40,6.17
lab experiment,18,36,6.17
nicotine seeking behavior,36,72,6.17
rehabilitation research,14,28,6.17
monocyte-derived tnf,73,146,6.17
intestinal permeability,12,24,6.17
traumatic event,51,102,6.17
orphan disease,12,24,6.17
lab assignment,18,36,6.17
macrophage-derived tnf,73,146,6.17
tobacco use reduction,40,80,6.17
reduction in tobacco use,40,80,6.17
cardiovascular health,13,26,6.17
microbiota,20,40,6.17
sexual risk taking,10,20,6.17
orphan disorder,12,24,6.17
tissue repair,10,20,6.17
g protein-coupled receptor kinase family,13,26,6.17
nicotine seeking,36,72,6.17
laboratory experiment,18,36,6.17
musculoskeletal diseases,17,34,6.17
microfluidic microchips,11,22,6.17
hallucinogenic substances,47,94,6.17
microbial imbalance,14,28,6.17
somatostatin,55,110,6.17
hallucinogenic drugs,47,94,6.17
c-reactive,26,52,6.17
hallucinogenic agents,47,94,6.17
specific or class,26,52,6.17
native people,20,40,6.17
c-reactive protein,26,52,6.17
two-arm trial,11,22,6.17
ipsc,84,168,6.17
dysbacteriosis,14,28,6.17
native-born,20,40,6.17
heart function,15,30,6.17
hrsa,15,30,6.17
musculoskeletal disorder,17,34,6.17
editorial,20,40,6.17
intestinal hyperpermeability,12,24,6.17
microfluidic device,11,22,6.17
microfluidic lab-on-a-chip,11,22,6.17
risk stratification,20,40,6.17
drug abused,550,1103,6.15
prescription opiate,540,1083,6.15
abused drug,550,1103,6.15
cigarette use,250,503,6.13
targeted therapeutic,386,778,6.12
targeted drug treatments,386,778,6.12
targeted therapeutic agents,386,778,6.12
scale up,210,423,6.12
targeted drug therapy,386,778,6.12
dogs mammals,69,139,6.12
sleep disturbances,144,290,6.12
new therapy,686,1384,6.11
novel drug treatments,686,1384,6.11
new drug treatments,686,1384,6.11
new drugs,686,1384,6.11
smoking dependent,51,103,6.11
smoking dependence,51,103,6.11
novel therapy,686,1384,6.11
neuroinflammation,204,412,6.11
novel drugs,686,1384,6.11
neural control,284,575,6.09
neural regulation,284,575,6.09
preterm delivery,36,73,6.08
premature delivery,36,73,6.08
affinity purification,35,71,6.08
preterm birth,36,73,6.08
premature childbirth,36,73,6.08
premature birth,36,73,6.08
treat symptom,32,65,6.07
molecular biomarker,32,65,6.07
financial assistance,33,67,6.07
symptom treatment,32,65,6.07
dangerousness,90,183,6.07
symptomatic treatment,32,65,6.07
rural health,29,59,6.06
remifentanil,28,57,6.06
causal model,25,51,6.05
causal diagram,25,51,6.05
smoking cessation treatment,156,318,6.05
anti-cancer research,27,55,6.05
serotonin 2a receptor,23,47,6.04
cloud based,24,49,6.04
transcription co-activator,24,49,6.04
transcriptional co-activator,24,49,6.04
anti-retroviral treatment,112,229,6.03
personalized medicine,167,342,6.02
personalized therapy,167,342,6.02
sleepiness,21,43,6.02
personalized treatment,167,342,6.02
learning skill,20,41,6.02
agitation,19,39,6.01
indel,19,39,6.01
phase i clinical trials,75,154,6.01
phase i protocol,75,154,6.01
restlessness,19,39,6.01
psychomotor agitation,19,39,6.01
psychomotor restlessness,19,39,6.01
psychomotor hyperactivity,19,39,6.01
8th grade,18,37,6.0
sepsis,18,37,6.0
residential care,18,37,6.0
pparalpha,18,37,6.0
ppar alpha,18,37,6.0
bloodstream infection,18,37,6.0
peroxisome proliferator-activated receptor alpha,18,37,6.0
epidemiologic data,53,109,6.0
proliferating,90,185,6.0
μ opioid receptors,322,663,5.99
opiate therapy,102,210,5.99
opioid therapy,102,210,5.99
clinical outcome prediction,16,33,5.98
nucleus solitarius,16,33,5.98
predictor of clinical outcome,16,33,5.98
solitary nucleus,16,33,5.98
shared decision making,32,66,5.98
career path,49,101,5.98
nucleus tractus solitarii,16,33,5.98
anxiety-like behavior,144,297,5.98
periaqueductal gray,60,124,5.97
interneuron function,15,31,5.97
acute pain,227,469,5.97
annulus of the aqueduct,60,124,5.97
mesencephalic central gray,60,124,5.97
midbrain central gray,60,124,5.97
diabetic neuropathies,15,31,5.97
diabetes-associated neuropathy,15,31,5.97
microsomes,14,29,5.95
hiv and hcv,83,172,5.95
hiv and hepatitis c,83,172,5.95
hiv-hcv,83,172,5.95
industry partner,14,29,5.95
mushroom bodies,14,29,5.95
commercial application,14,29,5.95
years of life lost,14,29,5.95
beta-adrenergic receptor,14,29,5.95
ips,84,174,5.95
induced pluripotent stem cell,84,174,5.95
antibiotic resistance,13,27,5.94
drug prescriptions,174,361,5.94
dnaseq,13,27,5.94
dna sequencing,13,27,5.94
dna seq,13,27,5.94
exposed to ethanol,410,851,5.94
c. elegans,40,83,5.94
exposure to ethanol,410,851,5.94
pl104-191,25,52,5.93
observation research,75,156,5.93
mechanics,166,345,5.93
differential gene expression,38,79,5.93
pl 104-191,25,52,5.93
united states health insurance portability and accountability act,25,52,5.93
behavioral economics,113,235,5.93
metabonomics,62,129,5.93
assay development,38,79,5.93
model-based simulation,51,106,5.93
observation study,75,156,5.93
models and simulation,51,106,5.93
observational research,75,156,5.93
tissue-specific differential gene expression,38,79,5.93
public law 104-191,25,52,5.93
tissue-specific gene expression,38,79,5.93
kennedy kassebaum act,25,52,5.93
hipaa,25,52,5.93
health insurance portability and accountability act,25,52,5.93
cd8 t cells,12,25,5.92
waiver,48,100,5.92
hind brain,24,50,5.92
hindbrain,24,50,5.92
scientific inquiry,12,25,5.92
cd8+ t cell,12,25,5.92
minority-serving institution,36,75,5.92
knockin,48,100,5.92
amyloid beta,23,48,5.91
abeta,23,48,5.91
soluble amyloid precursor protein,23,48,5.91
integrative healing,23,48,5.91
autoimmune disorder,23,48,5.91
integrative medicine,23,48,5.91
mcaf,23,48,5.91
taxonomy,23,48,5.91
beta amyloid fibril,23,48,5.91
amyloid-b protein,23,48,5.91
bone,34,71,5.91
a beta peptide,23,48,5.91
personal care,34,71,5.91
amyloid protein a4,23,48,5.91
amyloid beta-peptide,23,48,5.91
alzheimer's amyloid,23,48,5.91
therapy selection,23,48,5.91
alzheimer beta-protein,23,48,5.91
carrageenan,11,23,5.9
carrageenin,11,23,5.9
mental status,22,46,5.9
ecb signaling,55,115,5.9
endoplasmic reticulum stress,22,46,5.9
mental state,22,46,5.9
m tuberculosis infection,11,23,5.9
endocannabinoid signaling,55,115,5.9
nicotine use disorder,22,46,5.9
m.tb infection,11,23,5.9
preventative strategy,225,470,5.9
m. tb infection,11,23,5.9
neuro-surgeon,11,23,5.9
non-medical use of prescription opioids,105,220,5.89
opioid medication misuse,105,220,5.89
anesthesia procedures,64,134,5.89
nonmedical use of prescription opiates,105,220,5.89
opioid analgesic misuse,105,220,5.89
knockdown,292,611,5.89
nonmedical use of prescription opioids,105,220,5.89
non-medical use of prescription opiates,105,220,5.89
opioid prescription medication misuse,105,220,5.89
neurodevelopment,200,419,5.89
cancer care,21,44,5.89
neural development,200,419,5.89
prescription opiate misuse,105,220,5.89
postpartum period,75,157,5.89
immunological response,91,191,5.88
cephalgia,41,86,5.88
bio-markers,501,1051,5.88
cephalodynia,41,86,5.88
cranial pain,41,86,5.88
head pain,41,86,5.88
mechanical allodynia,31,65,5.88
immunoregulatory,31,65,5.88
immunomodulatory,31,65,5.88
immune regulation,31,65,5.88
cephalalgia,41,86,5.88
mammary tumor model,10,21,5.87
prostate cancer cell,10,21,5.87
mechanical,166,349,5.87
mammary cancer model,10,21,5.87
breast cancer model,10,21,5.87
stromal cells,10,21,5.87
acetaminophen,20,42,5.87
science teacher,10,21,5.87
noninvasive imaging,10,21,5.87
science professional,10,21,5.87
historically black university,20,42,5.87
science educator,10,21,5.87
hiv anti-retroviral,10,21,5.87
brain blood flow,19,40,5.86
cerebrovascular blood flow,19,40,5.86
life expectancy,87,183,5.86
therapy resistant,67,141,5.86
mglur5b,19,40,5.86
grm5,19,40,5.86
gprc1e,19,40,5.86
mglur5a,19,40,5.86
grm5 gene,19,40,5.86
resistant to therapy,67,141,5.86
resistance to therapy,67,141,5.86
tobacco dependent,160,337,5.86
mglu5,19,40,5.86
mglur5,19,40,5.86
drug adherence,101,213,5.85
drug compliance,101,213,5.85
cell body,1629,3437,5.85
opioid maintenance therapy,36,76,5.84
cancer initiation,18,38,5.84
opioid maintenance treatment,36,76,5.84
opiate replacement therapy,36,76,5.84
opioid replacement therapy,36,76,5.84
opiate substitution treatment,36,76,5.84
precision prevention,18,38,5.84
opioid replacement treatment,36,76,5.84
opioid substitution therapy,36,76,5.84
opioid substitution treatment,36,76,5.84
basal transcription factor genes,223,471,5.84
opiate substitution therapy,36,76,5.84
personalized prevention,18,38,5.84
improved outcome,264,558,5.84
canine species,69,146,5.83
canis familiaris,69,146,5.83
designer receptors exclusively activated by designer drugs,237,501,5.83
dreadds,237,501,5.83
canine,69,146,5.83
domestic dog,69,146,5.83
public health practice,17,36,5.82
smoke addiction,51,108,5.82
smoking addiction,51,108,5.82
cost analysis,74,157,5.81
environmental health,24,51,5.8
palliative care,16,34,5.8
comfort care,16,34,5.8
environmental health science,24,51,5.8
palliative treatment,16,34,5.8
environmental impact,16,34,5.8
healthcare expenditure,23,49,5.79
dna injury,38,81,5.79
antidepressant effect,30,64,5.78
novel drug target,443,946,5.78
anti-depressant effect,30,64,5.78
sensor,247,527,5.78
new drug target,443,946,5.78
novel pharmacotherapy target,443,946,5.78
statistical linear mixed models,74,158,5.78
predictive analytics,15,32,5.78
baccalaureate degree,15,32,5.78
new therapy target,443,946,5.78
probability models,74,158,5.78
statistical linear models,74,158,5.78
new pharmacotherapy target,443,946,5.78
bachelor's degree,15,32,5.78
novel therapy target,443,946,5.78
sexual minority,29,62,5.77
thc exposure,22,47,5.77
tetrahydrocannabinol exposure,22,47,5.77
basal transcription factor,223,477,5.77
general transcription factors,223,477,5.77
neutrophil,22,47,5.77
pruritic disorder,28,60,5.76
data archive,14,30,5.76
spinal cord injury,28,60,5.76
federal policy,21,45,5.76
itching,28,60,5.76
heroin use,99,212,5.76
sterility,21,45,5.76
preventive care,14,30,5.76
preventative care,14,30,5.76
heroin intake,99,212,5.76
sterile,21,45,5.76
salt,43,92,5.76
sodium chloride,43,92,5.76
pruritus,28,60,5.76
drug regulations,27,58,5.74
ninds,65,140,5.73
national institute of neurological disorders and stroke,65,140,5.73
reducing agents,13,28,5.73
endomicroscopy,13,28,5.73
microendoscopy,13,28,5.73
neuropsychiatric symptom,13,28,5.73
pathologic,337,725,5.73
secondary student,66,142,5.73
dental procedure,13,28,5.73
tnf alpha,73,157,5.73
whole genome,86,185,5.73
brain-derived neurotrophic factor receptor,13,28,5.73
entire genome,86,185,5.73
tnfa,73,157,5.73
dental care,13,28,5.73
proteome,73,157,5.73
secondary school student,66,142,5.73
low blood pressure,13,28,5.73
hallucinations,19,41,5.72
fetal alcohol spectrum disorder,25,54,5.71
fasd,25,54,5.71
biosensor,99,214,5.71
tnf-α,73,158,5.7
titrations,37,80,5.7
tnfα,73,158,5.7
tenth grade,12,26,5.69
high school sophomore,12,26,5.69
backache,30,65,5.69
back ache,30,65,5.69
anzatax,18,39,5.69
asotax,18,39,5.69
bristaxol,18,39,5.69
paclitaxel,18,39,5.69
paclitaxel (taxol),18,39,5.69
praxel,18,39,5.69
taxol,18,39,5.69
prostatic gland,18,39,5.69
prostate gland,18,39,5.69
taxol a,18,39,5.69
data analytics,78,169,5.69
taxol konzentrat,18,39,5.69
therapeutic outcome,24,52,5.69
back pain,30,65,5.69
il-1 β,36,78,5.69
legalized cannabis,54,117,5.69
incentive salience,84,182,5.69
il-1β,36,78,5.69
marijuana legalization,54,117,5.69
legalized marijuana,54,117,5.69
symposia,317,687,5.69
legal marijuana,54,117,5.69
il1-β,36,78,5.69
cannabis legalization,54,117,5.69
alcohol risk,149,323,5.69
gynecology,18,39,5.69
summit,317,687,5.69
interleukin-1β,36,78,5.69
convention,317,687,5.69
cirrhotic,48,104,5.69
behavioral health intervention,12,26,5.69
real time monitoring,18,39,5.69
targeted treatment,386,838,5.68
targeted therapy,386,838,5.68
opiate user,99,215,5.68
opioid drug user,99,215,5.68
opioid user,99,215,5.68
ablation,134,291,5.68
dsm5,75,163,5.67
dsm-5,75,163,5.67
cannabinoid receptor type 2,51,111,5.67
p38 map kinase,17,37,5.67
sleep architecture,23,50,5.67
socio-economic,250,544,5.67
emergency department patient,28,61,5.66
brain initiative,28,61,5.66
translation strategy,61,133,5.66
health care settings,101,220,5.66
translational strategy,61,133,5.66
healthcare settings,101,220,5.66
dna damage,38,83,5.65
compassion,11,24,5.65
process optimization,11,24,5.65
infertile,11,24,5.65
infertility,11,24,5.65
neurosurgeon,11,24,5.65
evaluation/testing,11,24,5.65
university medical centers,71,155,5.65
academic medical centers,71,155,5.65
repetitive transcranial magnetic stimulation,33,72,5.65
short interfering rna,60,131,5.65
female gonadectomy,11,24,5.65
difficulty conceiving,11,24,5.65
cannot achieve a pregnancy,11,24,5.65
evidence based intervention,236,515,5.65
nchs,16,35,5.64
hybrids,202,442,5.64
cell membrane lipids,16,35,5.64
united states national center for health statistics,16,35,5.64
national center for health statistics,16,35,5.64
neuropsychopharmacology,16,35,5.64
receptor tyrosine kinase gene,16,35,5.64
prevention trial,16,35,5.64
sexual health,21,46,5.63
medication-assisted treatment,146,320,5.63
multi-modal imaging,21,46,5.63
resilience,228,500,5.62
collaborative environment,31,68,5.62
interactive environment,31,68,5.62
peer-group environment,31,68,5.62
interdisciplinary environment,31,68,5.62
business-friendly environment,31,68,5.62
emotional regulation,103,226,5.62
undergraduate student,126,277,5.61
wound repair,15,33,5.61
anxious symptom,60,132,5.61
population sizes,15,33,5.61
clinical trial protocol,10,22,5.61
economic models,25,55,5.61
social engagement,10,22,5.61
homeless persons,10,22,5.61
social involvement,10,22,5.61
the jackson laboratory,25,55,5.61
toxicokinetics,15,33,5.61
förster resonance energy transfer,20,44,5.61
social participation,10,22,5.61
immobilization,20,44,5.61
anti-inflammatories,120,264,5.61
fmrp protein,10,22,5.61
fmr1 protein,10,22,5.61
orthopedic freezing,20,44,5.61
fmr-1 protein,10,22,5.61
newborn care,10,22,5.61
immune suppression,30,66,5.61
baby care,10,22,5.61
computational science,20,44,5.61
fragile x mental retardation protein,10,22,5.61
fragile x fmr1 protein,10,22,5.61
fragile x mental retardation-1 protein,10,22,5.61
general transcription factor gene,223,491,5.6
transcription factor proto-oncogene,223,491,5.6
inpatient service,29,64,5.59
maximally tolerated dose,24,53,5.58
maximal tolerated dose,24,53,5.58
frequencies,516,1140,5.58
maximum tolerated dose,24,53,5.58
psychological well being,19,42,5.58
mental well-being,19,42,5.58
self wellness,19,42,5.58
ventilatory depression,199,440,5.58
respiratory depression,199,440,5.58
psychological wellness,19,42,5.58
electrostimulation,71,157,5.58
emotional well being,19,42,5.58
feels well,19,42,5.58
normal mental condition,19,42,5.58
normal mental state,19,42,5.58
normal psyche,19,42,5.58
sense of well-being,19,42,5.58
well in self,19,42,5.58
spinal ganglia,88,195,5.57
liver transplantation,28,62,5.57
neuropsychiatric disorder,287,636,5.57
pruritis,28,62,5.57
androgen receptor,14,31,5.57
neuropsychiatric disease,287,636,5.57
amyloid beta-protein,23,51,5.56
individualized prevention,18,40,5.55
pancreas ductal adenocarcinoma,18,40,5.55
health hazards,18,40,5.55
il1β,36,80,5.55
guide rna,27,60,5.55
grna,27,60,5.55
pancreatic ductal adenocarcinoma,18,40,5.55
drug prescribing,174,387,5.55
family support,18,40,5.55
exome-seq,22,49,5.54
memantine,13,29,5.53
memantin,13,29,5.53
trainers training,13,29,5.53
rat genome,17,38,5.52
excretory function,47,105,5.52
telemedicine,60,134,5.52
societal costs,64,143,5.52
beta-arrestin,64,143,5.52
incubated,59,132,5.51
anatomy,414,927,5.51
opioid analgesia,226,507,5.5
opiate analgesic,226,507,5.5
anti-inflammatory agents,120,269,5.5
opiate analgesia,226,507,5.5
clinical predictors,29,65,5.5
transcription factor genes,223,500,5.5
ion channel gating,45,101,5.5
low socio-economic position,77,173,5.49
mhealth,130,292,5.49
mobile health,130,292,5.49
care seeking,49,110,5.49
low socio-economic status,77,173,5.49
m-health,130,292,5.49
low socioeconomic position,77,173,5.49
disease marker,12,27,5.48
preventative treatment,12,27,5.48
preventive treatment,12,27,5.48
arthroplasty,12,27,5.48
oncology cancer,40,90,5.48
immune drugs,12,27,5.48
telemetries,24,54,5.48
post-synaptic neurons,28,63,5.48
electrophysiological,836,1880,5.48
neuron death,36,81,5.48
postsynaptic neurons,28,63,5.48
psychiatric symptom,52,117,5.48
post-synaptic nerves,28,63,5.48
nerve cell death,36,81,5.48
nerve cell loss,36,81,5.48
neuron cell loss,36,81,5.48
neuronal death,36,81,5.48
neuronal cell loss,36,81,5.48
postsynaptic nerves,28,63,5.48
environmental exposure,106,239,5.47
neuronal circuit,148,334,5.47
community outreach,39,88,5.47
excretion,47,106,5.47
reproductive,83,187,5.47
alcohol co-morbidity,51,115,5.47
alcohol comorbidity,51,115,5.47
predictive factor,47,106,5.47
chronic low back pain,55,124,5.47
privacy,46,104,5.46
inbred strains rats,23,52,5.46
freund's complete adjuvant,23,52,5.46
handheld mobile device,54,122,5.46
interruption,101,228,5.46
mobile device,54,122,5.46
image-based method,73,165,5.46
talents,76,172,5.45
major depression disorder,131,297,5.44
virtual,272,617,5.44
smoking during pregnancy,15,34,5.44
alcohol consequences,94,213,5.44
mild cognitive disorder,11,25,5.43
therapeutic response,215,488,5.43
olfactory pathways,11,25,5.43
mild cognitive impairment,11,25,5.43
relapse patients,22,50,5.43
slow-wave sleep,22,50,5.43
delta wave sleep,22,50,5.43
delta wave,22,50,5.43
reproductive health,22,50,5.43
meta data,22,50,5.43
response to treatment,215,488,5.43
alcohol prevention,40,91,5.42
colo-rectal cancer,18,41,5.41
gene expression analysis,93,212,5.41
candidate marker,18,41,5.41
capital,43,98,5.41
spottings,32,73,5.41
screening program,25,57,5.41
eighth grade,18,41,5.41
monetary incentive,50,114,5.41
anesthesia,64,146,5.41
parent grant,90,205,5.41
morphine equivalent,18,41,5.41
morphine equivalence,18,41,5.41
financial reward,50,114,5.41
support tools,49,112,5.4
peripheral blood mononuclear cell,42,96,5.4
b cell receptor,14,32,5.4
hiv antibody positive,42,96,5.4
resistance mechanism,46,105,5.4
resistant mechanism,46,105,5.4
dorsal root ganglion,88,201,5.4
serious adverse event,35,80,5.4
care givers,123,281,5.4
complication,28,64,5.4
cost analyses,74,169,5.4
morphine tolerance,14,32,5.4
pbmc,42,96,5.4
eeg,189,432,5.4
dorsal root ganglia,88,201,5.4
respiration disorders,14,32,5.4
pregnant,132,302,5.39
uropancreozymin,24,55,5.38
hypoglycemic,17,39,5.38
hypoglycemic episodes,17,39,5.38
faculty research,24,55,5.38
caregivers,123,282,5.38
intern,24,55,5.38
migraine headache,37,85,5.37
chronic neuropathic pain,54,124,5.37
2 year old,10,23,5.36
nodule,10,23,5.36
subfamily iiia,10,23,5.36
platinum,10,23,5.36
age 2 years,10,23,5.36
two year old,10,23,5.36
drug withdrawal symptoms,10,23,5.36
young woman,30,69,5.36
clinical risk,20,46,5.36
health care service use,90,207,5.36
drug quality,10,23,5.36
healthcare service use,90,207,5.36
antibiotic resistant,13,30,5.34
cognitive reappraisal,26,60,5.34
good laboratory practice,13,30,5.34
stressful event,65,150,5.34
cognitive regulation,26,60,5.34
outcome prediction,58,134,5.34
resistant to antibiotics,13,30,5.34
resistance to antibiotics,13,30,5.34
pediatric patients,19,44,5.33
child patients,19,44,5.33
multicenter trials,16,37,5.33
support network,38,88,5.33
computational technique,25,58,5.32
activities of daily living,22,51,5.32
penetrance,22,51,5.32
functional capacity,22,51,5.32
neuropathic pain,202,468,5.32
painful neuropathy,202,468,5.32
daily living functionality,22,51,5.32
activities of everyday life,22,51,5.32
antisense oligonucleotides,25,58,5.32
disease of the lung,41,95,5.32
disorder of the lung,41,95,5.32
neuropathic,99,230,5.31
neuronal injury,34,79,5.31
opiate dependence,1157,2687,5.31
cognitive performance,56,130,5.31
opiate addiction,1157,2687,5.31
managed care,34,79,5.31
neuron injury,34,79,5.31
metadate,31,72,5.31
daytrana,31,72,5.31
concerta,31,72,5.31
e-cig,202,470,5.3
e-cigarette,202,470,5.3
electronic cigarette,202,470,5.3
health insurance for disabled,45,105,5.29
nosology,21,49,5.29
il1f2,36,84,5.29
il-1-b,36,84,5.29
disorder classification,21,49,5.29
medicare,45,105,5.29
il1-beta,36,84,5.29
health insurance for disabled title 18,45,105,5.29
il1b protein,36,84,5.29
health insurance for aged and disabled,45,105,5.29
prevent tobacco use,15,35,5.29
preinterleukin 1 beta,36,84,5.29
interleukin-1 beta,36,84,5.29
disease classification,21,49,5.29
interleukin 1beta,36,84,5.29
pain patient,54,126,5.29
il-1 beta,36,84,5.29
child development disorders,12,28,5.29
beta proprotein interleukin 1,36,84,5.29
rhombencephalon,24,56,5.29
neuranatomy,79,185,5.27
neuroanatomies,79,185,5.27
positive allosteric modulator,44,103,5.27
epigenome,85,199,5.27
neuranatomies,79,185,5.27
digital education,35,82,5.26
multimedia learning,35,82,5.26
computer-based training,35,82,5.26
computer-based learning,35,82,5.26
computer-based instruction,35,82,5.26
elearning,35,82,5.26
e-learning,35,82,5.26
sexual orientation,29,68,5.26
internet-based training,35,82,5.26
online education,35,82,5.26
online learning,35,82,5.26
health organization,26,61,5.26
technology-enhanced learning,35,82,5.26
virtual learning,35,82,5.26
web-based training,35,82,5.26
cognitive process,104,244,5.26
monocyte chemotactic and activating factor,23,54,5.25
monocyte chemoattractant protein-1,23,54,5.25
monocyte chemotactic and activating protein,23,54,5.25
sicklemia,20,47,5.25
monocyte secretory protein je,23,54,5.25
sickle disease,20,47,5.25
permission,60,141,5.25
authorization,60,141,5.25
authorization documentation,60,141,5.25
monocyte chemotactic protein-1,23,54,5.25
hemoglobin s disease,20,47,5.25
hemoglobin sickle cell disorder,20,47,5.25
sickle cell disease,20,47,5.25
5-ht2a receptor,23,54,5.25
5-ht(2a) receptor,23,54,5.25
hbss disease,20,47,5.25
hemoglobin sickle cell disease,20,47,5.25
hb ss disease,20,47,5.25
mint,17,40,5.24
genus mentha,17,40,5.24
crying,17,40,5.24
p38 sapk,17,40,5.24
p38 protein kinase,17,40,5.24
neuropathy,99,233,5.24
mentha,17,40,5.24
peripheral nerve injury,25,59,5.23
ip injection,14,33,5.23
cocaine dependence,235,554,5.23
optimism,25,59,5.23
physical function,39,92,5.23
novel therapeutic intervention,304,718,5.22
smart phone,163,385,5.22
pediatric department,11,26,5.22
new therapeutic intervention,304,718,5.22
novel therapeutic approach,304,718,5.22
tumor genome,11,26,5.22
attentional control,33,78,5.22
community surveys,11,26,5.22
cancer cell genome,11,26,5.22
methamphetamine effect,55,130,5.22
iphone,163,385,5.22
vaporizer,11,26,5.22
smartphone,163,385,5.22
meth effect,55,130,5.22
new therapeutic approach,304,718,5.22
spatiotemporal,126,298,5.21
headache,41,97,5.21
preclinical safety,19,45,5.21
routine care,30,71,5.21
third trimester,19,45,5.21
cannabidiol,49,116,5.21
third pregnancy trimester,19,45,5.21
interpersonal relationship,19,45,5.21
b cells,30,71,5.21
b cell,30,71,5.21
hepatitis c virus treatment,27,64,5.2
hcv therapy,27,64,5.2
unborn,189,448,5.2
hcv treatment,27,64,5.2
prenatal,189,448,5.2
hepatitis c treatment,27,64,5.2
pleiotropic effect,27,64,5.2
training status,53,126,5.19
educational level,53,126,5.19
cck,24,57,5.19
pancreozymin,24,57,5.19
bacterial infections,16,38,5.19
tribes,48,114,5.19
educational status,53,126,5.19
training achievement,53,126,5.19
cannabis use,249,592,5.19
bacterial disease,16,38,5.19
educational achievement,53,126,5.19
biosignature,16,38,5.19
child well being,29,69,5.18
nociceptive,219,521,5.18
nociception,219,521,5.18
anti-retroviral therapy,112,267,5.17
anti-hypertensive agents,13,31,5.17
anti-hypertensives,13,31,5.17
anti-hypertensive drugs,13,31,5.17
frontotemporal dementia,13,31,5.17
hypotensive drugs,13,31,5.17
hypotensive agent,13,31,5.17
frontotemporal lobar dementia,13,31,5.17
psychiatric illness,801,1912,5.17
gwa study,227,541,5.17
assessment tool,36,86,5.16
g protein-coupled receptor genes,249,595,5.16
gpcr,249,595,5.16
computational tools,54,129,5.16
computerized tools,54,129,5.16
assessment instrument,36,86,5.16
prescription misuse,36,86,5.16
recommendation,397,951,5.15
gene expression pattern,142,340,5.15
certification,43,103,5.15
histopathology,28,67,5.15
tumor biology,15,36,5.14
filament,10,24,5.14
prenatally exposed,103,247,5.14
internet portal,10,24,5.14
scientific accomplishments,93,223,5.14
iron,25,60,5.14
fe element,25,60,5.14
rural community,85,204,5.14
anesthestic drugs,55,132,5.14
vesicle release,20,48,5.14
abdomen,15,36,5.14
scientific advances,93,223,5.14
intranasal administration,15,36,5.14
withdrawal-induced anxiety,25,60,5.14
scientific advances and accomplishments,93,223,5.14
clinical care,207,497,5.14
web portal,10,24,5.14
safety monitoring boards,15,36,5.14
ethanol during adolescence,80,192,5.14
alcohol use in adolescents,80,192,5.14
anesthetic agents,55,132,5.14
alcohol use in adolescence,80,192,5.14
anesthetic drugs,55,132,5.14
relapse risk,188,451,5.14
data and safety monitoring boards,15,36,5.14
data monitoring committees,15,36,5.14
tissue basophils,10,24,5.14
intranasal drug administration,15,36,5.14
gaba-b receptor,10,24,5.14
prenatal exposure,103,247,5.14
mastocyte,10,24,5.14
marrow mast cell,10,24,5.14
vesicular release,20,48,5.14
clinical trials data monitoring committees,15,36,5.14
fibrosis,30,72,5.14
painful,1259,3019,5.14
baclofen receptors,10,24,5.14
perinatal,83,199,5.14
health communication,37,89,5.13
population heterogeneity,163,392,5.13
chip sequencing,87,209,5.13
cognitive testing,59,142,5.12
calories,22,53,5.12
hepatitis c therapeutics,27,65,5.12
electronic health record,213,513,5.12
standard of care,179,431,5.12
cognitive assessment,59,142,5.12
ownership,22,53,5.12
personalized patient care,17,41,5.11
individualized care,17,41,5.11
individualized patient care,17,41,5.11
phase 1 clinical trials,75,181,5.11
class development,17,41,5.11
early-stage clinical trials,75,181,5.11
course development,17,41,5.11
course material development,17,41,5.11
precision care,17,41,5.11
cell type,795,1924,5.1
cognitive syndrome,24,58,5.1
disease resistance,12,29,5.1
devices,329,796,5.1
adolescent brain development,19,46,5.09
relapse against cocaine,76,184,5.09
cocaine relapse,76,184,5.09
sleep monitoring,33,80,5.09
dna repair,26,63,5.09
systems integration,19,46,5.09
intramuscular,19,46,5.09
cutaneous,19,46,5.09
cancer survivor,19,46,5.09
primary care provider,90,218,5.09
kinase family gene,33,80,5.09
student training,26,63,5.09
neural model,28,68,5.08
candidate selection,14,34,5.08
pregnant women,222,539,5.08
career choice,49,119,5.08
nonsteroidal antiinflammatory agents,46,112,5.07
biopsy,37,90,5.07
neuroaids,51,124,5.07
non steroidal antiinflammatory agents,46,112,5.07
hcv/hiv,83,202,5.07
serotonin receptor agonists,16,39,5.06
needle exchange,48,117,5.06
chronic constriction injury,16,39,5.06
prospective test,16,39,5.06
syringe-exchange programs,48,117,5.06
needle-exchange programs,48,117,5.06
urban indian,16,39,5.06
serotonin agonists,16,39,5.06
suicide rate,16,39,5.06
serotonergic agonists,16,39,5.06
5-hydroxytrytamine agonist,16,39,5.06
5-hydroxytryptamine agonists,16,39,5.06
modifiable risk,55,134,5.06
5-ht agonists,16,39,5.06
wrist,16,39,5.06
automation,16,39,5.06
two-photon,126,307,5.06
cultural values,18,44,5.05
data warehouse,36,88,5.05
population intervention,27,66,5.05
hospital stay,77,188,5.05
hepatitis c therapy,27,66,5.05
hospital days,77,188,5.05
number of days in hospital,77,188,5.05
industrialization,18,44,5.05
title 18,90,220,5.05
rdoc,45,110,5.05
rheumatoid arthritis,18,44,5.05
length of stay,77,188,5.05
transportation,69,169,5.04
toll homologue,31,76,5.03
homolog of drosophila toll,31,76,5.03
habenula,126,309,5.03
neuroplastic,237,582,5.02
γ-aminobutyric acid,286,703,5.02
faah inhibitor,11,27,5.02
oncogenomics,11,27,5.02
fatty acid amide hydrolase inhibitor,11,27,5.02
health service use,41,101,5.01
powders,26,64,5.01
health service utilization,41,101,5.01
powder dose form,26,64,5.01
approach-avoidance conflict,13,32,5.01
enzyme gene,315,775,5.01
tobacco-related cancer,15,37,5.0
wound healing,15,37,5.0
tobacco-induced cancer,15,37,5.0
lofexidine,15,37,5.0
digestion,15,37,5.0
hallucinogens,47,116,5.0
anxiety symptoms,60,148,5.0
tobacco-related carcinoma,15,37,5.0
adverse reactions,15,37,5.0
calcium mobilization,19,47,4.99
histone deacetylase inhibition,19,47,4.99
medicaid,134,331,4.99
release of sequestered calcium ion into cytoplasm,19,47,4.99
biophysical characteristics,23,57,4.98
biophysical measurement,23,57,4.98
biophysical characterization,23,57,4.98
biophysical properties,23,57,4.98
biophysical parameters,23,57,4.98
virtual reality,50,124,4.97
visceral,25,62,4.97
economic outcome,27,67,4.97
inflammatory pain,76,189,4.96
mentorship,646,1605,4.96
memory retrieval,39,97,4.96
qualitative research,99,246,4.96
professional positions,59,147,4.95
ko mice,242,603,4.95
tissue chip,18,45,4.93
sickle cell anemia,20,50,4.93
opioid tolerance,56,140,4.93
na+ element,10,25,4.93
sickle red blood cell,12,30,4.93
unintentional injury,16,40,4.93
genome engineering,10,25,4.93
non-invasive imaging,10,25,4.93
general anesthetics,10,25,4.93
accidental injury,16,40,4.93
sickle erythrocyte,12,30,4.93
peptide hormone gene,12,30,4.93
sickle rbc,12,30,4.93
alabama,30,75,4.93
sickle cell,12,30,4.93
tissue microarray,18,45,4.93
hematological tumor,16,40,4.93
tissue arrays,18,45,4.93
computational resources,12,30,4.93
ecb system,62,155,4.93
telemetry,24,60,4.93
tat protein,10,25,4.93
transactivating regulatory protein,10,25,4.93
trans-activator of transcription of hiv,10,25,4.93
socioeconomically,250,625,4.93
hematologic cancer,16,40,4.93
integrative treatment,16,40,4.93
neuroimmune processes,26,65,4.93
integrative therapy,16,40,4.93
trans-activation of transcription protein,10,25,4.93
hematologic malignancies,16,40,4.93
hematologic neoplasms,16,40,4.93
hematological malignancies,16,40,4.93
hematological neoplasms,16,40,4.93
malignant hematologic neoplasm,16,40,4.93
neuroimmune mechanisms,26,65,4.93
vocabulary words,18,45,4.93
vocabulary,18,45,4.93
adaptive immunity,12,30,4.93
hematopoietic cancer,16,40,4.93
bone fracture,32,80,4.93
fracture,32,80,4.93
hdac3,12,30,4.93
ontology,24,60,4.93
alcohol-related death,16,40,4.93
hdac3 gene,12,30,4.93
study population,36,90,4.93
neuro-imaging,508,1272,4.93
rpd3-2,12,30,4.93
signaling factor proto-oncogene,97,243,4.92
individualized patient treatment,99,248,4.92
investigational new drug application,53,133,4.91
biomedical engineering,37,93,4.91
bioengineering,37,93,4.91
cell injury,29,73,4.9
cell damage,29,73,4.9
cellular injury,29,73,4.9
neurocognitive decline,64,161,4.9
sex orientation,29,73,4.9
neurocognitive impairment,64,161,4.9
emergency care,44,111,4.89
clampings,21,53,4.89
closure by clamp,21,53,4.89
vulnerable group,327,824,4.89
freund's adjuvant,23,58,4.89
patient safety,23,58,4.89
substance use disorder,1514,3816,4.89
stress reactivity,61,154,4.89
neutralizing antibody,23,58,4.89
care access,244,615,4.89
cytochrome p450 family gene,23,58,4.89
centers for medicare and medicaid services,17,43,4.88
united states centers for medicare and medicaid services,17,43,4.88
united states health care financing administration,17,43,4.88
transgender,19,48,4.88
health care financing administration,17,43,4.88
signaling pathway gene,97,245,4.88
acupuncture therapy,19,48,4.88
last trimester,19,48,4.88
national institutes of health,1355,3435,4.87
dissociation,105,266,4.87
united states national institutes of health,1355,3435,4.87
nih,1355,3435,4.87
cats mammals,15,38,4.87
small business technology transfer research,41,104,4.86
sttr,41,104,4.86
drug discovery,234,594,4.86
inflammatory,326,827,4.86
program dissemination,13,33,4.86
project dissemination,13,33,4.86
nonsteroidal anti-inflammatory agents,46,117,4.85
west virginia,37,94,4.85
poststroke,11,28,4.85
post stroke,11,28,4.85
nalmefene,11,28,4.85
case report form,11,28,4.85
chronic back pain,22,56,4.85
food craving,22,56,4.85
polysomnographic,33,84,4.85
somnography,33,84,4.85
ifn,33,84,4.85
drug evaluation studies,11,28,4.85
extracellular calcium-ion sensing receptor,11,28,4.85
sleep polysomnography,33,84,4.85
calcium-sensing receptor protein,11,28,4.85
ca2+-sensing receptor,11,28,4.85
interventional trial,57,145,4.85
casr protein,11,28,4.85
alzheimer's disease model,11,28,4.85
addiction to prescription opioids,24,61,4.85
dependence on prescription opioids,24,61,4.85
prescription opiate addiction,24,61,4.85
prescription opioid addiction,24,61,4.85
prescription opioid dependence,24,61,4.85
hyperglycemic,11,28,4.85
sleep measurement,33,84,4.85
politics,24,61,4.85
advanced development,59,150,4.85
ad model,11,28,4.85
nonsteroidal antiinflammatory drug,46,117,4.85
walking,48,122,4.85
not painful,11,28,4.85
nonsteroidal anti-inflammatory drugs,46,117,4.85
non-painful,11,28,4.85
painless,11,28,4.85
alcohol-induced damage,11,28,4.85
readmission rates,11,28,4.85
tobacco smoking behavior,69,176,4.84
clinical medical sciences,20,51,4.84
viral genes,20,51,4.84
training level,53,135,4.84
visualization,149,380,4.84
people who inject drugs,90,230,4.83
people who inject illicit drugs,90,230,4.83
research domain criteria,45,115,4.83
pwid,90,230,4.83
social conditions,18,46,4.83
societal conditions,18,46,4.83
persons who inject drugs,90,230,4.83
cannabinoid receptor type 1,116,296,4.83
interleukins,18,46,4.83
opioid-receptor-like 1 protein,18,46,4.83
orl1 receptor,18,46,4.83
deep brain stimulation,56,143,4.83
neuroprogenitor,25,64,4.82
improve access,120,307,4.82
transcriptome,274,701,4.82
neuronal stem cells,25,64,4.82
neuron progenitors,25,64,4.82
nervous system trauma,23,59,4.81
polymers,39,100,4.81
behavioral response,297,761,4.81
behavior response,297,761,4.81
bypass,64,164,4.81
derivation,21,54,4.8
opioid addiction,1157,2970,4.8
derivation procedure,21,54,4.8
psychophysics,28,72,4.8
opioid dependence,1157,2970,4.8
receptor up-regulation,14,36,4.8
experiential learning,33,85,4.79
pain,1259,3242,4.79
low back ache,43,111,4.78
low backache,43,111,4.78
alcohol intervention,98,253,4.78
low back pain,43,111,4.78
lumbago,43,111,4.78
rural area,138,356,4.78
c sativa,12,31,4.77
cnr2,51,132,4.77
hypoglycemia,17,44,4.77
opioid abuser,17,44,4.77
opiate abuser,17,44,4.77
molecular profile,102,264,4.77
cannabinoid receptor 2,51,132,4.77
computing resources,12,31,4.77
cb2r,51,132,4.77
missouri,48,124,4.77
cannabinoid receptor cb2,51,132,4.77
neural ganglion,29,75,4.77
cnr2 gene,51,132,4.77
experimental therapeutics,24,62,4.77
experimental therapeutic agents,24,62,4.77
women of childbearing age,22,57,4.76
female of childbearing age,22,57,4.76
female of child bearing age,22,57,4.76
response markers,22,57,4.76
women of child bearing age,22,57,4.76
response biomarker,22,57,4.76
explosion,32,83,4.76
biophysical sciences,59,153,4.76
biophysical principles,59,153,4.76
anti-inflammatory,120,311,4.76
biophysical foundation,59,153,4.76
opsin,54,140,4.76
rod-opsin,54,140,4.76
dogs,69,179,4.75
waiting lists,52,135,4.75
race,414,1075,4.75
drug treatment,685,1777,4.75
receptor bound,53,138,4.74
ethnic minority,126,328,4.74
systems theory,10,26,4.74
risk estimate,10,26,4.74
tenofovir,10,26,4.74
behavioral trial,10,26,4.74
computational chemistry,20,52,4.74
facial expression,15,39,4.74
genetically engineered,33,86,4.73
small inducible cytokine a2,23,60,4.73
pediatric hospitals,46,120,4.73
laudacon,26,68,4.72
neurocognitive disorder,13,34,4.72
cultural diversity,18,47,4.72
passive smoke exposure,13,34,4.72
protocol screening,108,282,4.72
phosphoric diester hydrolase,13,34,4.72
multiculturalism,18,47,4.72
hymorphan,26,68,4.72
dihydromorphinone,26,68,4.72
hydromorphon,26,68,4.72
eligibility,108,282,4.72
novolauden,26,68,4.72
loss of sensation,13,34,4.72
dilaudid,26,68,4.72
hydromorphone,26,68,4.72
international statistical classification of diseases and related health problems,13,34,4.72
population genetics,13,34,4.72
specific biomarkers,13,34,4.72
eligibility determination,108,282,4.72
laudicon,26,68,4.72
hydrostat,26,68,4.72
dimorphone,26,68,4.72
dilaudid hp,26,68,4.72
numbness,13,34,4.72
advisory team,115,301,4.71
health system,258,675,4.71
behavior outcome,126,330,4.71
scholars program,29,76,4.71
biometry,219,574,4.71
behavioral outcome,126,330,4.71
biometrics,219,574,4.71
biostatistics,219,574,4.71
phosphotransferase gene,136,357,4.7
milligram,16,42,4.7
institutional review boards,91,239,4.7
irbs,91,239,4.7
community intervention,24,63,4.7
neurological development disorder,38,100,4.69
neurodevelopmental disorder,38,100,4.69
prescription opioid,540,1421,4.69
under-represented minority,100,263,4.69
alcohol induced injury,11,29,4.68
cytokine synthesis inhibitory factor,22,58,4.68
treatment choice,11,29,4.68
il-10,22,58,4.68
sodium ion channels,30,79,4.68
csif-10,22,58,4.68
developmental delay disorders,11,29,4.68
us state,30,79,4.68
csif,22,58,4.68
developmental delay,11,29,4.68
guanosine cyclic monophosphate,44,116,4.68
cancer genomics,11,29,4.68
amendment,11,29,4.68
il10a,22,58,4.68
interleukin 10 precursor,22,58,4.68
interleukin-10,22,58,4.68
nerve fibers,22,58,4.68
policy analysis,11,29,4.68
β-catenin,11,29,4.68
alcohol-induced disorders,11,29,4.68
ethanol induced injury,11,29,4.68
il10,22,58,4.68
ethanol-induced disorder,11,29,4.68
cgmp,44,116,4.68
advanced disease,14,37,4.67
commercialization,111,293,4.67
sex risk behavior,14,37,4.67
vulnerable populations,327,864,4.67
accountability,25,66,4.67
muscular rheumatism,14,37,4.67
ct imaging,17,45,4.66
oxycodeinon,185,490,4.66
tumor necrosis factor-alpha,73,193,4.66
cachectin,73,193,4.66
health care organization,34,90,4.66
preteen,17,45,4.66
calibration,45,119,4.66
and blood institute,17,45,4.66
nhlbi,17,45,4.66
preadolescence,17,45,4.66
oxycodone,185,490,4.66
oxycodone sr,185,490,4.66
oxycontin,185,490,4.66
dihydrohydroxycodeinone,185,490,4.66
roxicodone,185,490,4.66
national heart,17,45,4.66
chronic pain,701,1854,4.66
hyperalgia,138,366,4.65
validation studies,52,138,4.65
hyperalgesic sensations,138,366,4.65
nonsmoking,20,53,4.65
pulmonary function,23,61,4.65
sensory system,20,53,4.65
fast-wave sleep,23,61,4.65
phenotypic data,41,109,4.64
gene expression pattern analysis,93,247,4.64
gene expression monitoring,93,247,4.64
transcript expression analysis,93,247,4.64
transcript expression analyses,93,247,4.64
health technology,64,170,4.64
health care technology,64,170,4.64
rare disorder,12,32,4.62
rare diseases,12,32,4.62
developing resistance,27,72,4.62
adipose cell,12,32,4.62
resistant development,27,72,4.62
resistance development,27,72,4.62
patient response,15,40,4.62
adipocytes,12,32,4.62
mature lipocyte,12,32,4.62
fat cells,12,32,4.62
cardiotoxic,12,32,4.62
responsive patient,15,40,4.62
new hampshire,15,40,4.62
vocalization,27,72,4.62
mature fat cell,12,32,4.62
lipocytes,12,32,4.62
inflammation marker,52,139,4.61
long-term depression,46,123,4.61
gestation,270,722,4.61
inflammatory marker,52,139,4.61
qualitative methods,113,302,4.61
repression,59,158,4.61
advocacy,52,139,4.61
meth use,120,322,4.6
molecule imaging,25,67,4.6
methamphetamine use,120,322,4.6
periaqueductal gray matter,60,161,4.6
computing methodologies,84,225,4.6
computational methodology,84,225,4.6
policy making,22,59,4.6
fluorescent imaging,22,59,4.6
data reporting,50,134,4.6
computer methods,84,225,4.6
computational methods,84,225,4.6
insertion-deletion mutation,19,51,4.59
insertion-deletion,19,51,4.59
insertion/deletion,19,51,4.59
insertion/deletion mutation,19,51,4.59
user friendly software,16,43,4.59
hepatic damage,38,102,4.59
user friendly computer software,16,43,4.59
liver damage,38,102,4.59
nano,16,43,4.59
hepatic injury,38,102,4.59
malignant mouth tumor,19,51,4.59
ultrasound,38,102,4.59
liver injury,38,102,4.59
malignant mouth neoplasm,19,51,4.59
interest group,13,35,4.58
clinical implementation,13,35,4.58
pain reliever,560,1512,4.57
open source,40,108,4.57
teleconferences,20,54,4.57
mrna sequencing,10,27,4.57
pain killer,560,1512,4.57
pain medication,560,1512,4.57
painkiller,560,1512,4.57
mrna-seq,10,27,4.57
mast cell,10,27,4.57
human imaging,30,81,4.57
electrical microstimulation,10,27,4.57
interpersonal violence,20,54,4.57
targeted agent,27,73,4.56
inflammatory mediator,44,119,4.56
radiotherapeutics,17,46,4.56
xeno-transplantation,54,146,4.56
automobile driving,519,1403,4.56
driving,519,1403,4.56
personalized care,17,46,4.56
radiation therapy,17,46,4.56
radiotherapy,17,46,4.56
xeno-transplant,54,146,4.56
tnf gene,73,198,4.55
tnf,73,198,4.55
quinine,31,84,4.55
tnf a,73,198,4.55
united states national academy of sciences,14,38,4.54
fibrositis,14,38,4.54
diffuse myofascial pain syndrome,14,38,4.54
national academy of sciences,14,38,4.54
fibromyositis-fibromyalgia syndrome,14,38,4.54
myofascial pain dysfunction syndrome,14,38,4.54
race discrimination,14,38,4.54
beds,39,106,4.54
mpd syndrome,14,38,4.54
racial discrimination,14,38,4.54
fibromyalgia syndrome,14,38,4.54
incremental cost-effectiveness,18,49,4.53
punishment,148,403,4.53
theriacs,18,49,4.53
nichd,40,109,4.53
colorectal cancer,25,68,4.53
national institute of child health and human development,40,109,4.53
sensory neurons,107,291,4.53
afferent neurons,107,291,4.53
neuroregulation,284,774,4.53
adverse event,207,565,4.52
adverse experience,207,565,4.52
therapeutic development,208,567,4.52
metadata,22,60,4.52
exercise intervention,11,30,4.52
neuronal signaling,377,1029,4.52
behavioral monitoring,11,30,4.52
polytobacco use,11,30,4.52
structural anomalies,11,30,4.52
structural abnormalities,11,30,4.52
structural malformation,11,30,4.52
structural defect,11,30,4.52
missense mutation,11,30,4.52
neural signaling,377,1029,4.52
poly-tobacco use,11,30,4.52
nerve signaling,377,1029,4.52
glial signaling,377,1029,4.52
glia signaling,377,1029,4.52
axonal signaling,377,1029,4.52
axon-glial signaling,377,1029,4.52
axon signaling,377,1029,4.52
clinical decision-making,44,120,4.52
associative conditioning,134,366,4.52
inflammation mediators,44,120,4.52
diverse populations,163,445,4.52
neonatology,11,30,4.52
tumor necrosis factor,73,199,4.52
heterogeneous population,163,445,4.52
co-infection,26,71,4.52
coinfection,26,71,4.52
t-type calcium channels,11,30,4.52
pre-clinical model,275,751,4.52
preclinical models,275,751,4.52
mind body wellness,15,41,4.51
mind body treatments,15,41,4.51
alcohol related consequences,38,104,4.51
enterobacteria phage p1 cre recombinase,64,175,4.51
mind body therapy,15,41,4.51
mind body techniques,15,41,4.51
mind body medicine skills,15,41,4.51
mind-body intervention,15,41,4.51
multilevel modeling,71,194,4.51
multilevel model,71,194,4.51
multilevel analysis,71,194,4.51
methods to study multiple-level influences,71,194,4.51
mind body approach,15,41,4.51
mind-body medicine,15,41,4.51
prediction of response,34,93,4.51
prescription opioid misuse,105,287,4.51
acetates,19,52,4.51
hepatic disorder,85,233,4.5
high school student,66,181,4.5
hepatopathy,85,233,4.5
residential site,31,85,4.5
liver diseases,85,233,4.5
cost-effective analysis,55,151,4.49
symptomatology,47,129,4.49
emergency medicine,36,99,4.48
optogenetics,669,1841,4.48
rights,20,55,4.48
association learning,89,245,4.48
mathematic model,49,135,4.48
arthritic,32,88,4.48
in vivo imaging,60,165,4.48
ecological impact,16,44,4.48
disorder control,28,77,4.48
pregnancy outcome,16,44,4.48
adapter protein,16,44,4.48
disease control,28,77,4.48
transplant,42,116,4.47
hiv diagnosis,25,69,4.47
rhythmicity,125,345,4.47
diagnostic and statistical manual of mental disorders-v,75,207,4.47
5th edition,75,207,4.47
non-hispanic,66,182,4.47
not hispanic or latino,66,182,4.47
genetic resource,25,69,4.47
dsm-v,75,207,4.47
periodicity,125,345,4.47
health services availability,244,673,4.47
availability of services,244,673,4.47
access to treatment,244,673,4.47
optical fiber,21,58,4.47
cyclicity,125,345,4.47
access to services,244,673,4.47
health services accessibility,244,673,4.47
imaging instrument,29,80,4.47
access to health services,244,673,4.47
respiratory mechanism,55,152,4.46
formalin,17,47,4.46
nuclear receptors,17,47,4.46
alcohol use among adolescents,80,221,4.46
dental health,13,36,4.45
field test,44,122,4.45
field learning,44,122,4.45
si element,13,36,4.45
silicon,13,36,4.45
neural correlate,104,289,4.44
molecular targeted treatment,18,50,4.44
molecular targeted therapeutics,18,50,4.44
neural dysfunction,18,50,4.44
molecular targeted therapies,18,50,4.44
gliosis,18,50,4.44
astroglia,190,528,4.44
astrocytus,190,528,4.44
pediatrician,18,50,4.44
epigenetic regulation,64,178,4.43
rural,226,629,4.43
educational materials,28,78,4.43
behavior assessment,119,331,4.43
predicting response,46,128,4.43
high-risk adolescents,14,39,4.43
behavioral assessment,119,331,4.43
nervous system injuries,23,64,4.43
hiv/hepatitis c,83,231,4.43
neurological injury,23,64,4.43
hiv/hcv,83,231,4.43
neurological trauma,23,64,4.43
neurological damage,23,64,4.43
nervous system damage,23,64,4.43
cancer diagnosis,24,67,4.42
utah,29,81,4.42
child health,44,123,4.41
inflammation,359,1003,4.41
coping behavior,34,95,4.41
treatment group,64,179,4.41
germ lines,10,28,4.4
low socioeconomic status,77,216,4.4
smoking cue,20,56,4.4
screenings,295,827,4.4
curiosities,10,28,4.4
healthcare service,35,98,4.4
vanilloid,10,28,4.4
south american,10,28,4.4
antisense agent,25,70,4.4
metabolic activation,10,28,4.4
t cell response,10,28,4.4
cue to smoke,20,56,4.4
astrocytes,190,532,4.4
specialist,135,378,4.4
liver carcinoma,20,56,4.4
noncancer chronic pain,20,56,4.4
access to care,240,673,4.4
non-cancer chronic pain,20,56,4.4
clinical effect,46,129,4.4
bacteriophage p1 recombinase cre,64,180,4.39
ssris,21,59,4.39
metabolism measurement,62,174,4.39
breast tumor patient,16,45,4.39
evidence base,841,2365,4.39
associate faculty,26,73,4.39
mid-career faculty,26,73,4.39
professional organizations,31,87,4.39
associate professor,26,73,4.39
immunoglobulin m,11,31,4.38
wellness program,11,31,4.38
respiration,55,155,4.38
population health,91,256,4.38
computer studies,28,79,4.37
csaid-binding protein 1,17,48,4.37
csaid-binding protein 2,17,48,4.37
cytokine-suppressive antiinflammatory drug-binding protein 1,17,48,4.37
cytokine-suppressive antiinflammatory drug-binding protein 2,17,48,4.37
mapk14 mitogen-activated protein kinase,17,48,4.37
mitogen-activated protein kinase 14,17,48,4.37
p38-alpha,17,48,4.37
health care service organization,34,96,4.37
computational studies,28,79,4.37
attentional bias,34,96,4.37
care providers,77,218,4.36
community based design,24,68,4.35
community based research,24,68,4.35
cellular telephone,163,462,4.35
practice setting,30,85,4.35
manufacturing process,18,51,4.35
transducers,18,51,4.35
immune signaling,18,51,4.35
resistant to disease,12,34,4.35
resistant disease,12,34,4.35
resistance to disease,12,34,4.35
complex thinking,12,34,4.35
immunologically,36,102,4.35
endocannabinoid system,62,176,4.34
infiltration,26,74,4.33
historically black colleges,20,57,4.33
hbcus,20,57,4.33
malignant head and neck tumor,13,37,4.33
leadership development,13,37,4.33
serotonin type 1dbeta receptor,13,37,4.33
populations at risk,94,268,4.33
vascular hypotensive disorder,13,37,4.33
5-hydroxytryptamine 1b receptor,13,37,4.33
historically black institution,20,57,4.33
historically black colleges and universities,20,57,4.33
active learning,33,94,4.33
interferons,33,94,4.33
cell assay,20,57,4.33
immunological markers,14,40,4.32
pge2,14,40,4.32
prostaglandin e2alpha,14,40,4.32
krebs cycle,14,40,4.32
citric acid cycle,14,40,4.32
tca cycle,14,40,4.32
cancer induction,27,77,4.32
tricarboxylic acid cycle,14,40,4.32
dinoprostone,14,40,4.32
immune-based biomarkers,14,40,4.32
immunological biomarkers,14,40,4.32
metabolomics,62,177,4.32
fibromyalgia,14,40,4.32
microscope,42,120,4.32
pge2 alpha,14,40,4.32
prostaglandin e2,14,40,4.32
tolerance to opiates,56,160,4.32
ibogaine,14,40,4.32
opiate tolerance,56,160,4.32
prostaglandin e2 alpha,14,40,4.32
pge2alpha,14,40,4.32
hospital length of stay,77,220,4.32
self-injurious behavior,22,63,4.31
behavior observation,29,83,4.31
cell phone,163,466,4.31
climate,37,106,4.31
meteorological climate,37,106,4.31
climatic,37,106,4.31
immunologically directed therapy,43,123,4.31
behavioral observation,29,83,4.31
immune therapy,43,123,4.31
deliberate self harm,22,63,4.31
microbial,51,146,4.31
ganglia,29,83,4.31
self injury,22,63,4.31
self harm,22,63,4.31
migraine,37,106,4.31
intentional self harm,22,63,4.31
intentional self injury,22,63,4.31
cellular phone,163,466,4.31
deliberate self-harm,22,63,4.31
patient-centered care,29,83,4.31
rhombencephalic sleep,23,66,4.3
dreaming sleep,23,66,4.3
knock-down,292,838,4.3
absorption,85,244,4.3
rapid eye movement sleep,23,66,4.3
learning activity,30,86,4.3
learning method,30,86,4.3
paradoxical sleep,23,66,4.3
learning strategy,30,86,4.3
surgical interventions,333,958,4.29
surgical,333,958,4.29
prenatally exposed to alcohol,32,92,4.29
in utero alcohol exposure,32,92,4.29
pregnancy etoh exposure,32,92,4.29
gestation ethanol exposure,32,92,4.29
in utero ethanol exposure,32,92,4.29
gestation alcohol exposure,32,92,4.29
operative surgical procedures,333,958,4.29
clinical protocols,32,92,4.29
operative procedures,333,958,4.29
prenatal alcohol exposure,32,92,4.29
prenatal etoh exposure,32,92,4.29
q levoglutamide,24,69,4.29
fetal alcohol exposure,32,92,4.29
gestation etoh exposure,32,92,4.29
exposed to alcohol prenatally,32,92,4.29
prenatal ethanol exposure,32,92,4.29
imaging study,112,322,4.29
surgical procedure,333,958,4.29
pregnancy alcohol exposure,32,92,4.29
genome scale,195,560,4.29
fetal ethanol exposure,32,92,4.29
in utero etoh exposure,32,92,4.29
fetal etoh exposure,32,92,4.29
alcohol-exposed pregnancy,32,92,4.29
pregnancy ethanol exposure,32,92,4.29
prenatally alcohol exposed,32,92,4.29
cortical pain,26,75,4.28
cardiovascular physiology,25,72,4.28
zinc finger motifs,17,49,4.28
glutamate signaling,86,248,4.28
glutamatergic dendrodendritic synapses,86,248,4.28
liver disorder,85,245,4.28
zinc fingers,17,49,4.28
genetic engineering molecular biology,33,95,4.28
central pain,26,75,4.28
marrow monocyte,58,167,4.28
surgery,333,959,4.28
blood monocyte,58,167,4.28
program effectiveness,26,75,4.28
zinc finger domain,17,49,4.28
genetic engineering biotechnology,33,95,4.28
glutamatergic signaling,86,248,4.28
computer-assisted instruction,35,101,4.27
feeling suicidal,55,159,4.27
thoughts about suicide,55,159,4.27
computer-based education,35,101,4.27
web-based instruction,35,101,4.27
internet-assisted education,35,101,4.27
translational research program,18,52,4.27
suicide ideation,55,159,4.27
suicidal thinking,55,159,4.27
hyperalgesia,138,399,4.27
suicidal ideation,55,159,4.27
suicidal thoughts,55,159,4.27
antidotes,18,52,4.27
debrisoquine 4-monooxygenase,19,55,4.26
cytochrome p450 subfamily iid polypeptide 6,19,55,4.26
cypiid6,19,55,4.26
cytochrome p-450 cyp2d6,19,55,4.26
cytochrome p450 2d6,19,55,4.26
p450-2d6,19,55,4.26
p450db1,19,55,4.26
imipramine 2-hydroxylase,19,55,4.26
annual reports,28,81,4.26
vendor,28,81,4.26
sparteine monooxygenase,19,55,4.26
cyp 2d6,19,55,4.26
subfamily iid-like 1 cytochrome p450,19,55,4.26
subfamily iid cytochrome p450,19,55,4.26
debrisoquine hydroxylase,19,55,4.26
cirrhosis,48,139,4.26
debrisoquine 4-hydroxylase,19,55,4.26
buprenorphine/naloxone,28,81,4.26
buprenorphine + naloxone,28,81,4.26
dorsal horn neurons,19,55,4.26
mammary neoplasms,19,55,4.26
mammary cancer,19,55,4.26
breast tumors,19,55,4.26
adoption,475,1376,4.26
buprenorphine-naloxone,28,81,4.26
buprenorphine with naloxone,28,81,4.26
buprenorphine and naloxone,28,81,4.26
posterior horn neurons,19,55,4.26
zubsolv,28,81,4.26
suboxone,28,81,4.26
bunavail,28,81,4.26
specimen collection,37,107,4.26
mammary tumor,19,55,4.26
economic burden,150,434,4.26
collaborative care,38,110,4.26
presynaptic nerve,20,58,4.25
pre-synaptic neurons,20,58,4.25
primary care services,10,29,4.25
presynaptic neurons,20,58,4.25
somatosensory,31,90,4.25
neural injury,62,180,4.25
clinical medicine,20,58,4.25
social exclusion,10,29,4.25
pre-synaptic nerve,20,58,4.25
phenocopy,20,58,4.25
freezing,50,145,4.25
frailty,10,29,4.25
tamoxifen,30,87,4.25
qol,437,1271,4.24
t-type vdcc,11,32,4.24
socioeconomics,250,727,4.24
t-type voltage-dependent calcium channels,11,32,4.24
approach avoidance behavior,11,32,4.24
transient-type calcium channels,11,32,4.24
diagnostic biomarker,11,32,4.24
enhancer elements,11,32,4.24
cre recombinase,64,186,4.24
diagnostic marker,11,32,4.24
macrophage,101,294,4.24
oxygen consumption,11,32,4.24
grin1,11,32,4.24
b-cell differentiation factor,54,157,4.24
n-methyl d-aspartate 1,11,32,4.24
ionotropic,11,32,4.24
cancer subtypes,11,32,4.24
cancer sub-types,11,32,4.24
n-methyl-d-aspartate receptor subunit nr1,11,32,4.24
glun1,11,32,4.24
nodal,12,35,4.23
children's hospital,46,134,4.23
adverse outcome,232,676,4.23
adverse consequence,232,676,4.23
molecular epidemiology,12,35,4.23
behavior study,154,449,4.23
shapes,419,1222,4.23
segregation,48,140,4.23
nanostring,12,35,4.23
nano-string,12,35,4.23
behavioral study,154,449,4.23
stress buffering,23,67,4.23
genetic manipulation,147,429,4.23
capsules,25,73,4.22
language acquisition,13,38,4.22
language learning,13,38,4.22
chromatin,187,547,4.22
behavior mechanism,115,336,4.22
hypersensitivity,117,342,4.22
cancer patient,99,289,4.22
regulatory element,51,149,4.22
brief advice,25,73,4.22
gem model,25,73,4.22
acquiring language skills,13,38,4.22
epidemiologist,51,149,4.22
medicare/medicaid,13,38,4.22
cannabis user,70,205,4.21
implant,149,436,4.21
molecular dynamics simulation,44,129,4.21
genetic protein engineering,29,85,4.21
locus ceruleus structure,59,173,4.21
unique treatment,99,290,4.21
corticoids,14,41,4.21
customized therapy,99,290,4.21
adrenal cortex hormones,14,41,4.21
δ-or,29,85,4.21
tailored medical treatment,99,290,4.21
hormonal change,14,41,4.21
risk reduction,163,477,4.21
δor,29,85,4.21
tailored treatment,99,290,4.21
individualized treatment,99,290,4.21
superior colliculus,14,41,4.21
individualized medicine,99,290,4.21
delta opioid receptor,29,85,4.21
vascular dysfunction,14,41,4.21
customized treatment,99,290,4.21
cyclic gmp,44,129,4.21
adjuvant therapy,15,44,4.2
immunosuppressive effect,30,88,4.2
cognitive defects,125,367,4.2
pup,30,88,4.2
surveillance data,16,47,4.2
immunosuppression effect,30,88,4.2
analytical method,81,238,4.2
alcohol monitoring,15,44,4.2
critical developmental period,30,88,4.2
allodynia,48,141,4.2
tumor growth,66,194,4.2
craniocerebral injuries,16,47,4.2
plasmacytoma growth factor,54,159,4.19
interferon beta 2,54,159,4.19
myeloid differentiation-inducing protein,54,159,4.19
xray computed tomography,17,50,4.19
x-ray computerized tomography,17,50,4.19
mgi-2,54,159,4.19
allergy,117,344,4.19
x-ray cat scan,17,50,4.19
stress-activated protein kinase 2a,17,50,4.19
sensory,397,1169,4.19
interleukin-6,54,159,4.19
b cell stimulating factor 2,54,159,4.19
bsf-2,54,159,4.19
hepatocyte-stimulating factor,54,159,4.19
bcdf,54,159,4.19
secure,185,544,4.19
b-cell stimulatory factor-2,54,159,4.19
bsf2,54,159,4.19
hpgf,54,159,4.19
b-cell differentiation factor-2,54,159,4.19
hybridoma growth factor,54,159,4.19
il6 protein,54,159,4.19
il-6,54,159,4.19
ifnb2,54,159,4.19
b cell differentiation factor,54,159,4.19
ifn-beta 2,54,159,4.19
analgesic agents,560,1653,4.18
cyp2dl1,19,56,4.18
cyp2d6 gene,19,56,4.18
antinociceptive agents,560,1653,4.18
cell lineage,21,62,4.18
harvest,43,127,4.18
p450c2d,19,56,4.18
cyp2d6,19,56,4.18
cyp2d,19,56,4.18
mental hygiene services,76,224,4.18
cpd6,19,56,4.18
peripheral blood,19,56,4.18
analgesic drugs,560,1653,4.18
social status,19,56,4.18
anodynes,560,1653,4.18
antinociceptive drugs,560,1653,4.18
p450-db1,19,56,4.18
analgesic preparation,560,1653,4.18
resource sharing,50,148,4.17
mild traumatic brain injury,22,65,4.17
signal transduction second messengers,24,71,4.17
mild brain trauma,22,65,4.17
human whole genome,75,222,4.17
mild tbi,22,65,4.17
mtbi,22,65,4.17
heart rate variability,44,130,4.17
protein activation,45,133,4.17
human genome,75,222,4.17
in vivo model,103,305,4.17
spinal cord posterior horn,25,74,4.17
dorsal horn of the spinal cord,25,74,4.17
rem sleep,23,68,4.17
relapse prediction,71,210,4.17
neuronal circuitry,148,438,4.17
safety net,53,157,4.16
pharmaceutical chemistry,159,471,4.16
legal patent,90,267,4.16
patents,90,267,4.16
12th grade,28,83,4.16
carcinogenesis,27,80,4.16
productivity,361,1070,4.16
desire for food,134,397,4.16
consummatory behavior,26,77,4.16
epigenetic process,443,1316,4.15
epigenetic,443,1316,4.15
epigenetic mechanism,443,1316,4.15
under served population,118,351,4.15
epigenetic change,443,1316,4.15
underserved people,118,351,4.15
underserved population,118,351,4.15
anesthetics,55,164,4.14
flexible,383,1142,4.14
rna expression,523,1557,4.14
gene transcription,523,1557,4.14
genetic biomarker,45,134,4.14
brain trauma,80,239,4.13
bound protein,68,203,4.13
thymus derived lymphocyte,59,176,4.13
self management,60,179,4.13
longitudinal analysis,64,191,4.13
t-lymphocyte,59,176,4.13
chemotherapy,106,317,4.12
cancer cell metabolism,18,54,4.11
gustatory processing,52,156,4.11
suicidal morbidity,16,48,4.11
intervention cost,19,57,4.11
catalyst,37,111,4.11
hormone regulation,12,36,4.11
gustatory response,52,156,4.11
hyperglycemia,11,33,4.11
neurofibrillary pathology,12,36,4.11
transgenic trait,10,30,4.11
immunologic diseases,33,99,4.11
taste processing,52,156,4.11
rna polymerase ii,11,33,4.11
neurofibrillary lesion,12,36,4.11
taste response,52,156,4.11
immunological diseases,33,99,4.11
tumor cell metabolism,18,54,4.11
predictor algorithm,14,42,4.11
predictive algorithm,14,42,4.11
rna polymerase b,11,33,4.11
irritation,17,51,4.11
tangle,12,36,4.11
suicide death,16,48,4.11
posterior horn cells,19,57,4.11
lifestyle-related disorder,21,63,4.11
gene expression profiling,93,279,4.11
behavior-related problem,21,63,4.11
workplace environment,17,51,4.11
behavior-related disorder,21,63,4.11
2-dimensional,21,63,4.11
optic imaging,40,120,4.11
policy analyses,11,33,4.11
optical imaging,40,120,4.11
calcium ion,11,33,4.11
cannabinoid receptor 1,116,348,4.11
icd-10,10,30,4.11
aqueous,28,84,4.11
gustatory perception,52,156,4.11
cannabinoid receptor cb1,116,348,4.11
cnr1 gene,116,348,4.11
workplace climate,17,51,4.11
church,10,30,4.11
cb1r,116,348,4.11
hormonal regulation,12,36,4.11
suicide morbidity,16,48,4.11
gait,10,30,4.11
immune dysfunction,33,99,4.11
lifestyle-related problem,21,63,4.11
deposition,88,264,4.11
software systems,12,36,4.11
dna-dependent rna polymerase ii,11,33,4.11
pharmacies,126,378,4.11
histone acetyltransferase p300,10,30,4.11
wayfinding,10,30,4.11
kat3b,10,30,4.11
spatial navigation,10,30,4.11
immune disorders,33,99,4.11
e1a binding protein p300,10,30,4.11
way finding,10,30,4.11
alpha,14,42,4.11
health care visit,12,36,4.11
breast neoplasms,19,57,4.11
biofeedback,14,42,4.11
tenth revision (icd-10),10,30,4.11
motor disorder,18,54,4.11
mindfulness-based stress reduction,14,42,4.11
motor disease,18,54,4.11
immune diseases,33,99,4.11
bench to clinic,17,51,4.11
transcend,11,33,4.11
healthcare visit,12,36,4.11
mcp1,23,69,4.11
immune system disorder,33,99,4.11
nerve tissue,10,30,4.11
genetic transcription,523,1568,4.11
immune system diseases,33,99,4.11
dorsal horn cells,19,57,4.11
neurofibrillary degeneration,12,36,4.11
probiotics,10,30,4.11
scya2,23,69,4.11
nervous tissue,10,30,4.11
psychoeducational,12,36,4.11
ccl2 gene,23,69,4.11
pharmacy facility,126,378,4.11
newborn intensive care units,13,39,4.11
deposit,88,264,4.11
ccl2,23,69,4.11
lifestyle-related condition,21,63,4.11
brain circuitry,103,310,4.1
brain cell,126,379,4.1
stem,247,744,4.09
nerve injury,62,187,4.09
contextual factors,118,356,4.09
application context,118,356,4.09
hazardous drinking,61,184,4.09
substance use among adolescents,81,245,4.08
cancer center,42,127,4.08
field based data,44,133,4.08
in vitro model,48,145,4.08
mental health services,76,230,4.08
expression signature,142,429,4.08
sex,726,2198,4.07
poor sleep,33,100,4.07
network models,37,112,4.07
gender-associated difference,59,179,4.07
recombinant dna technology,33,100,4.07
t-cells,59,179,4.07
sample collection,37,112,4.07
growth and development function,25,76,4.06
intellectual property,25,76,4.06
mobile computing,50,152,4.06
mobile platform,50,152,4.06
growth and development,25,76,4.06
next generation,349,1060,4.06
mobile technology,50,152,4.06
minority groups,117,355,4.06
tablets,52,158,4.06
genotoxicity,27,82,4.06
american indians,83,252,4.06
narcanti,150,457,4.05
narcan,150,457,4.05
predictors of outcomes,44,134,4.05
cognitive ability,23,70,4.05
mcp-1,23,70,4.05
systematic review,42,128,4.05
predictive outcomes,44,134,4.05
closure by ligation,42,128,4.05
quality of life,437,1330,4.05
ligation,42,128,4.05
investigational therapies,24,73,4.05
point of care,44,134,4.05
biologic sciences,45,137,4.05
life sciences,45,137,4.05
intracellular second messenger,24,73,4.05
biological sciences,45,137,4.05
distant,45,137,4.05
administrative data base,21,64,4.05
administrative database,21,64,4.05
modality,377,1151,4.04
public policy,120,366,4.04
floxed,54,165,4.04
ramp,20,61,4.04
temperature,54,165,4.04
gene expression signature,142,434,4.04
regulatory pathway,57,174,4.04
brain-injured,60,183,4.04
gene expression profile,142,434,4.04
dropout,109,333,4.04
interpeduncular nucleus,36,110,4.04
health disparity,337,1030,4.04
multidisciplinary,593,1811,4.04
peripheral nervous system,58,177,4.04
catscan,17,52,4.03
self care,34,104,4.03
tomodensitometry,17,52,4.03
national institute of diabetes and digestive and kidney diseases,16,49,4.03
computerized axial tomography,17,52,4.03
ct x ray,17,52,4.03
computed tomography,17,52,4.03
computed axial tomography,17,52,4.03
prevent drug addiction,83,254,4.03
toxicant,50,153,4.03
breast cancer patient,16,49,4.03
x-ray computed tomography,17,52,4.03
ct scan,17,52,4.03
polysomnography,33,101,4.03
melanophore-concentrating hormone,15,46,4.02
bisulfite sequencing,14,43,4.02
bs-seq,14,43,4.02
cancermodel,31,95,4.02
cancer model,31,95,4.02
health facilities,30,92,4.02
melanosome concentrating hormone,15,46,4.02
healthcare facility,30,92,4.02
bisulfite-seq,14,43,4.02
unplanned pregnancy,15,46,4.02
music,15,46,4.02
community health,61,187,4.02
melanin-concentrating hormone,15,46,4.02
behavioral plasticity,31,95,4.02
serotonin 1b receptor,13,40,4.01
ekg,26,80,4.01
5-ht(1dbeta) receptor,13,40,4.01
calcium,389,1197,4.01
electrocardiogram,26,80,4.01
5-ht(1b) receptor,13,40,4.01
ecg,26,80,4.01
genetic recombination,53,163,4.01
epidemic,649,1998,4.01
serotonin 1dbeta receptor,13,40,4.01
data systems,64,197,4.01
5-ht1dbeta receptor,13,40,4.01
clinical research site,76,234,4.01
5-ht1b receptor,13,40,4.01
serotonin 1d beta receptor,13,40,4.01
development plans,209,643,4.01
clinical site,76,234,4.01
experimental therapies,24,74,4.0
histone deacetylase 3,12,37,4.0
paraventricular hypothalamic nucleus,23,71,4.0
leanness,24,74,4.0
neurofibrillary tangles,12,37,4.0
investigational treatments,24,74,4.0
therapy outcome,24,74,4.0
hdac3 enzyme,12,37,4.0
prevent substance abuse,23,71,4.0
thinness,24,74,4.0
tumor tissue,12,37,4.0
floxed allele,54,167,3.99
clinical management,65,201,3.99
loxp-flanked allele,54,167,3.99
arthritis,32,99,3.99
preventative intervention,189,584,3.99
test result,43,133,3.99
novel therapeutic target,443,1369,3.99
age 15 years,11,34,3.99
community services,32,99,3.99
l-type calcium channels,11,34,3.99
new therapeutic target,443,1369,3.99
investments,169,522,3.99
striosome,11,34,3.99
assertiveness,11,34,3.99
study of the population,31,96,3.98
alcohol use disorder,969,3002,3.98
studies of populations,31,96,3.98
ethanol use disorder,969,3002,3.98
population-level study,31,96,3.98
population-based study,31,96,3.98
traumatic brain damage,80,248,3.98
discovery mining,10,31,3.98
text mining,10,31,3.98
literature searching,10,31,3.98
research methodology,269,833,3.98
akap,10,31,3.98
text searching,10,31,3.98
literature mining,10,31,3.98
case series,10,31,3.98
traumatic brain injury,80,248,3.98
gene fusion,10,31,3.98
lack of energy,40,124,3.98
bacs,10,31,3.98
outreach,171,530,3.98
spectroscopic imaging,10,31,3.98
protease gene,20,62,3.98
bac clone,10,31,3.98
eicosanoids,10,31,3.98
analytic chemistry,19,59,3.97
opiate abuse,357,1109,3.97
clinical depression,131,407,3.97
ambulatory care,65,202,3.97
antiinflammatories,85,264,3.97
biological material,28,87,3.97
opioid abuse,357,1109,3.97
dsm-4,19,59,3.97
calcium signaling,58,180,3.97
calcium ion signaling,58,180,3.97
cancer pain,51,159,3.96
height,26,81,3.96
accelerometry,17,53,3.96
opioid,2130,6634,3.96
activity tracker,17,53,3.96
activity monitor,17,53,3.96
viral replication,18,56,3.96
viral multiplication,18,56,3.96
sleeplessness,90,280,3.96
insomnia disorder,90,280,3.96
insurers,42,131,3.95
sleep deprivation,41,128,3.95
common treatment,24,75,3.95
suicide risk,50,156,3.95
suicidal risk,50,156,3.95
insurance carriers,42,131,3.95
genetic study,158,493,3.95
feline species,15,47,3.94
pathogen,38,119,3.94
domestic cats,15,47,3.94
felis sylvestris catus,15,47,3.94
felis domestica,15,47,3.94
ancillary study,23,72,3.94
felis catus,15,47,3.94
felis domesticus,15,47,3.94
critical period,116,364,3.93
island,22,69,3.93
leadership,445,1395,3.93
monocyte,58,182,3.93
observational study,77,242,3.92
mood and affect disturbance,27,85,3.92
phosphatidylinositol 3-kinase,27,85,3.92
underrepresented minority,100,315,3.92
exploratory behavior,14,44,3.92
disturbance in affect,27,85,3.92
b-raf-1,20,63,3.92
mood dysfunction,27,85,3.92
mood disturbance,27,85,3.92
braf,20,63,3.92
client satisfaction,47,148,3.92
brain tissue,187,588,3.92
mood alteration,27,85,3.92
v-raf murine sarcoma viral oncogene homolog b1,20,63,3.92
rafb1,20,63,3.92
braf gene,20,63,3.92
patient satisfaction,47,148,3.92
bone marrow reticuloendothelial system,20,63,3.92
insomnia,90,284,3.91
metabolic studies,19,60,3.91
science,1001,3155,3.91
stool,13,41,3.91
metabolic abnormality assessment,19,60,3.91
metabolism studies,19,60,3.91
abnormal assessment of metabolism,19,60,3.91
cancer type,50,158,3.9
interventional study,134,424,3.9
parturition,199,630,3.9
interventional research,134,424,3.9
flexibility,383,1214,3.89
lc/ms,41,130,3.89
unhealthy alcohol use,168,532,3.89
racial difference,36,114,3.89
pharmaceutic chemistry,159,504,3.89
teaching module,12,38,3.89
constipation,78,247,3.89
atheromatosis,18,57,3.89
critical thinking,12,38,3.89
atherosclerotic vascular disease,18,57,3.89
medicinal chemistry,159,504,3.89
learning module,12,38,3.89
evaluative thinking,12,38,3.89
atherosclerotic cardiovascular disease,18,57,3.89
educational module,12,38,3.89
institution,487,1545,3.89
education module,12,38,3.89
race differences,36,114,3.89
conflict resolution,11,35,3.88
alcohol-nad+ oxidoreductase,17,54,3.88
psychosocial stress,33,105,3.88
varicosity,11,35,3.88
proxy,55,175,3.88
human subject research,11,35,3.88
scholarship,22,70,3.88
varices,11,35,3.88
trpv1,22,70,3.88
varicose veins,11,35,3.88
trpv1 gene,22,70,3.88
medically underserved,11,35,3.88
risk-associated variant,57,181,3.88
discipline of obstetrics,51,162,3.88
computerized tomography,17,54,3.88
benchmarking,79,252,3.87
best practice analysis,79,252,3.87
disorder risk,169,539,3.87
disease risk,169,539,3.87
illicit drug use,131,417,3.87
cytoplasm,43,137,3.87
antimicrobial,16,51,3.87
anti-microbial,16,51,3.87
drug development,284,906,3.87
co-morbidity,808,2577,3.87
genetic epidemiologic study,16,51,3.87
directed evolution,16,51,3.87
obstetrics,51,163,3.86
sleep,280,894,3.86
chemokine,83,265,3.86
coordinating care,29,93,3.85
cre-loxp,10,32,3.85
cre/loxp,10,32,3.85
birth,199,638,3.85
full professor,15,48,3.85
senior faculty,15,48,3.85
advanced system,10,32,3.85
care coordination,29,93,3.85
cre-lox,10,32,3.85
formulation,253,810,3.85
pre-clinical research,105,336,3.85
transcription,523,1674,3.85
social sciences,34,109,3.85
cancer in the colon,10,32,3.85
excitatory neuron,35,112,3.85
preclinical research,105,336,3.85
cost efficient analysis,55,176,3.85
cost effectiveness analysis,55,176,3.85
exosome,10,32,3.85
animal behavior,75,240,3.85
disability,294,942,3.85
pharmacology and toxicology,29,93,3.85
transplantation,42,135,3.84
attributable mortality,19,61,3.84
tumor cell metastasis,70,225,3.84
disabled people,43,138,3.84
attributable death,19,61,3.84
malignant oral cavity tumor,19,61,3.84
professional education,14,45,3.84
persons with disabilities,43,138,3.84
people with disabilities,43,138,3.84
handicapped,43,138,3.84
disabled population,43,138,3.84
malignant oral cavity neoplasm,19,61,3.84
disabled persons,43,138,3.84
malignant oral neoplasm,19,61,3.84
mouth cancer,19,61,3.84
oral cancer,19,61,3.84
cofactor,38,122,3.84
emergency medical service,14,45,3.84
apical,18,58,3.83
skin,83,267,3.83
cardiovascular diseases,192,619,3.83
confocal microscopy,64,206,3.83
alcohol access,67,216,3.83
access to alcohol,67,216,3.83
fda approved,471,1516,3.83
antiinflammatory agents,85,274,3.83
user-friendly,60,193,3.83
phosphodiesterases,13,42,3.82
respiratory,138,445,3.82
multicomponent intervention,31,100,3.82
multimodal intervention,31,100,3.82
multi-modal intervention,31,100,3.82
multi-faceted intervention,31,100,3.82
dna recombination,53,171,3.82
pancreas cancer,31,100,3.82
malignant neoplasm of pancreas,31,100,3.82
malignant pancreatic neoplasm,31,100,3.82
pancreatic cancer,31,100,3.82
multi-component intervention,31,100,3.82
smell,43,139,3.82
muscular,65,210,3.82
feces,13,42,3.82
oral health,13,42,3.82
smell perception,43,139,3.82
multifaceted intervention,31,100,3.82
olfaction,43,139,3.82
feels no pain,266,862,3.81
exposed human population,17,55,3.81
documentation,75,243,3.81
absence of sensibility to pain,266,862,3.81
county,202,654,3.81
no sensitivity to pain,266,862,3.81
necropsy,173,560,3.81
autopsy,173,560,3.81
human exposure,17,55,3.81
memory encoding,21,68,3.81
risk assessment,62,201,3.8
cd8-positive lymphocytes,12,39,3.79
gene-based therapy,47,153,3.79
cd8+ t-lymphocyte,12,39,3.79
cd8 lymphocyte,12,39,3.79
cd8 cell,12,39,3.79
xenograft model,39,127,3.79
review committee,12,39,3.79
newly diagnosed,32,104,3.79
cd8-positive t-lymphocytes,12,39,3.79
cancer health disparity,12,39,3.79
cancer disparity,12,39,3.79
t8 lymphocytes,12,39,3.79
cardiac chronotropism,101,329,3.79
dna therapy,47,153,3.79
oncology,40,130,3.79
t8 cells,12,39,3.79
sensory nerve,12,39,3.79
recombinant inbred strain,20,65,3.79
absence of pain sensation,264,862,3.78
enhancers,95,310,3.78
public health intervention,23,75,3.78
interpersonal interaction,19,62,3.78
nontranslated rna,73,238,3.78
untranslated rna,73,238,3.78
molecular mechanisms of action,19,62,3.78
noncoding rna,73,238,3.78
cancer addiction,19,62,3.78
compensation,50,163,3.78
health care facility,30,98,3.78
generalists,11,36,3.77
general practitioners,11,36,3.77
alcohol misuse,168,549,3.77
compulsion,26,85,3.77
work load,11,36,3.77
ethanol misuse,168,549,3.77
beta cadherin-associated protein,11,36,3.77
beta-1 catenin,11,36,3.77
workload,11,36,3.77
melatonin,22,72,3.77
android,11,36,3.77
risk management,11,36,3.77
follow up assessment,65,213,3.76
psychotomimetic drug,47,154,3.76
conventional therapy,18,59,3.76
conventional treatment,18,59,3.76
immune,236,777,3.75
cardiovascular disorder,192,632,3.75
dizziness,14,46,3.75
abate,14,46,3.75
nausea,38,125,3.75
rabies virus,14,46,3.75
liver function,24,79,3.75
two-dimensional,21,69,3.75
opioid analgesics,226,746,3.74
regional difference,20,66,3.74
internuncial cell,213,703,3.74
cyp3,10,33,3.74
connector neuron,213,703,3.74
cp34,10,33,3.74
cyp3a4,10,33,3.74
intercalary neuron,213,703,3.74
intercalated neurons,213,703,3.74
nuclear translocation,10,33,3.74
internuncial neuron,213,703,3.74
a kinase anchoring protein,10,33,3.74
cyp3a,10,33,3.74
cyp3a4 gene,10,33,3.74
learning network,10,33,3.74
ortholog,34,112,3.74
receptor inhibition,30,99,3.74
epidemiologic confounding factor,10,33,3.74
natural experiment,37,122,3.74
peripheral pain,10,33,3.74
p450pcn1,10,33,3.74
p450c3,10,33,3.74
debilitating symptom,10,33,3.74
fatigue,40,132,3.74
patient care delivery,186,613,3.74
research dissemination,27,89,3.74
genetically predisposed,71,234,3.74
research data dissemination,27,89,3.74
viral genetics,27,89,3.74
high throughput assay,106,350,3.74
orthologous gene,34,112,3.74
high throughput screening,106,350,3.74
community based service,13,43,3.73
mood symptom,13,43,3.73
adolescent ethanol exposure,33,109,3.73
mindfulness intervention,23,76,3.73
mindfulness-based intervention,23,76,3.73
biological markers,501,1658,3.73
adolescent alcohol exposure,33,109,3.73
threonine,13,43,3.73
allele variant,170,562,3.73
transdisciplinary collaboration,36,119,3.73
subsaharan africa,23,76,3.73
ethanol exposure during adolescence,33,109,3.73
terminology,13,43,3.73
alcohol exposure during adolescence,33,109,3.73
biologic marker,501,1658,3.73
genomic variant,170,562,3.73
sub-saharan africa,23,76,3.73
africa south of the sahara,23,76,3.73
innate immunity,16,53,3.72
metastatic tumor,70,232,3.72
native immunity,16,53,3.72
head,159,527,3.72
non-specific immunity,16,53,3.72
accelerometer,16,53,3.72
natural immunity,16,53,3.72
randomization trial,176,583,3.72
injectable,97,322,3.72
metastasize,70,232,3.72
secondary neoplasm,70,232,3.72
dietary fruit,22,73,3.72
neoplasm metastasis,70,232,3.72
fruit,22,73,3.72
metastatic neoplasm,70,232,3.72
career development,532,1766,3.72
cancer metastasis,70,232,3.72
supportive environment,22,73,3.72
secondary tumor,70,232,3.72
reward circuitry,196,649,3.72
enthusiastic environment,22,73,3.72
substance use prevention,64,213,3.71
prevent substance use,64,213,3.71
vapor,165,548,3.71
infectious disease transmission,21,70,3.7
disease transmission,21,70,3.7
medicine,566,1888,3.7
angiogenesis,21,70,3.7
endothelium,21,70,3.7
drug preparation,12,40,3.7
drug compounding,12,40,3.7
medical cannabis,27,90,3.7
medicinal cannabis,27,90,3.7
suspensions,12,40,3.7
negative reinforcements,127,423,3.7
transforming growth factor-beta family gene,12,40,3.7
anti-sense oligonucleotides,21,70,3.7
continuum of care,84,280,3.7
neurophysiology / electrophysiology,836,2789,3.7
electrophysiology (science),836,2789,3.7
post intervention,98,327,3.7
k-ras,18,60,3.7
suspension substance,12,40,3.7
economic impact,48,160,3.7
genetic engineering,33,110,3.7
continuity of care,84,280,3.7
functional genomics,69,230,3.7
immunological,36,120,3.7
tube,15,50,3.7
continuity of patient care,84,280,3.7
molecular weight,29,97,3.69
ethanol availability,67,224,3.69
ethanol accessibility,67,224,3.69
therapeutic target,499,1666,3.69
open label,64,214,3.69
open label study,64,214,3.69
alcohol availability,67,224,3.69
alcohol accessibility,67,224,3.69
validation,454,1518,3.69
volition,23,77,3.68
immune activation,46,154,3.68
program evaluation,48,161,3.68
neuronal excitability,118,395,3.68
feeling upset,31,104,3.68
feeling distress,31,104,3.68
emotional distress,31,104,3.68
pregnancy,270,906,3.68
shame,17,57,3.68
medulla spinalis,133,446,3.68
photoactivation,14,47,3.67
gtp gdp exchange factor,11,37,3.67
exchange factor,11,37,3.67
guanyl-nucleotide releasing factor,11,37,3.67
guanyl-nucleotide exchange factor,11,37,3.67
guanine nucleotide releasing factors,11,37,3.67
guanine nucleotide exchange protein,11,37,3.67
corticosteroids,14,47,3.67
heterogeneity,301,1012,3.67
gdp exchange factors,11,37,3.67
animal disease models,14,47,3.67
gdp-gtp reversing factors,11,37,3.67
genomic region,28,94,3.67
gdp-gtp exchange protein,11,37,3.67
funding opportunities,42,141,3.67
survival rate,42,141,3.67
gdp dissociation factor,11,37,3.67
gdp dissociation stimulators,11,37,3.67
sex differences,358,1206,3.66
computer biology,19,64,3.66
color,91,307,3.66
american indian,83,280,3.66
pleiotropy,27,91,3.66
neurites,19,64,3.66
care systems,95,320,3.66
ethnicity,303,1024,3.65
infancy,66,223,3.65
ethnic origin,303,1024,3.65
ms contin,455,1538,3.65
secondary outcome,292,988,3.65
inhibitory neuron,32,108,3.65
bipolar disease,58,196,3.65
salutogenesis,63,213,3.65
toxicology,243,822,3.65
clinical data,167,565,3.65
chromatin structure,37,125,3.65
imaging marker,21,71,3.65
adaptor signaling protein,16,54,3.65
adaptor protein,16,54,3.65
health promotion,63,213,3.65
pyramidal neuron,126,426,3.65
hippocampal pyramidal neuron,126,426,3.65
solitary tract nucleus,16,54,3.65
biomedical research,150,508,3.64
pancreatic cancer cells,13,44,3.64
knockin mice,41,139,3.64
healthy lifestyle,13,44,3.64
new therapeutics,686,2324,3.64
ki mice,41,139,3.64
atherosclerosis,18,61,3.64
grk,13,44,3.64
breast tumor cell,18,61,3.64
transport protein gene,26,88,3.64
anxiety treatment,13,44,3.64
hepatic failure,13,44,3.64
next generation therapeutics,686,2324,3.64
novel therapeutics,686,2324,3.64
hypotension,13,44,3.64
behavioral health,229,776,3.64
liver failure,13,44,3.64
substance abuse screening,15,51,3.63
feasibility studies,125,425,3.63
hctr2,10,34,3.63
mental processes,10,34,3.63
cigar,33,112,3.63
preclinical evaluation,25,85,3.63
cell killing,10,34,3.63
ischemic stroke,10,34,3.63
motor impairment,25,85,3.63
lung injury,10,34,3.63
marijuana use,249,845,3.63
hypocretin receptor 2 gene product,10,34,3.63
orexin receptor 2,10,34,3.63
data acquisition,35,119,3.63
oresin receptor 2,10,34,3.63
recurrence,160,544,3.63
recurrent,160,544,3.63
hcrtr2 gene product,10,34,3.63
hcrt receptor 2,10,34,3.63
sustained attention,15,51,3.63
orexin b receptor,10,34,3.63
hypocretin-2 receptor,10,34,3.63
academy,65,221,3.63
hospitalization,210,715,3.62
ohio,47,160,3.62
research priority,149,508,3.62
appetite,134,457,3.62
neurotoxicant,22,75,3.62
qualitative evaluations,12,41,3.61
miniaturize,24,82,3.61
fingerprint,19,65,3.61
biological testing,19,65,3.61
cephalic,19,65,3.61
socioeconomic position,103,352,3.61
cranial,19,65,3.61
coping skills,76,260,3.61
early detection,74,253,3.61
socio-economic position,103,352,3.61
socioeconomic status,103,352,3.61
interneurons,213,728,3.61
patient care,186,637,3.6
emergency service,14,48,3.6
postnatal,135,462,3.6
craniocerebral trauma,16,55,3.59
normal tissue,23,79,3.59
membrane lipids,16,55,3.59
head trauma,16,55,3.59
head injuries,16,55,3.59
normal tissue morphology,23,79,3.59
financial incentive,50,172,3.59
adolescent and young adult,75,258,3.59
responsible research conduct,104,358,3.58
yoga,18,62,3.58
metastasis,70,241,3.58
cytokine,216,745,3.58
cancer control science,20,69,3.57
ribosomes,40,138,3.57
provider,622,2149,3.57
caring,1002,3466,3.57
cancer control,20,69,3.57
architecture,165,570,3.57
engineering / architecture,165,570,3.57
guanine nucleotide exchange factors,11,38,3.57
community setting,77,266,3.57
depression model,11,38,3.57
biobehavioral,111,383,3.57
biobehavior,111,383,3.57
ligand binding protein gene,68,235,3.57
chronology,11,38,3.57
depressive model,11,38,3.57
regulator genes,66,228,3.57
genetic intervention,47,163,3.56
veterans,335,1159,3.56
low income population,15,52,3.56
gene transfer clinical,47,163,3.56
malignant head and neck neoplasm,13,45,3.56
genetic therapy,47,163,3.56
dorsal horn,28,97,3.56
diarrhea,13,45,3.56
cancer cell growth,13,45,3.56
hematology,13,45,3.56
biocompatible materials,28,97,3.56
head and neck cancer,13,45,3.56
social work,105,364,3.56
small gtpases,23,80,3.55
small g-proteins,23,80,3.55
blue nucleus,59,205,3.55
nucleus pigmentosus pontis,59,205,3.55
drowsiness,21,73,3.55
somnolence,21,73,3.55
monomeric gtp-binding proteins,23,80,3.55
analytical tool,38,132,3.55
effectiveness clinical trial,19,66,3.55
spontaneous pain,19,66,3.55
research subjects,19,66,3.55
monomeric g-proteins,23,80,3.55
policies,675,2347,3.55
liver microsomes,19,66,3.55
neurofeedback,23,80,3.55
statistical models,74,257,3.55
car crash,25,87,3.54
motor vehicle crash,25,87,3.54
vehicle crash,25,87,3.54
vehicular crash,25,87,3.54
vehicular collision,25,87,3.54
motor vehicle collision,25,87,3.54
car collision,25,87,3.54
alcohol seeking behavior,198,690,3.54
ethics,194,676,3.54
ethanol-seeking behavior,198,690,3.54
alcohol seeking,198,690,3.54
hepatic organ system,148,515,3.54
hepatic body system,148,515,3.54
automobile collision,25,87,3.54
automobile crash,25,87,3.54
ethanol seeking,198,690,3.54
prescription opiate abuse,48,167,3.54
fluorescence-activated cell sortings,25,87,3.54
opioid prescription drug abuse,48,167,3.54
opioid medication abuse,48,167,3.54
fluorescence activated cell sorting fractionation,25,87,3.54
fatal suicide,131,458,3.53
intent to die,131,458,3.53
cellular targeting,53,185,3.53
fatal attempt,131,458,3.53
viral vector,186,650,3.53
health care systems,319,1113,3.53
uptake,427,1492,3.53
data collection,425,1483,3.53
biological availability,118,413,3.52
tumor suppressor,36,126,3.52
clinical phenotype,22,77,3.52
tumor suppressor proteins,36,126,3.52
selective expression,71,249,3.52
twelve years of age,10,35,3.52
selectively expressed,71,249,3.52
physiologic availability,118,413,3.52
vital statistics,12,42,3.52
association cortex,10,35,3.52
psychologic stress,10,35,3.52
data aggregation,16,56,3.52
oral drug administration,44,154,3.52
hypoxic,22,77,3.52
dexamethasone,14,49,3.52
oxygen deficiency,22,77,3.52
bioavailability,118,413,3.52
public health priorities,69,242,3.52
terpene compound,10,35,3.52
terpenes,10,35,3.52
terpenoids,10,35,3.52
muscle relaxants,12,42,3.52
12 years of age,10,35,3.52
mitochondrial dysfunction,18,63,3.52
motor control,44,154,3.52
tgfβ,12,42,3.52
tgf-β,12,42,3.52
degenerative diseases of motor and sensory neurons,97,341,3.51
obsessive-compulsive neurosis,112,394,3.51
obsessive-compulsive disorder,112,394,3.51
msm,33,116,3.51
neural degenerative diseases,97,341,3.51
neural degenerative disorders,97,341,3.51
drinking initiation,39,137,3.51
information technology systems,64,225,3.51
it systems,64,225,3.51
math,27,95,3.51
endogenous cannabinoid system,62,218,3.51
degenerative neurological diseases,97,341,3.51
syringes,39,137,3.51
career,1086,3814,3.51
liquid chromatography mass spectrometry,41,144,3.51
reduce tobacco use,40,141,3.5
repaired,71,250,3.5
clinical infrastructure,19,67,3.5
repair,71,250,3.5
mucosa,17,60,3.49
regulatory affairs,15,53,3.49
cat scan,17,60,3.49
substance use,1213,4282,3.49
language development,13,46,3.49
mucous membrane,17,60,3.49
usfda,180,637,3.49
united states food and drug administration,180,637,3.49
investigator training,13,46,3.49
transmembrane protein gene,13,46,3.49
treatment adherence,85,300,3.49
food and drug administration,180,637,3.49
mucosal tissue,17,60,3.49
biomaterials,28,99,3.49
idaho,15,53,3.49
seasons,26,92,3.49
enroll,685,2418,3.49
cytogenetic or molecular genetic abnormality,11,39,3.48
reduced alcohol use,93,330,3.48
visual processing,11,39,3.48
flow microfluorometry,44,156,3.48
or protein abnormality,11,39,3.48
flow cytofluorometry,44,156,3.48
support contracts,11,39,3.48
genetic abnormality,11,39,3.48
relapsed disease,44,156,3.48
molecular abnormality,11,39,3.48
data modeling,35,124,3.48
methylome,11,39,3.48
solubility,50,177,3.48
spinal,82,291,3.48
neurobehavioral signs and symptoms,35,124,3.48
drug standard,11,39,3.48
trauma,238,844,3.48
recurrent disease,44,156,3.48
electronic data,18,64,3.47
bone marrow,20,71,3.47
early diagnosis,74,263,3.47
research methods,269,955,3.47
affective symptoms,29,103,3.47
golgi complex,27,96,3.47
pleiotropism,27,96,3.47
emotion regulation,103,366,3.47
cigarette smoke,96,341,3.47
golgi,27,96,3.47
disease progression,128,455,3.47
fitness,40,142,3.47
lead series,20,71,3.47
electroencephalography,189,671,3.47
competence,116,412,3.47
nano particle,37,132,3.46
serotonergic system,25,89,3.46
stress management,23,82,3.46
quality control,66,235,3.46
inhibit pain,16,57,3.46
nanoparticle,37,132,3.46
immunosuppression,30,107,3.46
marketing,248,883,3.46
serotonergic pathway,25,89,3.46
serotonin system,25,89,3.46
peripheral,336,1198,3.46
5-ht system,25,89,3.46
mitochondria,95,339,3.46
combinatorial,83,296,3.46
pain inhibition,16,57,3.46
recombination,53,189,3.46
5-ht pathway,25,89,3.46
wakefulness,32,114,3.46
serotonin pathway,25,89,3.46
neural circuit,833,2980,3.45
malignant neoplasm treatment,116,415,3.45
information systems,64,229,3.45
ensure,752,2689,3.45
single molecule,40,143,3.45
sexually abused,14,50,3.45
malignant neoplasm therapy,116,415,3.45
cancer therapy,116,415,3.45
non fatal attempt,38,136,3.45
pharmacogenomics,33,118,3.45
cancer cell,158,565,3.45
synaptic circuitry,833,2980,3.45
malignant cell,158,565,3.45
synaptic circuit,833,2980,3.45
suicide attempt,38,136,3.45
suicidal attempt,38,136,3.45
imaging biomarker,21,75,3.45
cancer treatment,116,415,3.45
neural circuitry,833,2980,3.45
house call,12,43,3.44
cardiac toxicity,12,43,3.44
cholecystokinin,24,86,3.44
immunomodulation,31,111,3.44
immune modulation,31,111,3.44
multi-electrode arrays,12,43,3.44
immunologic reactivity control,31,111,3.44
affective neuroscience,17,61,3.44
public health schools,31,111,3.44
transcription repressor,12,43,3.44
cardiotoxicity,12,43,3.44
data set,646,2313,3.44
epithelial cells,41,147,3.44
solid neoplasm,29,104,3.44
axon,167,598,3.44
transcriptional repressor,12,43,3.44
multielectrode arrays,12,43,3.44
oncogene addiction,61,219,3.44
program development,114,409,3.44
solid tumor,29,104,3.44
defined contribution,31,111,3.44
provincial government,15,54,3.43
general anesthetic drugs,10,36,3.43
anxious,15,54,3.43
state government,15,54,3.43
position,772,2779,3.43
antiretroviral therapy,174,625,3.43
agriculture,10,36,3.43
fundamental research,10,36,3.43
sodium ion,10,36,3.43
plasma proteins,20,72,3.43
positioning attribute,772,2779,3.43
genetic epistasis,10,36,3.43
cytoplasmic tail,10,36,3.43
motivated behavior,286,1028,3.43
mindfulness,82,295,3.43
tumor cell line,10,36,3.43
fluorescence-activated cell sorting,25,90,3.43
scalp structure,15,54,3.43
medical marijuana,27,97,3.43
robotics,10,36,3.43
medicinal marijuana,27,97,3.43
genetic heterogeneity,20,72,3.43
scalp,15,54,3.43
cytoplasmic domain,10,36,3.43
public health research,27,97,3.43
neuronal cell death,36,130,3.42
maps,646,2330,3.42
catalogs,51,184,3.42
policy maker,165,595,3.42
neuronal loss,36,130,3.42
infrastructure,482,1739,3.42
neuron loss,36,130,3.42
neuron cell death,36,130,3.42
timeline,117,422,3.42
inwardly rectifying k+ channels,18,65,3.42
inwardly rectifying potassium channels,18,65,3.42
retinal s-antigen,56,202,3.42
post-traumatic neuroses,316,1142,3.41
percocet,13,47,3.41
quality of care,100,362,3.41
posttraumatic neuroses,316,1142,3.41
national institute of allergy and infectious disease,13,47,3.41
niaid,13,47,3.41
transcriptional regulatory elements,66,239,3.41
qoc,100,362,3.41
mitochondrial,95,344,3.41
trans acting element,66,239,3.41
research assistant,13,47,3.41
post-traumatic stress disorders,316,1142,3.41
feedback,591,2139,3.41
genetic technology,13,47,3.41
acupuncture,19,69,3.4
disorder model,87,316,3.4
postmortem,173,627,3.4
risk genotype,57,207,3.4
risk allele,57,207,3.4
sodium channel,32,116,3.4
licensing,75,272,3.4
risk locus,57,207,3.4
cognitive discrimination,159,576,3.4
risk gene,57,207,3.4
acupuncture procedure,19,69,3.4
risk loci,57,207,3.4
translational medicine,16,58,3.4
knockout animal,24,87,3.4
clinic visits,28,102,3.39
needles,41,149,3.39
glioblastoma multiforme,22,80,3.39
spongioblastoma multiforme,22,80,3.39
twelfth grade,28,102,3.39
high school senior,28,102,3.39
dental,25,91,3.39
genomic segment,28,102,3.39
quantitative evaluations,11,40,3.39
education projects,14,51,3.39
r25 mechanism,14,51,3.39
grade iv astrocytoma,22,80,3.39
r25 program,14,51,3.39
fees for service,11,40,3.39
pro2286,11,40,3.39
deterioration,30,109,3.39
marijuana user,70,255,3.39
medical rehabilitation,86,313,3.39
area under curve,11,40,3.39
healthcare systems,319,1162,3.39
l-type voltage-dependent calcium channels,11,40,3.39
fee-for-service plans,11,40,3.39
financial support,33,120,3.39
beta catenin,11,40,3.39
glioblastoma,22,80,3.39
cul-2,11,40,3.39
smokeless,11,40,3.39
grade iv astrocytic neoplasm,22,80,3.39
long-lasting calcium channels,11,40,3.39
medical emergency,11,40,3.39
grade iv astrocytic tumor,22,80,3.39
l-type vdcc,11,40,3.39
network analysis,107,391,3.38
cessation of life,911,3322,3.38
behavioral clinical trial,20,73,3.38
oligo,17,62,3.38
discrimination,159,581,3.38
alcohol dehydrogenase,17,62,3.38
pathway analysis,107,391,3.38
cocaine overdose,20,73,3.38
biophysics,59,215,3.38
eligible participant,17,62,3.38
cause of death,251,919,3.37
neuroglia,182,666,3.37
kolliker's reticulum,182,666,3.37
contracts,178,652,3.37
technology,1125,4113,3.37
glial cells,182,666,3.37
scientist,859,3146,3.37
fighting,44,161,3.37
contracting opportunities,178,652,3.37
neuroglial cells,182,666,3.37
nerve cement,182,666,3.37
non-neuronal cell,182,666,3.37
muscle tissue,65,238,3.37
adolescent binge drinking,12,44,3.36
carfentanil,15,55,3.36
fetal,90,330,3.36
mortality,830,3043,3.36
carfentanyl,15,55,3.36
home,347,1273,3.36
death,911,3343,3.36
4-methoxycarbonyl fentanyl,15,55,3.36
endothelial cells,33,121,3.36
rodent model,359,1316,3.36
directs attention,12,44,3.36
prenatal smoking,15,55,3.36
directed attention,12,44,3.36
4-methoxycarbonylfentanyl,15,55,3.36
oxymorphone,12,44,3.36
chronic inflammatory pain,18,66,3.36
2-arachidonoyl-sn-glycerol,30,110,3.36
methylnaloxone,12,44,3.36
misuse of prescription only drugs,36,132,3.36
2-ag,30,110,3.36
prescription drug misuse,36,132,3.36
care given by nurses,12,44,3.36
recreational drugs,12,44,3.36
n-methylnaloxone,12,44,3.36
sleep regulation,21,77,3.36
preventive measure,12,44,3.36
sleep control,21,77,3.36
preventative measure,12,44,3.36
focus groups,206,758,3.35
therapy adherence,47,173,3.35
mouse model,598,2203,3.35
recruit,1401,5152,3.35
glp-1,19,70,3.35
uninsured,19,70,3.35
camp response element-binding protein 1,22,81,3.35
imaging genetics,19,70,3.35
glucagon-like peptide 1,19,70,3.35
kidney carcinoma,13,48,3.34
compare effectiveness,68,251,3.34
consumption measures,13,48,3.34
peptide receptor,23,85,3.34
plasmids,23,85,3.34
renal carcinoma,13,48,3.34
renal cancer,13,48,3.34
electronic healthcare record,75,277,3.34
kidney cancer,13,48,3.34
sprague-dawley rats,32,118,3.34
postiive attitude,16,59,3.34
engineering,275,1015,3.34
niddk,16,59,3.34
renal function,10,37,3.33
genome sequencing,50,185,3.33
local government,10,37,3.33
blood glucose regulation,10,37,3.33
glucose regulation,10,37,3.33
golgi apparatus,27,100,3.33
liver cells carcinoma,20,74,3.33
analgesics,560,2076,3.33
glucose control,10,37,3.33
lipid peroxidation,10,37,3.33
glucose homeostasis,10,37,3.33
foundations,894,3309,3.33
immunohistochemistry cell/tissue,219,812,3.33
receptor-interacting protein,10,37,3.33
kidney function,10,37,3.33
premature mortality,27,100,3.33
innovate,2279,8461,3.32
laboratory finding,25,93,3.32
tissues,679,2525,3.32
lab findings,25,93,3.32
hepatocyte,38,141,3.32
viral,644,2394,3.32
respiratory disorder,14,52,3.32
body tissues,679,2521,3.32
innovative,2279,8466,3.32
tlr4,31,115,3.32
cerebrovascular,14,52,3.32
large cell diffuse non-hodgkin's lymphoma,14,52,3.32
malignant breast neoplasm,63,234,3.32
malignant breast tumor,63,234,3.32
tlr4 gene,31,115,3.32
innovation,2279,8461,3.32
breast cancer,63,234,3.32
multimodality imaging,21,78,3.32
familiarity,39,145,3.32
small molecule,353,1312,3.32
vasculopathy,14,52,3.32
multi-modality imaging,21,78,3.32
uganda,11,41,3.31
older population,11,41,3.31
neuroglia tumor,18,67,3.31
magnetoencephalography,11,41,3.31
nmdar1,11,41,3.31
relative effectiveness,11,41,3.31
nmda receptor a1,11,41,3.31
nmdara1 protein,11,41,3.31
neuroglia neoplasm,18,67,3.31
glial-derived tumor,18,67,3.31
translations,391,1458,3.31
ovarian hormone,29,108,3.31
data management,102,380,3.31
native americans,72,268,3.31
cross-over designs,37,138,3.31
output,433,1619,3.3
oxidative damage,15,56,3.3
childrearing,65,243,3.3
research resources,1303,4873,3.3
resources,1303,4876,3.3
tobacco exposure,27,101,3.3
accidents,62,232,3.3
spirituality,15,56,3.3
optical,178,665,3.3
src protein-tyrosine kinases,15,56,3.3
oncogenic,121,452,3.3
data sources,79,295,3.3
iq deficit,64,239,3.3
neurocognitive deficit,64,239,3.3
optics,178,668,3.29
ethyl alcohol measurements,81,304,3.29
united states,1312,4911,3.29
economically deprived,24,90,3.29
economically disadvantaged,24,90,3.29
drinking water,20,75,3.29
research support,219,822,3.29
phase 1 study,55,206,3.29
risk variant,57,214,3.29
scaffolding,164,615,3.29
pilot trial,112,420,3.29
alcohol level,81,304,3.29
quality-adjusted life years,28,105,3.29
sound,117,438,3.29
scaffold,164,615,3.29
case report,48,180,3.29
inflammatory response,61,229,3.29
phase i study,55,206,3.29
organ,132,495,3.29
treatment as usual,268,1004,3.29
location,456,1711,3.29
translation research,390,1460,3.29
usual care,268,1004,3.29
alcohol measurement,81,304,3.29
case study,48,180,3.29
etoh level,81,304,3.29
ethanol measurement,81,304,3.29
response prediction,34,128,3.28
health services delivery,91,342,3.28
elisa,42,158,3.28
pharmacists,37,139,3.28
predictive response,34,128,3.28
enzyme-linked immunosorbent assay,42,158,3.28
predictor of response,34,128,3.28
clinical and translational science awards,21,79,3.28
health care delivery,91,342,3.28
dentists,17,64,3.28
adolescent boy,33,124,3.28
male adolescents,33,124,3.28
mutagenesis molecular biology,72,271,3.28
mothers,194,730,3.28
nasal passages nose,37,139,3.28
bmi percentile,26,98,3.27
permeability,104,392,3.27
depressive disorder,22,83,3.27
socioeconomic factors,13,49,3.27
cholinergic neuron,39,147,3.27
study models,90,339,3.27
data analysis,471,1778,3.27
body mass index,26,98,3.27
quetelet index,26,98,3.27
socio-economic status,103,389,3.27
discipline of nursing,48,181,3.27
nursing profession,48,181,3.27
nursing field,48,181,3.27
sports,13,49,3.27
bmi z-score,26,98,3.27
glia,182,687,3.27
glial tumor,18,68,3.26
glial cell tumors,18,68,3.26
glial neoplasm,18,68,3.26
impaired behavior,42,159,3.26
behavioral impairment,42,159,3.26
hyperactivity,132,499,3.26
fluorophore,18,68,3.26
gene therapy,47,178,3.26
neuroglial neoplasm,18,68,3.26
targeted research,23,87,3.26
diffuse large b-cell lymphoma,14,53,3.26
dlbcl,14,53,3.26
disease subtype,14,53,3.26
suicide,131,496,3.26
loss of function,95,359,3.26
disorder subtype,14,53,3.26
ketamine,54,204,3.26
neuroglial tumor,18,68,3.26
learning behavior,57,216,3.25
academia,40,152,3.25
undergraduate research,15,57,3.25
research activity,152,577,3.25
logistics,68,258,3.25
immunocompetent,15,57,3.25
learned behavior,57,216,3.25
never smoker,10,38,3.25
glean,34,129,3.25
protocols documentation,836,3177,3.25
healthy volunteer,50,190,3.25
face expression,15,57,3.25
cell separation technology,20,76,3.25
cell separation,20,76,3.25
cell segregation,20,76,3.25
cell isolation,20,76,3.25
surgeon,74,281,3.25
reversal learning,45,171,3.25
pragmatic clinical trial,24,91,3.25
pragmatic trial,50,190,3.25
molecular dynamics,44,167,3.25
mifeprex,10,38,3.25
mifegyne,10,38,3.25
infectious diseases,140,533,3.24
diaries,53,202,3.24
problematic alcohol consumption,383,1458,3.24
infectious disorder,140,533,3.24
problematic alcohol use,383,1458,3.24
government agencies,21,80,3.24
informant,53,202,3.24
neuroimmunomodulation,26,99,3.24
educational aspects,498,1895,3.24
female health,53,202,3.24
infectious disease pathway,140,533,3.24
vesicular glutamate transporter 2,11,42,3.23
psychological distress,43,164,3.23
chemistry,173,661,3.23
recombinant proteins,17,65,3.23
dnpi protein,11,42,3.23
thalamic,187,715,3.23
inhibitory synapse,34,130,3.23
thalamic structure,187,715,3.23
differentiation-associated na-dependent inorganic phosphate cotransporter,11,42,3.23
arm,305,1163,3.23
data storage,11,42,3.23
vglut2 protein,11,42,3.23
flow microfluorimetry,44,168,3.23
data storage and retrieval,11,42,3.23
flow cytofluorometries,44,168,3.23
r24,11,42,3.23
data retrieval,11,42,3.23
clinic,613,2341,3.23
flow cytophotometry,44,168,3.23
bisexual,24,92,3.22
primary tumor,24,92,3.22
hepatic fibrosis,12,46,3.22
primary neoplasm,24,92,3.22
selection for treatments,23,88,3.22
liver fibrosis,12,46,3.22
recombinant oxytocin,48,184,3.22
ocytocin,48,184,3.22
lactation,12,46,3.22
healthcare delivery,91,349,3.22
neoplasm/cancer,602,2310,3.21
pre-clinical study,314,1206,3.21
preclinical study,314,1206,3.21
alcohol initiation,39,150,3.21
alcohol use initiation,39,150,3.21
malignancy,602,2310,3.21
immigrant,26,100,3.21
malignant tumor,602,2310,3.21
junior high,26,100,3.21
health training,13,50,3.21
genomic alteration,19,73,3.21
demographics,101,388,3.21
dna sequence alteration,19,73,3.21
alaska,19,73,3.21
binge eating disorder,13,50,3.21
attentional deficit,13,50,3.21
cancers,602,2310,3.21
malignant neoplasms,602,2310,3.21
communicable diseases,140,539,3.2
release factor,14,54,3.2
stereotyping,21,81,3.2
effective intervention,218,841,3.2
hair,40,154,3.2
signaling protein,97,374,3.2
g protein-coupled receptor signaling,60,231,3.2
gpcr signaling,60,231,3.2
social impacts,22,85,3.19
ultrasound medical imaging,15,58,3.19
sympathetic nervous system,22,85,3.19
implantation,31,120,3.19
gastrointestinal,36,139,3.19
delta(1)-tetrahydrocannabinol,82,317,3.19
lung adenocarcinoma,15,58,3.19
therapy failure,22,85,3.19
alkaloids,46,178,3.19
mentors,1034,3997,3.19
9-ene-tetrahydrocannabinol,82,317,3.19
metabolic,305,1180,3.19
delta-9-tetrahydrocannabinol,82,317,3.19
paraventricular nucleus,23,89,3.19
delta(9)-tetrahydrocannabinol,82,317,3.19
delta(9)-thc,82,317,3.19
behavioral symptoms,22,85,3.19
ultrasound diagnosis,15,58,3.19
dimensions,252,974,3.19
excitotoxicity,23,89,3.19
pancreas,30,116,3.19
pancreatic,30,116,3.19
tetrahydrocannabinol,82,317,3.19
resolution,525,2029,3.19
medical ultrasound,15,58,3.19
delta(1)-thc,82,317,3.19
police,37,143,3.19
toll-like receptor family gene,22,85,3.19
structural biology,49,190,3.18
msir,455,1766,3.18
morphia,455,1766,3.18
minor tranquilizing agents,94,365,3.18
use effectiveness,24,93,3.18
infumorph,455,1766,3.18
dependoparvovirus,34,132,3.18
kadian,455,1766,3.18
oramorph sr,455,1766,3.18
cell number,32,124,3.18
cell adhesion molecule gene,16,62,3.18
cell count,32,124,3.18
roxanol,455,1766,3.18
oramorph,455,1766,3.18
statex sr,455,1766,3.18
update,198,769,3.18
evidence based treatment,246,958,3.17
technological innovation,18,70,3.17
custom,91,354,3.17
chemotactic cytokines,46,179,3.17
cognitive enhancement,27,105,3.17
social service,105,408,3.17
hep c,70,272,3.17
fellowship program,18,70,3.17
mental hygiene,716,2790,3.17
cannabis,252,980,3.17
discover genes,44,171,3.17
fright,211,820,3.17
psychological health,716,2790,3.17
drug candidate,89,346,3.17
personal satisfaction,254,992,3.16
adolescent alcohol problem,10,39,3.16
rho gtp-binding proteins,11,43,3.16
adolescent alcohol abuse,10,39,3.16
adhesives,10,39,3.16
in situ hybridization genetics,102,398,3.16
bacteria,32,125,3.16
computational framework,10,39,3.16
intramural research program,22,86,3.16
intramural program,22,86,3.16
tool development,31,121,3.16
computer framework,10,39,3.16
15 year old,11,43,3.16
fifteen year old,11,43,3.16
rho g-proteins,11,43,3.16
rho gtpases,11,43,3.16
critical pathways,32,125,3.16
informed consent forms,10,39,3.16
informed consent documents,10,39,3.16
consent forms,10,39,3.16
consent documents,10,39,3.16
rho protein p21,11,43,3.16
receptor upregulation,21,82,3.16
problem drinking in adolescents,10,39,3.16
problem alcohol use in adolescents,10,39,3.16
adolescent ethanol abuse,10,39,3.16
well-being,254,992,3.16
rho small gtp-binding proteins,11,43,3.16
critical paths,32,125,3.16
severity of illness,25,98,3.15
pain tolerance level,35,137,3.15
rabbits mammals,12,47,3.15
pain tolerance,35,137,3.15
disease severity,25,98,3.15
rna gene products,201,786,3.15
non-polyadenylated rna,201,786,3.15
computer models,186,729,3.15
domestic rabbit,12,47,3.15
water consumption,12,47,3.15
collection,303,1185,3.15
water intake,12,47,3.15
arrestins,56,219,3.15
patient centered,160,626,3.15
patient oriented,160,626,3.15
clinical effectiveness,35,137,3.15
film,15,59,3.14
anhedonia,83,326,3.14
intraoral drug delivery,44,173,3.14
alcohol involvement,29,114,3.14
geospatial information system,13,51,3.14
vulnerable adolescent,13,51,3.14
war,30,118,3.14
filamentous actin,14,55,3.14
blood sugar,15,59,3.14
involvement with alcohol,29,114,3.14
vascular disorder,14,55,3.14
blood vessel disorder,14,55,3.14
catalytic site,27,106,3.14
catalytic region,27,106,3.14
catalytic domain,27,106,3.14
catalytic core,27,106,3.14
drug market,26,102,3.14
f-actin,14,55,3.14
anorexia nervosa,13,51,3.14
junior high school,26,102,3.14
nurse practitioners,13,51,3.14
safety,621,2438,3.14
peptidomimetics,14,55,3.14
brain abnormalities,17,67,3.13
ptsd,316,1247,3.13
cancer metabolism,18,71,3.13
lung,153,602,3.13
clinical assessments,64,252,3.13
tumor metabolism,18,71,3.13
clinical practice,282,1110,3.13
traumatic neurosis,316,1247,3.13
hepatic parenchymal cell,34,134,3.13
hepatic cells,34,134,3.13
education,498,1964,3.13
urban american indian,16,63,3.13
neurobehavioral manifestations,35,138,3.13
paracrine,18,71,3.13
cognitive symptoms,35,138,3.13
weight management,18,71,3.13
aggregated data,16,63,3.13
cognitive manifestations,35,138,3.13
assault,18,71,3.13
histology,52,205,3.13
mouse genome,16,63,3.13
mental health,716,2819,3.13
cell sorting,20,79,3.12
reporter,177,700,3.12
gene x environment interaction,38,150,3.12
phase ii study,46,182,3.12
prophylactic,20,79,3.12
in situ,66,261,3.12
cancer etiology,80,316,3.12
gxe interaction,38,150,3.12
n-methylmorphine,19,75,3.12
cancer cause,80,316,3.12
brief alcohol intervention,23,91,3.12
lipids,145,574,3.12
particle,49,194,3.12
practice guidelines,22,87,3.12
risk marker,19,75,3.12
translational research,390,1549,3.11
methadose,339,1343,3.11
adanon,339,1343,3.11
gene regulation process,133,528,3.11
translational science,390,1549,3.11
rodents mammals,739,2935,3.11
gene regulation,133,528,3.11
althose,339,1343,3.11
gene action regulation,133,528,3.11
primary outcome,398,1577,3.11
efficacy testing,228,904,3.11
gene expression regulation,133,528,3.11
dolophine,339,1343,3.11
medical specialties,228,904,3.11
estrogen receptors,25,99,3.11
virus genetics,27,107,3.11
menthol,48,191,3.1
muscle,65,259,3.1
health care,532,2116,3.1
life span,162,644,3.1
crossover design,37,147,3.1
sedation,105,418,3.1
nutrition,49,195,3.1
sedation procedure,105,418,3.1
manuscripts,179,712,3.1
lifespan,162,644,3.1
lung respiratory system,114,453,3.1
probabilistic models,74,294,3.1
brainstem,83,330,3.1
consumption,541,2156,3.09
interdisciplinary study,200,797,3.09
research specimen,97,387,3.09
skills,999,3987,3.09
specimen,97,387,3.09
protective effect,72,287,3.09
in utero,71,283,3.09
cancer genome,11,44,3.08
catalytic subunit,28,112,3.08
malignant prostatic tumor,28,112,3.08
neonate,43,172,3.08
malignant tumor of the prostate,28,112,3.08
disease diagnosis,10,40,3.08
poverty,117,469,3.08
p38 mitogen activated protein kinase,17,68,3.08
mifepristone,10,40,3.08
malignant neoplasm of prostate,28,112,3.08
nursing care,12,48,3.08
disease phenotype,14,56,3.08
mimetics,21,84,3.08
spleen reticuloendothelial system,11,44,3.08
ghrelin receptor,11,44,3.08
prostate ca,28,112,3.08
puericulture,29,116,3.08
prostate cancer,28,112,3.08
marble,10,40,3.08
hearing,20,80,3.08
training activity,111,445,3.08
b lymphoma,12,48,3.08
causation,488,1953,3.08
b-cell lymphomas,12,48,3.08
cardiovascular risk factor,26,104,3.08
cardiovascular risk,26,104,3.08
germinal center,10,40,3.08
blood glucose,15,60,3.08
economic disadvantage,12,48,3.08
kentucky,38,152,3.08
group interviews,12,48,3.08
justice,98,392,3.08
malignant stem cell,10,40,3.08
direct application,17,68,3.08
cardiology,14,56,3.08
aerosols,28,112,3.08
ritalin,31,124,3.08
structure of germinal center of lymph node,10,40,3.08
heat stimulus,11,44,3.08
prostatic cancer,28,112,3.08
p53 genes,24,96,3.08
k-series research career programs,179,720,3.07
post-doc,249,1000,3.07
postdoc,249,1000,3.07
child rearing,65,261,3.07
postdoctoral fellow,249,1000,3.07
sociobehavioral,71,285,3.07
research associate,249,1000,3.07
negative emotional state,60,241,3.07
stains,58,233,3.07
translational approach,61,245,3.07
adaptive behaviors,54,217,3.07
acute stress,59,237,3.07
motion,53,213,3.07
protocol development,55,221,3.07
analgesia,266,1068,3.07
post-doctoral,249,1000,3.07
sociobehavior,71,285,3.07
evolution,103,415,3.06
clinical evaluation,77,310,3.06
michigan,65,262,3.06
memory impairment,70,282,3.06
immunohistochemistry staining method,219,883,3.06
satisfaction,200,807,3.06
active control,27,109,3.06
clinical test,77,310,3.06
memory deficit,70,282,3.06
research clinical testing,77,310,3.06
clinical testing,77,310,3.06
e-health,31,125,3.06
combat,214,862,3.06
cns nervous system,301,1212,3.06
ehealth,31,125,3.06
experience,2623,10606,3.05
hepatoma,20,81,3.05
educational activities,25,101,3.05
clinically relevant,372,1505,3.05
lipophilicity,23,93,3.05
g protein-coupled inwardly-rectifying potassium channel,22,89,3.05
injury,270,1093,3.05
electrophysiology,836,3377,3.05
neurophysiological,249,1008,3.05
hepatocellular cancer,20,81,3.05
delta4-pregnene-3,41,166,3.05
corpus luteum hormone,41,166,3.05
hepatocellular carcinoma,20,81,3.05
route,198,800,3.05
heterotrimeric gtp-binding proteins,21,85,3.05
heterotrimeric g-proteins,21,85,3.05
social interaction,91,368,3.05
disclosure,21,85,3.05
pregnenedione,41,166,3.05
fear,211,853,3.05
behavioral paradigm,107,432,3.05
site-directed mutagenesis,43,174,3.05
hepatic cirrhosis,21,85,3.05
liver cirrhosis,21,85,3.05
primary carcinoma of the liver cells,20,81,3.05
conduct clinical trials,92,372,3.05
information disclosure,21,85,3.05
rhode island,44,178,3.05
g protein-complex receptor,249,1008,3.05
clinical relevance,372,1505,3.05
g-protein-coupled receptors,249,1008,3.05
therapeutic progesterone,41,166,3.05
controlled release,16,65,3.04
medical center,155,628,3.04
japan,17,69,3.04
pigs,15,61,3.03
family suidae,15,61,3.03
metabolic diseases,40,163,3.03
docking,58,236,3.03
matrix metalloproteinases,13,53,3.03
microbiology,14,57,3.03
oral,387,1573,3.03
adulthood,1391,5669,3.03
cell-to-cell interaction,26,106,3.03
suidae,15,61,3.03
emotional experience,14,57,3.03
mmps,13,53,3.03
cell interaction,26,106,3.03
cell communication,26,106,3.03
metabolism disorder,40,163,3.03
thesaurismosis,40,163,3.03
metabolic disorder,40,163,3.03
neuroprotection,43,175,3.03
statistics,201,817,3.03
polysubstance abuse,13,53,3.03
bio-informatics,230,937,3.03
addictive disorder,4553,18553,3.03
porcine,15,61,3.03
confidence intervals,15,61,3.03
drug abuse detection,15,61,3.03
drug abuse screening,15,61,3.03
hydrophobicity,14,57,3.03
population research,13,53,3.03
micro-tubule,15,61,3.03
substance abuse detection,15,61,3.03
substance abuse testing,15,61,3.03
drug abuse testing,15,61,3.03
microtubules,15,61,3.03
liver,148,602,3.03
multisubstance abuse,13,53,3.03
tgf-beta,12,49,3.02
bone-derived transforming growth factor,12,49,3.02
transforming growth factor beta,12,49,3.02
drug combinations,49,200,3.02
platelet transforming growth factor,12,49,3.02
selection criteria,12,49,3.02
tgf b,12,49,3.02
cancer risk,46,188,3.02
member 1,12,49,3.02
milk growth factor,12,49,3.02
visual cortical,23,94,3.02
trial design,103,421,3.02
juvenile justice system,12,49,3.02
tgfbeta,12,49,3.02
buprenorphine,445,1815,3.02
negative reinforcer,11,45,3.01
cohesion,32,131,3.01
b-cell,30,123,3.01
age 18 years,44,180,3.01
immunology,52,213,3.01
qualifying,143,586,3.01
stimulus processing,11,45,3.01
infant care,10,41,3.01
immunotherapy,43,176,3.01
infant health care,10,41,3.01
drug kinetics,336,1378,3.01
intergenerational,39,160,3.01
copy number variant,10,41,3.01
precipitation,10,41,3.01
psychological factors,28,115,3.0
community health centers,27,111,3.0
vermont,18,74,3.0
neoplastic disease chemotherapeutic agents,36,148,3.0
predict relapse,51,210,3.0
neonatal,79,325,3.0
portability,27,111,3.0
tissue sample,38,156,3.0
thalamus,187,768,3.0
intervention trial,57,235,2.99
bioinformatics,230,949,2.99
psychosocial assessment,24,99,2.99
program research project grants,23,95,2.99
psychosocial care,24,99,2.99
program project grant,23,95,2.99
psychosocial support,24,99,2.99
spinal cord,133,548,2.99
research program projects,23,95,2.99
p01 program,23,95,2.99
psychosocial studies,24,99,2.99
intervention effect,133,549,2.99
penetration,105,433,2.99
neuromodulator,109,449,2.99
p01 mechanism,23,95,2.99
biophysical techniques,16,66,2.99
biophysical methods,16,66,2.99
virus,199,822,2.99
buffers,69,285,2.99
urban native american,16,66,2.99
biophysical methodology,16,66,2.99
biophysical approaches,16,66,2.99
psychosocial assessment and care,24,99,2.99
ires,15,62,2.98
sensory cortex,15,62,2.98
elasticity,14,58,2.98
vascular diseases,14,58,2.98
relaxation,36,149,2.98
protein engineering,29,120,2.98
toxicities,311,1285,2.98
staining method,58,240,2.98
ribosome entry site,15,62,2.98
hypoxia,22,91,2.98
toxic effect,311,1285,2.98
molecular analysis,30,124,2.98
amine,15,62,2.98
internal ribosome entry segment,15,62,2.98
enhancing factor,15,62,2.98
internal ribosome entry site,15,62,2.98
adolescent welfare,29,120,2.98
chemical library,32,133,2.97
small molecule libraries,32,133,2.97
cholesterol,32,133,2.97
scoring method,13,54,2.97
sis cytokines,46,191,2.97
dopamine beta hydroxylase,13,54,2.97
cell model,73,303,2.97
cellular model,73,303,2.97
physical health,141,586,2.97
physical conditioning,141,586,2.97
regenerate,20,83,2.97
disease model,87,361,2.97
natural regeneration,20,83,2.97
l-threonine,13,54,2.97
chemoattractant cytokine,46,191,2.97
intercrines,46,191,2.97
homologous chemotactic cytokines,46,191,2.97
blood capillaries,13,54,2.97
dopamine-beta-monooxygenase,13,54,2.97
solvents,20,83,2.97
regeneration,20,83,2.97
economical income,107,445,2.97
natural hypothermia,19,79,2.97
pro-drugs,39,162,2.97
drug precursors,39,162,2.97
analytical chemistry,19,79,2.97
drug design,82,341,2.97
behavioral assay,128,532,2.97
algorithms,199,825,2.97
economic income,107,445,2.97
glucocorticoid receptor,38,158,2.97
c. sativa,12,50,2.96
tremor,25,104,2.96
inattention,24,100,2.96
inattentiveness,24,100,2.96
viral gene products,18,75,2.96
neural mechanism,446,1857,2.96
viral gene proteins,18,75,2.96
clinical diagnosis,12,50,2.96
viral proteins,18,75,2.96
immunofluorescence immunologic,25,104,2.96
functional status,24,100,2.96
communities,1463,6094,2.96
gatekeeping,12,50,2.96
experimental designs,153,637,2.96
national institute on drug abuse,1041,4342,2.96
gatekeeper,12,50,2.96
neuromechanism,446,1857,2.96
risk sharing,12,50,2.96
disabled,33,138,2.95
sbir,109,456,2.95
pallidum,103,430,2.95
neurosciences,649,2714,2.95
positron emitting tomography,99,414,2.95
positron emission tomographic imaging,99,414,2.95
globus pallidus,103,430,2.95
positron emission tomographic (pet) imaging,99,414,2.95
migration,50,209,2.95
nmda receptor antagonist,22,92,2.95
ovarian,17,71,2.95
coupled,455,1902,2.95
thirst,11,46,2.95
conditioned response,17,71,2.95
allopregnanolone,16,67,2.95
fellowship,175,731,2.95
conditioned reflex,17,71,2.95
src-family tyrosine kinases,15,63,2.94
registries,85,356,2.94
injection drug use,71,298,2.94
older adult,129,541,2.94
src tyrosine kinases,15,63,2.94
response elements,10,42,2.94
b-cell activation,10,42,2.94
src-family kinases,15,63,2.94
model development,47,197,2.94
triage,15,63,2.94
functional plasticity,15,63,2.94
alcohol testing,36,151,2.94
treatment effectiveness,87,365,2.94
ethanol testing,36,151,2.94
src kinases,15,63,2.94
confounding factors (epidemiology),10,42,2.94
confounding variables,10,42,2.94
disseminated sclerosis,20,84,2.94
experimental models,47,197,2.94
survey instrument,616,2595,2.93
ethanol related behavior,101,425,2.93
pre-clinical,651,2744,2.93
mass spectrum analyses,113,476,2.93
mass spectroscopy,113,476,2.93
immunologic markers,14,59,2.93
publishing,763,3212,2.93
ethanol induced behavior,101,425,2.93
mass photometry/spectrum analysis,113,476,2.93
alcohol related behavior,101,425,2.93
immune markers,14,59,2.93
cb2,51,215,2.93
intervention strategies,2367,9979,2.93
epinephrine receptors,47,198,2.93
ethanol behavior,101,425,2.93
intervention therapy,294,1239,2.93
therapeutic intervention,294,1239,2.93
cb2 receptor,51,215,2.93
alcohol induced behavior,101,425,2.93
positive reinforcements,54,227,2.93
pressure,74,311,2.93
healthcare,532,2243,2.93
interventional strategy,2367,9979,2.93
mass spectrum analysis,113,476,2.93
rest,304,1280,2.93
alcohol behavior,101,425,2.93
tumor,210,888,2.92
lipid bilayers,13,55,2.92
visual cortex,23,97,2.92
motor deficit,13,55,2.92
premalignant,13,55,2.92
meth abuse,31,131,2.92
dehydrogenases,13,55,2.92
oxidoreductase,13,55,2.92
reductases,13,55,2.92
approach behavior,35,148,2.92
precancerous,13,55,2.92
irk1 channel,18,76,2.92
inward rectifier potassium channel,18,76,2.92
chronic ethanol consumption,135,570,2.92
rodent,739,3126,2.92
tobacco control research,13,55,2.92
inwardly rectifying postassium channels,18,76,2.92
monitoring device,13,55,2.92
gene discovery,44,186,2.92
inward rectifier k+ channels,18,76,2.92
health benefit,91,384,2.92
chronic alcohol drinking,135,570,2.92
chronic alcohol ingestion,135,570,2.92
cellular morphology,13,55,2.92
chronic alcohol use,135,570,2.92
chronic etoh drinking,135,570,2.92
chronic alcohol consumption,135,570,2.92
small business innovation research,109,460,2.92
chronic ethanol ingestion,135,570,2.92
appointment,81,342,2.92
chronic ethanol drinking,135,570,2.92
fibroblasts,26,110,2.92
small business innovation research grant,109,460,2.92
overexpress,270,1144,2.91
overexpression,270,1144,2.91
alternative treatment,47,199,2.91
therapeutic index,21,89,2.91
patient population,202,857,2.91
collaborations,1070,4539,2.91
awareness,200,849,2.91
facial,312,1322,2.91
nasal,37,157,2.91
logic,38,161,2.91
face,312,1323,2.91
faces,312,1322,2.91
medial,463,1963,2.91
r-series research projects,564,2400,2.9
rodentia,739,3141,2.9
canada,43,183,2.9
virtual environment,12,51,2.9
aging brain,16,68,2.9
genomics,406,1728,2.9
loss of function mutation,15,64,2.89
health occupations,11,47,2.89
severities,707,3021,2.89
intracellular skeleton,45,192,2.89
object recognition,15,64,2.89
united states dept. of health and human services,34,145,2.89
health professions,11,47,2.89
united states department of health and human services,34,145,2.89
performance tests,19,81,2.89
department of health and human services,34,145,2.89
cytoskeletal system,45,192,2.89
tk inhibitors,15,64,2.89
genetic enhancer element,11,47,2.89
nucleus,451,1923,2.89
preclinical,651,2779,2.89
hepatitis c virus transmission,22,94,2.89
tyrosine kinase inhibitor,15,64,2.89
lytotoxicity,26,111,2.89
protein tyrosine kinase inhibitors,15,64,2.89
ptk inhibitors,15,64,2.89
cellular matrix,45,192,2.89
wireless,33,141,2.89
sound measurement,15,64,2.89
child care,29,124,2.88
cell nucleus,451,1930,2.88
redox,28,120,2.88
sleep wake cycle,18,77,2.88
predictive value,49,210,2.88
analgesic management,53,227,2.88
functional impairment,60,257,2.88
mental depression,942,4034,2.88
opiate receptors,326,1395,2.88
oxidation-reduction,28,120,2.88
pharmacologic management,53,227,2.88
writing,285,1222,2.88
cardiovascular function,25,107,2.88
primary prevention,21,90,2.88
medication management,53,227,2.88
libraries,167,716,2.88
ovocylin,46,198,2.87
oxidants,10,43,2.87
estradiol-17beta,46,198,2.87
fasts,17,73,2.87
dimenformon,46,198,2.87
estradiol-17 beta,46,198,2.87
estraldine,46,198,2.87
therapeutic estradiol,46,198,2.87
progynon,46,198,2.87
driving force,24,103,2.87
diogyn,46,198,2.87
electron acceptor,10,43,2.87
ovocyclin,46,198,2.87
estrace,46,198,2.87
fasted,17,73,2.87
diogynets,46,198,2.87
aquadiol,46,198,2.87
translating,597,2564,2.87
genomewide association scan,227,975,2.87
genome wide association scan,227,975,2.87
anxiety sensitivity,10,43,2.87
self perception,17,73,2.87
personal awareness,17,73,2.87
treatment compliance,61,262,2.87
advocate,74,318,2.87
genome wide association studies,227,975,2.87
self knowledge,17,73,2.87
self awareness,17,73,2.87
genome wide association study,227,975,2.87
hypermethylation,10,43,2.87
genomewide association study,227,975,2.87
o element,30,129,2.87
genomewide association studies,227,975,2.87
self view,17,73,2.87
o2 element,30,129,2.87
reconstruction,37,159,2.87
gwas,227,975,2.87
whole genome association analysis,227,975,2.87
genome wide association,227,975,2.87
whole genome association study,227,975,2.87
whole genome association studies,227,975,2.87
self image,17,73,2.87
extramural activities,67,289,2.86
morbidity,579,2494,2.86
extramural,67,289,2.86
molecular conformation,107,461,2.86
tutoring and outreach,26,112,2.86
poisoned,13,56,2.86
poisoning,13,56,2.86
anti-cancer agents,36,155,2.86
education and outreach,26,112,2.86
morbidity - disease rate,579,2494,2.86
extmr,67,289,2.86
antineoplastic drugs,36,155,2.86
antineoplastic agents,36,155,2.86
instruction and outreach,26,112,2.86
training and outreach,26,112,2.86
molecular configuration,107,461,2.86
conformational state,107,461,2.86
tumor-specific treatment agents,36,155,2.86
cost efficient,26,112,2.86
oxytocin,48,207,2.86
healthcare policy,95,409,2.86
data analyses,471,2030,2.86
specialty,228,982,2.86
energy balance,13,56,2.86
c57bl/6 mouse,19,82,2.86
novel diagnostics,19,82,2.86
next generation diagnostics,19,82,2.86
new diagnostics,19,82,2.86
intravenous,263,1135,2.86
cancer drug,36,155,2.86
liposomal,22,95,2.86
molecular stereochemistry,107,461,2.86
proteomics,161,695,2.86
fostering,381,1644,2.86
computer based models,186,804,2.85
swine,15,65,2.85
math models,49,212,2.85
administrator,99,429,2.85
non-small-cell lung carcinoma,18,78,2.85
ipsilateral,12,52,2.85
mathematical modeling,49,212,2.85
cocultivation,34,147,2.85
computerized models,186,804,2.85
glioma,18,78,2.85
phase 2 study,46,199,2.85
avoidance behavior,53,229,2.85
computational models,186,804,2.85
oryctolagus cuniculus,12,52,2.85
success,900,3895,2.85
co-culture,34,147,2.85
computational modeling,186,804,2.85
coculture techniques,34,147,2.85
malignant - descriptor,43,186,2.85
neuronal dysfunction,18,78,2.85
coculture,34,147,2.85
computerized modeling,186,804,2.85
remission,83,361,2.84
benefits and risks,35,152,2.84
alcohol screening,23,100,2.84
clinical trials,1084,4715,2.84
phase ii protocol,53,230,2.84
ribonucleic acid,201,873,2.84
disease remission,83,361,2.84
wistar rats,26,113,2.84
repository,70,304,2.84
phase ii clinical trials,53,230,2.84
clinical study,780,3401,2.83
immunohistochemistry,219,954,2.83
risk factors,749,3267,2.83
toddler,14,61,2.83
prevent,1450,6309,2.83
bolus infusion,17,74,2.83
american,687,2997,2.83
liver cells,34,148,2.83
neurotensin receptors,11,48,2.83
systematics,185,806,2.83
visual attention,11,48,2.83
classification,185,806,2.83
kidney urinary system,39,170,2.83
automobile accident,11,48,2.83
collegiate,204,888,2.83
aversive stimulus,67,292,2.83
intercept,14,61,2.83
bolus,17,74,2.83
preventing,1450,6309,2.83
hdac inhibitor,19,83,2.82
research techniques,19,83,2.82
0-11 years old,450,1967,2.82
child youth,450,1967,2.82
internships,24,105,2.82
maine,16,70,2.82
children (0-21),450,1967,2.82
youngster,450,1967,2.82
data quality,30,131,2.82
social workers,38,166,2.82
visit,348,1520,2.82
equipment,86,376,2.82
pregabalin,13,57,2.81
hypothalamic-pituitary-adrenal (hpa) axis,63,277,2.81
animal experiments,13,57,2.81
species difference,13,57,2.81
post-doctoral training,63,277,2.81
manpower,155,681,2.81
atheroscleroses,13,57,2.81
human resources,155,681,2.81
hypothalmus-pituitary-adrenal axis,63,277,2.81
unhoused,80,351,2.81
methamphetamine exposure,36,158,2.81
hispanic americans,18,79,2.81
meth exposure,36,158,2.81
methodology,738,3240,2.81
brief motivational intervention,13,57,2.81
hypothalamic-pituitary-adrenal axis,63,277,2.81
homelessness,80,351,2.81
adaptive behavior,54,237,2.81
adaptation behavior,54,237,2.81
simulation,111,487,2.81
3-isobutyl gaba,13,57,2.81
lipid bilayer membrane,13,57,2.81
multi-site trial,38,167,2.81
postdoctoral training,63,277,2.81
sleep problem,79,348,2.8
cognitive control,160,706,2.8
injured,39,172,2.8
british columbia,15,66,2.8
tobacco control,96,423,2.8
neurological disease,314,1384,2.8
joints,156,688,2.8
clinical sciences,88,387,2.8
chronic stress,91,401,2.8
neurological disorders,314,1384,2.8
refractory,71,313,2.8
neurologic disorders,314,1384,2.8
new agents,20,88,2.8
hospitals,300,1323,2.8
high risk,725,3188,2.8
genetic models,89,392,2.8
biology,363,1600,2.8
income,107,472,2.8
nervous system diseases,314,1384,2.8
cancer cell line,35,154,2.8
olfactory stimulus,10,44,2.8
health related quality of life,39,172,2.8
suid,17,75,2.8
adult human,1391,6117,2.8
autonomic nervous system,24,106,2.79
biogenesis,29,128,2.79
origin of life,29,128,2.79
peer,328,1450,2.79
cue reactivity,133,588,2.79
benzodiazepine compounds,88,389,2.79
home visitation,12,53,2.79
comprehensive health care,12,53,2.79
atrophic,12,53,2.79
training and education,74,327,2.79
comprehensive healthcare,12,53,2.79
physiological homeostasis,208,919,2.79
autoregulation,208,919,2.79
home visit,12,53,2.79
monitor,921,4065,2.79
running,212,936,2.79
immunochemical immunologic,36,159,2.79
causality,488,2157,2.79
disease causation,488,2157,2.79
mirnas,68,301,2.79
ligand binding,87,385,2.79
transmembrane domain,37,164,2.78
fiber optics,25,111,2.78
tm domain,37,164,2.78
resistant,403,1788,2.78
transmembrane region,37,164,2.78
alcohol abuse therapy,359,1590,2.78
oligodendrocytus,18,80,2.78
pulmonary,114,506,2.78
oligodendrocytes,18,80,2.78
strains cell lines,216,958,2.78
oligodendroglia,18,80,2.78
oligodendroglia cell,18,80,2.78
alcohol abuse treatment,359,1590,2.78
alcohol treatment,359,1590,2.78
malignant liver tumor,18,80,2.78
liver cancer,18,80,2.78
malignant neoplasm of liver,18,80,2.78
phase iii trial,21,93,2.78
alternative rna splicing,23,102,2.78
hepatic cancer,18,80,2.78
young adulthood,353,1567,2.78
stress disorder,16,71,2.78
homeostasis,208,923,2.78
transcriptional coactivator,24,107,2.77
blood reticuloendothelial system,264,1174,2.77
lipopolysaccharides,24,107,2.77
anxiolytic agents,94,418,2.77
regulatory gene product,37,165,2.77
genetic regulatory protein,37,165,2.77
therapeutic effect,113,503,2.77
wyoming,11,49,2.77
anti-anxiety drugs,94,418,2.77
transcription activator,24,107,2.77
child welfare,29,129,2.77
memory acquisition,11,49,2.77
touch sensation,24,107,2.77
research ethics,31,138,2.77
regulatory protein,37,165,2.77
tandem mass spectrometry,20,89,2.77
doxycycline,11,49,2.77
service utilization,47,209,2.77
support system,50,223,2.77
social support system,50,223,2.77
receptor signaling,298,1325,2.77
transcription coactivator,24,107,2.77
transcription factor coactivator,24,107,2.77
electric stimulation,71,316,2.77
anxiolytics,94,418,2.77
anti-anxiety agents,94,418,2.77
olfactory bulb,11,49,2.77
drug abstinence,100,445,2.77
transcriptional activator,24,107,2.77
alpha-6-deoxyoxytetracycline,11,49,2.77
neural network,110,490,2.77
transcriptional activator/coactivator,24,107,2.77
vibramycin,11,49,2.77
daily functioning,22,98,2.77
patient monitoring,19,85,2.76
tissue growth,381,1700,2.76
interdisciplinary research,200,895,2.76
behavioral sciences,78,349,2.76
behavioral model,165,738,2.76
novel strategy,579,2588,2.76
multidisciplinary collaboration,200,895,2.76
antineoplastics,36,161,2.76
new approaches,579,2588,2.76
novel approaches,579,2588,2.76
hepatitis virus infection,13,58,2.76
oxygen,30,134,2.76
lateral,273,1221,2.76
scientific publication,433,1932,2.76
novel strategies,579,2588,2.76
generalized growth,381,1700,2.76
community networks,13,58,2.76
nucleic acids,13,58,2.76
ontogeny,381,1700,2.76
multidisciplinary research,200,895,2.76
resistance,403,1798,2.76
alcohol during adolescence,80,359,2.75
growth,381,1711,2.75
respiratory physiology,23,103,2.75
prodrugs,39,175,2.75
youth alcohol consumption,80,359,2.75
drinking during adolescence,80,359,2.75
nose,74,332,2.75
relapse prevention,224,1005,2.75
innovative technologies,45,202,2.75
guidelines,290,1299,2.75
suicidality,102,458,2.75
health services,187,840,2.75
kras,18,81,2.74
nervous system disorder,314,1412,2.74
future generations,18,81,2.74
k-ras-2 oncogene,18,81,2.74
k-ras 2a,18,81,2.74
k-ras2b,18,81,2.74
k-ras2a,18,81,2.74
kras2,18,81,2.74
kras2 gene,18,81,2.74
c-k-ras,18,81,2.74
chronic hepatitis c,10,45,2.74
ki-ras,18,81,2.74
oncogene k-ras,18,81,2.74
rask2,18,81,2.74
v-ki-ras2 kirsten rat sarcoma 2 viral oncogene homolog,18,81,2.74
anxiety states,12,54,2.74
disasters,10,45,2.74
nsclc,18,81,2.74
nsclc - non-small cell lung cancer,18,81,2.74
non-small cell lung cancer,18,81,2.74
chronic hcv infection,10,45,2.74
chronic hepatitis c virus infection,10,45,2.74
implementation research,97,436,2.74
trp53,24,108,2.74
tp53 gene,24,108,2.74
tp53,24,108,2.74
orexin 1 receptor,16,72,2.74
rna-binding proteins,18,81,2.74
tumor protein p53 gene,24,108,2.74
biological function,111,500,2.74
skeletal muscle,10,45,2.74
feeling,100,450,2.74
nurses,89,401,2.74
cancer stem cell,10,45,2.74
parent child interaction,28,126,2.74
feelings,100,450,2.74
parent-child relations,28,126,2.74
functional rna,73,328,2.74
award,696,3132,2.74
non-coding,73,328,2.74
non-coding rna,73,328,2.74
parent-child relationship,28,126,2.74
biological process,111,500,2.74
polypeptide 1,10,45,2.74
satiety,53,239,2.74
voluntary muscle,10,45,2.74
research career program,179,808,2.73
genome-wide,195,880,2.73
adenoreceptor,47,212,2.73
clinical efficacy,72,325,2.73
treatment response,215,971,2.73
career development awards,179,808,2.73
tumor cell,78,352,2.73
career development programs k-series,179,808,2.73
physiology,339,1532,2.73
respiratory expiration,21,95,2.73
career development awards and programs,179,808,2.73
adrenoceptors,47,212,2.73
model design,21,95,2.73
therapeutic uses,49,221,2.73
genomewide,195,880,2.73
k-awards,179,808,2.73
biodistribution,24,109,2.72
brain vascular accident,95,431,2.72
palate,30,136,2.72
sexual attack,17,77,2.72
oxidation reduction reaction,28,127,2.72
anxiety,770,3493,2.72
woman,683,3093,2.72
heritability,147,666,2.72
chronic mental illness,30,136,2.72
persistent mental illness,30,136,2.72
develop therapy,405,1835,2.72
severe mental disorder,30,136,2.72
opiate antagonist,131,593,2.72
serious mental disorder,30,136,2.72
general population,346,1576,2.71
cardiovascular organ system,139,632,2.71
legal,218,993,2.71
health resources,18,82,2.71
effective therapy,686,3117,2.71
adherence,338,1541,2.71
receptosomes,22,100,2.71
nerve supply,93,424,2.71
early alcohol use,22,100,2.71
endosomes,22,100,2.71
early onset alcohol use,22,100,2.71
effective treatment,686,3117,2.71
dna modification process,11,50,2.71
emergency room,164,745,2.71
semantics,11,50,2.71
inbred mouse,18,82,2.71
emergency department,164,745,2.71
withdrawal symptom,296,1346,2.71
cannulas,20,91,2.71
general public,346,1576,2.71
dna modification,11,50,2.71
accident and emergency department,164,745,2.71
heart vascular,139,632,2.71
early childhood,42,192,2.7
dorsum,256,1169,2.7
awake,119,544,2.7
wellbutrin,30,137,2.7
animal genetics,14,64,2.7
histone acetylation,53,242,2.7
transgenic mice,193,883,2.7
opioid switching,16,73,2.7
opioid rotation,16,73,2.7
narcotic switching,16,73,2.7
age 17 years,14,64,2.7
neural pathways,67,306,2.7
indoles,14,64,2.7
back,256,1169,2.7
microfluidics,23,105,2.7
narcotic rotation,16,73,2.7
narcotic substitution,16,73,2.7
label,403,1838,2.7
discipline,214,976,2.7
high-throughput sequencing,14,64,2.7
high-throughput nucleotide sequencing,14,64,2.7
opioid substitution,16,73,2.7
child maltreatment,41,188,2.69
distress,130,595,2.69
childhood maltreatment,41,188,2.69
educational workshop,241,1107,2.69
child abuse and neglect,41,188,2.69
episodic drinking,199,914,2.69
carcinoma cell,12,55,2.69
information dissemination,46,211,2.69
binge alcohol consumption,199,914,2.69
cellular motility,31,142,2.69
malignant epithelial cell,12,55,2.69
binge drinking,199,914,2.69
hcv transmission,22,101,2.69
synthetic chemistry,17,78,2.69
neuraxis,301,1380,2.69
puerto rico,26,119,2.69
millisecond,34,156,2.69
hepatitis c transmission,22,101,2.69
msec,34,156,2.69
synthesis chemistry,17,78,2.69
genetics-mutagenesis,72,330,2.69
r38486,10,46,2.68
ultrasonogram,15,69,2.68
methylase,10,46,2.68
dissection,83,382,2.68
cohort studies,109,501,2.68
concurrent studies,109,501,2.68
transmethylase,10,46,2.68
sonography,15,69,2.68
r 38486,10,46,2.68
preventive strategy,225,1034,2.68
impact evaluation,10,46,2.68
ru-486,10,46,2.68
emotional,456,2102,2.68
ultrasound test,15,69,2.68
diagnostic ultrasound,15,69,2.68
epigenetic biomarker,10,46,2.68
epigenetic marker,10,46,2.68
precipitating factors,10,46,2.68
ultrasonic imaging,15,69,2.68
ru-38486,10,46,2.68
translational study,81,373,2.68
sonogram,15,69,2.68
demographic factors,20,92,2.68
ru38486,10,46,2.68
federally qualified health center,28,129,2.68
echotomography,15,69,2.68
ultrasound imaging,15,69,2.68
ultrasound scanning,15,69,2.68
echography,15,69,2.68
ec 2.1.1,10,46,2.68
methyltransferase,10,46,2.68
ultrasonography,15,69,2.68
image,749,3448,2.68
prevention strategy,225,1034,2.68
psychologist,83,382,2.68
ru486,10,46,2.68
national institute of drug abuse,1041,4815,2.67
histone acetylase,18,83,2.67
satiation,53,245,2.67
flies,56,259,2.67
fly,56,259,2.67
18 year old,44,203,2.67
histone acetyltransferase,18,83,2.67
cytochrome p450,67,309,2.67
synaptic cleft,26,120,2.67
soldier,13,60,2.67
student retention,26,120,2.67
nida,1041,4815,2.67
toll-like receptor 4,31,143,2.67
clinical skills,16,74,2.67
heterologous transplantation,54,249,2.67
eighteen year old,44,203,2.67
hdac agent,19,88,2.66
puberty,22,102,2.66
cellular expansion,43,199,2.66
histone deacetylase inhibitor,19,88,2.66
cell growth,43,199,2.66
neglect,73,339,2.66
foot,28,130,2.66
plasma serum,221,1024,2.66
immunologics,36,167,2.66
pilot study,483,2236,2.66
cellular growth,43,199,2.66
authority,86,398,2.66
disease outcome,22,102,2.66
rehabilitation therapy,86,399,2.66
pilot projects,483,2236,2.66
orphan,27,125,2.66
circulatory shock,62,287,2.66
circulatory collapse,62,287,2.66
cytoskeleton,45,209,2.66
rehabilitative,86,399,2.66
tau factor,19,88,2.66
tau proteins,19,88,2.66
shock,62,288,2.66
microtubule-bound tau,19,88,2.66
microtubule bound tau,19,88,2.66
rapamycin,14,65,2.66
tau,19,88,2.66
neoplastic cell,78,362,2.66
neuropathogenesis,19,88,2.66
mt-bound tau,19,88,2.66
rapamune,14,65,2.66
minimally invasive,19,88,2.66
cellular proliferation,58,270,2.65
standard treatment,125,582,2.65
standard care,125,582,2.65
cell multiplication,58,270,2.65
reader,23,107,2.65
brain stem,83,386,2.65
epidemiologic investigation,106,494,2.65
cell growth in number,58,270,2.65
self-help groups,37,172,2.65
health economics,83,387,2.65
prescription medication abuse,17,79,2.65
phase 2 clinical trials,53,247,2.65
in vitro activity,17,79,2.65
support groups,37,172,2.65
clinical trials design,80,372,2.65
faculty,400,1866,2.64
prototype,149,696,2.64
global health,43,201,2.64
agreement,95,443,2.64
genetic risk factor,68,318,2.64
xenotransplantation,54,252,2.64
insurance status,30,140,2.64
xenograft procedure,54,252,2.64
dorsal raphe nucleus,33,154,2.64
sleep disorders,79,369,2.64
clinical applicability,84,392,2.64
neurologic,200,935,2.64
insurance coverage,30,140,2.64
prevention approach,55,257,2.64
clinical application,84,392,2.64
virus protein,18,84,2.64
drug monitoring,18,84,2.64
alcoholic phenotype,24,112,2.64
inherited factor,68,318,2.64
slide,24,112,2.64
alcohol phenotype,24,112,2.64
elements,463,2162,2.64
advanced age,116,541,2.64
approaches to prevention,55,257,2.64
generation effect,12,56,2.64
secondary to,43,201,2.64
behavioral mechanisms,115,537,2.64
ethnic difference,18,84,2.64
geriatric,116,541,2.64
cohort effect,12,56,2.64
depression symptom,186,870,2.64
heterograft,54,252,2.64
senior citizen,116,541,2.64
down-regulation,142,664,2.64
xenograft,54,252,2.64
mechanisms of behavior and behavior change,115,537,2.64
anabolism,44,206,2.63
infection,264,1239,2.63
tumor initiation,13,61,2.63
biosynthesis,44,206,2.63
basal forebrain,32,150,2.63
phone,190,892,2.63
tumorigenic,19,89,2.63
tetraethylthiuram disulfide,46,216,2.63
consult,69,323,2.63
antabuse,46,216,2.63
pathway interactions,1721,8072,2.63
massachusetts,69,324,2.63
lung function,23,108,2.63
neuronal survival,13,61,2.63
psychosocial variables,58,273,2.62
computer software,167,786,2.62
neurological,200,940,2.62
chronic viral hepatitis c,10,47,2.62
risk behavior in youth,10,47,2.62
hydrolase family gene,10,47,2.62
adolescent risk taking,10,47,2.62
fetus,35,165,2.62
telephone,190,896,2.62
hydrolase gene,10,47,2.62
psychosocial factor,58,273,2.62
chronic type c viral hepatitis,10,47,2.62
biologic factor,59,278,2.62
grasp,10,47,2.62
grips,10,47,2.62
immersion,30,141,2.62
combined modality therapy,95,447,2.62
depression comorbidity,17,80,2.62
mass spectrum,113,531,2.62
outpatient clinics,17,80,2.62
ambulatory care facilities,17,80,2.62
comorbid depression,17,80,2.62
exhalation,21,99,2.62
exhaling,21,99,2.62
early drinking,10,47,2.62
combined treatment,95,447,2.62
comorbid with depression,17,80,2.62
comorbidity with depression,17,80,2.62
combined modality treatment,95,447,2.62
multimodal treatment,95,447,2.62
multimodal therapy,95,447,2.62
consultations,107,506,2.61
suburbia,25,118,2.61
mindfulness meditation,11,52,2.61
extirpation,121,572,2.61
fire,37,175,2.61
excision,121,572,2.61
suburb,25,118,2.61
suburban,25,118,2.61
nasal passages,37,175,2.61
abscission,121,572,2.61
iv infusion,11,52,2.61
surgical removal,121,572,2.61
chronic obstructive pulmonary disease,29,137,2.61
neural precursor,25,118,2.61
neural progenitor,25,118,2.61
exome sequencing,22,104,2.61
removal,121,572,2.61
thoughts,117,553,2.61
meth user,18,85,2.61
withdrawal from alcohol,180,852,2.61
social controls,15,71,2.61
neurobiological mechanism,288,1362,2.61
methamphetamine user,18,85,2.61
cancer biology,43,203,2.61
interdisciplinary collaboration,36,170,2.61
transcript,139,657,2.61
ethanol withdrawal,180,852,2.61
alcohol withdrawal,180,852,2.61
alcohol withdrawal syndrome,180,852,2.61
laboratory research,52,246,2.61
intravenous infusion procedures,11,52,2.61
resection,121,572,2.61
starvation,11,52,2.61
memory decline,11,52,2.61
rabbits,12,57,2.6
decision making,532,2526,2.6
presynaptic nerve endings,84,398,2.6
health science research,20,95,2.6
exposure to,1167,5533,2.6
organismal process,76,361,2.6
circadian clock,19,90,2.6
medical college,209,992,2.6
physiological processes,76,361,2.6
prognostic biomarker,12,57,2.6
behavior change,202,960,2.6
physiologic processes,76,361,2.6
new mexico,27,128,2.6
circadian pacemaker,19,90,2.6
medical schools,209,992,2.6
news,19,90,2.6
organism-level process,76,361,2.6
evaluation research,12,57,2.6
afghanistan,23,109,2.6
u-series cooperative agreements,27,128,2.6
effectiveness research,39,185,2.6
adolescent trauma,21,100,2.59
tobacco industry,29,138,2.59
health policy,95,452,2.59
childhood trauma,21,100,2.59
mentored research scientist development award,102,486,2.59
pediatric trauma,21,100,2.59
in situ hybridization staining method,102,485,2.59
motivation,1001,4761,2.59
rotation,17,81,2.59
dwi-mri,37,176,2.59
avoidance learning,13,62,2.59
mentored training award,102,486,2.59
diffusion-weighted magnetic resonance imaging,37,176,2.59
biologic models,208,992,2.59
k01 program,102,486,2.59
dmri,37,176,2.59
research scientist development award,102,486,2.59
bilateral,63,300,2.59
esthesia,111,529,2.59
serotonin receptor 5-ht2c,13,62,2.59
health insurance,39,186,2.59
multidisciplinary approach,142,676,2.59
interdisciplinary approach,142,676,2.59
italy,13,62,2.59
k01 mechanism,102,486,2.59
k01 award,102,486,2.59
liquid,99,474,2.58
gtp-regulatory proteins,194,926,2.58
ethanol exposure,410,1960,2.58
guanine nucleotide coupling protein,194,926,2.58
ethanol exposed,410,1960,2.58
alcohol exposed,410,1960,2.58
guanine nucleotide regulatory proteins,194,926,2.58
alcohol exposure,410,1960,2.58
liquid substance,99,474,2.58
life experience,38,182,2.58
services,800,3818,2.58
burn injury,14,67,2.58
virus-induced disease,52,249,2.58
gtp-binding proteins,194,926,2.58
categories,159,761,2.58
liver metabolism,14,67,2.58
incarcerated,137,655,2.58
consensus,96,459,2.58
residence,31,148,2.58
g-proteins,194,926,2.58
side effect,612,2920,2.58
exposed to alcohol,410,1960,2.58
research technics,19,91,2.58
racial and ethnic,100,478,2.58
exposure to alcohol,410,1960,2.58
visual function,110,528,2.57
gi tract,15,72,2.57
cognitive decline,244,1171,2.57
renal,39,187,2.57
cognitive dysfunction,244,1171,2.57
fluid,99,475,2.57
conditioned taste aversion,10,48,2.57
nutrient,41,197,2.57
impaired cognition,244,1171,2.57
emergency situation,53,254,2.57
cognitive impairment,244,1171,2.57
lysosomes,10,48,2.57
disturbance in cognition,244,1171,2.57
cognitive function abnormal,244,1171,2.57
gastrointestinal tract structure,15,72,2.57
emergencies,53,254,2.57
drug action,94,451,2.57
phenotype,906,4352,2.57
digestive canal,15,72,2.57
psychobiologic,10,48,2.57
cognitive loss,244,1171,2.57
psychobiological,10,48,2.57
alimentary canal,15,72,2.57
sphingolipids,10,48,2.57
retrieval,51,245,2.57
sight,110,528,2.57
taste aversion,10,48,2.57
cognitive disturbance,244,1171,2.57
alimentary tract,15,72,2.57
sensation,111,533,2.57
digestive tract,15,72,2.57
forgetting,11,53,2.56
molecular signature,102,491,2.56
alcohol abstinence,83,400,2.56
abstaining from ethanol,83,400,2.56
molecular fingerprinting,102,491,2.56
r&d,175,842,2.56
research and development,175,842,2.56
abstinence from alcohol,83,400,2.56
development and research,175,842,2.56
resistant to drug,68,328,2.56
abstinence from ethanol,83,400,2.56
molecular profiling,102,491,2.56
r & d,175,842,2.56
resistance to drug,68,328,2.56
abstaining from alcohol,83,400,2.56
advisory committees,115,554,2.56
research grants,564,2714,2.56
secreted and transmembrane 1,11,53,2.56
site,1353,6508,2.56
solid,115,555,2.56
r01 mechanism,564,2714,2.56
healthcare professional,92,443,2.56
outcome study,95,458,2.56
ethanol abstinence,83,400,2.56
cancer research,27,130,2.56
peer review,130,627,2.56
r01 program,564,2714,2.56
synaptic receptors,22,106,2.56
task forces,115,554,2.56
research project grants,564,2714,2.56
intoxication,141,680,2.56
health care professional,92,443,2.56
extracellular domain,21,101,2.56
external domain,21,101,2.56
health professional,92,443,2.56
pro-oxidants,38,184,2.55
reactive oxygen species,38,184,2.55
underage alcohol use,80,387,2.55
gain of function,49,237,2.55
physicochemical phenomena related to the senses,35,169,2.55
geographical location,56,271,2.55
alcohol use during adolescence,80,387,2.55
geographic area,56,271,2.55
sensory stimulus,35,169,2.55
systems biology,48,232,2.55
geographic region,56,271,2.55
geographic locations,56,271,2.55
teenager alcohol use,80,387,2.55
malignant,43,208,2.55
oxygen radicals,38,184,2.55
teenage alcohol use,80,387,2.55
under age alcohol consumption,80,387,2.55
synapse inhibition,18,87,2.55
synaptic inhibition,18,87,2.55
adrenergic receptor antagonists,12,58,2.55
measurable,51,247,2.55
under age alcohol use,80,387,2.55
alcohol intake among adolescents,80,387,2.55
perceptual stimulus,35,169,2.55
adolescent alcohol consumption,80,387,2.55
healthcare quality,18,87,2.55
underage alcohol consumption,80,387,2.55
active oxygen,38,184,2.55
clinically significant,110,535,2.54
clinical significance,110,535,2.54
businesses,50,243,2.54
aversive conditioning,13,63,2.54
energy expenditure,29,141,2.54
wild type mouse,100,486,2.54
energy metabolism,29,141,2.54
burns,14,68,2.54
drug targeting,243,1181,2.54
behavioral test,168,816,2.54
assay,844,4103,2.54
contralateral,20,97,2.54
biological assay,844,4103,2.54
ethanol metabolism,38,185,2.53
alcohol metabolism,38,185,2.53
v-fos fbj murine osteosarcoma viral oncogene homolog,86,419,2.53
eyeball,38,185,2.53
payment,39,190,2.53
novel technologies,152,742,2.53
health status,72,351,2.53
level of health,72,351,2.53
pyramidal cells,43,210,2.53
statistical methods,121,590,2.53
reservations,16,78,2.53
receptor cell,17,83,2.53
social behavior,71,346,2.53
phosphatidylinositol-3-oh kinase,15,73,2.53
phosphoinositide 3-hydroxykinase,15,73,2.53
pi3-kinase,15,73,2.53
geographic site,56,273,2.53
brain control,33,161,2.53
behavioral pharmacology,131,639,2.53
phase i trial,23,112,2.53
protooncogene fos,86,419,2.53
ptdins 3-kinase,15,73,2.53
c fos,86,419,2.53
g0s7,86,419,2.53
c-fos proto-oncogenes,86,419,2.53
pi-3 kinase,15,73,2.53
c-fos gene,86,419,2.53
fos gene,86,419,2.53
1-phosphatidylinositol 3-kinase,15,73,2.53
type iii phosphoinositide 3-kinase,15,73,2.53
type i phosphatidylinositol kinase,15,73,2.53
new technology,152,742,2.53
dna methylation,83,406,2.52
addiction,4553,22270,2.52
laser scanning microscopy,10,49,2.52
21+ years old,1391,6819,2.52
vision,110,538,2.52
diabetes,174,853,2.52
alcohol related research,186,909,2.52
depression,942,4605,2.52
interventions research,134,656,2.52
emerging adulthood,35,171,2.52
hepatoxicity,20,98,2.52
toxic effect on liver cells,20,98,2.52
bioassay,844,4132,2.52
glutamate translocase,37,181,2.52
effectiveness,841,4122,2.52
oxidizing agents,10,49,2.52
liver toxicity,20,98,2.52
environment,1057,5164,2.52
hepatotoxicity,20,98,2.52
chimera,20,98,2.52
chimera organism,20,98,2.52
hepatotoxic effect,20,98,2.52
glutamate transport glycoprotein,37,181,2.52
brain research,20,98,2.52
aging,144,705,2.52
confection,10,49,2.52
epistatic deviation,10,49,2.52
candy,10,49,2.52
genetic epistases,10,49,2.52
gene x gene interaction,10,49,2.52
affinity chromatography,35,171,2.52
graduate student,96,470,2.52
interaction deviation,10,49,2.52
atrophy,12,59,2.51
protein family,39,192,2.51
notch receptors,11,54,2.51
notch protein,11,54,2.51
notch,11,54,2.51
neuropsychologic,64,314,2.51
zebra fish,35,172,2.51
neuropsychologies,64,314,2.51
zebra danio,35,172,2.51
floor,12,59,2.51
danio rerio,35,172,2.51
men who have sex with other men,33,162,2.51
men who have sex with men,33,162,2.51
retina,11,54,2.51
age group,93,457,2.51
behavior monitoring,11,54,2.51
brachydanio rerio,35,172,2.51
thick,34,167,2.51
thickness,34,167,2.51
neurobehavioral,183,899,2.51
touch,24,118,2.51
eye,38,187,2.51
positive attitude,22,108,2.51
dwi (diffusion weighted imaging),37,182,2.51
tropanes,11,54,2.51
industry,105,516,2.51
diffusion weighted imaging,37,182,2.51
frontier,25,123,2.51
executive control,221,1086,2.51
sales,73,359,2.51
metabolic stress,11,54,2.51
cancer progression,52,257,2.5
sirolimus,14,69,2.5
morphine dependence,31,153,2.5
targeted modification,43,212,2.5
patch clamp,189,931,2.5
congresses,30,148,2.5
locus coeruleus,59,291,2.5
targeted dna modification,43,212,2.5
site-specific mutagenesis,43,212,2.5
neoplasm progression,52,257,2.5
genetic risk,100,494,2.5
neoplastic progression,52,257,2.5
tumor progression,52,257,2.5
cognitive behavioral treatment,171,843,2.5
morphine addiction,31,153,2.5
cell culture,85,420,2.5
inpatients,189,934,2.5
executive function,221,1092,2.5
specified,175,863,2.5
ethanol relapse,100,493,2.5
cost effective,232,1143,2.5
specific qualifier value,175,863,2.5
homeless,80,394,2.5
neurocognitive test,15,74,2.5
l-cystine,15,74,2.5
cell culture techniques,85,420,2.5
alcohol relapse,100,493,2.5
workshop,241,1189,2.5
clinical investigator,57,282,2.49
synapse function,118,585,2.49
limbs,22,109,2.49
4-amino-butanoic acid,286,1419,2.49
metabolism,297,1471,2.49
limb structure,22,109,2.49
cd4 cells,26,129,2.49
non-trunk,22,109,2.49
salivary,43,213,2.49
early onset substance use,21,104,2.49
prevent relapse to cocaine,20,99,2.49
cocaine relapse prevention,20,99,2.49
prefrontal cortex,714,3531,2.49
early initiation substance use,21,104,2.49
insular sclerosis,20,99,2.49
host response,91,450,2.49
cultured cell line,216,1070,2.49
multiple sclerosis,20,99,2.49
dna binding,24,119,2.49
dna binding interaction,24,119,2.49
channel blockers,20,99,2.49
breast cancer cell,18,89,2.49
member,586,2900,2.49
cell proliferation,58,287,2.49
5-ht-2a gene,23,114,2.49
electromyography,18,89,2.49
immunoresponse,91,450,2.49
cellline,216,1070,2.49
prematurity,105,521,2.49
serotonin 5-ht-2 receptor gene,23,114,2.49
htr2a,23,114,2.49
5-hydroxytryptamine (serotonin) receptor 2a gene,23,114,2.49
synaptic function,118,585,2.49
htr2 gene,23,114,2.49
extremities,22,109,2.49
htr2a gene,23,114,2.49
htr2,23,114,2.49
5-hydroxytryptamine receptor 2a gene,23,114,2.49
late life,109,541,2.48
centers for disease control and prevention (u.s.),158,786,2.48
centers for disease control and prevention,158,786,2.48
united states centers for disease control and prevention,158,786,2.48
copd,29,144,2.48
chronic obstructive lung disease,29,144,2.48
reward processing,202,1004,2.48
centers for disease control,158,786,2.48
sedative,60,298,2.48
immunoregulation,31,154,2.48
united states centers for disease control,158,786,2.48
diacetylmorphine,368,1831,2.48
diamorphine,368,1831,2.48
multi-center clinical trial,58,289,2.48
research design,456,2265,2.48
multi-site clinical trial,58,289,2.48
drug resistant,68,338,2.48
south carolina,44,219,2.48
structure function relationship,93,463,2.48
structure-activity relationship,93,463,2.48
multi-institutional clinical trial,58,289,2.48
alcohol chemical class,1375,6838,2.48
study type,456,2265,2.48
study design,456,2265,2.48
spinal nerve structure,12,60,2.47
underclass,18,90,2.47
economically deprived population,18,90,2.47
disorder prevention,65,324,2.47
tail,74,369,2.47
pharmacokinetic model,15,75,2.47
heart rate,101,504,2.47
osteoporosis,13,65,2.47
synaptic potentials,11,55,2.47
mrna expression,90,450,2.47
neurontin,37,185,2.47
p53,24,120,2.47
symposium,317,1586,2.47
disease prevention,65,324,2.47
savings,44,220,2.47
early adulthood,84,420,2.47
chemical structure,28,140,2.47
human disease,109,544,2.47
emerging technologies,24,120,2.47
fractionation radiotherapy,11,55,2.47
m. tuberculosis infection,11,55,2.47
traction,11,55,2.47
immunologic,36,180,2.47
homicide,17,85,2.47
emergent technologies,24,120,2.47
optical methods,15,75,2.47
premature,105,525,2.47
chemical fractionation,11,55,2.47
outreach program,21,105,2.47
cellular immune function,45,225,2.47
m.tuberculosis infection,11,55,2.47
rewards,1719,8580,2.47
endotoxins,17,85,2.47
evidence based recommendations,23,115,2.47
targeted cancer therapy,10,50,2.47
cytotoxicity,26,130,2.47
central nervous system,301,1504,2.47
acoustics,23,115,2.47
cognitive task,23,115,2.47
tumorigenesis,64,319,2.47
polymerization,15,75,2.47
immune response,91,455,2.47
oncogenesis,64,319,2.47
glucocorticoids,44,220,2.47
healthcare service availability,70,349,2.47
mycobacterium tuberculosis infection,11,55,2.47
actins,45,225,2.47
grooming,12,60,2.47
somatic mutation,11,55,2.47
mtb infection,11,55,2.47
evidence based practice guidelines,23,115,2.47
infection due to mycobacterium tuberculosis,11,55,2.47
emerging adult,84,420,2.47
innervation,93,464,2.47
fracn,11,55,2.47
evidence based guidelines,23,115,2.47
mycobacterium tuberculosis (mtb) infection,11,55,2.47
evidence based practice,120,602,2.46
regulatory gene,66,331,2.46
willingness,76,381,2.46
generations,442,2217,2.46
addiction to methamphetamine,48,241,2.46
universities,970,4869,2.46
human immunodeficiency virus type 1,67,336,2.46
nextgen sequencing,48,241,2.46
next gen sequencing,48,241,2.46
inhibitor,487,2444,2.46
ngs system,48,241,2.46
ngs method,48,241,2.46
longitudinal design,63,316,2.46
cell differentiation process,24,121,2.45
nuclear magnetic resonance imaging,250,1260,2.45
amentia,57,287,2.45
nmr tomography,250,1260,2.45
natural products,60,302,2.45
magnetic resonance / nuclear magnetic resonance,250,1260,2.45
nmr imaging,250,1260,2.45
zeugmatography,250,1260,2.45
reporting,1794,9025,2.45
conference,317,1594,2.45
meditation,25,126,2.45
transforming genes,76,382,2.45
cancer genes,76,382,2.45
mr imaging,250,1260,2.45
nondrug,108,543,2.45
neural patterning,33,166,2.45
cancer-promoting gene,76,382,2.45
non-drug,108,543,2.45
mr tomography,250,1260,2.45
measurement,578,2909,2.45
source,535,2692,2.45
intervention efficacy,290,1463,2.44
treatment efficacy,290,1463,2.44
tobacco marketing,18,91,2.44
membrane-associated proteins,51,258,2.44
therapy efficacy,290,1463,2.44
self efficacy,209,1056,2.44
genetic technics,41,207,2.44
therapeutic efficacy,290,1463,2.44
surface proteins,51,258,2.44
training programs,265,1341,2.44
national institute on alcohol abuse and alcoholism,339,1713,2.44
training support,55,278,2.44
steroid compound,35,177,2.44
adrenergic agonists,17,86,2.44
adrenergic receptor agonist,17,86,2.44
adrenomimetics,17,86,2.44
urinary,22,111,2.44
slice,435,2197,2.44
niaaa,339,1713,2.44
island of reil,111,563,2.43
type ii dm,35,178,2.43
human t-lymphotropic virus type iii infections,223,1133,2.43
drug seeking behavior,297,1510,2.43
central lobe,111,563,2.43
cerebrovascular stroke,95,483,2.43
laws,86,436,2.43
insula,111,563,2.43
insula of reil,111,563,2.43
cerebrovascular apoplexy,95,483,2.43
type ii diabetes mellitus,35,178,2.43
prognostic marker,12,61,2.43
apoplexy,95,483,2.43
type 2 dm,35,178,2.43
cerebral stroke,95,483,2.43
ethnic group,90,456,2.43
minority health,15,76,2.43
type 2 diabetes mellitus,35,178,2.43
oncogenic agent,26,132,2.43
rho,15,76,2.43
flow cytometry,44,223,2.43
neuronal differentiation,12,61,2.43
cerebrovascular accident,95,483,2.43
mission,420,2133,2.43
cerebral vascular accident,95,483,2.43
brain attack,95,483,2.43
adult-onset diabetes mellitus,35,178,2.43
instrumental learning,52,264,2.43
ketosis-resistant diabetes mellitus,35,178,2.43
non-insulin-dependent diabetes mellitus,35,178,2.43
logistic regressions,38,193,2.43
oncogens,26,132,2.43
slow-onset diabetes mellitus,35,178,2.43
cancer causing agents,26,132,2.43
trkb receptor,13,66,2.43
stable diabetes mellitus,35,178,2.43
instrumental conditioning,52,264,2.43
t2 dm,35,178,2.43
companions,29,147,2.43
public sector,11,56,2.42
treatment development,405,2065,2.42
intervention development,405,2065,2.42
therapy development,405,2065,2.42
withdrawal,809,4123,2.42
physicians' extenders,11,56,2.42
estradiol,46,234,2.42
pill,49,250,2.42
classical conditioning,134,683,2.42
buccal cavity head and neck,19,97,2.42
national government,19,97,2.42
federal government,19,97,2.42
spatial distribution,10,51,2.42
metabolic processes,281,1435,2.42
intermediary metabolism,281,1435,2.42
cardiac failure,10,51,2.42
collaboratory,11,56,2.42
physician assistants,11,56,2.42
africa,20,102,2.42
ovariectomy,11,56,2.42
efficacy trial,89,453,2.42
security,23,117,2.42
bowel,29,148,2.42
influentials,59,301,2.42
doctor's assistants,11,56,2.42
infrastructure development,10,51,2.42
chromatin remodeling,31,158,2.42
medical records,33,168,2.42
household,62,316,2.42
records,119,607,2.42
iraq,23,117,2.42
pump,27,138,2.41
inhaling,97,497,2.41
outpatient care,65,332,2.41
informatics,66,338,2.41
evidence based program,24,123,2.41
research facility,16,82,2.41
drug resistance,68,348,2.41
anticancer therapy,81,415,2.41
aldehydes,16,82,2.41
bench to bedside,17,87,2.41
bench bedside,17,87,2.41
fat metabolism,17,87,2.41
bench to bed side,17,87,2.41
progesterone,41,210,2.41
saccharose,131,671,2.41
international,299,1530,2.41
smoking cessation intervention,156,798,2.41
bench bed side,17,87,2.41
nucleotides,40,205,2.41
life cycle stages,56,287,2.41
life course,56,287,2.41
virus multiplication,18,92,2.41
hypothalamic structure,212,1088,2.4
sampling,1309,6723,2.4
financial cost,15,77,2.4
health care worker,296,1523,2.4
parents,325,1669,2.4
animal models and related studies,999,5134,2.4
treatment protocols,107,550,2.4
medical personnel,296,1523,2.4
animal model,999,5134,2.4
inhalation,97,498,2.4
social support,154,792,2.4
north carolina,45,231,2.4
working group,34,175,2.4
gays,15,77,2.4
treatment provider,296,1523,2.4
healthcare worker,296,1523,2.4
healthcare providers,296,1523,2.4
hypothalamic,212,1088,2.4
glycerol-ester acylhydrolase,15,77,2.4
glycerol monoester hydrolases,15,77,2.4
psychologic,374,1920,2.4
healthcare personnel,296,1523,2.4
stroke,95,489,2.4
malignant melanoma,21,108,2.4
motor learning,21,108,2.4
locomotor learning,21,108,2.4
stressor,229,1177,2.4
monoglyceride lipases,15,77,2.4
intestinal,29,149,2.4
monoglyceride hydrolase,15,77,2.4
health provider,296,1523,2.4
health care providers,296,1523,2.4
health personnel,296,1523,2.4
monoglyceride esterases,15,77,2.4
breast,15,77,2.4
pharmacodynamics,90,462,2.4
monoacylglycerol lipases,15,77,2.4
genetic information,12,62,2.39
movie,12,62,2.39
peptide domain,26,134,2.39
theories,549,2830,2.39
protein domains,26,134,2.39
college,204,1054,2.39
review literature,33,170,2.39
tertiary protein structure,26,134,2.39
older person,105,541,2.39
clinical treatment moab,24,124,2.39
elderly,116,598,2.39
autophagocytosis,25,129,2.39
gabapentin,37,191,2.39
falls,133,687,2.39
gonadal hormones,18,93,2.39
technology development,26,134,2.39
glycoproteins,12,62,2.39
autophagy,25,129,2.39
stress,1110,5751,2.38
reflex action,29,150,2.38
tobacco policy,26,135,2.38
alternative splicing,23,119,2.38
clinical psychology,32,166,2.38
admission activity,122,633,2.38
tobacco control policy,26,135,2.38
pharmacological substance,186,962,2.38
public policy on tobacco,26,135,2.38
distraction,11,57,2.38
admission,122,633,2.38
pharmacologic substance,186,962,2.38
immune system,70,362,2.38
alternate splicing,23,119,2.38
brain region,1048,5441,2.38
3-trihydroxypropane,11,57,2.38
astroprotein,21,109,2.38
gfa-protein,21,109,2.38
gfap,21,109,2.38
glial fibrillary acid protein,21,109,2.38
glial intermediate filament protein,21,109,2.38
kinase inhibitor,34,176,2.38
cancer prevention,33,171,2.38
hour,355,1842,2.38
complement,373,1936,2.38
complement proteins,373,1933,2.38
production,298,1547,2.38
seizures,72,373,2.38
liquid chromatography,17,88,2.38
magnetic,22,114,2.38
pharmaceuticals,186,962,2.38
ovary,11,57,2.38
pharmaceutical agent,186,962,2.38
proteins growth factors,32,166,2.38
glycerin,11,57,2.38
magnetism,22,114,2.38
health care personnel,296,1533,2.38
exercise,120,622,2.38
alcohol related cue,79,409,2.38
half-life,75,390,2.37
effectiveness measure,10,52,2.37
healthcare utilization,90,469,2.37
heterosexuals,36,187,2.37
longevity,124,646,2.37
cell movement,31,161,2.37
cell locomotion,31,161,2.37
recreational drug use,10,52,2.37
minocycline,10,52,2.37
length of life,124,644,2.37
necrocytosis,80,417,2.37
quantitative genetics,15,78,2.37
major depressive disorder,131,682,2.37
maryland,41,213,2.37
health care utilization,90,469,2.37
zebrafish,35,182,2.37
cellular migration,31,161,2.37
kidney,39,203,2.37
california,131,681,2.37
healthcare service utilization,90,469,2.37
cell motility,31,161,2.37
gain of function mutation,10,52,2.37
membrane,253,1324,2.36
orphanin fq receptor,18,94,2.36
ofq receptor,18,94,2.36
gene silencing,26,136,2.36
gene inactivation,26,136,2.36
posttranslational protein processing,53,277,2.36
neighborhoods,96,501,2.36
post-translational modification protein/amino acid biochemistry,53,277,2.36
metabolic pathway,37,193,2.36
post-translational protein modification,53,277,2.36
post-translational protein processing,53,277,2.36
chronic illness,193,1008,2.36
adrenergics,27,141,2.36
social cognition,13,68,2.36
chronic disease,193,1008,2.36
chronic disorder,193,1008,2.36
adrenergic drugs,27,141,2.36
shipping,13,68,2.36
g protein coupled receptor kinase,13,68,2.36
demethylation,13,68,2.36
drug testing,72,376,2.36
sugar,32,167,2.36
l-serine,32,167,2.36
new england,36,189,2.35
informal social control,71,372,2.35
virus infection,52,273,2.35
peptide hormone,12,63,2.35
nicotine craving,29,152,2.35
northeastern united states,36,189,2.35
food consumption,29,152,2.35
oncogenes,76,399,2.35
virus diseases,52,273,2.35
viral infection,52,273,2.35
incarceration,137,719,2.35
physicians,314,1645,2.35
imprisonment,137,719,2.35
viral diseases,52,273,2.35
translational neuroscience,20,105,2.35
hypocretins/orexins,65,341,2.35
hypocretin/orexin,65,341,2.35
hypocretin,65,341,2.35
hcrts/orxs,65,341,2.35
hcrt/orx,65,341,2.35
hcrt protein,65,341,2.35
mitotic,12,63,2.35
web site,106,557,2.35
reagent,94,493,2.35
treatment strategy,411,2154,2.35
single cell analysis,24,126,2.35
α subunit,24,126,2.35
affective disorders,192,1006,2.35
trees,20,105,2.35
g(s)α,24,126,2.35
gtp-binding protein α subunits,24,126,2.35
phosphatides,20,105,2.35
website,106,557,2.35
gsα,24,126,2.35
gαs,24,126,2.35
preclinical testing,21,110,2.35
α-gs,24,126,2.35
physiologic,880,4620,2.35
skin conductance,25,131,2.35
psychogalvanic reflex,25,131,2.35
odors,48,252,2.35
psychiatry,234,1228,2.35
nursing,48,252,2.35
dorsal,313,1640,2.35
graph,20,105,2.35
physiological,880,4640,2.34
carcinogens,26,137,2.34
epidemiologic,251,1325,2.34
statutes and laws,45,237,2.34
standardize measure,19,100,2.34
posters,61,322,2.34
neurobiological,905,4776,2.34
plants,49,258,2.34
preparation,391,2060,2.34
neural stem cell,25,132,2.34
neural progenitor cells,25,132,2.34
neuronal progenitor,25,132,2.34
electrocardiography,26,137,2.34
neuronal progenitor cells,25,132,2.34
blood sample,67,353,2.34
blood specimen,67,353,2.34
affective,300,1579,2.34
serine,32,169,2.34
myelin,11,58,2.34
adrenergic receptor,47,248,2.34
backbone,119,626,2.34
vertebral column,119,626,2.34
followed up,650,3429,2.34
follow up,650,3429,2.34
pediatrics,42,221,2.34
spine,119,626,2.34
spinal column,119,626,2.34
biological adaptation to stress,171,906,2.33
glial fibrillary acidic protein,21,111,2.33
crisis,171,906,2.33
perception,260,1375,2.33
pre-doc,77,408,2.33
blood plasma,221,1172,2.33
neurotransmitter release,98,519,2.33
pre-doctoral,77,408,2.33
life cycle,56,296,2.33
brain scan,10,53,2.33
stress response,171,906,2.33
youth,367,1943,2.33
ukraine,14,74,2.33
psychological,374,1976,2.33
regimen,185,981,2.33
mass spectrometry,113,598,2.33
early identification,43,228,2.33
genome-wide analysis,27,143,2.33
catheters,17,90,2.33
distal,79,419,2.33
disulfiram,46,243,2.33
predoctoral,77,408,2.33
youth 10-21,367,1943,2.33
recovery of function,23,122,2.33
functional recovery,23,122,2.33
central nervous system diseases,54,286,2.33
model system,208,1102,2.33
cns disorder,54,286,2.33
cns diseases,54,286,2.33
field study,44,234,2.32
blood vessels,49,260,2.32
government,78,414,2.32
ethanol use,1149,6109,2.32
ethanol drinking,1149,6109,2.32
exposure to ets,13,69,2.32
ethanol product use,1149,6109,2.32
disease frequency surveys,50,266,2.32
exposure to shs,13,69,2.32
urban area,44,234,2.32
ethanol consumption,1149,6109,2.32
cell morphology,13,69,2.32
abnormal psychology,225,1194,2.32
programs,2119,11266,2.32
alcohol drinking,1149,6109,2.32
alcoholic drink intake,1149,6109,2.32
cross-sectional studies,50,266,2.32
alcohol use,1149,6109,2.32
alcohol product use,1149,6109,2.32
alcohol intake,1149,6109,2.32
etoh drinking,1149,6109,2.32
etoh use,1149,6109,2.32
alcohol ingestion,1149,6109,2.32
alpha subunit,26,138,2.32
cross-sectional survey,50,266,2.32
cross-sectional analyses,50,266,2.32
second hand smoke exposure,13,69,2.32
epithelium,16,85,2.32
legislation,45,239,2.32
peptide signal sequences,13,69,2.32
functional restoration,13,69,2.32
noninsulin dependent diabetes mellitus,35,186,2.32
restore function,13,69,2.32
restore functionality,13,69,2.32
restore lost function,13,69,2.32
cross sectional analysis,50,266,2.32
older patient,13,69,2.32
elderly patient,13,69,2.32
secondhand smoke exposure,13,69,2.32
noradrenergic,68,361,2.32
dysphoria,52,277,2.32
alcohol consumption,1149,6110,2.32
exposure to tobacco smoke,13,69,2.32
exposure to environmental tobacco smoke,13,69,2.32
cb1 receptor,116,616,2.32
microscopy,110,585,2.32
ethanol ingestion,1149,6109,2.32
cb1,116,616,2.32
ethanol intake,1149,6109,2.32
youth drinking,80,428,2.31
teen drinking,80,428,2.31
immunotherapeutics,12,64,2.31
nerve impulse transmission,377,2013,2.31
adolescent drinking,80,428,2.31
chemicals,403,2148,2.31
gas-liquid-mass spectrometry chromatography,12,64,2.31
immunotherapeutic agent,12,64,2.31
teenage drinking,80,428,2.31
tobacco use prevention,15,80,2.31
mass-gas chromatography spectrometry,12,64,2.31
mass-gas chromatography spectrum analysis,12,64,2.31
neurotransmission,377,2013,2.31
tobacco prevention,15,80,2.31
adolescent alcohol use,80,428,2.31
protective behavior,12,64,2.31
nerve transmission,377,2013,2.31
underage drinking,80,428,2.31
neuronal transmission,377,2013,2.31
orexin,65,347,2.31
failure,241,1285,2.31
presynaptic terminals,84,448,2.31
maturity onset diabetes,35,187,2.31
synaptic terminals,84,448,2.31
melanoma,21,112,2.31
characteristics,835,4460,2.31
designer drugs,30,160,2.31
synaptic boutons,84,448,2.31
type 2 diabetes,35,187,2.31
randomly assigned,930,4959,2.31
customized drugs,30,160,2.31
axon terminals,84,448,2.31
δ opioid receptors,29,155,2.31
randomization,930,4959,2.31
t2dm,35,187,2.31
maturity-onset diabetes mellitus,35,187,2.31
inbreeding,32,171,2.31
type ii diabetes,35,187,2.31
t2d,35,187,2.31
adult onset diabetes,35,187,2.31
lymphoma,26,139,2.31
niddm,35,187,2.31
non-insulin dependent diabetes,35,187,2.31
weight maintenance regimen,18,96,2.31
ketosis resistant diabetes,35,187,2.31
randomisation,930,4959,2.31
excessive drinking,415,2222,2.3
ligand binding domain,11,59,2.3
extreme drinking,415,2222,2.3
developed country,17,91,2.3
revia,236,1267,2.3
developed nation,17,91,2.3
excessive ethanol ingestion,415,2222,2.3
depressive symptoms,186,996,2.3
nalorex,236,1267,2.3
nemexin,236,1267,2.3
recording of previous events,707,3798,2.3
mammalia,88,471,2.3
glass,11,59,2.3
excessive alcohol ingestion,415,2222,2.3
research projects,564,3028,2.3
neurophysiology,249,1336,2.3
biological systems,37,198,2.3
placebo effect,30,161,2.3
central nervous system disorders,54,290,2.3
expectancy effect,30,161,2.3
placebo response,30,161,2.3
history,707,3798,2.3
nocebo,30,161,2.3
expectation effect,30,161,2.3
excessive alcohol intake,415,2222,2.3
heavy alcohol use,415,2222,2.3
binding site domain,11,59,2.3
drink heavily,415,2222,2.3
fats,44,236,2.3
fatty acid glycerol esters,44,236,2.3
membrane structure,253,1359,2.3
emotional depression,186,996,2.3
gel,19,102,2.3
heavy drinking,415,2222,2.3
nerve stem cell,25,134,2.3
brain volume,22,118,2.3
structure of terminal stria nuclei of preoptic region,79,423,2.3
stria terminalis nucleus,79,423,2.3
bed nucleus of stria terminalis,79,423,2.3
excessive alcohol consumption,415,2222,2.3
emotions,224,1199,2.3
high prevalence,187,1004,2.3
health care costs,170,916,2.29
blood serum,97,523,2.29
healthcare costs,170,916,2.29
health costs,170,916,2.29
tobacco advertising,18,97,2.29
adult youth,353,1903,2.29
forensics,18,97,2.29
retrograde transport,13,70,2.29
gamma-l-glu-l-cys-gly,16,86,2.29
gamma-l-glutamyl-l-cysteinylglycine,16,86,2.29
epidemiologic research,106,572,2.29
epidemiologic studies,106,572,2.29
epidemiological studies,106,572,2.29
applications grants,207,1117,2.29
respiratory function,23,124,2.29
cd4 positive t lymphocytes,26,140,2.29
cd4 t cells,26,140,2.29
cd4 lymphocyte,26,140,2.29
cd4+ t-lymphocyte,26,140,2.29
cd4-positive lymphocytes,26,140,2.29
t4 cells,26,140,2.29
epidemiology research,106,572,2.29
tobacco ads,18,97,2.29
t4 lymphocytes,26,140,2.29
diabetes mellitus,174,936,2.29
respiratory system,45,242,2.29
cardiovascular body system,139,749,2.29
genetic techniques,41,221,2.29
cardiovascular system,139,749,2.29
circulatory system,139,749,2.29
language,71,382,2.29
health care expenditure,23,124,2.29
health expenditures,23,124,2.29
3'5'-cyclic ester of amp,103,556,2.28
genetic variant,170,918,2.28
marijuana use in adolescence,10,54,2.28
equipment and supply inventories,52,281,2.28
depressive,186,1008,2.28
cannabis use among adolescents,10,54,2.28
adenosine cyclic monophosphate,103,556,2.28
cognitive psychotherapy,171,925,2.28
adolescent marijuana use,10,54,2.28
disinhibition,81,439,2.28
camp,103,556,2.28
inventory,52,281,2.28
educational curriculum,130,702,2.28
exhibits,739,4005,2.28
marijuana use among adolescents,10,54,2.28
qtl,74,400,2.28
adenosine cyclic 3',103,556,2.28
cognition therapy,171,925,2.28
cystine,15,81,2.28
methadone maintenance,71,384,2.28
adenosine 3'5' monophosphate,103,556,2.28
drug craving,164,893,2.27
rats mammals,1063,5766,2.27
synapse,748,4068,2.27
seventeen year old,14,76,2.27
prevent drug use,83,451,2.27
inbred strain,25,136,2.27
healthcare service access,70,380,2.27
naloxone,225,1223,2.27
social cognitive theory,32,174,2.27
social learning theory,32,174,2.27
17 year old,14,76,2.27
locomotion,89,483,2.27
glutathione,16,87,2.27
phase 3 trial,21,114,2.27
health care service access,70,380,2.27
health care availability,70,380,2.27
prevent drug abuse,83,451,2.27
access to healthcare,70,380,2.27
drug screening,79,429,2.27
comparative,99,539,2.27
steroids,35,190,2.27
up-regulation,199,1080,2.27
accessibility of health care,70,380,2.27
phase ii trial,27,147,2.27
access to health care,70,380,2.27
gene activation,15,82,2.26
functional disability,47,257,2.26
small interfering rna,60,327,2.26
gastrointestinal tract,15,82,2.26
attenuated,573,3132,2.26
metropolitan,47,257,2.26
physical dependence,79,431,2.26
benign,11,60,2.26
alcohol research,186,1013,2.26
ethanol research,186,1013,2.26
molecular target,161,880,2.26
core facility,37,202,2.26
high blood pressure,68,371,2.26
geographic information systems,13,71,2.26
cognitive disorder,24,131,2.26
self-report,509,2782,2.26
patient self-report,509,2782,2.26
cognitive disease,24,131,2.26
meta-analysis,107,584,2.26
elders,99,541,2.26
normal cell,35,191,2.26
later life,99,541,2.26
gs,48,262,2.26
g(s),48,262,2.26
syndrome,131,716,2.26
epileptogenic,127,697,2.25
therapy design,189,1036,2.25
mri scans,29,159,2.25
self help organization,37,203,2.25
code,249,1363,2.25
coding system,249,1363,2.25
treatment design,189,1036,2.25
intervention design,189,1036,2.25
biological factors,59,324,2.25
epilepsia,127,697,2.25
epileptic seizures,127,697,2.25
ethanol craving,112,614,2.25
epileptics,127,697,2.25
receptor activation,242,1325,2.25
early intervention,86,472,2.25
computational biology,19,104,2.25
alcohol craving,112,614,2.25
intestines,29,159,2.25
criminal justice,121,664,2.25
adrenergic blockaders,12,66,2.24
imaging device,29,160,2.24
nematoda,28,154,2.24
pacific northwest,14,77,2.24
country,293,1613,2.24
x-ray/neutron crystallography,14,77,2.24
reaction,484,2666,2.24
mediation,166,914,2.24
trend,206,1132,2.24
doubt,83,456,2.24
uncertainty,83,456,2.24
ventral tegmentum,426,2342,2.24
ventral tegmental area,426,2342,2.24
x-ray diffraction crystallography,14,77,2.24
negotiating,166,914,2.24
negotiation,166,914,2.24
mood disorders,192,1056,2.24
psychological stress,10,55,2.24
achievement attainment,93,511,2.24
x-ray crystallography,14,77,2.24
chicago,32,176,2.24
matrix-assisted laser desorption-ionization,12,66,2.24
seizure disorder,127,700,2.24
self administration,958,5275,2.24
antiadrenergics,12,66,2.24
adrenolytic drugs,12,66,2.24
adrenergic-blocking agents,12,66,2.24
imaging tool,29,160,2.24
nematodes,28,154,2.24
adrenergic receptor blockaders,12,66,2.24
adrenolytic agents,12,66,2.24
bulimic,10,55,2.24
xray crystallography,14,77,2.24
matched group,12,66,2.24
adrenolytics,12,66,2.24
adrenergic blockers,12,66,2.24
adrenergic antagonists,12,66,2.24
anti-adrenergics,12,66,2.24
roundworm,28,154,2.24
hiv-1,67,371,2.23
intervention research,134,741,2.23
suicide behavior,23,127,2.23
lectures,60,332,2.23
data bases,261,1442,2.23
carbon,26,144,2.23
hiv-i,67,371,2.23
skin electric conductance,25,138,2.23
general radiology,17,94,2.23
psychopathology,225,1244,2.23
anticancer drug,28,155,2.23
friends,89,493,2.23
hiv1,67,371,2.23
services research,121,668,2.23
medical care research,121,668,2.23
sociology,13,72,2.23
health services research,121,668,2.23
electrodermal response,25,138,2.23
health services evaluation,121,668,2.23
intervention studies,134,741,2.23
medical research,24,133,2.23
suicidal behavior,23,127,2.23
time use,62,343,2.23
intelligence,24,133,2.23
synaptic plasticity,329,1821,2.23
germinoblastic sarcoma,19,105,2.23
malignant lymphoma,19,105,2.23
check-up,17,94,2.23
checkup,17,94,2.23
noise,50,277,2.23
medication compliance,101,559,2.23
intimate partner violence,19,105,2.23
checkup examination,17,94,2.23
codeine,19,105,2.23
knockout mice,242,1339,2.23
new jersey,13,72,2.23
anticancer agent,28,155,2.23
x-radiation,19,105,2.23
amygdaloid nuclear complex,556,3071,2.23
amygdaloid structure,556,3071,2.23
medication adherence,101,559,2.23
knock-out mice,242,1339,2.23
neurobiology,905,5014,2.23
amygdaloid nucleus,556,3071,2.23
roentgen rays,19,105,2.23
amygdaloid body,556,3071,2.23
training intervention,48,267,2.22
imaging modality,73,406,2.22
cellular function,164,911,2.22
instruction intervention,48,267,2.22
educational intervention,48,267,2.22
education for intervention,48,267,2.22
cellular physiology,164,911,2.22
ethnic minority population,59,328,2.22
sucrose,131,728,2.22
instructional intervention,48,267,2.22
knock-out,244,1355,2.22
cell physiology,164,911,2.22
knockout,244,1355,2.22
subcellular process,164,911,2.22
anterior,238,1322,2.22
cell process,164,911,2.22
cell function,164,911,2.22
patients who use opioids,11,61,2.22
questionnaires,229,1275,2.22
cellular process,164,911,2.22
imaging method,73,406,2.22
primary care setting,82,455,2.22
pharmaceutical preparations,3229,17966,2.22
drug/agent,3229,17966,2.22
appetitive behavior,25,139,2.22
doctor of philosophy,213,1186,2.22
ph.d.,213,1186,2.22
investigation,874,4845,2.22
phd,213,1186,2.22
diagnostic tests,16,89,2.22
conformation,107,595,2.22
school of medicine,209,1162,2.22
oxides,32,178,2.22
midbrain structure,221,1230,2.22
midbrain,221,1230,2.22
mid-brain,221,1230,2.22
mapk14 gene,17,95,2.21
mapk14,17,95,2.21
drug detection,72,402,2.21
mediator,468,2607,2.21
androgenic agents,14,78,2.21
membrane proteins,51,284,2.21
androgenic compounds,14,78,2.21
therapeutic androgen,14,78,2.21
csbp2,17,95,2.21
mathematics,28,156,2.21
environmental enrichment for laboratory animals,19,106,2.21
behavior control,172,959,2.21
behavioral manipulation,172,959,2.21
mxi2,17,95,2.21
neuroplasticity,237,1324,2.21
neuronal plasticity,237,1324,2.21
cns plasticity,237,1324,2.21
behavioral control,172,959,2.21
brief treatment,97,541,2.21
environmental enrichment,19,106,2.21
environment enrichment for laboratory animals,19,106,2.21
brief therapy,97,541,2.21
environment enrichment,19,106,2.21
insurance,52,290,2.21
therapeutic steroid hormone,12,67,2.21
p38 mapk gene,17,95,2.21
stress related disorder,28,156,2.21
assaulted sexually,17,95,2.21
sapk2a,17,95,2.21
p38,17,95,2.21
p38alpha,17,95,2.21
health care policy,95,529,2.21
sexual assault,17,95,2.21
self regulation,71,396,2.21
signal peptide,13,73,2.2
asian americans,25,140,2.2
cynomolgus monkey,10,56,2.2
hiv env protein gp120,13,73,2.2
confusion,15,84,2.2
symporter,10,56,2.2
bulimia nervosa,10,56,2.2
prognostic,28,157,2.2
crab-eating monkey,10,56,2.2
injection drug user,90,504,2.2
adenosine,136,764,2.2
confusional state,15,84,2.2
indiana,47,263,2.2
life style,72,404,2.2
mental confusion,15,84,2.2
biomedical ethics,10,56,2.2
co-transporters,10,56,2.2
hiv envelope glycoprotein gp120,13,73,2.2
biotechnology,31,174,2.2
injecting drug user,90,504,2.2
body temperature,20,112,2.2
exclusion criteria,18,101,2.2
transcription regulation,70,393,2.2
transcriptional regulation,70,393,2.2
evoked potentials,15,84,2.2
transcriptional control,70,393,2.2
socialization,25,140,2.2
randomized controlled clinical trials,23,129,2.2
alcohols,1375,7722,2.2
enzymes,315,1776,2.19
electronics,73,411,2.19
therapeutic testosterone,25,141,2.19
computational neuroscience,25,141,2.19
trans-testosterone,25,141,2.19
therapeutic estrogen,45,253,2.19
paralytic,11,62,2.19
cell line,216,1219,2.19
paralysed,11,62,2.19
plegia,11,62,2.19
adeno-associated virus vector,24,135,2.19
psychiatric treatment,43,242,2.19
psychiatric therapeutic procedure,43,242,2.19
implanted electrodes,11,62,2.19
cognitive function,240,1352,2.19
gene expression,641,3604,2.19
crossover trials,11,62,2.19
estrous,11,62,2.19
saline,149,841,2.19
aminalone,286,1614,2.19
trial treatment,134,753,2.19
aminalon,286,1614,2.19
psychiatric therapy,43,242,2.19
psychiatric care,43,242,2.19
saline solution,149,840,2.19
gaba,286,1614,2.19
trial regimen,134,753,2.19
adeno-associated viral vector,24,135,2.19
4-aminobutyric acid,286,1614,2.19
4-aminobutanoic acid,286,1614,2.19
aav vector,24,135,2.19
palsy,11,62,2.19
alpha subunit stimulatory gtp-binding protein,24,135,2.19
stimulatory gs g-protein,24,135,2.19
regulatory ns protein,24,135,2.19
gs alpha family g-protein,24,135,2.19
social development,14,79,2.19
cross-over trials,11,62,2.19
5-ht receptors,34,192,2.18
achievement,93,526,2.18
texas,73,413,2.18
5-hydroxytryptamine receptors,34,192,2.18
research institute,102,578,2.18
opioid receptor binding,18,102,2.18
lipid metabolism,17,96,2.18
diffusion,74,419,2.18
psychosocial,327,1847,2.18
biological models,208,1178,2.18
extinction,256,1448,2.18
applied science,26,147,2.18
neural receptors,17,96,2.18
applied research,26,147,2.18
at-risk drinking,48,271,2.18
alcoholic beverage consumption,1149,6487,2.18
oral administration,44,249,2.18
oligonucleotides,17,96,2.18
g(s)alpha,24,136,2.18
plasma,442,2503,2.18
epidemiological,251,1417,2.18
co-occurring disorders,29,164,2.18
ligands,469,2651,2.18
alpha-gs,24,136,2.18
high risk drinking,48,271,2.18
risky drinking,48,271,2.18
ethanol cue,79,450,2.17
cannabinoidergic,57,324,2.17
cannabinergic,57,324,2.17
oregon,53,301,2.17
htlv-iii-lav infections,223,1268,2.17
htlv-iii infections,223,1268,2.17
fluorescence microscopy,22,125,2.17
proliferative phase menstrual cycle,13,74,2.17
follicular phase menstrual cycle,13,74,2.17
alcohol cue,79,450,2.17
blinded,32,182,2.17
synaptic,748,4251,2.17
galvanic skin response,25,142,2.17
bioenergetics,19,108,2.17
k23 award,76,431,2.17
epilepsy,127,722,2.17
prevention service,48,273,2.17
hormonal system,10,57,2.16
minnesota,53,302,2.16
akt protein,17,97,2.16
glutamatergic,605,3459,2.16
transgenic organisms,185,1058,2.16
drug exposure,176,1003,2.16
homo,10,57,2.16
l-glutamate,605,3459,2.16
text,88,503,2.16
ion channel,130,743,2.16
pricing,60,343,2.16
metabolic/endocrine body system,10,57,2.16
immunofluorescence,25,143,2.16
endocrine system,10,57,2.16
endocrine gland/system,10,57,2.16
neural function,58,331,2.16
endocrine/metabolic organ system,10,57,2.16
neurophysiology - biologic function,58,331,2.16
ionic channels,130,743,2.16
protein kinase b,17,97,2.16
noci-r,18,103,2.16
akt,17,97,2.16
c-akt protein,17,97,2.16
proto-oncogene proteins c-akt,17,97,2.16
functional outcomes,44,251,2.16
price,60,343,2.16
related to a and c-protein,17,97,2.16
tumor xenograft,18,103,2.16
rac-pk protein,17,97,2.16
adjuvant,36,206,2.16
nociceptin receptor,18,103,2.16
proto-oncogene protein rac,17,97,2.16
proto-oncogene protein akt,17,97,2.16
movement,155,883,2.16
blood,264,1504,2.16
rac protein kinase,17,97,2.16
anti-epileptic,15,86,2.15
pulmonary malignant neoplasm,97,556,2.15
pulmonary cancer,97,556,2.15
basic science,273,1567,2.15
clinical treatment,134,770,2.15
censuses,40,229,2.15
malignant tumor of the lung,97,556,2.15
basic research,273,1567,2.15
malignant neoplasm of lung,97,556,2.15
cats,15,86,2.15
human genetics,65,373,2.15
indexing,350,2005,2.15
metabolic glycosylation,11,63,2.15
intention,75,431,2.15
lung cancer,97,556,2.15
cavitas oris,19,109,2.15
grain,27,155,2.15
ethanol effect,333,1913,2.15
neural adaptation,268,1538,2.15
sectm1 gene,11,63,2.15
genetic defect,292,1673,2.15
genetic change,292,1673,2.15
sectm1,11,63,2.15
genetic alteration,292,1673,2.15
neuroadaptation,268,1538,2.15
upregulation,199,1142,2.15
alcohol effect,333,1913,2.15
genome mutation,292,1673,2.15
glycerol,11,63,2.15
oral cavity,19,109,2.15
cytosol,11,63,2.15
adopted,206,1187,2.14
response to stimulus physiology,32,184,2.14
mutation,292,1679,2.14
nutritious,17,98,2.14
associative learning,134,773,2.14
stimulus/response,32,184,2.14
nature,613,3534,2.14
research into practice,32,184,2.14
biotinylation,13,75,2.14
research to practice,32,184,2.14
potassium ion channels,38,219,2.14
transformed cells,16,92,2.14
instrumentation,38,219,2.14
pavlovian conditioning,134,773,2.14
estrogens,45,259,2.14
military,66,380,2.14
active technique,28,161,2.14
active treatment,28,161,2.14
washington,102,587,2.14
armed forces personnel,66,380,2.14
active method,28,161,2.14
human figure,13,75,2.14
functional ability,22,127,2.14
environmental factor,224,1292,2.14
human body,13,75,2.14
environmental risk factor,224,1292,2.14
environmental risk,224,1292,2.14
ice,10,58,2.13
environmental change,14,81,2.13
p44 mapk,10,58,2.13
role model,34,197,2.13
extracellular signal-regulated kinase 1,10,58,2.13
hcv,78,451,2.13
pstkinase p44mpk,10,58,2.13
military personnel,66,382,2.13
gamma-aminobutyric acid,286,1654,2.13
erk1 kinase,10,58,2.13
photons,29,168,2.13
stimulus,716,4137,2.13
primary care,259,1500,2.13
erk 1,10,58,2.13
androgens,14,81,2.13
fluorescence,107,620,2.13
neurocognitive,163,942,2.13
relapse,1329,7705,2.13
low income,86,497,2.13
heart failure,10,58,2.13
gtp-binding protein alpha subunits,24,139,2.13
health literacy,10,58,2.13
hypothalamus,212,1229,2.13
mitogen-activated protein kinase 3,10,58,2.13
trait impulsivity,10,58,2.13
map kinase 3,10,58,2.13
social norm,15,87,2.13
valium,14,81,2.13
resting potentials,30,174,2.13
transmembrane potentials,30,174,2.13
infusion,209,1212,2.13
mapk3 mitogen-activated protein kinase,10,58,2.13
infusion procedures,209,1212,2.13
contingency management,100,582,2.12
intake,364,2115,2.12
post-translational modifications,53,308,2.12
tobacco use,382,2222,2.12
genome,169,983,2.12
metabolic syndrome,11,64,2.12
medical imaging,252,1467,2.12
advertising,43,250,2.12
reflex,29,169,2.12
serum,318,1850,2.12
life,799,4648,2.12
major depression,131,761,2.12
fluorescence imaging,22,128,2.12
transcription factor,223,1297,2.12
gonadal steroid hormones,37,215,2.12
cues,775,4506,2.12
neuronal degeneration,110,641,2.12
neurodegenerative,110,641,2.12
neurodegeneration,110,641,2.12
sex steroid hormones,37,215,2.12
tobacco consumption,382,2222,2.12
gonadal steroids,37,215,2.12
neuron degeneration,110,641,2.12
nerve degeneration,110,641,2.12
quality assurance,31,180,2.12
sex steroid,37,215,2.12
behavior influence,83,483,2.12
behavioral influence,83,483,2.12
5'-(hydrogen phosphate),103,601,2.11
antisocial behavior,13,76,2.11
memory process,53,310,2.11
5'-monophosphate,103,601,2.11
forensic medicine,18,105,2.11
psychotic illness,31,181,2.11
alzheimer type dementia,158,924,2.11
synapses,748,4374,2.11
orphanin fq,27,158,2.11
basal nuclei,113,659,2.11
attenuation,96,562,2.11
glutamates,605,3535,2.11
recessive oncogenes,14,82,2.11
drug therapy,685,4007,2.11
cancer suppressor genes,14,82,2.11
hypnotic,20,117,2.11
pharmacotherapy,685,4005,2.11
cyclic 3',103,601,2.11
steroid hormone,12,70,2.11
mouth,19,111,2.11
side,85,497,2.11
quantitative trait loci,74,432,2.11
ligand binding protein,68,397,2.11
onco-suppressor genes,14,82,2.11
blood pressure,79,461,2.11
glutamate transporter,37,216,2.11
body movement,155,904,2.11
women's health,53,311,2.1
monoclonal antibodies,24,141,2.1
motivational processes,33,194,2.1
liposomes,22,129,2.1
reinforced behavior,26,153,2.1
psychoactive compound,52,306,2.1
cell transformation,16,94,2.1
masks,25,147,2.1
psychoactive agents,52,306,2.1
sirna,60,352,2.1
cardiovascular disease risk,16,94,2.1
chronic care,17,100,2.1
somatosensory cortex,15,88,2.1
sensory receptors,17,100,2.1
psychopharmaceuticals,52,306,2.1
psychoactive drugs,52,306,2.1
neurocognition,24,141,2.1
social,818,4819,2.09
carbohydrates,10,59,2.09
knockout gene,20,118,2.09
paralysis,11,65,2.09
operation,144,849,2.09
muscarinic receptors,20,118,2.09
belief,132,779,2.09
k23 program,76,448,2.09
mentored patient-oriented research career development award,76,448,2.09
sample size,160,942,2.09
k23 mechanism,76,448,2.09
neuropeptides,234,1380,2.09
north america,28,165,2.09
cell survival,58,343,2.09
mentored patient-oriented research career development award (k23),76,448,2.09
diffuse,40,236,2.09
charge,69,408,2.09
dna molecular biology,80,471,2.09
hedonic,80,472,2.09
animal data,18,106,2.09
thermal hyperalgesias,10,59,2.09
residual state,30,177,2.09
sigma-1 receptor,10,59,2.09
cell viability,58,343,2.09
residual,30,178,2.08
restraint,26,154,2.08
action potentials,85,503,2.08
tobacco,566,3363,2.08
health sciences,90,534,2.08
risk ratio,13,77,2.08
analog,273,1615,2.08
mri,250,1485,2.08
substantia grisea,50,297,2.08
tobacco cessation,81,481,2.08
tobacco use cessation,81,481,2.08
software development,35,208,2.08
cigarette smoker,97,576,2.08
probability,222,1315,2.08
signal sequences,13,77,2.08
subcutaneous,25,148,2.08
develop software,35,208,2.08
developing computer software,35,208,2.08
cross-product ratio,13,77,2.08
relative odds,13,77,2.08
odds ratio,13,77,2.08
and treatment,43,256,2.07
adrenergic agents,27,161,2.07
mesencephalon,221,1314,2.07
corpus striatum structure,606,3604,2.07
striatal,606,3604,2.07
risk perception,30,179,2.07
deoxyribonucleic acid,216,1288,2.07
mutagenesis,72,429,2.07
food intake,116,690,2.07
referral,43,256,2.07
non-human primate,158,940,2.07
and referral to treatment,43,256,2.07
sbirt,43,256,2.07
striate body,606,3604,2.07
nonhuman primate,158,940,2.07
organization charts,19,113,2.07
viet nam,20,119,2.07
organizational structure,19,113,2.07
reinforcement,409,2447,2.06
non-malignant,12,72,2.06
nonmalignant,12,72,2.06
crab-eating macaque,10,60,2.06
membrane transport proteins,13,78,2.06
promotor,178,1067,2.06
promoter,178,1067,2.06
detergents,12,72,2.06
adolescent development,31,186,2.06
health priorities,10,60,2.06
mass fragmentometry,12,72,2.06
ion trap mass spectrometry,12,72,2.06
mass fragmentography,12,72,2.06
mass fragmentographies,12,72,2.06
gcms,12,72,2.06
gc ms,12,72,2.06
3-propanetriol,13,78,2.06
rehabilitation,86,515,2.06
cell migration,31,186,2.06
population based,72,432,2.06
physiologic imaging,56,335,2.06
functional imaging,56,335,2.06
ergastoplasm,27,162,2.06
histones,68,407,2.06
prize,14,84,2.06
cardiac infarct,17,102,2.06
tactile,15,90,2.06
in vitro assay,43,257,2.06
heart infarction,17,102,2.06
heart infarct,17,102,2.06
heart attack,17,102,2.06
coronary infarction,17,102,2.06
coronary infarct,17,102,2.06
cell death,80,478,2.06
coronary attack,17,102,2.06
human subject protection,11,66,2.06
myocardial infarct,17,102,2.06
cardiac infarction,17,102,2.06
peptides,228,1367,2.06
drinking,640,3854,2.05
lifestyle,72,434,2.05
nuclear,73,439,2.05
hepatitis c virus,78,469,2.05
total human and non-human gene mapping,38,229,2.05
medical,973,5864,2.05
membrane channels,130,782,2.05
prevention research,55,331,2.05
neural degeneration,110,661,2.05
gene mapping genetics,38,229,2.05
biological chemistry,69,415,2.05
immune function,45,271,2.05
commentary,43,260,2.04
motoneuron,18,109,2.04
research training,332,2003,2.04
gray matter,50,302,2.04
college student,85,515,2.04
methylation,73,441,2.04
forest,21,127,2.04
comment,43,260,2.04
motility,30,181,2.04
motor cell,18,109,2.04
coupling,129,779,2.04
editorial comment,43,260,2.04
published comment,43,260,2.04
viewpoint,43,260,2.04
adolescence,338,2054,2.03
help seeking,28,170,2.03
12-20 years old,338,2054,2.03
protein signal sequence,13,79,2.03
curriculum,130,789,2.03
3d structure,25,152,2.03
help-seeking behavior,28,170,2.03
amygdala,556,3371,2.03
3-dimensional structure,25,152,2.03
3-d structure,25,152,2.03
5-ht2a,23,140,2.03
capillary,13,79,2.03
bioluminescence,12,73,2.03
hunger,26,158,2.03
three dimensional structure,25,152,2.03
cardiovascular disorder risk,16,97,2.03
physiologic pulse,71,432,2.03
next generation sequencing,48,292,2.03
manufacturer,26,158,2.03
pulse,71,432,2.03
ingestion,44,267,2.03
drug use,1117,6835,2.02
bacterial artificial chromosomes,10,61,2.02
drug metabolic detoxification,77,470,2.02
reticulolymphosarcoma,19,116,2.02
drug relapse,148,903,2.02
drug metabolic detoxication,77,470,2.02
receptor-mediated signaling,20,122,2.02
drug usage,1117,6835,2.02
physical activity,53,324,2.02
liability to disease,11,67,2.02
growth substances,32,195,2.02
growth agents,32,195,2.02
hyperpiesis,68,415,2.02
disease susceptibility,11,67,2.02
diathesis,11,67,2.02
economics,265,1614,2.02
tramadol,11,67,2.02
osmotic minipump,10,61,2.02
hypertensive disease,68,415,2.02
vascular hypertensive disease,68,415,2.02
food,298,1816,2.02
vascular hypertensive disorder,68,415,2.02
hyperpiesia,68,415,2.02
europe,37,226,2.02
germinoblastoma,19,116,2.02
prescription opioid overdose,10,61,2.02
n-arachidonoylethanolamine,18,110,2.02
prescription opiate overdose,10,61,2.02
cerebral spinal fluid,23,141,2.01
cooperative agreements,27,166,2.01
fishes,15,92,2.01
rattus,1063,6528,2.01
economic cost,74,453,2.01
common rat strains,1063,6528,2.01
illumination,15,92,2.01
brief intervention,183,1121,2.01
drinking behavior,191,1170,2.01
l-lysine,31,190,2.01
lav-htlv-iii,523,3210,2.01
small hairpin rna,81,498,2.01
imaging technics,105,644,2.01
fees,24,147,2.01
short hairpin rna,81,498,2.01
alcohol preferring rats,15,92,2.01
ethanol perferring rats,15,92,2.01
shrna,81,498,2.01
phase iii protocol,15,92,2.01
phase iii clinical trials,15,92,2.01
virus-hiv,523,3210,2.01
boston,60,369,2.01
aids virus,523,3210,2.01
acquired immune deficiency syndrome virus,523,3210,2.01
acquired immunodeficiency syndrome virus,523,3210,2.01
human immunodeficiency viruses,523,3210,2.01
striatum,606,3710,2.01
lymphadenopathy-associated virus,523,3210,2.01
cellular structures,14,86,2.01
protein expression,134,822,2.01
b-cells,30,184,2.01
molecular interaction,652,4010,2.01
b-lymphocytes,30,184,2.01
post treatment,229,1402,2.01
transmission,544,3342,2.01
cell components,14,86,2.01
cell structure,14,86,2.01
b blood cells,30,184,2.01
transmission process,544,3336,2.01
attitude,180,1110,2.0
health care service availability,70,431,2.0
hiv,523,3232,2.0
methadone,339,2088,2.0
presynaptic,206,1269,2.0
nervous system degenerative diseases,97,599,2.0
siv,11,68,2.0
treatment outcome,420,2588,2.0
simian immunodeficiency viruses,11,68,2.0
rapid growth,12,74,2.0
subgroup,214,1319,2.0
histone modification,47,290,2.0
imaging technology,33,204,2.0
estrus,11,68,2.0
larva,13,80,2.0
glycolysis,11,68,2.0
organelles,19,117,2.0
reticuloendothelial system,221,1361,2.0
binding,652,4011,2.0
immediate-early genes,49,304,1.99
null mouse,242,1502,1.99
lesbian,15,93,1.99
procedures,628,3891,1.99
co-immunoprecipitations,16,99,1.99
continuance of education,15,93,1.99
trial comparing,81,501,1.99
biochemical,431,2668,1.99
functional mri,358,2215,1.99
other genetics,15,93,1.99
target populations,67,415,1.99
computerized medical record,36,223,1.99
physiologic psychology,50,310,1.99
physiological psychology,50,310,1.99
epistasis,10,62,1.99
group intervention,45,281,1.98
care manager,27,168,1.98
jobless,46,287,1.98
functional group,13,81,1.98
case manager,27,168,1.98
youth substance use,81,504,1.98
viral hepatitis,13,81,1.98
muscarinic agents,14,87,1.98
jobs,59,367,1.98
restoration,53,330,1.98
synaptic transmission,209,1305,1.98
new york,85,530,1.98
gtpases,25,156,1.98
joblessness,46,287,1.98
transgenic,185,1151,1.98
age 21 years,27,168,1.98
out of work,46,287,1.98
adolescent substance use,81,504,1.98
cellular biology,64,398,1.98
dna,216,1345,1.98
cardiovascular,139,866,1.98
unemployed,46,287,1.98
guanosine triphosphate phosphohydrolases,25,156,1.98
age 21,27,168,1.98
myocardial infarction,17,106,1.98
gtp phosphohydrolases,25,156,1.98
radiology specialty,17,106,1.98
unemployment,46,287,1.98
viral burden,59,369,1.97
alcohol intoxication,59,370,1.97
montana,11,69,1.97
lysine,31,194,1.97
grant proposals,207,1297,1.97
sobriety,50,313,1.97
lighting,15,94,1.97
drunkenness,59,370,1.97
etoh intoxication,59,370,1.97
ethanol intoxication,59,370,1.97
viral load,59,369,1.97
property,1020,6397,1.97
cellular assay,20,125,1.97
gene testing,11,69,1.97
viral load result,59,369,1.97
sex hormones,37,232,1.97
family member,98,613,1.97
gene-based testing,11,69,1.97
electronic,69,432,1.97
sober,50,313,1.97
nociceptin,27,169,1.97
food or food product,120,752,1.97
endoplasmic reticulum,27,169,1.97
racial group,172,1075,1.97
da neuron,353,2213,1.97
dopamine neuron,353,2213,1.97
dopaminergic neuron,353,2213,1.97
comprehension,21,132,1.96
cardiac disorders,71,447,1.96
phospholipids,20,126,1.96
cardiac diseases,71,447,1.96
reinforcement schedule,47,295,1.96
surface,152,955,1.96
latino,38,239,1.96
heart diseases,71,447,1.96
hydrogen oxide,95,598,1.96
single crystal diffraction,14,88,1.96
x ray crystallographies,14,88,1.96
molecular and cellular biology,14,88,1.96
gp120(hiv),13,82,1.96
fos protein,10,63,1.96
oxidation,24,151,1.96
cytochrome p-450,23,145,1.96
cytochrome p-450 enzyme system,23,145,1.96
htlv-iii gp120,13,82,1.96
gp120,13,82,1.96
gp120 env glycoprotein,13,82,1.96
panic,10,63,1.96
health care quality,18,113,1.96
compulsive behavior,46,290,1.96
p450,23,145,1.96
ethyl alcohol,339,2148,1.95
water,95,600,1.95
randomized trial,176,1114,1.95
brain tumors,15,95,1.95
pharmacological treatment,210,1329,1.95
brain neoplasms,15,95,1.95
brain neoplasia,15,95,1.95
posttranslational modifications,53,336,1.95
childhood abuse,15,95,1.95
trait,256,1619,1.95
equilibrium,239,1515,1.95
tumors in the brain,15,95,1.95
oxidative stress,63,398,1.95
balance function,239,1515,1.95
tlr protein,22,139,1.95
alcoholic intoxication,59,373,1.95
toll-like receptors,22,139,1.95
in vitro testing,19,120,1.95
syringe sharing,24,152,1.95
basal ganglia,113,716,1.95
heart disorder,71,448,1.95
spinal nerves,12,76,1.95
motor neurons,18,114,1.95
cooking,15,95,1.95
choice behavior,50,318,1.94
ethanol dependence,104,661,1.94
mitogen-activated protein kinase gene,27,172,1.94
drunken driving,11,70,1.94
ethanol dependency,104,661,1.94
testosterone,25,159,1.94
cingulate cortex,118,750,1.94
alcohol influenced driving,11,70,1.94
balance,239,1519,1.94
electronic medical record,36,229,1.94
drunk driving,11,70,1.94
mapk,27,172,1.94
corpus striatum,606,3847,1.94
university student,85,539,1.94
cellular imaging,19,121,1.94
cell imaging,19,121,1.94
extracellular signal-regulated kinase gene,27,172,1.94
ethanol addiction,104,661,1.94
homologous serum hepatitis virus,11,70,1.94
map kinase gene,27,172,1.94
craving,731,4640,1.94
buccal cavity,19,121,1.94
ethanol influenced driving,11,70,1.94
receptor protein,1056,6729,1.94
growth factor,32,203,1.94
e coli,10,64,1.93
ethnography,24,153,1.93
intracranial central nervous system disorders,147,938,1.93
primates mammals,84,536,1.93
clinical pharmacology,18,115,1.93
ethnographic,24,153,1.93
men,300,1913,1.93
obesity treatment,16,102,1.93
bdnf/nt-3 growth factors receptor,13,83,1.93
homologous recombination,10,64,1.93
bdnf receptor,13,83,1.93
long-term study,217,1389,1.93
neurotrophic tyrosine kinase receptor type 2,13,83,1.93
protein modification,53,339,1.93
middle school,26,166,1.93
trkb(gp145) protein,13,83,1.93
gp145-trkb,13,83,1.93
proteins,812,5193,1.93
abstinence,866,5540,1.93
research proposals,123,785,1.93
ntrk2 receptor,13,83,1.93
trkb tyrosine kinase,13,83,1.93
oklahoma,13,83,1.93
drug addiction therapy,10,64,1.93
crh1 receptor,23,147,1.93
compare efficacy,55,352,1.93
cognitive change,16,102,1.93
sensitivity and specificity,29,185,1.93
crf receptor type 1,23,147,1.93
pharmacokinetics,336,2146,1.93
encephalon diseases,147,938,1.93
somesthetic sensory cortex,15,96,1.93
crf1 receptor,23,147,1.93
crh-1,23,147,1.93
corticotropin-releasing factor receptor 1,23,147,1.93
comparative efficacy,55,352,1.93
brain diseases,147,938,1.93
foster care,16,102,1.93
supervision,118,754,1.93
signal pathway,330,2114,1.93
noncompliant,13,83,1.93
noncompliance,13,83,1.93
non-compliant,13,83,1.93
virus replication,18,115,1.93
non-compliance,13,83,1.93
morphine,455,2911,1.93
crf-r1,23,147,1.93
cognitive training,10,64,1.93
intracranial cns disorders,147,938,1.93
fret,20,128,1.93
longitudinal studies,217,1389,1.93
interest,994,6359,1.93
social support network,154,984,1.93
myelination,12,77,1.92
twenty-one year old,27,173,1.92
endogenous cannabinoids,112,721,1.92
21 year old,27,173,1.92
literacy,19,122,1.92
binding proteins,68,437,1.92
manuals,152,975,1.92
protein complex,43,276,1.92
opioid peptide,60,385,1.92
occupations,59,379,1.92
advertisements,26,167,1.92
opiate peptides,60,385,1.92
cytoplasmic membrane,113,727,1.92
hiv/aids prevention,106,682,1.92
plasma membrane,113,727,1.92
neutrophin,29,186,1.92
knock-in,48,309,1.92
hiv prevention,106,682,1.92
aids prevention,106,682,1.92
desensitization,86,553,1.92
plasmalemma,113,727,1.92
neurosciences research,82,528,1.92
brain disorders,147,942,1.92
nanoscale,15,97,1.91
world health organization,40,258,1.91
nano meter scale,15,97,1.91
corticotropin releasing hormone,100,645,1.91
corticotropin-releasing hormone-41,100,645,1.91
ghrelin,17,110,1.91
nano meter sized,15,97,1.91
crf-41,100,645,1.91
pennsylvania,58,374,1.91
corticoliberin,100,645,1.91
menstrual proliferative phase,13,84,1.91
aging effect,17,110,1.91
preovulatory phase,13,84,1.91
nanometer scale,15,97,1.91
age effect,17,110,1.91
continuing education,15,97,1.91
nanometer sized,15,97,1.91
pharmacophore,40,258,1.91
multimedium,22,142,1.91
corticotropin-releasing factor,100,645,1.91
corticotropin-releasing factor-41,100,645,1.91
multimedia,22,142,1.91
social network,86,554,1.91
rna,208,1345,1.91
acth-releasing factor,100,645,1.91
crystallographies,11,71,1.91
behavioral research,45,291,1.91
protein binding,68,439,1.91
arousal,120,773,1.91
psychiatric diagnosis,19,123,1.91
vietnam,20,129,1.91
street drugs,11,71,1.91
hypertension,68,438,1.91
cornu ammonis,338,2191,1.9
modification,332,2150,1.9
nucleus accumbens,811,5257,1.9
alzheimer syndrome,158,1027,1.9
hippocampal,338,2193,1.9
ammon horn,338,2191,1.9
water pipe,18,117,1.9
waterpipe,18,117,1.9
muscarinic acetylcholine receptor,20,130,1.9
motor output,14,91,1.9
hookah,18,117,1.9
progenitor,26,169,1.9
alzheimer sclerosis,158,1027,1.9
stress tests,12,78,1.9
cell biology,64,415,1.9
jail,45,292,1.9
primary senile degenerative dementia,158,1027,1.9
catabolism,10,65,1.9
clinical epidemiology,10,65,1.9
senior scientist,24,156,1.9
dimer,27,175,1.9
alzheimers dementia,158,1027,1.9
national clinical trials network,10,65,1.9
senile dementia of the alzheimer type,158,1027,1.9
employment,101,656,1.9
primary degenerative dementia,158,1027,1.9
hiv infections,223,1452,1.89
substance withdrawal syndrome,40,261,1.89
vector,61,399,1.89
suprarenal gland,31,202,1.89
adrenals,31,202,1.89
cost effectiveness,155,1013,1.89
alzheimer's,158,1030,1.89
cities,98,638,1.89
medical complication,24,157,1.89
tennessee,21,137,1.89
mechanistic target of rapamycin,15,98,1.89
withdrawal syndrome,40,261,1.89
impulsivity,251,1638,1.89
neurotrophin,29,189,1.89
hdac,23,150,1.89
histone deacetylase,23,150,1.89
hdac proteins,23,150,1.89
motivational interview,117,766,1.88
meks,16,105,1.88
protein blotting,113,743,1.88
individual differences,265,1743,1.88
clinical practice guideline,37,243,1.88
drosophila genus,56,367,1.88
motivational enhancement therapy,117,766,1.88
series,525,3449,1.88
genetic markers,45,296,1.88
western immunoblotting,113,743,1.88
gene variant,170,1114,1.88
guanosinetriphosphatases,25,164,1.88
allelic variant,170,1114,1.88
travel,95,628,1.87
fasting,17,112,1.87
weight increase,31,204,1.87
wt gain,31,204,1.87
acids,34,224,1.87
guanosinetriphosphatase,25,165,1.87
alcohol reward,52,343,1.87
ethanol reward,52,343,1.87
carbon monoxide,40,264,1.87
body weight increase,31,204,1.87
body weight gain,31,204,1.87
raft1,15,99,1.87
mirna,68,449,1.87
nh2-terminal,31,204,1.87
micro rna,68,449,1.87
virginia,34,224,1.87
african,28,185,1.87
substances of abuse,41,270,1.87
substance of abuse,41,270,1.87
outpatients,254,1672,1.87
acoustic,18,119,1.87
nrsa,31,204,1.87
n-terminal,31,204,1.87
frap2,15,99,1.87
out-patients,254,1672,1.87
practice-based research network,27,178,1.87
national research service awards,31,204,1.87
remediation,17,112,1.87
frap1,15,99,1.87
frap1 gene,15,99,1.87
psychology,109,719,1.87
emerogenes,14,93,1.86
stem cells,52,345,1.86
antioncogenes,14,93,1.86
anti-oncogenes,14,93,1.86
parent offspring interaction,28,186,1.86
new york city,32,212,1.86
benzodiazepines,88,584,1.86
density,221,1465,1.86
tumor suppressing genes,14,93,1.86
oncogenes-tumor suppressors,14,93,1.86
corpulence,175,1159,1.86
health tutoring,36,239,1.86
calcium channel blocker receptors,22,146,1.86
aftercare,229,1521,1.86
magazine,107,710,1.86
adiposity,175,1159,1.86
health instruction,36,239,1.86
after care,229,1521,1.86
calcium ion channels,22,146,1.86
progenitor cells,52,344,1.86
active follow-up,650,4307,1.86
magnetic resonance imaging,250,1655,1.86
micrornas,68,450,1.86
journals,107,711,1.86
rare allele,14,93,1.86
expectation,134,887,1.86
oncosuppressor gene,14,93,1.86
treatment period,77,511,1.86
treatment days,77,511,1.86
rare variant,14,93,1.86
placebo control,116,768,1.86
treatment duration,77,511,1.86
follow-up,650,4307,1.86
after-treatment,229,1521,1.86
phase 1 trial,23,153,1.85
age dependent,57,381,1.85
clozapine,26,173,1.85
age related,57,381,1.85
metabotropic glutamate receptors,45,300,1.85
neuropathology,56,373,1.85
diamorphine overdose,12,80,1.85
information gathering,21,140,1.85
neurogenesis,47,314,1.85
heroin overdose,12,80,1.85
deoxyephedrine,253,1686,1.85
k channel,38,254,1.85
seminal,40,266,1.85
voltage,79,528,1.85
n-methylamphetamine,253,1686,1.85
methylamphetamine,253,1686,1.85
injections,400,2667,1.85
desoxyephedrine,253,1686,1.85
leukocytes reticuloendothelial system,15,100,1.85
postsynaptic,195,1297,1.85
crystal meth,253,1686,1.85
lymphocytic,21,140,1.85
magnetic field,15,100,1.85
anatomic,138,926,1.84
bipolar affective psychosis,58,388,1.84
manic-depressive psychosis,58,388,1.84
extended care,13,87,1.84
long-term care,13,87,1.84
transgenic model,10,67,1.84
weight gain,31,208,1.84
data mining,17,114,1.84
datamining,17,114,1.84
preoptic region,10,67,1.84
respiratory inspiration,57,382,1.84
respiratory aspiration,57,382,1.84
cardiac,56,375,1.84
anatomical sciences,138,925,1.84
psychophysical,28,188,1.84
prodynorphin,13,87,1.84
asthma,34,228,1.84
neuroreceptors,17,114,1.84
bronchial asthma,34,228,1.84
alzheimer's disease,158,1058,1.84
drug maintenance,10,67,1.84
cross-over studies,14,94,1.84
crossover studies,14,94,1.84
treatment schedule,107,716,1.84
mrna,217,1451,1.84
treatment regimen,107,716,1.84
emotional disorder,14,94,1.84
levarterenol,108,728,1.83
levonorepinephrine,108,728,1.83
comprehensive care,12,81,1.83
antianxiety agent,62,418,1.83
heroin,368,2481,1.83
messenger rna,217,1465,1.83
varenicline,81,546,1.83
metabolic networks,19,128,1.83
phosphoric monoester hydrolases,22,148,1.83
weight control,18,121,1.83
intraperitoneal,15,101,1.83
ethanol response,149,1006,1.83
happiness,16,108,1.83
phosphomonoesterases,22,148,1.83
phosphohydrolases,22,148,1.83
phosphatases,22,148,1.83
human tissue,47,317,1.83
dextrose,44,296,1.83
laboratories,958,6453,1.83
response to alcohol,149,1006,1.83
response to ethanol,149,1006,1.83
noradrenaline,108,728,1.83
health science profession,11,74,1.83
drug sensitivity,18,121,1.83
dopaminergic cell,15,101,1.83
alcohol response,149,1006,1.83
biochemical pathway,19,128,1.83
photoradiation,385,2592,1.83
air,45,304,1.83
visual,100,673,1.83
c.elegans,40,271,1.82
readiness,90,611,1.82
human immunodeficiency virus 1,67,453,1.82
sorting,48,326,1.82
preparedness,90,611,1.82
marihuana,173,1175,1.82
social functioning,36,244,1.82
ethanol reinforcement,36,244,1.82
event related potential,29,197,1.82
maintenance,512,3463,1.82
hepatitus c,70,475,1.82
preventional intervention strategy,189,1280,1.82
alcohol reinforcement,36,244,1.82
preventive intervention,189,1280,1.82
fra(x)(28) syndrome,16,109,1.81
renpenning syndrome 2,16,109,1.81
longterm effects,98,668,1.81
autism-fragile x (afrax) syndrome,16,109,1.81
mental retardation-macroorchidism syndrome,16,109,1.81
fra(x) syndrome,16,109,1.81
biochemistry,69,471,1.81
lung disorder,41,280,1.81
fmri,358,2434,1.81
pulmonary disorder,41,280,1.81
pulmonary diseases,41,280,1.81
c elegans,40,272,1.81
fra(x)(q27) syndrome,16,109,1.81
fra(x)(q27-28) syndrome,16,109,1.81
behavior conditioning therapy,419,2854,1.81
behavioral intervention,419,2854,1.81
marijuana,173,1178,1.81
training project,15,102,1.81
martin-bell syndrome,16,109,1.81
fragile x syndrome,16,109,1.81
fragile x,16,109,1.81
x-linked mental retardation with fragile x syndrome,16,109,1.81
x-linked mental retardation-fragile site 1 syndrome,16,109,1.81
conditioning therapy,419,2854,1.81
behavioral treatment,419,2854,1.81
behavior intervention,419,2854,1.81
behavioral therapy,419,2854,1.81
behavioral modification,419,2854,1.81
behavioral conditioning therapy,419,2854,1.81
escalante syndrome,16,109,1.81
behavior treatment,419,2854,1.81
martin-bell-renpenning syndrome,16,109,1.81
x-linked mental deficiency-megalotestes syndrome,16,109,1.81
fragile xq syndrome,16,109,1.81
fragile x-mental retardation syndrome,16,109,1.81
adolescent youth,521,3552,1.81
population group,10,68,1.81
motor vehicle accident,10,68,1.81
allostases,11,75,1.81
blood alcohol level,36,245,1.81
motor carrier accident,10,68,1.81
blood alcohol concentration,36,245,1.81
blood alcohol level measurement,36,245,1.81
juvenile,521,3552,1.81
vehicular accident,10,68,1.81
clinical trials network,131,895,1.81
juvenile human,521,3552,1.81
metabotropic glutamate receptor 2,17,116,1.81
blood alcohol content,36,245,1.81
marker x syndrome,16,109,1.81
mar(x) syndrome,16,109,1.81
mglur2,17,116,1.81
macro-orchidism-marker x syndrome,16,109,1.81
allostasis,11,75,1.81
hostility,10,68,1.81
neurologic organ system,167,1138,1.81
immunosuppressants,10,68,1.81
cognitive neuroscience,46,313,1.81
fragile site mental retardation 1,16,109,1.81
early adolescence,39,266,1.81
drug reward,132,898,1.81
macro-orchidism-marker x (momx) syndrome,16,109,1.81
mesolimbic dopamine system,86,586,1.81
immunosuppressive agents,10,68,1.81
mesolimbic system,86,586,1.81
neurologic body system,167,1138,1.81
students,245,1675,1.8
health behavior change,22,151,1.8
neurodegenerative diseases,97,663,1.8
neurodegenerative illness,97,663,1.8
neurologic degenerative conditions,97,663,1.8
immunoglobulin enhancer-binding protein,19,130,1.8
followup studies,34,233,1.8
transcription factor nf-kb,19,130,1.8
imaging techniques,105,721,1.8
follow-up studies,34,233,1.8
obesity,175,1201,1.8
radius,12,82,1.8
degenerative neurologic disorders,97,663,1.8
antioxidants,31,212,1.8
neurodegenerative disorders,97,663,1.8
nf-kb,19,130,1.8
molecular models,29,199,1.8
glucose,44,301,1.8
imaging procedures,105,721,1.8
nuclear factor kappa b,19,130,1.8
membrane potentials,30,206,1.8
controlled study,31,212,1.8
nuclear transcription factor nf-kb,19,130,1.8
nfkb,19,130,1.8
event-related potentials,29,199,1.8
deprivation,53,364,1.8
process measure,24,164,1.8
systems analyses,14,96,1.8
deep sequencing,14,96,1.8
nf-kappab,19,130,1.8
systems analysis,14,96,1.8
nf-kappa b,19,130,1.8
regular insulin,22,151,1.8
kappa b enhancer binding protein,19,130,1.8
tumor suppressor genes,14,96,1.8
functional magnetic resonance imaging,358,2458,1.8
drops,77,531,1.79
neurological function,39,269,1.79
nervous system physiology,39,269,1.79
intravenous infusion,11,76,1.79
lung diseases,41,282,1.79
neurologic function,39,269,1.79
nervous system function,39,269,1.79
eating disorders,50,344,1.79
communicable disease transmission,21,145,1.79
diabetic,10,69,1.79
eating,116,801,1.79
bioethics,10,69,1.79
beverages,17,117,1.79
auditory,26,179,1.79
psychiatrist,53,366,1.79
drug use disorder,76,523,1.79
molecular modeling nucleic acid biochemistry,29,200,1.79
molecular modeling protein/amino acid biochemistry,29,200,1.79
transphosphorylases,136,937,1.79
patient adherence,38,262,1.79
phosphotransferases,136,938,1.79
patient compliance,38,262,1.79
cognitive therapy,171,1178,1.79
kinases,136,937,1.79
patient cooperation,38,262,1.79
d1 receptor,89,613,1.79
letters,91,627,1.79
dopamine d1 receptor,89,613,1.79
corticotropin-releasing hormone,100,689,1.79
dendritic spines,87,602,1.78
serum hepatitis,14,97,1.78
achievement mainstream education,34,235,1.78
molecular imaging,25,173,1.78
societies,426,2952,1.78
animal tissue,13,90,1.78
prescription opioid abuse,48,333,1.78
cognitive deficits,125,866,1.78
computerized,66,457,1.78
smoking history,24,166,1.78
conscious,35,243,1.78
parole,19,132,1.78
gold,66,457,1.78
klofenil,17,118,1.78
predisposing factor,30,208,1.78
names,88,610,1.78
radiology,17,118,1.78
restraint stress,12,83,1.78
light,385,2664,1.78
viral hepatitis b,14,97,1.78
cholinergic,98,679,1.78
interpersonal relations,19,132,1.78
dendrite spine,87,602,1.78
dyskinesia syndromes,26,181,1.77
cognition disorders,24,167,1.77
arizona,20,139,1.77
movement disorder syndromes,26,181,1.77
movement disorders,26,181,1.77
disease recurrence prevention,144,1005,1.77
intervention program,60,419,1.77
signaling molecule,67,468,1.77
behavioral measure,122,849,1.77
long-term synaptic depression,46,320,1.77
motor,195,1357,1.77
adrenal glands,31,216,1.77
genetically engineered mouse,25,174,1.77
scaffolding protein,27,188,1.77
d-glucose,44,306,1.77
behavior measurement,122,849,1.77
behavioral measurement,122,849,1.77
psychophysiological,50,349,1.77
physiopsychology,50,349,1.77
psycho-physiological,50,349,1.77
euphoria,46,320,1.77
recurrence prevention,144,1005,1.77
equation,62,433,1.77
cell differentiation,24,168,1.76
service intervention,16,112,1.76
instrument,106,743,1.76
illinois,19,133,1.76
electrical stimulation,45,316,1.76
supplementation,24,168,1.76
tracer,65,455,1.76
vigilance,11,77,1.76
genetic condition,17,119,1.76
learning extinction,33,231,1.76
instruction,111,777,1.76
hbv,11,77,1.76
hepatitis b virus,11,77,1.76
nucleic acid regulator regions,22,154,1.76
double-blind method,187,1307,1.76
nucleic acid regulatory sequences,22,154,1.76
double-blind study,187,1307,1.76
double-blinded,187,1307,1.76
double-masked method,187,1307,1.76
double-masked study,187,1307,1.76
copy number polymorphism,10,70,1.76
body weight,36,252,1.76
copy number variation,10,70,1.76
cognition,342,2397,1.76
defect,87,608,1.76
longitudinal surveys,12,84,1.76
disorder management,39,275,1.75
occupational,39,275,1.75
brain-derived neurotrophic factor,70,494,1.75
urine,216,1518,1.75
negative mood,33,232,1.75
network-based,30,211,1.75
social context,86,607,1.75
postpartum,28,197,1.75
social climate,86,607,1.75
genetic diseases,17,120,1.75
lesion,137,963,1.75
bdnf,70,494,1.75
social environment,86,607,1.75
immunity,20,141,1.75
disease management,39,275,1.75
endocannabinoids,112,789,1.75
moods,222,1562,1.75
neuroeconomics,20,141,1.75
wages,32,225,1.75
salaries,32,225,1.75
molecular marker,32,225,1.75
adolescence (12-20),338,2393,1.74
chromosome mapping,38,269,1.74
treatment organization,11,78,1.74
gene localization,38,269,1.74
sum,71,503,1.74
tobacco abstinence,35,248,1.74
peer pressure,10,71,1.74
length,137,972,1.74
perinatal exposure,14,99,1.74
circulation,33,234,1.74
crosslink,21,149,1.74
embryo,42,298,1.74
quit line,37,263,1.74
quitline,37,263,1.74
k24 award,20,142,1.74
mid-career clinical scientist award (k24),20,142,1.74
cell membrane,113,799,1.74
bulimia,10,71,1.74
feeding,111,789,1.74
naltrexone,236,1675,1.74
burden of illness,63,446,1.74
embryonic,42,297,1.74
conflict (psychology),108,764,1.74
disease burden,63,446,1.74
sti/hiv,12,85,1.74
cigarette smoking,250,1771,1.74
hiv/sti,12,85,1.74
burden of disease,63,446,1.74
hiv/std,12,85,1.74
quebrachine,12,85,1.74
corynine,12,85,1.74
std/hiv,12,85,1.74
problem solving,49,349,1.73
electrodes,60,428,1.73
florida,43,307,1.73
self-administered,358,2556,1.73
etoh,339,2423,1.73
absolute ethanol,339,2423,1.73
theoretic models,42,299,1.73
cannabinoids,141,1003,1.73
grain alcohol,339,2423,1.73
anxiety disorders,141,1006,1.73
conflict,108,768,1.73
consciousness,35,250,1.73
methylcarbinol,339,2423,1.73
lymph cell,17,121,1.73
cluster analysis,14,100,1.73
exploratory developmental study,15,107,1.73
muscarinics,14,100,1.73
baltimore,34,242,1.73
cluster analyses,14,100,1.73
il1,13,93,1.72
interleukin i,13,93,1.72
inclusion criteria,13,93,1.72
tuberculous spondyloarthropathy,11,79,1.72
il-1,13,93,1.72
interleukin-1,13,93,1.72
disseminated tuberculosis,11,79,1.72
disseminated tb,11,79,1.72
relative risks,13,93,1.72
ingestive behavior,31,222,1.72
typology,12,86,1.72
lymphocyte-stimulating hormone,13,93,1.72
t helper factor,13,93,1.72
dependovirus,34,244,1.72
control groups,175,1252,1.72
geographic state,11,79,1.72
time interval,12,86,1.72
macrophage cell factor,13,93,1.72
lymphocyte activating factor,13,93,1.72
dimerization,18,129,1.72
protein dimerization,18,129,1.72
therapeutic agents,87,623,1.72
drug user,131,941,1.72
dynorphins,81,581,1.72
psychological reinforcement,409,2927,1.72
adeno-associated viruses,34,244,1.72
motivational intervention,16,115,1.72
voice,38,273,1.72
anticancer research,18,130,1.71
anti-retroviral,46,332,1.71
hormonal,57,410,1.71
follicular phase,13,94,1.71
esteroproteases,20,144,1.71
proteases,20,144,1.71
proteinases,20,144,1.71
proteolytic enzymes,20,144,1.71
gene repression,15,108,1.71
transcriptional repression,15,108,1.71
gene down-regulation,15,108,1.71
san francisco,36,259,1.71
spinal fluid,23,166,1.71
antibodies,121,875,1.71
client,124,894,1.71
adeno associated virus group,34,245,1.71
transcription repression,15,108,1.71
peptide hydrolases,20,144,1.71
anti-retroviral agents,46,332,1.71
gustation,52,376,1.71
taste perception,52,376,1.71
preventive,52,374,1.71
human study,26,188,1.71
drug evaluation,11,80,1.7
nicotine replacement therapy,113,820,1.7
needle sharing,24,174,1.7
coagulation factor i,16,116,1.7
coagulation factor one,16,116,1.7
macaque,28,203,1.7
factor i,16,116,1.7
synapse formation,42,305,1.7
blood coagulation factor i,16,116,1.7
blood coagulation factor one,16,116,1.7
factor one,16,116,1.7
law enforcement,21,152,1.7
glycosylation,11,80,1.7
blood factor one,16,116,1.7
cannabis sativa,12,87,1.7
cognitive behavior intervention,171,1242,1.7
cannabis sativa plant,12,87,1.7
expectancy,68,494,1.7
meetings,497,3616,1.7
cognitive behavioral therapy,171,1242,1.7
cognitive behavior modification,171,1242,1.7
cognitive behavioral modification,171,1242,1.7
fibrinogen,16,116,1.7
cognitive behavioral intervention,171,1242,1.7
transcription activation,18,131,1.69
ubiquitilation,13,95,1.69
transcriptional activation,18,131,1.69
prevention intervention,189,1377,1.69
extracellular,225,1645,1.69
5 cyclic amp synthetase,37,270,1.69
ubiquitination,13,95,1.69
adenylyl cyclase,37,270,1.69
adenyl cyclase,37,270,1.69
ubiquitinoylation,13,95,1.69
serious mental illness,30,219,1.69
cigarette,284,2078,1.69
biologic assays,561,4103,1.69
hypothermia,19,139,1.69
severe mental illness,30,219,1.69
ubiquitin conjugation,13,95,1.69
ubiquination,13,95,1.69
drug delivery,87,634,1.69
united states substance abuse and mental health services administration,75,549,1.68
mainstreaming,34,250,1.68
cytotoxic,15,110,1.68
nci organization,14,103,1.68
comparative effectiveness,56,411,1.68
national cancer institute,14,103,1.68
educational mainstreaming,34,250,1.68
heroin users,18,132,1.68
neural plasticity,237,1743,1.68
phase 3 clinical trials,15,110,1.68
schedule,208,1523,1.68
substance abuse and mental health services administration,75,549,1.68
factor analyses,25,183,1.68
factor analysis,25,183,1.68
cost savings,20,147,1.68
samhsa,75,549,1.68
mutate,62,454,1.68
mammalian target of rapamycin,15,110,1.68
cognitive behavior therapy,171,1259,1.68
child behavior,16,118,1.67
chlorides,10,74,1.67
preoptic areas,10,74,1.67
positive emotional state,10,74,1.67
cyclic amp,103,759,1.67
positive emotion,10,74,1.67
n methyl d aspartic acid,93,693,1.66
coping,150,1114,1.66
outcome measure,174,1291,1.66
radial,12,89,1.66
amino acids,77,572,1.66
multimodal imaging,21,156,1.66
high school,73,543,1.66
nmda,93,693,1.66
n-methyl-d-aspartate,93,693,1.66
hippocampus,338,2511,1.66
case management,29,216,1.66
reactive site,112,832,1.66
molecular probes,18,134,1.66
n methyl d aspartate,93,693,1.66
body weight decreased,30,223,1.66
combining site,112,832,1.66
endocrine gland secretion,96,712,1.66
feeding behaviors,31,231,1.66
molecular biology,80,595,1.66
wt-loss,30,223,1.66
body weight loss,30,223,1.66
fruit fly,56,417,1.66
therapeutic hormone,96,712,1.66
weight reduction,30,223,1.66
patient oriented study,56,417,1.66
feeding-related behaviors,31,231,1.66
white blood corpuscle,15,112,1.65
blood leukocyte,15,112,1.65
methamphetamine,253,1895,1.65
neuroanatomy,79,592,1.65
cerebrocirculation,19,142,1.65
disadvantaged,59,440,1.65
cerebral blood flow,19,142,1.65
marrow leukocyte,15,112,1.65
white blood cells,15,112,1.65
postsynaptic membrane,11,82,1.65
dendrites,67,502,1.65
white cell,15,112,1.65
fore-brain,80,599,1.65
genehomolog,39,291,1.65
white blood cell,15,112,1.65
empathy,11,82,1.65
forebrain,80,599,1.65
treatment failure,22,164,1.65
cocaine exposure,146,1091,1.65
homolog,39,291,1.65
exposed to cocaine,146,1091,1.65
homologous gene,39,291,1.65
exposure to cocaine,146,1091,1.65
homologue,39,291,1.65
cocaine-exposed,146,1091,1.65
reconstitution,31,232,1.65
cerebrovascular circulation,19,142,1.65
hormones,96,717,1.65
nuclear factor kappa beta,19,142,1.65
mammalian cell,29,217,1.65
synaptic vesicles,26,194,1.65
morphogenesis,11,82,1.65
health care service utilization,90,673,1.65
natural history,30,224,1.65
reconstitute,31,232,1.65
gender,303,2270,1.65
nicotine dependence,419,3141,1.65
structural models,21,158,1.64
gene family,14,105,1.64
behavior modification,419,3145,1.64
breathing,57,429,1.64
binding sites,112,842,1.64
agonist,582,4371,1.64
efficacy research,12,90,1.64
protein purification,12,90,1.64
caenorhabditis elegans,40,300,1.64
drosophila,64,481,1.64
drug controls,43,324,1.64
protein protein interaction,51,383,1.64
selective serotonin re-uptake inhibitor,21,158,1.64
serotonin reuptake inhibitor,21,158,1.64
dc washington,16,120,1.64
selective serotonin reuptake inhibitor,21,158,1.64
systems research,10,75,1.64
hepatic,53,399,1.64
ssri,21,158,1.64
speech,10,75,1.64
ventral striatum,150,1128,1.64
los angeles,30,225,1.64
d.c. washington,16,120,1.64
circadian,45,338,1.64
combination therapy,95,715,1.64
bipolar affective disorder,58,438,1.63
judgment,23,174,1.63
plant roots,42,318,1.63
patient training,11,83,1.63
metabolism of toxic agents,77,583,1.63
manic depressive disorder,58,438,1.63
patient instruction,11,83,1.63
tyrosine hydroxylase,34,257,1.63
ampa receptors,77,583,1.63
patient education,11,83,1.63
gene delivery,22,166,1.63
flavoring,30,227,1.63
bipolar disorder,58,438,1.63
tyrosine 3-monooxygenase,34,257,1.63
electrochemistry,20,151,1.63
fractionation,11,83,1.63
mouse strains,41,310,1.63
rat strains,11,83,1.63
root,42,318,1.63
flavoring agents,30,227,1.63
nicotine withdrawal,101,762,1.63
stream,33,249,1.63
manic depressive illness,58,438,1.63
metabolic drug detoxications,77,583,1.63
genetic screening,41,310,1.63
nimh,87,661,1.62
racial and ethnic disparities,11,84,1.62
erk1,10,76,1.62
aminoacid,77,587,1.62
mapk3 gene,10,76,1.62
mitogen-activated protein kinase 3 gene,10,76,1.62
mapk3,10,76,1.62
national institute of mental health,87,661,1.62
nci scholars program,10,76,1.62
p44erk1,10,76,1.62
pituitary nervous system,25,190,1.62
early therapy,40,305,1.62
neuropsychiatry,138,1050,1.62
isocortex,15,114,1.62
homotypical cortex,15,114,1.62
neopallium,15,114,1.62
weight loss,30,229,1.62
enantiomer,16,122,1.62
costs and benefits,37,281,1.62
neuropsychiatric,138,1050,1.62
blood - brain barrier anatomy,84,643,1.61
transgenes,26,199,1.61
policy implication,14,107,1.61
2-arachidonylglycerol,30,230,1.61
c-terminal,27,207,1.61
2-arachidonyl-glycerol,30,230,1.61
2-arachidonoylglycerol,30,230,1.61
2-arachidonoyl-glycerol,30,230,1.61
high speed liquid chromatography,30,230,1.61
tobacco smoke,47,361,1.61
high pressure liquid chromatography,30,230,1.61
blood-brain barrier,84,643,1.61
scanning,182,1394,1.61
cocaine use,213,1628,1.61
endophenotype,57,436,1.61
hemato-encephalic barrier,84,643,1.61
developmental process,21,161,1.61
substance abuse control,23,176,1.61
vdcc,22,169,1.61
genetic analyses,81,619,1.61
genetic analysis,81,619,1.61
human volunteers,17,130,1.61
rhesus monkey,63,482,1.61
rhesus macaque,63,482,1.61
tobacco dependence,160,1228,1.61
calcium channel antagonist receptor,22,169,1.61
fluorescence resonance energy transfer,20,153,1.61
novolin r,22,169,1.61
voltage-dependent calcium channels,22,169,1.61
software tools,12,92,1.61
therapy research,18,138,1.61
therapeutic studies,18,138,1.61
humulin r,22,169,1.61
substance abuse prevention,23,176,1.61
5-ht2c receptor,13,100,1.6
5-hydroxytryptamine type 2c receptors,13,100,1.6
serotonin 2c receptor,13,100,1.6
drug dependence,964,7441,1.6
acamprostate,33,255,1.6
n-acetylhomotaurine,33,255,1.6
counselor,71,546,1.6
compliance behavior,34,262,1.6
ecology,17,131,1.6
professional counselor,71,546,1.6
antismoking,14,108,1.6
spleen,11,85,1.6
morphometry,17,131,1.6
whole blood,11,85,1.6
effectiveness of interventions,63,486,1.6
mind control,22,170,1.6
5-ht(2c) receptor,13,100,1.6
hiv envelope protein gp120,13,100,1.6
excitatory synapse,52,400,1.6
hydrolase,10,77,1.6
peer influence,23,178,1.59
spectrum analyses,24,186,1.59
hydroxytyramine,719,5592,1.59
brain damage,60,464,1.59
glycine receptors,13,101,1.59
discounting,83,644,1.59
brain injuries,60,464,1.59
acquired brain injury,60,464,1.59
long-term effects,98,760,1.59
vascular,49,379,1.59
candidate disease gene,146,1139,1.58
pain threshold,35,274,1.58
candidate gene,146,1139,1.58
minority,149,1161,1.58
parkinsonian disorders,11,86,1.58
parkinsonian,11,86,1.58
colon carcinoma,10,78,1.58
western blotting,113,883,1.58
computer aided,33,258,1.58
computer assisted,33,258,1.58
glucuronides,14,109,1.58
parkinsonian syndrome,11,86,1.58
parkinsonism,11,86,1.58
pharmaceutic industry,15,117,1.58
parkinsonian diseases,11,86,1.58
parkinsonian condition,11,86,1.58
crystallization,29,228,1.57
hycon,22,173,1.57
hydrocodone,22,173,1.57
anti-hiv positivity,42,330,1.57
double-blind placebo controlled trial,21,165,1.57
double-masked controlled trial,21,165,1.57
hiv positive,42,330,1.57
secondary prevention,14,110,1.57
htlv-iii seropositivity,42,330,1.57
nerve transmitter substances,335,2634,1.57
htlv-iii seroconversion,42,330,1.57
hiv seroconversion,42,330,1.57
hiv positivity,42,330,1.57
hiv seropositivity,42,330,1.57
dihydrocodeinone,22,173,1.57
hycodan,22,173,1.57
chemical structure function,93,735,1.56
neurology,17,134,1.56
technology transfer,40,317,1.56
isoforms,82,648,1.56
ischemia,13,103,1.56
neuroendocrine,54,428,1.56
genetic disorder,17,134,1.56
swimming,28,221,1.56
acamprosate,33,261,1.56
neurosecretory systems,54,428,1.56
half-cystine,24,190,1.56
preference,401,3173,1.56
gases,12,95,1.56
satellite centers,14,111,1.56
mutant,219,1730,1.56
cannabinoid receptor,80,633,1.56
psychotropic drugs,52,412,1.56
l-cysteine,24,190,1.56
memory loss,11,87,1.56
peptidases,20,158,1.56
appearance,24,190,1.56
productivity loss,17,135,1.55
endocrine,40,319,1.55
psychometrics,65,518,1.55
educational process of instructing,119,946,1.55
polyphagia,27,215,1.55
neurosteroids,19,151,1.55
granule cell,15,119,1.55
professor,91,724,1.55
neuroactive steroids,19,151,1.55
linear models,20,159,1.55
parenting behavior,65,518,1.55
hyperphagia,27,215,1.55
health behavior,89,707,1.55
emotional stimulus,19,151,1.55
therapy cooperation,33,262,1.55
treatment trial,31,249,1.54
eating behavior,20,160,1.54
externalizing behavior,22,176,1.54
spectroscopy,33,264,1.54
brain imaging,148,1185,1.54
acquired immunodeficiency syndrome,105,840,1.54
recycling,34,272,1.54
anti-smoking,14,112,1.54
twin multiple birth,61,489,1.54
pacific island americans,12,96,1.54
internal medicine,24,192,1.54
pacific islander american,12,96,1.54
acquired immune deficiency,105,840,1.54
schools,195,1559,1.54
parenting,65,521,1.54
hepatitis b,14,112,1.54
intravenous drug use,12,96,1.54
addictive behavior,189,1509,1.54
ions,32,256,1.54
teaching,119,953,1.54
empirical research,18,144,1.54
dopamine d3 receptor,19,152,1.54
physical abuse,14,113,1.53
artifacts,16,129,1.53
morphologic artifacts,16,129,1.53
physical maltreatment,14,113,1.53
potassium channel,40,323,1.53
early treatment,40,323,1.53
cortril,64,516,1.53
nutracort,64,516,1.53
hydrocortone,64,516,1.53
hydrocortisone,64,516,1.53
eldecort,64,516,1.53
dermacort,64,516,1.53
spectrum analysis,24,194,1.53
cortispray,64,516,1.53
clinical research,780,6288,1.53
cortenema,64,516,1.53
cortef,64,516,1.53
cort-dome,64,516,1.53
cetacort,64,516,1.53
aeroseb-hc,64,516,1.53
affinity,230,1859,1.53
proctocort,64,516,1.53
hytone,64,516,1.53
cerebrospinal fluid,23,186,1.53
splicing,38,308,1.52
psychostimulant,185,1502,1.52
parietal cortex,17,138,1.52
parietal lobe,17,138,1.52
protein isoforms,82,665,1.52
pharmaceutic preparations,2217,17966,1.52
dbgap,11,89,1.52
non-smoker,69,561,1.52
maintenance therapy,21,170,1.52
radio,10,81,1.52
acetylcholine receptors,26,211,1.52
prosencephalon,80,650,1.52
acquired immune deficiency syndrome,105,852,1.52
taste,52,421,1.52
behavior therapy,419,3406,1.52
brain visualization,148,1200,1.52
database of genotypes and phenotypes,11,89,1.52
colon cancer,10,81,1.52
eastern europe,10,81,1.52
ach receptors,26,211,1.52
prisons,46,374,1.52
adhesions,11,89,1.52
nonsmoker,69,561,1.52
transgenic animals,16,130,1.52
drd2,47,383,1.51
non a,70,573,1.51
dopamine receptor d2 gene,47,383,1.51
d2r gene,47,383,1.51
non b hepatitis,70,573,1.51
d2r,47,383,1.51
d2dr gene,47,383,1.51
drd2 gene,47,383,1.51
d(2) dopamine receptor gene,47,383,1.51
visual stimulus,22,180,1.51
d2dr,47,383,1.51
neural cell body,53,434,1.51
neuronal cell body,53,434,1.51
province,12,98,1.51
social group,12,98,1.51
muscimol receptors,11,90,1.51
parenterally-transmitted,70,573,1.51
gaba-benzodiazepine receptors,11,90,1.51
non-a,140,1146,1.51
treatment center,51,417,1.51
hepatitis non a non b,70,573,1.51
hepatitis c virus infection,70,573,1.51
non-b,70,573,1.51
hcv infection,70,573,1.51
theoretical model,42,342,1.51
information technology,13,106,1.51
synaptogenesis,42,342,1.51
abused drugs,550,4535,1.5
allosteric site,10,82,1.5
twins,61,500,1.5
nutritional,17,140,1.5
treatment planning,32,263,1.5
response time,42,345,1.5
drug of abuse,550,4535,1.5
socioenvironment,86,709,1.5
drugs abused,550,4535,1.5
response rt,42,345,1.5
on-line systems,106,870,1.5
multivariate analyses,13,107,1.5
reaction time,42,345,1.5
multivariate analysis,13,107,1.5
online systems,106,870,1.5
drugs of abuse,550,4535,1.5
ethanal,13,107,1.5
reuptake,55,451,1.5
web based,106,870,1.5
clinical services,18,148,1.5
gestational cigarette smoke exposure,10,82,1.5
prenatal tobacco smoke,10,82,1.5
fetal tobacco exposure,10,82,1.5
prenatal tobacco exposure,10,82,1.5
chromatin modification,18,148,1.5
prenatally tobacco exposed,10,82,1.5
d2 receptor,128,1059,1.49
aids test,39,322,1.49
macaca,28,232,1.49
drd2 receptor,128,1059,1.49
centrally acting drug,17,141,1.49
hiv test,39,322,1.49
dopamine d2 receptor,128,1059,1.49
aids/hiv test,39,322,1.49
twin studies,32,265,1.49
protein phosphorylation,157,1298,1.49
galanin,10,83,1.49
radiation,24,198,1.49
angry,16,132,1.49
psychoses,44,364,1.49
primary parkinsonism,171,1412,1.49
parkinson disease,171,1412,1.49
parkinson,171,1412,1.49
ward,10,83,1.49
phase 2 trial,27,224,1.49
human immunodeficiency virus test,39,322,1.49
smoking status,33,273,1.49
comparison group,47,390,1.49
blood flow,18,149,1.49
policy research,16,132,1.49
paralysis agitans,171,1412,1.49
skills training,38,315,1.49
probation,20,165,1.49
cerebral circulation,19,157,1.49
angers,16,132,1.49
autocrine,11,91,1.49
crh receptors,25,207,1.49
corticotropin-releasing hormone receptors,25,207,1.49
capsaicin,12,99,1.49
diet,67,554,1.49
crf receptors,25,207,1.49
autocrine systems,11,91,1.49
inspiration,57,476,1.48
genetic variation,113,939,1.48
health care model,12,100,1.48
soma,53,443,1.48
overeating,27,225,1.48
hydrogen ions,26,217,1.48
h+ element,26,217,1.48
youth drug use,21,175,1.48
salts,12,100,1.48
method development,50,417,1.48
genetic diversity,113,939,1.48
protons,26,217,1.48
protein dephosphorylation,13,108,1.48
dephosphorylation,13,108,1.48
adolescent drug use,21,175,1.48
ethanol,339,2824,1.48
screening result,14,117,1.48
smoking prevalence,60,501,1.48
cell division cycle,16,134,1.47
nicotine replacement,113,950,1.47
immediate memory,88,736,1.47
chemosensitization,79,661,1.47
signal processing,29,244,1.47
breeding,60,502,1.47
receptor function,162,1360,1.47
cease smoking,355,2984,1.47
youth risk behavior,10,84,1.47
adolescent risk behavior,10,84,1.47
drug delivery systems,87,730,1.47
taxes,20,168,1.47
quit smoking,355,2984,1.47
mid life,26,218,1.47
n-methylaspartate receptors,98,820,1.47
chemosensitization/potentiation,79,661,1.47
middle age,26,218,1.47
computer software tools,12,101,1.47
juice,11,92,1.47
potentiation,79,661,1.47
mind,38,318,1.47
substantia alba,58,486,1.47
behavioral disorder,48,403,1.47
online computer,106,887,1.47
shortterm memory,88,736,1.47
counseling,235,1973,1.47
mid-life,26,218,1.47
midlife,26,218,1.47
stop smoking,355,2984,1.47
short-term memory,88,736,1.47
animal experimental use,26,219,1.46
mr spectroscopy,35,295,1.46
sequence alteration,19,161,1.46
animal research,26,219,1.46
magnetic resonance spectroscopy,35,295,1.46
genetic mutation,19,161,1.46
general hospitals,19,161,1.46
hepatitis,89,754,1.46
neurotransmitters,335,2830,1.46
animal experimentation,26,219,1.46
dna alteration,19,161,1.46
primates,84,712,1.46
dna mutation,19,161,1.46
teen years,65,552,1.45
stomach,12,102,1.45
academic achievement,14,119,1.45
white matter,58,494,1.45
low prevalence,10,85,1.45
sensitivity to ethanol,56,477,1.45
knock-in mouse,41,348,1.45
problem alcohol use,383,3257,1.45
microscopic,21,179,1.45
left,133,1129,1.45
sensory cell afferent neuron,37,315,1.45
lymphocyte,17,145,1.45
programmed cell death,51,435,1.45
gastric,12,102,1.45
immune precipitation,20,170,1.45
genetic association,45,382,1.45
cerebellum,38,324,1.45
macaca fascicularis,10,85,1.45
teen,65,552,1.45
teenagers,65,552,1.45
ethanol sensitivity,56,477,1.45
alcohol sensitivity,56,477,1.45
sensitivity to alcohol,56,477,1.45
therapeutically effective,167,1431,1.44
camp-dependent protein kinases,43,368,1.44
prospective studies,50,427,1.44
cdc,92,786,1.44
pka,43,368,1.44
tobacco addiction,160,1372,1.44
cyclic amp-dependent protein kinases,43,368,1.44
nyctohemeral rhythm,37,316,1.44
kinetics,100,858,1.44
fires,37,318,1.44
twenty-four hour rhythm,37,316,1.44
cysteine,24,206,1.44
wisconsin,29,248,1.44
circadian process,37,316,1.44
family practice,11,94,1.44
fire - disasters,37,318,1.44
daily biorhythm,37,316,1.44
adenosine cyclic monophosphate-dependent protein kinases,43,368,1.44
nicotine addiction,419,3587,1.44
ribosomal protein synthesis,30,259,1.43
risk prediction model,13,112,1.43
ribosomal protein biosynthesis,30,259,1.43
ribosomal peptide biosynthesis,30,259,1.43
neurotensin,18,155,1.43
computers,93,803,1.43
antiepileptics,10,86,1.43
senescent,10,86,1.43
antiepileptic drugs,10,86,1.43
antiepileptic agents,10,86,1.43
gene deletion,10,86,1.43
member 2,19,164,1.43
neocortex,15,129,1.43
welfare,21,181,1.43
norepinephrine system,10,86,1.43
ne system,10,86,1.43
venereal diseases,46,399,1.42
venereal disorders,46,399,1.42
habits,89,775,1.42
sexually transmitted infection,46,399,1.42
opioid receptor,326,2832,1.42
venereal infections,46,399,1.42
inherited,33,286,1.42
principal investigator,194,1684,1.42
anticonvulsive agents,21,182,1.42
mapk erk kinases,12,104,1.42
minor,47,407,1.42
medical students,24,209,1.42
fusion protein,24,209,1.42
positron emission tomography medical imaging,99,858,1.42
trafficking,143,1245,1.42
diagnostic findings,10,87,1.42
chimera protein,24,209,1.42
cell surface receptors,13,113,1.42
anticonvulsant agent,21,182,1.42
anticonvulsant drugs,21,182,1.42
sexually transmitted disorder,46,399,1.42
anticonvulsive drugs,21,182,1.42
substantia nigra structure,62,540,1.42
pacific islander,11,96,1.41
transmembrane protein,13,114,1.41
intrinsic membrane protein,13,114,1.41
integral membrane protein,13,114,1.41
health education,36,314,1.41
statistical regression,24,210,1.41
regression diagnostics,24,210,1.41
regression analysis,24,210,1.41
pamphlets,19,166,1.41
yohimbine,12,105,1.41
predominantly hyperactive-impulsive type attention-deficit disorder,114,1000,1.41
inferior frontal gyrus,11,96,1.41
regression analyses,24,210,1.41
incentives,159,1391,1.41
racial stocks,107,933,1.41
booklets,19,166,1.41
predominantly hyperactive-impulsive type hyperactivity disorder,114,1000,1.41
psychomotor reaction time,42,367,1.41
inferior frontal convolution,11,96,1.41
brochures,19,166,1.41
chemical dependence,964,8503,1.4
substance dependence,167,1467,1.4
chaperone,20,176,1.4
drug dependency,964,8503,1.4
drug industry,15,132,1.4
pharmaceutical industry,15,132,1.4
physics,16,141,1.4
neural transmission,209,1840,1.4
psyche structure,71,624,1.4
nano scale,11,97,1.4
hepatitis c,70,615,1.4
family medicine,11,97,1.4
drosophila melanogaster,19,167,1.4
enteramine,146,1285,1.4
gene alteration,17,150,1.4
5-hydroxytryptamine,146,1285,1.4
sympathins,24,212,1.4
violent behavior,74,651,1.4
5ht,146,1285,1.4
5-ht,146,1285,1.4
hippophaine,146,1285,1.4
tobacco smoking,69,610,1.4
acetaldehyde,13,115,1.39
genetic predisposition to disease,71,630,1.39
diameter,20,178,1.39
n-methylaspartate,93,827,1.39
nonsmall cell lung cancer,10,89,1.39
p-30 protein,19,169,1.39
treatment effect,117,1041,1.39
body system,25,222,1.39
genetic predisposition,71,630,1.39
inherited predisposition,71,630,1.39
inherited susceptibility,71,630,1.39
instructor,16,142,1.39
q. levoglutamide,24,213,1.39
gln,24,213,1.39
genetic etiology,71,630,1.39
l-glutamine,24,213,1.39
genetic mechanism of disease,71,630,1.39
embryonic development,14,124,1.39
genetic vulnerability,71,630,1.39
brain pathway,18,160,1.39
mathematical model,49,435,1.39
embryo development,14,124,1.39
p30,19,169,1.39
p30 protein,19,169,1.39
ranpirnase,19,169,1.39
huntington's disease,34,304,1.38
huntington chorea,34,303,1.38
smoker,397,3544,1.38
tyrosine kinase linked receptors,16,143,1.38
tyrosine kinase receptors,16,143,1.38
neurohumor receptors,34,303,1.38
data processing,22,196,1.38
huntington's,34,303,1.38
huntington disease,34,303,1.38
single base polymorphism,63,564,1.38
linkage mapping,38,339,1.38
computerized data processing,22,196,1.38
leukocytes,15,134,1.38
transmembrane receptor protein tyrosine kinase,16,143,1.38
huntingtons disease,34,303,1.38
school-age population,16,143,1.38
neurotoxins,22,197,1.38
degenerative neurologic diseases,67,599,1.38
voltage clamp,22,196,1.38
genotype,236,2111,1.38
alcohol dependency,583,5207,1.38
laboratory study,76,678,1.38
molecular chaperones,20,179,1.38
school age,16,143,1.38
ptk receptors,16,143,1.38
receptor protein-tyrosine kinases,16,143,1.38
alcohol addiction,583,5207,1.38
alcohol dependence,583,5207,1.38
detoxification,77,694,1.37
blood circulation,26,234,1.37
fear conditioning,45,404,1.37
cations,23,207,1.37
anger,16,144,1.37
population control,11,99,1.37
bloodstream,26,234,1.37
sexually transmitted diseases,46,413,1.37
district of columbia,16,144,1.37
mesoinositol,10,90,1.37
chiro-inositol,10,90,1.37
conditioned fear,45,404,1.37
mining,12,109,1.36
fatty acids,20,181,1.36
female adolescents,18,163,1.36
connecticut,28,253,1.36
neuron development,21,191,1.36
cerebral,43,390,1.36
obsessive compulsive behavior,17,154,1.36
neuronal development,21,191,1.36
adolescent girl,18,163,1.36
child abuse,15,136,1.36
rna splicing,38,344,1.36
acetylation,21,191,1.36
inositol,10,91,1.36
cell cycle,16,145,1.36
request for applications,54,488,1.36
insulin,22,200,1.36
nih rfa,54,488,1.36
prevention education,10,91,1.36
nutrient intake activity,31,281,1.36
effectiveness trial,45,409,1.36
anti-oxidant,23,210,1.35
adverse effects,285,2595,1.35
epidermal growth factor-urogastrone receptors,12,110,1.35
tgf-alpha receptor,12,110,1.35
sampling studies,27,247,1.35
antiadrenergic agents,12,110,1.35
living system,84,765,1.35
organism,84,765,1.35
egf receptor,12,110,1.35
cerebrum,43,392,1.35
urogastrone receptor,12,110,1.35
computer science,15,137,1.35
population study,31,285,1.34
residential treatment,18,166,1.34
temporal cortex,17,156,1.34
hypophysis cerebri,25,230,1.34
hypophysis,25,230,1.34
carrier proteins,26,240,1.34
dependence,812,7475,1.34
alpha-dimethyl-1,18,166,1.34
gene mapping,38,349,1.34
diagnostic and statistical manual of mental disorders,104,957,1.34
phosphorylase b kinase kinase,33,304,1.34
transporter protein,26,240,1.34
social stress,20,184,1.34
embryogenesis,14,129,1.34
non-b hepatitis,70,645,1.34
glycogen synthase a kinase,33,304,1.34
hydroxyalkyl protein kinase,33,304,1.34
heating,14,129,1.34
atp-protein phosphotransferase,33,304,1.34
asia,10,92,1.34
knowledge base,52,481,1.33
temporal lobe,17,158,1.33
aids/hiv,122,1134,1.33
apoptotic,28,259,1.33
hiv/aids,122,1134,1.33
drug induced behavior,10,93,1.33
laboratory animals,31,287,1.33
apoptosis pathway,51,473,1.33
organizational change,13,121,1.33
drug addiction prevention,83,771,1.33
circadian rhythms,37,342,1.33
survey methodology,11,102,1.33
survey method,11,102,1.33
drug use prevention,83,771,1.33
housing,84,781,1.33
residencies,20,185,1.33
operant conditioning,52,481,1.33
married persons,18,167,1.33
recombinants,53,491,1.33
halorhodopsin chromoprotein,16,149,1.32
cell adhesion protein,16,149,1.32
cell adhesion molecules,16,150,1.32
adhesion molecule,16,149,1.32
dopamine,719,6718,1.32
halorhodopsins,16,149,1.32
spouses,18,168,1.32
case management nurse,18,168,1.32
glutamine,24,224,1.32
expenditure,27,253,1.32
behavior disorders,48,449,1.32
leukemia,20,187,1.32
court,21,196,1.32
successful intervention,14,131,1.32
long term memory,29,271,1.32
genetic regulatory element,22,205,1.32
chimeric proteins,24,225,1.32
disease onset,13,122,1.31
neurokinin 1,13,122,1.31
job site,26,244,1.31
saccharin,13,122,1.31
job setting,26,244,1.31
in situ hybridization,102,958,1.31
job place,26,244,1.31
job location,26,244,1.31
working memory,88,829,1.31
smoking,498,4691,1.31
neurotrophic factor,29,274,1.31
onset of illness,13,122,1.31
treatment program,234,2210,1.31
sexual abuse,14,132,1.31
1-dioxide,13,122,1.31
work location,26,244,1.31
euler-gaddum substance p,13,122,1.31
performance site,10,94,1.31
neuron toxicity,44,415,1.31
escherichia coli,10,94,1.31
heart,57,538,1.31
neuronal toxicity,44,415,1.31
neurotoxicity,44,415,1.31
posttraumatic stress disorders,121,1142,1.31
2-benzisothiazol-3(2h)-one,13,122,1.31
radioligand,45,425,1.31
senescence,10,94,1.31
work-site,26,244,1.31
hplc,30,282,1.31
work place,26,244,1.31
work setting,26,244,1.31
worksite,26,244,1.31
workplace,26,244,1.31
disorder onset,13,122,1.31
task performances,42,397,1.3
molecular modeling,29,275,1.3
alcohol abuse,383,3633,1.3
problem drinking,383,3633,1.3
distress tolerance,11,104,1.3
drug interactions,76,723,1.3
ethanol abuse,383,3633,1.3
hazardous alcohol use,383,3633,1.3
health information technology,19,180,1.3
alcohol problem,383,3633,1.3
adult animal,23,219,1.3
sham therapy,235,2255,1.29
cholinoceptive sites,26,248,1.29
recidivism,42,402,1.29
violent,74,706,1.29
cholinoceptors,26,248,1.29
violence,74,709,1.29
european,50,477,1.29
cortisol,64,610,1.29
whole-cell recordings,24,230,1.29
aminoacetic acid,17,163,1.29
frontal cortex,80,766,1.29
hand,62,595,1.29
sham treatment,235,2255,1.29
norepinephrine,108,1034,1.29
cotinine,53,509,1.28
invertebrata,17,164,1.28
metals,10,96,1.28
frontal lobe,80,770,1.28
psychophysiology,50,481,1.28
study subject,27,261,1.28
afferent nerve,12,116,1.28
scotine,53,509,1.28
smoking cessation,355,3447,1.27
cocaine users,53,513,1.27
positron-emission tomography,99,961,1.27
narcolepsy,10,97,1.27
pet scan,99,961,1.27
calcium flux,19,184,1.27
pett,99,961,1.27
gelineau syndrome,10,97,1.27
virology,10,97,1.27
dna sequence,25,243,1.27
sex abuse,14,136,1.27
human data,43,417,1.27
nmda receptor-ionophore complex,98,954,1.27
n-methyl-d-aspartate receptors,98,954,1.27
paroxysmal sleep,10,97,1.27
receptor internalization,16,155,1.27
perfusion,26,253,1.27
france,10,97,1.27
positron emission tomography scan,99,961,1.27
smokeless tobacco,20,194,1.27
pet,99,961,1.27
alcoholic beverage heavy drinker,49,477,1.27
petscan,99,961,1.27
rad.-pet,99,961,1.27
apoptosis,51,497,1.27
narcoleptic syndrome,10,97,1.27
pet imaging,99,961,1.27
heavy drinker,49,477,1.27
molecular genetics,84,824,1.26
acquired immunologic deficiency syndrome,74,722,1.26
mrna translation,10,98,1.26
treatment cost,19,186,1.26
acetylcholine,75,733,1.26
blind,13,127,1.26
vaccination,22,216,1.26
pleasure,41,400,1.26
afro american,112,1106,1.25
environment effect on gene,38,374,1.25
radiolabel,37,364,1.25
afroamerican,112,1106,1.25
c-erbb-1,12,118,1.25
gilles de la tourette's disease,20,198,1.25
alcohol related problem,51,503,1.25
combined vocal and multiple motor,20,198,1.25
genetic risk for alcoholism,10,99,1.25
tourette syndrome,20,198,1.25
tourette's,20,198,1.25
computer programming,10,99,1.25
erbb protein,12,118,1.25
epidermal growth factor receptor,12,118,1.25
computer program,10,99,1.25
tourette's disease,20,198,1.25
guinon's disease,20,198,1.25
epidermal growth factor receptor kinase,12,118,1.25
epidermal growth factor receptor protein-tyrosine kinase,12,118,1.25
genetic vulnerability to alcoholism,10,99,1.25
genetics of alcoholism,10,99,1.25
receptor expression,168,1663,1.25
tourette's disorder,20,198,1.25
her1,12,118,1.25
pars compacta,14,138,1.25
tic de guinon,20,198,1.25
hiv risk,66,653,1.25
proto-oncogene protein c-erbb-1,12,118,1.25
aids,104,1026,1.25
erbb-1,12,118,1.25
erbb-1 proto-oncogene protein,12,118,1.25
transforming growth factor alpha receptor,12,118,1.25
nicotinic acetylcholine receptors,128,1267,1.25
erbbl,12,118,1.25
colorado,27,267,1.25
maladie des tics,20,198,1.25
phosphorylation,157,1553,1.25
gilles de la tourette syndrome,20,198,1.25
meeting reports,15,148,1.25
c-erbb-1 protein,12,118,1.25
heroin addiction,37,367,1.24
toxin,25,248,1.24
heroin dependence,37,367,1.24
brain behavior,45,446,1.24
abuse of substances,474,4706,1.24
fkbp12 rapamycin complex associated protein 1,15,149,1.24
mtor,15,149,1.24
drug reinforcement,27,268,1.24
amines,15,149,1.24
cholinergic receptors,26,259,1.24
placebos,235,2335,1.24
substance abuse problem,474,4706,1.24
smoking relapse,38,377,1.24
egfr,12,119,1.24
prevention program,84,835,1.24
extracellular signal regulated kinases,12,120,1.23
drug efficacy,18,181,1.23
extracellular signal-regulated map kinases,12,120,1.23
corticotropin releasing-factor receptors,25,251,1.23
neuropsychologic tests,19,191,1.23
genetic research,27,270,1.23
diffusion magnetic resonance imaging,37,372,1.23
menstrual cycle,21,211,1.23
protein structure,17,171,1.23
substantia nigra,62,620,1.23
adenylcyclase,27,270,1.23
threonine/tyrosine protein kinase,12,120,1.23
extracellular signal related kinase,12,120,1.23
diffusion weighted mri,37,372,1.23
tourette's syndrome,20,200,1.23
diffusion tensor imaging,37,372,1.23
erk map kinases,12,120,1.23
substance addiction,167,1671,1.23
budgets,51,511,1.23
exons,25,250,1.23
image processing,11,110,1.23
ep300 gene,10,100,1.23
ep300,10,100,1.23
corticosterone,32,322,1.23
diffusion mri,37,372,1.23
dopamine system,106,1074,1.22
monkeys,89,902,1.22
developmental disorder,10,101,1.22
suggestion,30,303,1.22
signs and symptoms,10,101,1.22
pituitary gland,25,252,1.22
active sites,10,101,1.22
cocaine addiction,235,2374,1.22
animal testing,11,111,1.22
long-term potentiation,48,486,1.22
smoke,230,2325,1.22
anticonvulsants,21,214,1.21
weight,66,670,1.21
illicit drugs,150,1535,1.21
transport proteins,26,266,1.21
stimulant abuse,53,540,1.21
p300,10,102,1.21
aggressive behavior,43,439,1.21
chip assay,26,264,1.21
psychostimulant abuse,53,540,1.21
binge eating,20,205,1.2
saliva,26,267,1.2
neuropsychology,64,659,1.2
non-smoking,20,206,1.2
smoking behavior,105,1082,1.2
attention deficit hyperactivity disorder,114,1173,1.2
adhd,114,1173,1.2
smoking intervention,16,164,1.2
psychotherapy,79,810,1.2
compulsive eating,20,205,1.2
chemical synthesis,33,338,1.2
www,85,876,1.2
web,85,876,1.2
world wide web,85,876,1.2
compulsive overeating,20,205,1.2
compulsive feeding,20,205,1.2
ad/hd,114,1173,1.2
heuristics,17,176,1.19
r21 mechanism,15,155,1.19
r21 program,15,155,1.19
vertebrate animals,20,207,1.19
teacher,36,374,1.19
antiretroviral,32,332,1.19
vertebrata,20,207,1.19
austin,11,114,1.19
exploratory/developmental grant,15,155,1.19
antiretroviral agents,32,332,1.19
vertebrates,20,207,1.19
substance abuse,474,4960,1.18
enkephalins,48,502,1.18
crystallography,11,115,1.18
gene transfer,31,325,1.18
second messenger systems,24,250,1.18
neuromediator receptors,34,356,1.18
gaba-a receptor,11,115,1.18
neuroregulator receptors,34,356,1.18
freedom,26,271,1.18
mutant strains mice,45,471,1.18
immunogen,16,167,1.18
liberty,26,271,1.18
na element,16,167,1.18
crime,58,611,1.17
cultured cells,19,201,1.17
chromatin immunoprecipitation,26,273,1.17
behavior prediction,24,254,1.17
gene cluster,13,137,1.17
nmda receptors,98,1036,1.17
neurochemical,209,2205,1.17
aged 65 and over,33,347,1.17
intravenous administration,22,231,1.17
informed consent,20,210,1.17
age of onset,24,254,1.17
genetic mapping,38,401,1.17
sadness,52,551,1.16
dementia,57,605,1.16
funding mechanisms,16,170,1.16
years of life lost to disease,42,446,1.16
years of life lost to disability,42,446,1.16
nicotinic receptors,128,1358,1.16
depressed mood,52,551,1.16
problem behavior,49,522,1.16
behavioral problem,49,522,1.16
control animal,21,226,1.15
tic disorder,20,215,1.15
choline,13,139,1.15
self stimulation,39,417,1.15
histone h3,11,118,1.15
chronic painful condition,99,1061,1.15
protein synthesis,30,323,1.15
mood regulation,10,107,1.15
20-dione,82,887,1.14
single nucleotide polymorphism,63,682,1.14
family study,19,206,1.14
protein kinase,35,378,1.14
special population,18,195,1.14
iowa,14,151,1.14
neurotoxic,35,378,1.14
serotonin receptor,34,369,1.14
point mutation,17,184,1.14
stoichiometry,12,130,1.14
alcohol and other drug,46,499,1.14
brain morphology,10,108,1.14
anisotropy,13,141,1.14
habit learning,14,152,1.14
nonalcoholic,16,174,1.13
handbook,11,120,1.13
tyrosylprotein kinase,13,142,1.13
eph-and elk-related kinase,13,142,1.13
tyrosine-specific protein kinase,13,142,1.13
empowered,11,120,1.13
tyrosine-protein kinase receptor eek,13,142,1.13
ephrin type-a receptor 8,13,142,1.13
eph- and elk-related tyrosine kinase,13,142,1.13
tyrosine kinase,13,142,1.13
non-alcoholic,16,174,1.13
protein kinase a,43,468,1.13
ephrin type-a receptor 8 precursor,13,142,1.13
tyrosyl protein kinase,13,142,1.13
vesicle,26,285,1.13
protein tyrosine kinase eek,13,142,1.13
in silico,68,740,1.13
hydroxyaryl protein kinase,13,142,1.13
request for proposals,17,187,1.12
intercellular space,10,110,1.12
meth dependence,48,529,1.12
methamphetamine dependence,48,529,1.12
extracellular space,10,110,1.12
meth addiction,48,529,1.12
major tranquilizing agents,20,220,1.12
methamphetamine addiction,48,529,1.12
nicotine skin patch,33,368,1.11
antidepressive agents,57,635,1.11
cocaine abuse,83,924,1.11
dataset,209,2313,1.11
conditioning,100,1111,1.11
antidepressant agent,57,632,1.11
phosphorylation site,14,155,1.11
antidepressant drugs,57,635,1.11
nicotine patch,33,368,1.11
baths,19,213,1.1
high risk behavior,26,291,1.1
antigens,16,180,1.1
psychotic disorders,31,349,1.1
monoamine,52,583,1.1
base of the brain,23,258,1.1
episodic memory,12,134,1.1
biologic availability,37,413,1.1
protein function,27,303,1.1
endocytosis,31,348,1.1
bathing,19,213,1.1
depressed,52,586,1.09
rimonabant,11,125,1.09
acomplia,11,125,1.09
risk behaviors,172,1939,1.09
boys,15,170,1.09
calcium channel,25,283,1.09
at risk behavior,172,1939,1.09
employee,13,147,1.09
dentate fascia,11,124,1.09
pathological processes,10,113,1.09
acquired immuno-deficiency syndrome,74,840,1.09
risky behavior,172,1939,1.09
zimulti,11,125,1.09
gyrus dentatus,11,124,1.09
fascia dentata,11,124,1.09
nicotine abuse,19,215,1.09
pathologic processes,10,113,1.09
genetic testing,11,126,1.08
african american,112,1284,1.08
australia,13,148,1.08
marriage,13,149,1.08
catecholamines,24,273,1.08
nicotine,490,5585,1.08
tuberculosis,11,126,1.08
randomized controlled trials,158,1806,1.08
neuroendocrine system,54,623,1.07
cerebral cortex,24,276,1.07
scheme,23,265,1.07
internet,85,980,1.07
glucose metabolism,20,231,1.07
research infrastructure,117,1349,1.07
victimization,11,127,1.07
developed nations,17,198,1.06
model organism,440,5134,1.06
industrialized countries,17,198,1.06
industrialized nations,17,198,1.06
parental monitoring,12,140,1.06
developed countries,17,198,1.06
parent monitoring,12,140,1.06
gene deletion mutation,10,117,1.05
group counseling,11,129,1.05
behavior genetics,41,481,1.05
genetic determinants of behavior,41,481,1.05
therapy compliance,54,633,1.05
regulatory regions,22,259,1.05
promotor regions,17,199,1.05
promoter regions,17,199,1.05
pituitary,25,294,1.05
locomotor activity,62,729,1.05
coloring agents,13,152,1.05
electron microscopy,29,342,1.05
linkage disequilibrium,14,165,1.05
motor activity,62,729,1.05
community based treatment,20,238,1.04
americas,28,332,1.04
lentivirinae,10,119,1.04
protein tyrosine kinase,13,154,1.04
stimulant addiction,56,661,1.04
stimulant dependence,56,661,1.04
mitogen-activated protein kinases,26,309,1.04
invertebrates,17,202,1.04
psychostimulant dependence,56,661,1.04
map kinase,26,309,1.04
lentivirus,10,119,1.04
psychostimulant addiction,56,661,1.04
impulsive behavior,39,465,1.03
genetic susceptibility,71,848,1.03
mature animal,23,275,1.03
screening and brief intervention,17,204,1.03
behavior test,168,2025,1.02
k element,13,157,1.02
camkii,24,290,1.02
dyes,13,157,1.02
binge drinker,12,145,1.02
bout drinker,12,145,1.02
calcium-dependent cam kinase ii,24,290,1.02
cam kii,24,290,1.02
calmodulin-dependent protein kinase ii,24,290,1.02
cam kinase ii,24,290,1.02
mexico,12,145,1.02
cd4 lymphocyte count,19,229,1.02
cam pk ii,24,290,1.02
cd4+ cell counts,19,229,1.02
abuse of drugs,512,6217,1.02
cd4+ counts,19,229,1.02
t4 lymphocyte count,19,229,1.02
aggression,43,522,1.02
episodic drinker,12,145,1.02
abuses drugs,512,6217,1.02
funding source,13,158,1.01
sodium,16,196,1.01
funding agency,13,158,1.01
philadelphia,17,207,1.01
baclofen,11,135,1.0
chlorophenyl gaba,11,135,1.0
pcp-gaba,11,135,1.0
dual diagnosis,29,356,1.0
oleamide hydrolase,16,197,1.0
accounting,198,2433,1.0
magnetic resonance,13,160,1.0
genetic epidemiology,16,197,1.0
mouse mutant,45,553,1.0
faah protein,16,197,1.0
fatty acid amide hydrolase,16,197,1.0
methamphetamine abuse,31,385,0.99
ecstasy,18,225,0.99
methylenedioxymethamphetamine,18,225,0.99
n-methyl-3,18,225,0.99
mdma,18,225,0.99
dependence relapse,13,162,0.99
microinjections,52,646,0.99
dominant-negative mutation,18,227,0.98
dominant-negative mutant,18,227,0.98
creb1 gene,22,277,0.98
4-methylenedioxyamphetamine,18,227,0.98
creb,22,277,0.98
creb1,22,277,0.98
gene environment interaction,38,476,0.98
antimorphic mutation,18,227,0.98
dominant negative,18,227,0.98
3-benzodioxole-5-ethanamine,18,227,0.98
dentate gyrus,11,138,0.98
personality traits,20,255,0.97
hydrolysis,17,216,0.97
protein biosynthesis,30,380,0.97
allelomorphs,87,1109,0.97
stratification,16,203,0.97
adenylate cyclase,37,470,0.97
antipsychotic drugs,20,254,0.97
major tranquilizers,20,254,0.97
life stress,14,178,0.97
neuroleptics,20,254,0.97
neuroleptic drugs,20,254,0.97
neuroleptic agents,20,254,0.97
antipsychotics,20,254,0.97
caliber,14,178,0.97
drug abuse prevention,83,1061,0.96
reproduction,11,142,0.96
antidepressants,57,730,0.96
randomized clinical trials,80,1028,0.96
age 12 years,10,130,0.95
macaca mulatta,63,820,0.95
environmental tobacco smoke exposure,13,169,0.95
car phone,13,168,0.95
dopamine receptor,158,2052,0.95
autoreceptors,20,259,0.95
predoc,31,408,0.94
placebo controlled study,30,394,0.94
archives,20,263,0.94
transfection,31,408,0.94
family medical history epidemiology,28,368,0.94
reverse transcriptase pcr,24,316,0.94
reverse transcriptase polymerase chain reaction,24,316,0.94
rtpcr,24,316,0.94
cell surface,34,448,0.94
work environment,17,222,0.94
information processing,34,444,0.94
job environment,17,222,0.94
rt-pcr,24,316,0.94
yeasts,12,158,0.94
public health service,12,159,0.93
usphs,12,159,0.93
drug addiction,964,12764,0.93
united states public health service,12,159,0.93
primary healthcare,113,1500,0.93
neuropeptide tyrosine,14,186,0.93
primary health care,113,1500,0.93
downregulation,50,661,0.93
second messengers,24,318,0.93
serotonin,147,1948,0.93
respondent,27,357,0.93
antipsychotic agents,20,265,0.93
fk506 binding protein 12-rapamycin associated protein 1,15,200,0.92
paired stimuli,12,160,0.92
condoms,14,187,0.92
nas/iom,23,309,0.92
institute of medicine (u.s.),23,309,0.92
institute of medicine,23,309,0.92
dl-amphetamine,102,1365,0.92
phenopromin,102,1365,0.92
phenamine,102,1365,0.92
receptor gene,40,538,0.92
desoxynorephedrin,102,1365,0.92
immunogenicity,14,187,0.92
immunoprecipitation,20,269,0.92
prescription drug abuse,17,228,0.92
radiolabeled,13,176,0.91
cdna,11,149,0.91
driving behavior,13,177,0.91
substance p,13,176,0.91
organ system,25,339,0.91
financial compensation,12,163,0.91
immunoreactivity,14,192,0.9
mucolyticum,12,164,0.9
n-acetylcysteine,12,164,0.9
mucocedyl,12,164,0.9
fluatox,12,164,0.9
fluimucil,12,164,0.9
mucolator,12,164,0.9
acetylin,12,164,0.9
mucomyst,12,164,0.9
clonidine,17,232,0.9
mucosolvin,12,164,0.9
airbron,12,164,0.9
mucret,12,164,0.9
nac zambon,12,164,0.9
fabrol,12,164,0.9
brunac,12,164,0.9
fluimucetin,12,164,0.9
broncholysin,12,164,0.9
green fluorescent proteins,15,206,0.9
over weight,11,150,0.9
parvolex,12,164,0.9
fluprowit,12,164,0.9
mercapturic acid,12,164,0.9
dopaminergic antagonists,15,206,0.9
muco sanigen,12,164,0.9
tixair,12,164,0.9
respaire,12,164,0.9
dopamine receptor antagonists,15,206,0.9
neo-fluimucil,12,164,0.9
overweight,11,150,0.9
couples,19,264,0.89
extinction (psychology),104,1448,0.89
genetic determinism,12,167,0.89
twelve year old,10,138,0.89
heroin abuse,13,181,0.89
phosphodiesterase protein activator,10,138,0.89
phosphodiesterase activating factor,10,138,0.89
glutamate receptor,88,1221,0.89
calcium-dependent regulator,10,138,0.89
12 year old,10,138,0.89
genetic determinant,12,167,0.89
calcium-dependent activator protein,10,138,0.89
drug discrimination,21,290,0.89
maternal behavior,11,154,0.88
racial segregation,10,140,0.88
epithelial,10,141,0.87
abbreviations,16,226,0.87
dosage,87,1228,0.87
post-transcriptional gene silencing,44,622,0.87
acetylcysteine,12,170,0.87
sequence-specific posttranscriptional gene silencing,44,622,0.87
rnai,44,622,0.87
rna silencing,44,622,0.87
posttranscriptional gene silencing,44,622,0.87
buproprion,30,429,0.86
amfebutamone,30,429,0.86
conditioned stimulus,14,200,0.86
image evaluation,18,258,0.86
image analysis,18,258,0.86
image analyses,18,259,0.86
sex activity,33,472,0.86
sexual activity,33,472,0.86
randomized placebo controlled trial,15,214,0.86
sexual behavior,33,472,0.86
rna interference,44,630,0.86
volunteer,38,545,0.86
brain chemistry,11,157,0.86
hereditary,33,477,0.85
cannabis dependence,16,235,0.84
caucasians,13,192,0.84
self-control as a personality trait,34,500,0.84
allergic/immunologic organ system,23,336,0.84
allergic/immunologic body system,23,336,0.84
narcotics,53,775,0.84
methylphenidate,31,457,0.84
glycine,17,249,0.84
self control,34,500,0.84
inferior,13,191,0.84
temperament,12,179,0.83
epileptiform,47,697,0.83
reading,33,493,0.83
genetic promoter element,17,253,0.83
neurochemistry,209,3096,0.83
plant zygotes,14,207,0.83
replacement therapy,11,165,0.82
problem drinker,117,1756,0.82
calcium phospholipid-dependent protein kinase,11,166,0.82
boozer,117,1756,0.82
dependent drinker,117,1756,0.82
4 methylenedioxymethamphetamine,18,272,0.82
neuropsychological tests,19,287,0.82
alcoholic,117,1763,0.82
gene function,18,272,0.82
synaptoneurosome,10,150,0.82
behavioral extinction,104,1556,0.82
calcium-activated phospholipid-dependent kinase,11,166,0.82
parity,13,195,0.82
phospholipid-sensitive calcium-dependent protein kinase,11,166,0.82
drug abuse,512,7830,0.81
calmodulin,10,152,0.81
5ht transporter,24,364,0.81
5htt protein,24,364,0.81
neurotransmitter receptor,34,517,0.81
sodium-dependent serotonin transporter,24,364,0.81
laser electromagnetic,18,273,0.81
needlesharing,10,152,0.81
laser radiation,18,273,0.81
voucher,13,199,0.81
mate,13,199,0.81
cocaine,715,10881,0.81
dat dopamine transporter,65,984,0.81
partner in relationship,13,197,0.81
blood oxygenation level dependent,17,261,0.8
blood oxygen level dependent,17,261,0.8
gene targeting,62,955,0.8
plant embryos,14,219,0.79
exocytosis,10,157,0.79
seeds,14,219,0.79
seed,14,219,0.79
solute carrier family 6 (neurotransmitter transporter,18,282,0.79
neuropeptide y,14,219,0.79
pharmacogenetics,52,815,0.79
urine urinary system,75,1173,0.79
amphetamines,102,1589,0.79
mediator of activation,164,2607,0.78
genetic polymorphism,70,1109,0.78
mediator of activation protein,164,2607,0.78
early onset,25,397,0.78
girls,12,190,0.78
thinking,117,1858,0.78
caucasoid race,13,209,0.77
caucasoid,13,209,0.77
caucasian race,13,209,0.77
caucasian,13,209,0.77
occidental,13,209,0.77
case control,26,418,0.77
white race,13,209,0.77
acculturation,10,163,0.76
attention deficit disorder,14,226,0.76
alcoholism,201,3266,0.76
pregn-4-ene-3,41,662,0.76
siblings,18,294,0.76
cultural assimilation,10,163,0.76
family history of,28,462,0.75
black populations,67,1106,0.75
endorphins,19,313,0.75
hemodynamics,16,262,0.75
gene proteins,10,165,0.75
protein gene products,10,165,0.75
science education,12,198,0.75
arachidonoyl ethanolamide,18,299,0.74
arachidonylethanolamide,18,299,0.74
n arachidonoyl 2 hydroxyethylamide,18,299,0.74
arachidonoylethanolamide,18,299,0.74
substance abuse treatment,65,1090,0.74
substance abuse therapy,65,1090,0.74
primary care physician,13,217,0.74
environmental stressor,12,201,0.74
marijuana dependence,16,268,0.74
hippocampus (brain),132,2191,0.74
dementia of the alzheimer type,61,1027,0.73
men's,114,1913,0.73
diazepam,14,237,0.73
microdialysis,77,1297,0.73
drug addict,19,320,0.73
parietal,14,237,0.73
vaccines,22,371,0.73
ethanol-dependent,39,661,0.73
alzheimers disease,61,1027,0.73
institutes,91,1531,0.73
alzheimer disease,61,1027,0.73
alzheimer,61,1027,0.73
neurogenetics,21,359,0.72
bupropion,30,512,0.72
imagery,22,377,0.72
potassium,13,222,0.72
haplotypes,22,377,0.72
lasers,18,307,0.72
health care service,35,607,0.71
adrenocorticotropin,11,190,0.71
putamen,19,329,0.71
sexual partners,10,174,0.71
group therapy,13,230,0.7
risky sexual behavior,23,404,0.7
antisocial personality disorder,10,176,0.7
sociopathic personality,10,176,0.7
high risk sex activity,23,404,0.7
high risk sex behavior,23,404,0.7
high risk sexual activity,23,404,0.7
high risk sexual behavior,23,404,0.7
corticotropin,11,196,0.69
acth,11,196,0.69
raclopride,12,215,0.69
anandamide,18,323,0.69
hispanic populations,35,629,0.69
hispanics,35,629,0.69
jail inmate,15,274,0.68
dietary,21,381,0.68
wood,11,199,0.68
wood material,11,199,0.68
reinforcer,124,2251,0.68
prison inmates,15,274,0.68
prisoner,15,274,0.68
correctional institution resident,15,274,0.68
outcomes research,44,807,0.67
gamma-aminobutyric acid receptors,10,184,0.67
gene mutation,17,320,0.66
disorder later incidence prevention,54,1005,0.66
respiratory disease,15,280,0.66
respiratory system disease,15,280,0.66
respiratory system disorder,15,280,0.66
genome-wide identification,27,501,0.66
disorder recurrence prevention,54,1005,0.66
underserved minority,10,186,0.66
behavioral genetics,41,765,0.66
social disturbance,13,244,0.66
genome wide analysis,27,501,0.66
genome wide studies,27,501,0.66
complementary dna,11,208,0.65
dopamine antagonists,15,283,0.65
age-years,15,285,0.65
drug metabolism,50,964,0.64
screening procedure,47,902,0.64
k02 award,12,234,0.63
independent scientist award,12,234,0.63
chromatography,12,236,0.63
limbic system,24,467,0.63
sex behavior,33,647,0.63
quelling,32,622,0.63
controlled clinical trials,23,452,0.63
social problems,13,253,0.63
μ receptors,14,274,0.63
dopamine receptor agonists,15,298,0.62
nervous system structure,57,1138,0.62
dopaminergic agonists,15,298,0.62
family medical history,28,556,0.62
knowledgebase,20,396,0.62
risk-taking,36,717,0.62
brain mapping,35,708,0.61
high-risk sex,15,301,0.61
disorders of conduct,12,243,0.61
unsafe sex,15,301,0.61
sex partner,10,202,0.61
disorder of conduct,12,243,0.61
unprotected sex,15,301,0.61
synaptosomes,10,205,0.6
dopamine transporter,65,1339,0.6
serotonin transporter,24,493,0.6
patient oriented research,56,1153,0.6
progress reports,19,397,0.59
gender difference,59,1246,0.58
personality,32,679,0.58
m.d.,19,403,0.58
articulation,21,443,0.58
doctor of medicine,19,403,0.58
huntington's disease pathway,14,303,0.57
asians,11,239,0.57
offender,12,270,0.55
alcohol-dependent,231,5207,0.55
criminal offender,12,270,0.55
conduct disorder,12,272,0.54
alcohol addiction therapy,38,891,0.53
alcohol dependence therapy,38,891,0.53
high performance liquid chromatography,30,696,0.53
alcoholism therapy,38,891,0.53
chromosomes,21,491,0.53
bears,20,470,0.52
ursidae family,20,470,0.52
bear,20,470,0.52
ursidae,20,470,0.52
drug receptors,12,286,0.52
dopamine agonists,15,353,0.52
recombinase,12,283,0.52
parkinsons disease,58,1412,0.51
caffeine,11,264,0.51
mammals,88,2142,0.51
aids/hiv problem,47,1134,0.51
hiv/aids problem,47,1134,0.51
teenage,65,1582,0.51
latino population,26,629,0.51
criminal behavior,14,347,0.5
drug formulations,15,373,0.5
sexual risk behavior,14,356,0.49
sorting - cell movement,13,326,0.49
parkinson's disease,58,1464,0.49
gambling,16,412,0.48
radiotracer,37,945,0.48
protein kinase c,11,280,0.48
drug withdrawal,79,2084,0.47
adrenocorticotropic hormone,11,296,0.46
chromosomal,11,293,0.46
receptor binding,53,1409,0.46
magnetic resonance imaging scan,29,800,0.45
enzyme activity,16,435,0.45
neuropeptide receptor,15,412,0.45
attention deficit hyperactive disorder,42,1173,0.44
data pooling,18,504,0.44
alcoholism treatment,38,1127,0.42
mass,12,358,0.41
antisocial personality,10,308,0.4
dsm-iv,19,622,0.38
diagnostic and statistical manual of mental disorders-iv,19,622,0.38
4th edition,19,622,0.38
dsm4,19,622,0.38
anti social,11,375,0.36
antisocial,11,375,0.36
behavioral sensitization,13,451,0.36
data repository,33,1130,0.36
databanks,33,1130,0.36
data banks,33,1130,0.36
neuropharmacology,55,1936,0.35
placebo controlled trial,11,385,0.35
clinical investigation,56,2061,0.34
receptor coupling,10,358,0.34
polymerase chain reaction,14,538,0.32
behavioral disinhibition,10,391,0.32
research study,167,6773,0.3
program announcement,11,451,0.3
home environment,29,1185,0.3
nih program announcements,11,451,0.3
active recruitment,16,687,0.29
gaba receptor,10,427,0.29
brain metabolism,16,697,0.28
mu receptors,14,609,0.28
human subject,103,4943,0.26
self medication,23,1196,0.24
black american,21,1106,0.23
translational research enterprise,18,973,0.23
translation research enterprise,18,973,0.23
computer based simulation,11,629,0.22
preclinical trial,10,600,0.21
pre-clinical trial,10,592,0.21
urinalysis,11,681,0.2
computerized simulation,11,704,0.19
computational simulation,11,704,0.19
computer simulation,11,888,0.15
alcohol,15,1232,0.15
drug tolerance,11,1249,0.11
man,10,1375,0.09
psychopharmacology,12,1973,0.08
gene product,18,3196,0.07
recruitment activity,16,3343,0.06
staging,10,2976,0.04
alcohol or other drugs use,11,3932,0.03
aod use,11,3932,0.03
